Methods of identifying anti-inflammatory macrolides

Abstract

The invention relates to the screening and selection of macrolide compounds for use as anti-inflammatory agents. The screening and selection of anti-inflammatory macrolides is based on the differential expression of one or more genes involved in the inflammatory process.

Description

FIELD OF THE INVENTION

The invention relates to methods for identifying macrolides having properties for reducing inflammation and associated sequalae (e.g., fibrosis).

BACKGROUND OF THE INVENTION

Macrolide antibiotics having 14- or 15-member lactone rings are known to have anti-inflammatory properties in patients with chronic airway inflammation. There is need in the art for methods of identifying other macrolides with anti-inflammatory properties. Such macrolides may be useful for treating airway or other inflammation and associated conditions (e.g., cystic fibrosis).

BRIEF SUMMARY OF THE INVENTION

The invention provides at least the following embodiments:

1. A method of screening test macrolides to identify potential anti-inflammatory agents, comprising:

1) contacting a first biological sample with a test macrolide; and

2) detecting, as an alteration, a first level of expression or activity of a target molecule involved in inflammation in the first biological sample relative to a second level of expression or activity of the target molecule involved in inflammation in a second biological sample that has not been contacted with the test macrolide.

2. The method of embodiment 1, wherein a test macrolide that alters the first level of alteration of expression or activity of the target molecule involved in inflammation relative to the second level of alteration of expression or activity of the target molecule involved in inflammation identifies the test macrolide as a potential anti-inflammatory agent.

3. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the level of de novo arachidonic acid biosynthesis.

4. The method of embodiment 3, wherein a macrolide compound that increases or decreases the level of de novo arachidonic acid biosynthesis is selected.

5. The method of embodiment 4, wherein the level of de novo arachidonic acid biosynthesis is detected by measuring incorporation of labeled arachidonic acid into phospholipids.

6. The method of embodiment 4, wherein the level of de novo arachidonic acid biosynthesis is detected by measuring incorporation of label into an intermediate in an arachidonic acid biosynthesis pathway.

7. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the level of extracellular matrix decomposition.

8. The method of embodiment 7, wherein a macrolide compound that decreases the level of extracellular matrix decomposition is selected.

9. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the leucocyte infiltration number.

10. The method of embodiment 9, wherein a macrolide compound that decreases the leucocyte infiltration number is selected.

11. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the level of expression of a gene involved in arachidonic acid biosynthesis or activation.

12. The method of embodiment 11, wherein a macrolide compound that increases or decreases the level of expression of the gene is selected.

13. The method of embodiment 11, wherein the gene is at least one type selected from the group consisting of A5 fatty acid desaturase (FADS1), A6 fatty acid desaturase (FADS2), fatty acid elongase, arachidonyl CoA synthetase, cyclooxygenase 2, prostaglandin E receptor EP4, cytosolic phospholipase A2, fatty acid desaturase, prostaglandin E synthase, prostaglandin E receptor EP1, prostaglandin 12 receptor, and secretory phospholipase A2 receptor 1.

14. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the level of expression of a gene involved in extracellular matrix decomposition.

15. The method of embodiment 14, wherein a macrolide compound that increases the level of expression of the gene is selected.

16. The method of embodiment 15, wherein the gene is at least one type selected from the group consisting of serine proteinase inhibitor, clade B (ovalbumin), and member 3 (SERPINB3).

17. The method of embodiment 14, wherein a macrolide compound that decreases the level of expression of the gene is selected.

18. The method of embodiment 17, wherein the gene is at least one type selected from the group consisting of matrix metalloproteinase 12 (MMP12), matrix metalloproteinase 19 (MMP19), matrix metalloproteinase 9 (MMP9), cathepsin C, and cathepsin K.

19. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the level of expression of a gene involved in leucocyte infiltration.

20. The method of embodiment 19, wherein a macrolide compound that decreases the level of expression of the gene is selected.

21. The method of embodiment 19, wherein the gene is at least one type selected from the group consisting of small inducible cytokine subfamily A (Cys-Cys) member 18 (CCL18), small inducible cytokine subfamily B (Cys-X-Cys) member 10 (CXCL10), small inducible cytokine subfamily B (Cys-X-Cys) member 11 (CXCL11), and small inducible cytokine subfamily B (Cys-X-Cys) member 9 (CXCL9).

22. The method of any one of embodiments 11, 14 and 19, wherein expression of the gene is determined by detecting mRNA, protein or protein synthesis.

23. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the activity of an enzyme involved in arachidonic acid biosynthesis.

24. The method of embodiment 23, wherein a macrolide compound that increases or decreases the activity of the enzyme is selected.

25. The method of embodiment 24, wherein the enzyme is at least one type selected from the group consisting of A5 fatty acid desaturase (FADS1), A6 fatty acid desaturase (FADS2), fatty acid elongase, and arachidonyl CoA synthetase.

26. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the activity of an enzyme involved in extracellular matrix decomposition.

27. The method of embodiment 26, wherein a macrolide compound that increases the activity of the enzyme is selected.

28. The method of embodiment 27, wherein the enzyme is at least one type selected from the group consisting of serine proteinase inhibitor, clade B (ovalbumin), and member 3 (SERPINB3).

29. The method of embodiment 26, wherein a macrolide compound that decreases the activity of the enzyme is selected.

30. The method of embodiment 29, wherein the enzyme is at least one type selected from the group consisting of matrix metalloproteinase 12 (MMP12), matrix metalloproteinase 19 (MMP19), matrix metalloproteinase 9 (MMP9), cathepsin C, and cathepsin K.

31. The method of embodiment 1, wherein the alteration of the target molecule in 2) above is an alteration in the activity of a chemokine involved in leucocyte infiltration.

32. The method of embodiment 31, wherein a macrolide compound that decreases the activity of the chemokine is selected.

33. The method of embodiment 32, wherein the chemokine is at least one type selected from the group consisting of small inducible cytokine subfamily A (Cys-Cys) member 18 (CCL18), small inducible cytokine subfamily B (Cys-X-Cys) member 10 (CXCL10), small inducible cytokine subfamily B (Cys-X-Cys) member 11 (CXCL11), and small inducible cytokine subfamily B (Cys-X-Cys) member 9 (CXCL9).

34. The method of embodiment 1, wherein the biological sample comprises cells.

35. The method of embodiment 1, wherein the biological sample comprises a cellular extract.

36. The method of embodiment 1, wherein the contacting in 1) above is carried out in vitro.

37. The method of embodiment 1, wherein the contacting in 1) above is carried out in VIVO.

38. The method of embodiment 1, wherein the contacting in 1) above is carried out in a cell culture.

39. The method of embodiment 38, wherein the cell culture comprises an epithelial cell line.

• • 40. The method of embodiment 38, wherein the epithelial cell line is a macrophage cell line.
  • 41. The method of embodiment 39, wherein the epithelial cell line is A549.
  • 42. The method of embodiment 40, wherein the epithelial cell line is THP-1.
  • 43. The method of embodiment 1, wherein the anti-inflammatory action is an action against inflammation in the lung.
  • 44. The method of embodiment 43, wherein the inflammation in the lung is pulmonary emphysema, bronchitis, pulmonary fibrosis, acute lung injury, viral pneumonia, bacterial pneumonia, or acute respiratory disease syndrome (ARDS).

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Schematic view of the arachidonic acid pathway.

FIG. 2. Overlapping transcriptional responses between arachidonic acid pathway inhibitors and macrolides. FIG. 2A, Arachidonic acid pathway inhibitors; FIG. 2B, Active anti-inflammatory macrolides; FIG. 2C, Active (clarithromycin, roxithromycin) and inactive (josamycin) macrolides; FIG. 2D, Triacsin C and active macrolides (clarithromycin, roxithromycin); FIG. 2E, Indomethacin and active macrolides (clarithromycin, roxithromycin); FIG. 2F, Clarithromycin, triacsin C and indomethacin.

FIG. 3. Inhibition of PGE₂ production by FADS1 inhibitor (CP-74006) and macrolides. FIG. 3A, Inhibition of PGE₂ production by FADS1 inhibitor (CP-74006); FIG. 3B, Inhibition of PGE₂ production by macrolides.

FIG. 4A and FIG. 4B show the cell counts of inflammatory cells (macrophages and neutrophiles) in bronchoalveolar lavage fluids from model mice with tobacco smoke-induced pulmonary emphysema after six months' exposure. FIG. 4A shows the cell count of macrophages. FIG. 4B shows the cell count of neutrophiles.

FIG. 5 shows the results of pulmonary compliance measured in the model mice with tobacco smoke-induced pulmonary emphysema after six month's exposure.

DETAILED DESCRIPTION OF THE INVENTION

In embodiments below, the screening method for a macrolide compound having anti-inflammatory action includes the following steps.

1) contacting a first biological sample with a test macrolide; and

2) detecting, as an alteration, a first level of expression or activity of a target molecule involved in inflammation in the first biological sample relative to a second level of expression or activity of the target molecule involved in inflammation in a second biological sample that has not been contacted with the test macrolide.

In this screening method, a test macrolide that alters the first level of alteration of expression or activity of the target molecule involved in inflammation relative to the second level of alteration of expression or activity of the target molecule involved in inflammation may be identified as the test macrolide as a potential anti-inflammatory agent.

Specific examples of the alteration of the target molecule in the above-mentioned step 2) include

(i) that related to arachidonic acid biosynthesis,

(ii) that related to extracellular matrix decomposition, and

(iii) that related to leucocyte infiltration.

Specific examples of (i) above include an alteration in the level of de novo arachidonic acid biosynthesis, an alteration in the level of expression of a gene involved in arachidonic acid biosynthesis or activity, and an alteration in the level of activity of an enzyme involved in arachidonic acid synthesis.

Specific examples of (ii) above include an alteration in the level of extracellular matrix decomposition, an alteration in the level of expression of a gene involved in extracellular matrix decomposition, and an alteration in the activity of an enzyme involved in extracellular matrix decomposition.

Specific examples of (iii) above include an alteration in the leucocyte infiltration number, an alteration in the level of expression of a gene involved in leucocyte infiltration, and an alteration in the activity of a chemokine involved in leucocyte infiltration.

Furthermore, in accordance with the screening method of this embodiment, it becomes possible to carry out screening for a macrolide compound useful for, for example, an inflammatory disease of the lung.

Examples of the inflammatory disease of the lung include pulmonary emphysema (COPD), bronchitis, pulmonary fibrosis, acute lung injury, viral pneumonia, bacterial pneumonia, and acute respiratory disease syndrome (ARDS).

In such lung diseases, examples of compounds involved in the inflammation include those described in Categories 1 to 3 below.

Category 1: In inflammatory disease of the lung, decomposition of extracellular matrix forming lung tissue is important, and a compound that controls (decreases) expression or activity thereof can become a therapeutic drug. Category 1 relates to such compounds, and specific examples thereof include serine or cystein proteinase inhibitor (SERPINB3), which is present in the living body. In particular, SERPINB3 localizes in the lung, inhibits the activity of a cathepsin, which is activated by an inflammatory reaction, and suppresses the inflammatory action. As described in Examples below, clarithromycin (CAM) has an effect of enhancing the expression of a SERPINB3 gene.

Category 2: In inflammatory disease of the lung, decomposition of extracellular matrix forming lung tissue is important, and a compound that controls (decreases) expression or activity thereof can become a therapeutic drug. Category 2 relates to such compounds, and specific examples thereof include MMP12, MMP9, MMP19, cathepsin K, and cathepsin C. These compounds are proteinases that are important in lung inflammation. As described in Examples below, CAM suppresses the expression of these proteinase genes, which are induced during inflammatory stimulation.

Category 3: In inflammatory disease of the lung, infiltration of leucocytes (T cells, macrophages, neutrophils, etc.) into lung tissue is important in making sickness chronic and more virulent. Category 3 is a group of chemokines that promote leucocyte infiltration. As described in Examples below, CAM suppresses expression of the chemokine gene, which is induced during inflammatory stimulation. Because of this, it is useful as a therapeutic drug for suppressing leucocyte infiltration.

In the screening method of this embodiment, detecting an alteration, due to contact with a macrolide compound, in the level of expression or the activity of a target molecule involved in inflammation in the lung enables the action of the macrolide compound on the lung inflammatory action to be reliably evaluated and a macrolide compound that alters the level of expression or the activity of the target molecule to be identified. Because of this, it is possible to select a macrolide compound having an anti-inflammatory action as a material that is useful as a therapeutic drug.

Furthermore, with regard to the above-mentioned (i), using microarray-based expression analysis, we have shown that macrolide treatment of lung epithelial cell lines alters expression of multiple components in the pathway leading to arachidonate, prostaglandin, and leukotriene production. Delta 5 and delta 6 desaturases are responsible for generation of arachidonate from linoleic acid in the diet. Arachidonate is then incorporated into phospholipids. Upon stimulation (e.g., by interleukin 1), arachidonate is cleaved from phospholipid by phospholipase A2 (PLA2) and then undergoes further reactions to generate bioactive lipids, i.e., prostaglandins and leukotrienes. Delta 5 desaturase (FADS1) is consistently upregulated in A549 epithelial cells treated with immune-active, but not inactive, macrolides. In addition to FADS1, active macrolides specifically alter expression of genes encoding PLA2, PGE synthase, and PGE2 receptors. The pathway leading from arachidonate to generation of prostaglandins is highly validated as a therapeutic target for anti-inflammatory drugs, such as aspirin, inhibiting cyclo-oxygenases (COX1 and COX2).

Macrolides have been used clinically, and have demonstrated anti-inflammatory activity with few serious side effects, suggesting that other macrolides identified on the basis of arachidonic acid inhibition will also be safe.

Screening Methods

The invention provides methods of identifying macrolides having anti-inflammatory activity. Methods of the invention can be used to develop macrolides with improved activity and increased efficacy to suppress inflammation, or alternatively to identify new structures with desirable properties.

Examples of the first and second biological samples used in screening include cells and cell extracts.

Contacting these biological samples with a macrolide compound may be carried out in vitro or may be carried out in vivo. It may be carried out in a cell culture. Examples of the cell culture here include an epithelial cell line such as A549 and a macrophage cell line such as THP-1.

The case of the above-mentioned (i), that is, the case in which the target molecule is arachidonic acid or a material involved in arachidonic acid biosynthesis, is explained below as an example, and when carrying out measurement with respect to the above-mentioned other target molecules, screening can be carried out in accordance with the method as in the case of (i).

In the case of the above-mentioned (i) related to arachidonic acid biosynthesis, specifically, methods of the embodiment involve assaying whether a test macrolide alters biosynthesis of arachidonic acid, alters the expression or activities of enzymes involved in the biosynthesis or activation of arachidonic acid (e.g., arachidonic acid CoA synthetase, delta-6 desaturase, fatty acid elongase, and delta-5 desaturase, AA-related genes in Tables 2 and 3), or alters the expression of genes identified as predictive for the anti-inflammatory macrolide effect (Appendix E). Assays in which arachidonic acid or gene expression or enzymatic activity is detected can be carried out after contacting a cell with a test macrolide. Any cell line that secretes prostaglandin or produces arachidonic acid can be used. Epithelial and macrophages lines (e.g., A549 or THP-1) are suitable for this purpose; other cell lines can be identified by carrying out assays such as those described in the specific Examples, below. Alternatively, screening assays can be carried out after adding a test macrolide to an in vitro cell system (e.g., a cellular extract or liver microsome preparation) or an in vitro enzyme assay system.

Furthermore, in the case of the above-mentioned (ii) related to extracellular matrix decomposition, the following can be selected as macrolide compounds.

Those that decrease the level of extracellular matrix decomposition;

those that increase the level of expression of a gene involved in extracellular matrix decomposition, such as serine proteinase inhibitor, clade B (ovalbumin), and member 3 (SERPINB3) (Appendix F);

those that decrease the level of expression of a gene involved in extracellular matrix decomposition, such as matrix metalloproteinase 12 (MMP12), matrix metalloproteinase 19 (MMP19), matrix metalloproteinase 9 (MMP9), cathepsin C, and cathepsin K (Appendix F);

those that increase the activity of an enzyme involved in extracellular matrix decomposition, such as serine proteinase inhibitor, clade B (ovalbumin), and member 3 (SERPINB3); or

those that decrease the activity of an enzyme involved in extracellular matrix decomposition, such as matrix metalloproteinase 12 (MMP12), matrix metalloproteinase 19 (MMP19), matrix metalloproteinase 9 (MMP9), cathepsin C, and cathepsin K.

In the case of the above-mentioned (iii) related to leucocyte infiltration, the following can be selected as macrolide compounds.

Those that decrease the leucocyte infiltration number;

with regard to chemokines such as small inducible cytokine subfamily A (Cys-Cys) member 18 (CCL18), small inducible cytokine subfamily B (Cys-X-Cys) member 10 (CXCL10), small inducible cytokine subfamily B (Cys-X-Cys) member 11 (CXCL11), and small inducible cytokine subfamily B (Cys-X-Cys) member 9 (CXCL9), those that decrease the level of expression of a gene involved in leucocyte infiltration (Appendix F); or

with regard to chemokines such as small inducible cytokine subfamily A (Cys-Cys) member 18 (CCL18), small inducible cytokine subfamily B (Cys-X-Cys) member 10 (CXCL10), small inducible cytokine subfamily B (Cys-X-Cys) member 11 (CXCL11), and small inducible cytokine subfamily B (Cys-X-Cys) member 9 (CXCL9), those that decrease the activity of a chemokine involved in leucocyte infiltration.

Test Macrolides

“Test macrolides” according to the invention include any macrolide desired to be tested for potential anti-inflammatory activity. Test macrolides may or may not be known to have anti-bacterial or other activities. Macrolides known to have anti-inflammatory activity can be screened in methods of the invention, for example to screen such macrolides for relative potency. Screening methods of the invention also can be used to assess relative potency after modification of test macrolides.

Preferred test macrolides have 14- or 15-member lactone rings and can be natural products or semi-synthetic derivatives thereof. Representatives of macrolides having 14-member lactone rings are the erythromycins, produced from Streptomyces erythreus, such as erythromycin A, erythromycin B, erythromycin C, erythromycin D, erythromycin E, erythromycin estolate, erythronolid, and clarithromycin. Other examples of macrolide antibiotics with 14-member lactone rings include megalomycin and its derivatives, picromycin, narbomycin, oleandomycin, triacetyl-oleandomycin; and the neutral compounds laukamycin, kujimycin A, albocyclin, and cineromycin B. Examples of macrolides having 15-member lactone rings include azalides, such as azithromycin.

Test macrolides can be synthesized using methods well known in the art. Methods of synthesizing macrolides are disclosed, for example, in U.S. Pat. Nos. 4,921,978; 4,933,474; 4,963,582; 5,023,348; 5,034,542; 5,116,968; and 6,100,239.

Typically, a test macrolide identified as a potential anti-inflammatory agent either (1) increases or decreases biosynthesis of arachidonic acid intermediates or products by at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, or 200% or more, (2) alters (i.e., increases or decreases) expression of a gene in the arachidonic acid biosynthesis pathway by at least 1.3-fold as determined by methods described in the specific examples, below, or (3) alters (i.e., increases or decreases) enzymatic activity of an enzyme in the arachidonic acid biosynthesis pathway by at least 10, 30, 40, 50, 60, 70, 80, 90, 100, 150, or 200% or more.

Assays for Decreased Arachidonic Acid Production

Quantitative in vitro or in vivo assays can be used to determine whether arachidonic acid production decreases in response to a test macrolide, e.g., by measuring a decrease in radiolabeled arachidonic acid or measuring an increase or decrease of radiolabeled precursors, as is known in the art. Free arachidonic acid can be measured, for example, as described in U.S. Pat. No. 5,663,053. Alternatively, liver microsomes can be incubated in the presence of radiolabeled linoleic acid or other precursor, and the production of labeled arachidonic acid can be detected, as is known in the art. Alternatively, incorporation of label into phospholipids containing arachidonic acid could be measured. See, e.g., Obukowicz et al., Biochem. Pharmacol. 55, 1045-58, 1998; Obukowicz et al., J. Pharm. Exptl. Ther. 287, 157-66, 1998. This type of assay can readily be adapted to high throughput screening (see below).

Determining Gene Expression

Either mRNA or protein can be detected to determine gene expression. mRNA can be detected a variety of methods well known in the art, including, but not limited to, RNA dot blots, slot blots, Northern blots, RT-PCR (including TaqMan RT-PCR), SAGE (serial analysis of gene expression), and electrochemical detection of nucleic acid hybridization (e.g., U.S. Pat. No. 6,361,951). See also US 20030096782; Liang & Pardee, Science 257, 967, 1992; Higuchi et al., BioTechnology 10, 413-17, 1992, and Higuchi et al., BioTechnology 11, 1026-30, 1993; Holland et al., Proc. Natl. Acad. Sci. U.S.A. 88, 7276-80, 1991; Heid et al., Genome Res. 6, 986-94, 1996; and Gibson et al., Genome Res. 6, 995-1001, 1996. Alternatively, mRNA products can be identified by contacting RNA with one or more oligonucleotide or cDNA probes unique to the FADS1, FADS2, or fatty acid (elongase) gene, either in solution or immobilized on a solid support, such as a membrane or a gene expression “chip.” Such chips can be purchased commercially (e.g., from Affymetrix or Motorola) or can be custom made.

Protein can be detected using a variety of techniques known to the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, protein synthesis can be determined in vivo, in a cell culture, or in an in vitro translation system by detecting incorporation of labeled amino acids into protein products.

Measuring Individual Enzyme Activity

Various assays are available to measure the activities of delta-6 desaturase (FADS2), fatty acid elongase, delta-5 desaturase (FADS1), and arachidonyl CoA synthetase. For delta-6 desaturase, these include, but are not limited to, assays described in U.S. Pat. No. 6,492,108 and references disclosed therein. For fatty acid elongase, assays include those described in Chang et al., J. Nutr. 122, 2074-80, 1992; U.S. Pat. No. 6,307,128; and US 20030104596. For FADS1 enzyme activity, assays include those described in de Gomez Dumm et al., Lipids 18, 781-88, 1983; Leikin & Brenner, Biochim. Biophys. Acta 963, 311-19, 1988; Chanussot et al., Diabetolgia 32, 786-91, 1989; Venkatesan et al., Biomed. Chromatography 4, 234-38, 1990; Maniongul et al., Lipids 28, 291-97, 1993; Su & Brenna, Anal. Biochem. 261, 43-50, 1998; Leonard et al., Biochem. J. 347, 719-24, 2000; Nishida et al., J. Pineal Res. 32, 26-33, 2002. Obukowicz et al., J. Pharm. Exptl. Ther. 287, 157-66, 1998, describes quantitative in vitro or in vivo assays for both delta-6 and delta-5 desaturase activities. See also Obukowicz et al., Biochem. Pharmacol. 55, 1045-58, 1998. Arachidonyl CoA synthetase activity can be measured as described, for example, in Bhat & Block, Am. J. Physiol. 262, L606-13, 1992; Beaumelle & Vial, Biochim. Biophys. Acta 958, 1-9, 1988; or Gerritsen & Perry, Biochim. Biophys. Acta 1045, 174-79, 1990.

Measuring Level of Extracellular Matrix Decomposition

An inflammatory substance (e.g. lipopolysaccharide, inflammatory cytokine, tobacco smoke, hydrochloric acid, anticancer agent) is pulmonarily or systemically administered to an animal. After administration of the inflammatory substance, lung lavage fluid or serum of an animal to which administration of the inflammatory substance has been carried out or has not been carried out is prepared. The amount of desmosine that is solubilized accompanying extracellular matrix decomposition is measured by the ELISA method (Laurent P et. al. J Immunol Methods. 1988 Feb. 24; 107(1): 1-11.)

Alternatively, the amount of solubilized hydroxyproline is measured in accordance with a standard method.

Measuring Leucocyte Infiltration Number

An inflammatory substance (e.g. lipopolysaccharide, inflammatory cytokine, tobacco smoke, hydrochloric acid, anticancer agent) is pulmonarily or systemically administered to an animal. After administration of the inflammatory substance, lung lavage fluid is recovered from a mouse to which administration of the inflammatory substance has been carried out or has not been carried out, and by counting the leucocyte infiltration number, the leucocyte infiltration number accompanying the inflammation can be measured.

Furthermore, after administration of the inflammatory substance, a lung pathological specimen is prepared from a mouse to which administration of the inflammatory substance has been carried out or has not been carried out, and by counting the number of cells that are stained by an antibody that recognizes leucocytes (e.g. MAC-1), the leucocyte infiltration number accompanying the inflammation can be measured.

Measuring Chemokine Activity

An inflammatory substance (e.g. lipopolysaccharide, inflammatory cytokine, tobacco smoke, chemical substance, anticancer agent) is pulmonarily or systemically administered to an animal. After administration of the inflammatory substance, a lung lavage fluid and a soluble fraction of lung lysate are prepared from an animal to which administration of the inflammatory substance has been carried out or has not been carried out. Alternatively, an inflammatory substance is added to cultured cells, and the cell supernatant is prepared to give a chemokine-containing liquid.

This chemokine-containing liquid is used to measure the activity of chemokine toward leucocytes by a Boyden chamber assay. Alternatively, the chemokine-containing liquid is contacted with highly chemokine receptor-expressing cells, and a transient increase in the intracellular Ca concentration is detected to give an activity.

High Throughput Screening

Using high throughput screening, many discrete test macrolides can be tested in parallel so that large numbers of test macrolides can be quickly screened. The most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500 μl. In addition to the plates, many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format. Alternatively, “free format assays,” or assays that have no physical barrier between samples, can be used. See, e.g., Jayawickreme et al., Proc. Natl. Acad. Sci. U.S.A. 19, 1614-18, 1994. Another high throughput screening method is described in Beutel et al., U.S. Pat. No. 5,976,813. In this method, test samples are placed in a porous matrix. One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support. When samples are introduced to the porous matrix they diffuse sufficiently slowly, such that the assays can be performed without the test samples running together.

All patents, patent applications, and references cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples, which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

EXAMPLE 1

Identification of Differentially Expressed Genes

Microarray experiments were carried out to identify genes that are differentially expressed in response to various immune stimuli in the presence or absence of macrolides. The data for each cell line (A549 and THP-1) are presented in Appendices A and B. For each cell line, the data for all of the hybridizations are represented together in the same table. For each hybridization, there are two columns: the weighted mean ratio (wtd mean ratio) and the minimum fold change (min fold change). The “min fold change” represents the minimum change in expression that meets the 95% confidence threshold. It can be estimated from the log ratio and standard deviation, assuming that the uncertainty in the ratio is normally distributed. Note that the minimum fold change can never be less than one (hence the minimum function). See also Cheng Li and Wing Hung Wong, “Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application,” Genome Biology 2001 2(8):research0032.1-0032.11 (published 3 Aug. 2001).

The analysis method to generate these tables was similar for A549 and THP-1, cells. All of the significance threshold criteria were set for the “min fold change” column, which ensured that the resulting genes would be differentially expressed by greater than the threshold value with 95% confidence (p value <0.05). The lowest significance threshold used was 1.3-fold, because it has been demonstrated that a 1.25-fold threshold has a false positive rate of less than 1 in 1000. It is important to note that the fold change threshold is an absolute number, and the direction of change (increased or decreased expression) must be determined by the looking at the weighted mean ratio. The significance threshold criteria are included in parentheses in each “min fold change” column. The weighted mean ratios representing significant differentials (95% confidence, p value <0.05) are in bold. The “Spot IDs” correspond to publicly available cDNA sequences for the region of the gene represented at that spot on the microarray chip.

For the A549 and THP-1 cell lines (Appendix A and B, respectively), the first table for each cell line (“total differentials”) represents all of the genes that show differential expression in at least one of the hybridizations. The second table for A549 and THP-1 cells (“drug effects, sum ≧4.5” and “drug effects, sum ≧5”, respectively) has an additional final column, “sum of min fold change.” This column represents the sum of the minimum fold changes for all of the groups except the stimulus alone. This column was used to rank the genes in order of the greatest global drug effect, independent of whether the drug used was Clarithromycin or FMA9045 and independent of stimulus effect. A sum min fold change of greater than or equal to 4.5 indicates that at least one of the four groups (Clari alone, FMA9045 alone, Clari+stimulus, FMA+stimulus) had a minimum fold change of at least 1.5.

For A549 cells, the tables of Appendix A include genes that met one or more of the following criteria: greater than 1.5-fold change for IL-1β stimulation and greater than 1.3-fold change for each of the drug groups. As noted above, a sum min fold change ≧4.5 was used as the threshold for ranking the most highly regulated drug effects. In both tables in Appendix A, the genes that meet this criterion (sum ≧4.5) are in bold, and those genes that are bold and italics are the most highly regulated genes and have a min fold change ≧5.0.

For THP-1 cells, the tables of Appendix B include genes that met one or more of the following criteria: greater than two-fold change for LPS stimulation, greater than 1.5-fold change for clarithromycin alone and for clarithromycin+/−LPS, and greater than 1.3-fold change for FMA9045 alone and for FMA9045+/−LPS. For THP-1 cells, a sum min fold change ≧5.0 was used as the threshold for ranking the most highly regulated drug effects. In both tables in Appendix B, the genes that meet this criterion (sum ≧5) are in bold and in italics. A larger sum min fold change threshold was used for THP-1 cells, because the macrolide response in this cell line was more robust than that in A549 cells.

Results Overview

The global transcription response to the various culture conditions is shown in Table 1, below. The min fold change threshold (noted next to each condition) was used to determine the total number of significant differentially expressed genes (95% confidence).

TABLE 1
		Min fold	Total # Differential
		change	Genes
Cell line	Condition	threshold	(95% confidence)
A549	+/−IL-1β	1.5	185
	+/−Clari	1.3	117
	+/−FMA	1.3	20
	IL-1 +/− Clari	1.3	127
	IL-1 +/− FMA	1.3	16
THP-1	+/−LPS	2.0	223
	+/−Clari	1.5	127
	+/−FMA	1.3	22
	LPS +/− Clari	1.5	120
	LPS +/− FMA	1.3	25

The results of the microarray experiments in the A549 cell line reveal that a large number of genes (>175) are regulated in response to IL-1β stimulation. Similarly, in the THP-1 macrophage line, a large group of genes (>200) are regulated in response to LPS stimulation. While these numbers of differentially expressed genes are similar, it is important to note that the min fold change threshold was set lower for the IL-1, stimulus response in A549 cells (1.5), as compared to a threshold of 2.0 for the LPS stimulus response in THP-1 cells. This is because the transcriptional response to stimulus was larger in THP-1 cells than in A549 cells.

In cells treated with clarithromycin alone, a similar number of genes were differentially expressed in each cell line (117 genes in A549 cells and 127 genes in THP-1 cells). In cells treated with stimulus (IL-1β or LPS)+clarithromycin, the number of differentially expressed genes also was similar (127 genes in A549 and 120 genes in THP-1). As with the stimulus alone condition, however, the min fold change threshold was set lower for the A549 cells for both the clarithromycin alone and the stimulus+/−clarithromycin conditions (1.3 for A549 versus 1.5 for THP-1). Again, this is because the global transcription response was not as robust in the A549 cells as it was in the THP-1 cells.

In both A549 and THP-1 cells, the response to FMA9045 treatment was much weaker than the response to Clarithromycin. In cells treated with FMA9045 alone, a similar number of genes were differentially expressed in both cell lines (20 genes in A549 cells and 22 genes in THP-1 cells). In response to stimulus (IL-1β or LPS)+FMA9045, 16 genes were differentially expressed in A549 cells, and 25 genes were differentially expressed in THP-1 cells. In contrast to the stimulus alone and the Clarithromycin conditions, the min fold change threshold was set at 1.3 for both A549 and THP-1 cells, because the overall response to FMA9045 was relatively weak.

EXAMPLE 2

Functions Associated with Macrolide Target Genes

Genes that were differentially expressed in one or more of the macrolide treatment groups were categorized into several groups, as shown in Tables 2 and 3. A selection of representative genes is included under each category, with the full number of differentially expressed genes in each category in parentheses next to the category name. Similar patterns were apparent in both the A549 and THP-1 cell lines, although the particular genes in each category were often different. The macrolide-regulated genes considered for these tables are from the “drug effects” tables in Appendices A and B. As discussed in Example 1, genes in these tables were ranked in order of their sum min fold change, and only the most highly regulated genes that were above a certain threshold were included. For THP-1 cells, genes that had a sum min fold change above 5.0 were included, whereas for A549 cells, genes that had a sum min fold change above 4.5 were included.

In THP-1 cells (Table 2), the largest number of responsive genes were those encoding the cytokines and chemokines (27 total). Interestingly, a large number of genes fell into the global category of tissue/matrix remodeling (30 total). Genes in this category included many protease-related genes (matrix metalloproteinases, thrombin-related genes), as well as structural/matrix genes (fibronectin and collagen) and EGF-related genes. Importantly, the expression of the matrix metalloproteinases was (in most cases) decreased in the presence of stimulus plus macrolide (compared to stimulus alone), while the expression of the metalloproteinase inhibitor TIMP2 was increased in the same treatment group, suggesting coordinate regulation. The signaling cascade of phospholipase A2 to prostaglandin E-related genes (arachidonic acid-related signaling) was another notable set of differentially expressed genes. In this case, PTGS2 and PLA2G4A showed increased expression in response to stimulus and then an additional increase in expression in response to stimulus plus macrolide.

TABLE 2
Macrolide Responsive Genes in THP1 Macrophage Cells (sum >5.0)
General Function/
Pathway (total gene #)	Gene	Gene Description
Tissue/Matrix
remodeling (30)
Structural/matrix (9)	FN1	Fibronectin
	*CTGF	Connective tissue growth factor
	Col7A1	Collagen type 7, alpha 1
	*PLOD	Lysyl hydroxylase
Protease-related (15)	*MMP3	Matrix metalloproteinase 3
	MMP7	Matrix metalloproteinase 7
	*MMP10	Matrix metalloproteinase 10
	TIMP2	Metalloprotease inhibitor 2
	*PLAU	Plasminogen activator, urokinase
	*F2	Thrombin
	*THBS1	Thrombospondin
	THBD	Thrombomodulin
EGF-related (6)	*AREG	Amphiregulin
	*NRG1	Neuregulin
	*DTR	HB-EGF
	*EREG	Epiregulin
	*FGF2	Fibroblast growth factor 2
	FGFR1	Fibroblast growth factor receptor
Arachidonic Acid-	*PTGS2	Cyclooxygenase 2
related sigenaling (3)	PTGER4	Prostaglandin E receptor, EP4
	*PLA2G4A	Cytosolic phospholipase A2
GPCR-related	*RGS14 & 16	Regulators of G-protein
signaling (7)		signaling
	*GRIN2C	Subunit of NMDA receptor
	GNG11	G protein gamma subunit 11
	GNAS	G protein alpha subunit s
	ADCY7	Adenylate cyclase 7
Chemokine/Cytokine	*IL8	Interleukin 8
signaling (27)	*IL1β	Interleukin 1β
	ECSIT	TIR adaptor
	CD14	LPS binding protein
	*SCYA20	MIP3a
	*SCYA3	MIP1α
*LPS regulated	Genes responsive in both THP-1 and A549 cells

In A549 cells (Table 3), the global transcriptional response to the various treatment conditions was not as robust as that seen in THP-1 cells, but the differentially expressed genes were in similar categories to those seen in THP-1 cells. Similar to THP-1 cells, a large number of genes were in the global category of tissue/matrix remodeling (26 total). There was quite a bit of overlap in the differentially expressed tissue/matrix remodeling-related genes between A549 and THP-1 cells, including several protease-related genes (MMP7, TIMP2, THBS1), and multiple EGF ligands (AREG, EREG, NRG). Also similar to THP-1 cells, genes involved in arachidonic acid signaling were differentially expressed in A549 cells (including FADS1, PTGES, PTGER1, and PLA2G4B), although the specific genes did not overlap with the differentially expressed genes in THP-1 cells. Similar to the observation in THP-1 cells, these arachidonic acid-related genes were up-regulated in response to macrolide. Up-regulation of gene expression is a common signaling feedback response following inhibition of enzyme(s) activity in that signaling pathway.

TABLE 3
Macrolide Responsive Genes in A549 Epithelial Cells (sum >4.5)
General Function/
Pathway (total gene #)	Gene	Gene Description
Tissue/Matrix
remodeling (26)
Structural/matrix (12)	LAMC2	laminin
	P4HA2	Prolyl-hydroxylase alpha 2 subunit
	PLOD	Lysyl hydroxylase
	*CTGF	Connective tissue growth factor
	*Col4A2	Collagen type 4, alpha 2
Protease-related (10)	*MMP7	Matrix metalloproteinase 7
	TIMP2	Metalloprotease inhibitor 2
	*PLAU	Plasminogen activator, urokinase
	*PLAUR	Urokinase plasminogen
		activator rec.
	*SerpinE1	Plasminogen activator inhibitor
	THBS1	Thrombospondin
EGF-related (4)	*AREG	Amphiregulin
	*EREG	Epiregulin
	NRG1	Neuregulin
	FRAG1	FGF receptor activating protein 1
Arachidonic Acid-	FADS1	Fatty acid desaturase
related signaling (7)		(catalyzes AA production)
	*PTGES	Prostaglandin E synthase
	PTGER1	Prostaglandin E receptor, EP1
	PTGIR	Prostaglandin I2 receptor
	*PLA2G4B	Cytosolic phospholipase A2
	PLA2R1	Secretory phospholipase
		A2 receptor 1
GPCR-related	*BDKRB1	Bradykinin B1 receptor
signaling (4)	GNB5	G protein beta 5 subunit
	GPRK7	G-protein coupled receptor
		kinase 7
	*P2RY1	P2Y purinergic receptor
Chemokine/Cytokine	*IL-8	Interleukin 8
signaling (8)	*SCYA20	MIP3a
	ECSIT	TIR adaptor
	SARM	TIR domain
*IL-1β regulated	Genes responsive in both THP-1 and A549 cells

EXAMPLE 3

Macrolide-dependent changes in gene expression in THP-1 and A549 cell lines fall into several functional categories which are relevant to airway inflammation, including tissue/matrix remodeling and arachidonic acid metabolism. Previous microarray results suggested a number of possible target signaling pathways, including thrombin/PAR-1, TGFβ, bradykinin B2 receptor, PGE₂, and arachidonic acid (AA) biosynthesis/metabolism. Experiments were then designed to determine which of these pathways was most likely to be the actual signaling pathway targeted by macrolides. In addition, a microarray experiment was carried out with THP-1 macrophages to examine the effect of macrolides on a larger number of genes on multiple microarray slides. The microarray data demonstrated that thrombin, TGFβ, and PGE₂ signaling pathways were not likely the direct targets of macrolide activity, although TGF-β may be indirectly affected.

The data from the initial microarray experiments suggested that either the PGE₂ signaling pathway or the AA pathway might be a target of macrolides. The PGE₂ signaling pathway is downstream of AA metabolism, and cells respond to PGE₂ stimulation by changes in cAMP or Ca levels.

A number of genes involved in PGE₂ biosynthesis from AA (PLA₂, PGE synthase/PTGES), as well as the PGE receptor (PGER) EP1 and EP4 subtypes, were differentially expressed in response to macrolides, suggesting the PGE₂ pathway as a possible macrolide target. However, in preliminary experiments, neither A549 nor THP-1 cells showed PGE-dependent changes in cAMP levels. This data suggested that it was unlikely that macrolides were inhibiting PGER-dependent signaling if the cells were not responsive to PGE₂. An additional experiment demonstrated, however, that macrolide treatment caused a small, but reproducible, decrease in PGE₂ production, in response to IL-1β stimulation. This indicates that macrolides have a regulatory effect on the AA pathway.

The AA pathway can be split into AA biosynthesis and AA metabolism. In the biosynthetic portion of the pathway, AA is synthesized from lipid in the diet and incorporated into phospholipids. AA metabolism involves AA release from phospholipids, usually in response to immune stimulation, and subsequent generation of a variety of lipid products, including prostaglandins and leukotrienes.

FADS1 is a key enzyme in the biosynthesis of AA (FIG. 1), and FADS1 was differentially expressed in response to 50 μM clarithromycin in every A549 array experiment. These data suggest that the AA pathway might be the macrolide target pathway and FADS1 might be a molecular target of macrolides in lung epithelial cells.

Prostaglandins (including PGE₂) and leukotrienes are inflammatory modulators generated from AA. This pathway is attractive as a target of macrolide anti-inflammatory activity, because interference with this pathway is well validated therapeutically by inhibitors of COX1 and 2. In addition to prostaglandins and leukotrienes, other lipid products generated from AA include prostacyclins (from COX enzymes), thromboxanes (from COX), and HETEs (from 12- and 15-lipoxygenases).

To better understand the ability of macrolides to regulate the AA signaling pathway, a microarray experiment was carried in A549 cells to compare the transcriptional response of macrolides to that of several inhibitors of the AA pathway (FIG. 1). One inhibitor, triacsin C, acts on AA biosynthesis by inhibiting arachidonyl CoA synthetases, blocking the incorporation of free AA into phospholipids. Triacsin C is reasonably specific for AA compared to other fatty acids. However, triacsin C structurally resembles AA so it also may interfere with other steps in the AA pathway. Indomethacin is an inhibitor of COX1 and COX2 enzyme activities and therefore specifically blocks metabolism of AA into prostaglandins. Dexamethasone is a glucocorticoid and has the broadest effects of these inhibitors. It inhibits transcription of PLA₂, and transcriptionally and post-transcriptionally regulates COX1 and COX2 activities. Dexamethasone has additional effects unrelated to AA through binding with the glucocorticoid receptor to glucocortcoid response elements.

A549 cells were pre-incubated overnight (17 hours) with macrolides (10 μM FMA-9045, 50 μM clarithromycin, 50 μM roxithromycin, 50 μM josamycin) and 15 μM triacsin C, and pre-incubated 2 hours with 100 nM indomethacin and 100 nM dexamethasone. All cells then were stimulated for 4 hours with IL-1β, because the activation of PLA₂ and downstream signaling events generally requires an inflammatory stimulus. The various treatment conditions are shown below in Table 4. Following macrolide and inhibitor pre-treatment and IL-1 stimulation, the cells were lysed, total RNA was collected, and the poly-A+ mRNA fraction was purified. Competitive hybridizations to the microarray were performed as shown in Table 5. The resulting microarray data (Appendix C) were analyzed using the methods described in the Examples above.

TABLE 4
Cell treatments for A549 microarray experiment
	4 hr stim	O/N pre-incubation	2 hr	O/N	2 hr
Culture	IL1β	FMA	Clari	Josa	Roxi	Indo	TriacsinC	Dex
condition	(10 ng/ml)	(10 uM)	(50 uM)	(50 uM)	(50 uM)	(100 nM)	(15 uM)	(100 nM)
1	−	−	−	−	−	−	−	−
2	+	−	−	−	−	−	−	−
3	+	+	−	−	−	−	−	−
4	+	−	+	−	−	−	−	−
5	+	−	−	+	−	−	−	−
6	+	−	−	−	+	−	−	−
7	+	−	−	−	−	+	−	−
8	+	−	−	−	−	−	+	−
9	+	−	−	−	−	−	−	+
10	+	−	−	−	+	−	+	−
11	+	−	+	−	−	−	+	−

TABLE 5
Hybridizations for A549 microarray experiment
Treatment Conditions     Hybridization Outcome
Untreated vs. IL-1β      IL-1β effect (Inflammation)
IL1 vs. IL1 + FMA        FMA-9045 effect
IL1 vs. IL1 + Clari      Clarithromycin effect
IL1 vs. IL1 + Roxi       Roxithromycin effect
IL1 vs. IL1 + Josa       Josamycin effect
IL1 vs. IL1 + Indo       Indomethacin effect
IL1 vs. IL1 + Triacsin C Triacsin C effect
IL1 vs. IL1 + Dex        Dexamethasone effect
IL1 + Triacsin vs. IL1 + Triacsin effect on Clari response
Triacsin + Clari
IL1 + Triacsin vs. IL1 + Triacsin effect on Roxi response
Triacsin + Roxi

Results

The tables in Appendix C represent the effects of the arachidonic acid pathway inhibitors (“AA pathway inhibitors”) and the effects of the macrolides (“IL1+macrolide effects”). The first table (“AA pathway inhibitors”) represents genes that show differential expression (>1.3-fold) in response to at least one of the inhibitors. The second table (“all macrolides”) represents genes that show differential expression (>1.3-fold) in response to at least one of the macrolides. In both tables in Appendix C, the genes that meet this criterion (≧1.3 min fold change) are indicated in bold.

The global transcriptional response to the various culture conditions is shown in Table 6. The min fold change threshold was used to determine the total number of significant differentially expressed genes (95% confidence).

TABLE 6
Global transcriptional response
	Conc. of	Min fold	Total # Differential
	macrolide	change	Genes
Condition	(μM)	threshold	(95% confidence)
+/− IL-1β	—	2.0	102
IL1 + Clari	50	1.3	54
IL1 + Roxi	50	1.3	65
IL1 + FMA	10	1.3	65
IL1 + Josa	50	1.3	73
IL1 + Triacsin C	—	1.3	228
IL1 + Indomethacin	—	1.3	37
IL1 + Dexamethasone	—	1.3	341
IL1 + Triacsin + Clari	50	1.3	4
IL1 + Triacsin + Roxi	50	1.3	7

The main focus of the analysis was to look at the similarities between the response to AA pathway inhibitors and the response to macrolides. It was anticipated that there would be an overlap in the transcriptional responses if the macrolides and the AA pathway inhibitors were acting on the same pathway. In contrast, if macrolides act on a pathway other than the AA pathway, the response to macrolides and the response to the inhibitors should be dissimilar. Additionally, an inhibitor that acts further upstream in a signaling pathway might be expected to affect more genes than an inhibitor acting lower in the pathway.

Arachidonic Acid Biosynthetic Pathway Inhibitors

A small number of genes responded to indomethacin treatment (37), while a larger number of genes responded to triacsin C treatment (228). This is consistent with the idea that inhibitors acting upstream in a pathway will influence transcription of more genes than inhibitors of final steps in a pathway. Triacsin interferes with the biosynthetic portion of the AA pathway by inhibiting AA incorporation into phospholipids. Triascin may also affect other steps in the AA pathway due to its structural similarity to AA, but this has not been demonstrated. Indomethacin inhibits AA metabolism induced by various stimuli by blocking COX enzyme activity, and thus PGE₂ production. Dexamethasone affects multiple steps in the AA pathway as well as other unrelated pathways. The number of genes responding to dexamethasone was quite large (341), as predicted based on the multiple transcriptional targets of glucocorticoid receptors.

Many genes were differentially regulated in response to more than one of the AA pathway inhibitors. The overlap of the responses is shown in a Venn diagram, in which numbers represent genes similarly regulated by the corresponding treatments (FIG. 2A). As shown in FIG. 2, there are 20 genes that are differentially regulated by all three AA pathway inhibitors (triacsin C, indomethacin, and dexamethasone). These 20 genes can be considered the core transcriptional response to manipulation of the AA pathway.

Looking at overlap between pairs of inhibitors, the indomethacin-dependent response is almost entirely a subset of the triacsin C response: 37 genes were differentially expressed in response to indomethacin, and 36 of these 37 genes were differentially expressed in response to both triacsin C and indomethacin. This is not unexpected, considering the known mechanism of action of these inhibitors. Indomethacin inhibits COX1 and COX2, and therefore acts downstream of triacsin C on the AA biosynthetic pathway (FIG. 1). It could be anticipated that the indomethacin response would be a subset of the response to triacsin C, and this is what was observed. Indomethacin specifically affects production of prostaglandins, but triacsin C inhibits AA incorporation into phospholipids, affecting production of other lipid products (i.e., leukotrienes, prostacyclins). This interference upstream of branchpoints in the AA pathway leading to lipid products other than PGE₂ by triascin C leads to further changes in transcription not seen with indomethacin.

In contrast to the strong overlap between triacsin C and indometbacin, the overlap between the response to dexamethasone and the response to triacsin C and indomethacin is smaller. Some overlap was expected, because dexamethasone does affect the AA pathway. However, dexamethasone is a more general inhibitor, affecting pathways other than the AA pathway, so there are also many other genes affected by dexamethasone presumably through other pathways.

Quantitative analysis was done to determine how well the responses to the different AA pathway inhibitors correlated. The correlation values were assigned a p-value to provide statistical confidence to the correlation value. Correlation between experiments, across all spots showing good detection, was assessed by cosine vector angle to generate the data shown in Tables 7-9. A correlation coefficient close to one indicates strong correlation, whereas a value near zero indicates no correlation. P-values for each correlation coefficient were estimated based on a Fisher permutation test. In this test, each spot's expression ratios were randomly re-ordered across experiments and the degree of correlation between experiments was then reassessed. This was done repeatedly. The p-value is the fraction of these random reorderings that result in a larger cosine vector angle than was observed for the unpermuted data. This method of assessing significance was the most conservative of several that were tested. Using Pearson correlation coefficient instead of cosine vector angle also gave equivalent results.

This analysis further supports the conclusions drawn from the amount of gene overlap between the different responses. The dexamethasone response is not strongly correlated with the response to either triacsin C (0.196, p-value 0.1) or indomethacin (0.266, p-value 0.009), reflecting its additional transcriptional targets outside the AA pathway. In contrast, the AA pathway inhibitors triacsin C and indomethacin show a significant correlation (0.485, p-value <0.001), consistent with their shared effect on PGE₂ biosynthesis. A related analysis, which only used the subset of genes differentially expressed in response to triacsin C for the correlation assessment, showed an even stronger correlation between triacsin C and indomethacin (0.621, p-value 0.1), while the correlation with the dexamethasone response was still low and was not significant (0.281, p-value 1.0).

TABLE 7
Similarity and significance of AA pathway inhibitor responses
(all spots) Values in boldface represent the correlations and
p-values of interest (the other numbers represent inhibitors
correlated with themselves or duplicate correlations).
Correlation coefficients are shown, with p-values for the
correlation coefficient in parentheses. A p-value of
1.00 means that the correlation is not significant.
	IL-1β	Dexamethasone	Triacsin C	Indomethacin
Dexamethasone	−0.608	Not applicable	0.196	0.266
	(1.000)		(0.103)	(0.009)
Triacsin C	−0.035	0.196	Not	0.485
	(1.000)	(0.103)	applicable	(<0.001)
Indomethacin	−0.195	0.266	0.485	Not applicable
	(1.000)	(0.009)	(<0.001)

Overlap Between Macrolide Responses

The genes differentially expressed in the presence of clarithromycin, FMA-9045, and roxithromycin overlapped moderately (FIG. 2B), as observed in previous experiments. It is not surprising that the responses to the active macrolides diverge somewhat. While there is much existing literature reporting that both clarithromycin and roxithromycin have anti-inflammatory activity in vivo, their anti-inflammatory efficacy varies in relation to each other, depending on the report. However, because our experiments have shown that the global response to these active macrolides can be represented by the same functional gene classes, it is expected that these 14-member macrolides are acting by a similar mechanism.

In this experiment, the transcriptional response to the active macrolides (clarithromycin and roxithromycin) also overlapped with the transcriptional response to josamycin (see Venn diagram, FIG. 2C). Josamycin is a 16-member macrolide and has not been reported to have anti-inflammatory activity. However, due to the related structure of the 14- and 16-member macrolides, it is not unexpected that the transcriptional response to josamycin would overlap somewhat with the response to the active macrolides. It may be that the overlapping response between josamycin and the actives represents a basic response to the macrolide class, but that the transcriptional responses that are unique to the active macrolides represent the genes or pathways involved in the specific 14-member macrolide anti-inflammatory activity. Importantly, FADS1 was differentially expressed in response to active macrolides (clarithromycin and roxithromycin) but not in response to josamycin.

As with the AA pathway inhibitors, the correlation analysis of the different macrolides (Table 8) reinforces the observed overlapping gene response. All the macrolides are well correlated with one another, and these correlation coefficients are statistically highly significant (p-values <0.001).

TABLE 8
Similarity and significance of macrolide responses (all spots)
	IL-1β	Clari	FMA	Roxi	Josa
Clari	−0.059	Not	0.430	0.683	0.601
	(1.000)	applicable	(0.000)	(0.000)	(0.000)
FMA	−0.154	0.430	Not	0.658	0.660
	(1.000)	(<0.001)	applicable	(0.000)	(0.000)
Roxi	−0.049	0.683	0.658	Not	0.721
	(1.000)	(<0.001)	(<0.001)	applicable	(0.000)
Josa	0.060	0.601	0.660	0.721	Not
	(0.967)	(<0.001)	(<0.001)	(<0.001)	applicable

Overlap Between Pathway Inhibitors and Macrolide Responses

An experiment was carried out to address whether macrolides affect the arachidonic acid pathway. The similarity or dissimilarity of macrolide and AA pathway inhibitor transcriptional profiles should reflect the degree to which they have similar effects on the pathway. The results support the hypothesis that macrolides inhibit the AA pathway.

The transcriptional response to clarithromycin and roxithromycin overlapped significantly with the response to triacsin C and indomethacin (FIGS. 2D and 2E). There is a larger overlap between macrolides and triacsin C than between macrolides and indomethacin. Forty-two of the 54 genes differentially expressed in response to clarithromycin were also differential in response to triacsin C, but only 25 clarithromycin-regulated genes also were differentially expressed in response to indomethacin (FIG. 2F). Triacsin C acts on AA biosynthesis, by inhibiting incorporation of AA into phospholipids. The target of triacsin C is one step downstream of FADS1 (FIG. 1), the proposed target of macrolides. Indomethacin is further downstream on the AA pathway, inhibiting COX enzymes in the stimulus-dependent metabolism part of the AA pathway. If the macrolide mechanism of action is similar to indomethacin (i.e., COX inhibition) the responses to macrolide are predicted to resemble the indomethacin response. However, the macrolide response is actually more similar to the triacsin C effect. Further, FADS1 expression is induced by treatment with either macrolide or triacsin C and not by indomethacin or dexamethasone. The significant overlap between macrolides and triacsin C, as well as the similar regulation of FADS1 expression, tends to support the idea that the target of macrolides is at, or upstream from, the step inhibited by triacsin C, and is acting on AA biosynthesis.

The quantitative analysis of the correlations between the response to active macrolides and the response to AA pathway inhibitors (Table 9) demonstrates that responses to all 3 active macrolides are significantly correlated with those to both triacsin C and indomethacin. Responses to clarithromycin and roxithromycin are most highly correlated with the triacsin C response. The effects of macrolides on epithelial cells are most similar to those of triacsin C and indomethacin, inhibitors targeting the AA pathway, supporting the hypothesis that the AA pathway is a likely macrolide target.

TABLE 9
Similarity and significance of macrolide and
AA pathway inhibitor responses
	IL-1β	Dexamethasone	Triacsin C	Indomethacin
Clari	−0.059	0.162	0.607	0.553
	(1.000)	(0.295)	(<0.001)	(<0.001)
FMA	−0.154	0.269	0.552	0.588
	(1.000)	(0.008)	(<0.001)	(<0.001)
Roxi	−0.049	0.188	0.681	0.639
	(1.000)	(0.137)	(<0.001)	(<0.001)

A similar analysis was performed using only the subset of genes differentially expressed in response to clarithromycin for the correlation assessment. The subset analysis demonstrates that clarithromycin-induced responses are significantly correlated with triacsin C (0.916, p-value 0.001). The correlation of clarithromycin with indomethacin for this subset of genes was less significant (0.848, p-value 0.07), and little correlation was observed with dexamethasone (0.430, p-value 1.0).

Effect of Triacsin C on Macrolide Response

If it is true that macrolides act on the AA pathway, then chemically inhibiting the pathway is expected to block the effects of macrolides on AA-related gene expression. For example, if the macrolide target is FADS1, then inhibition of AA biosynthesis with triascin should result in a similar gene expression profile with or without the addition of macrolide. This is true because FADS1 is upstream of the step blocked by triascin. The ability of macrolides to alter gene expression in the presence of triascin was tested directly by competitive hybridization of IL1+Triacsin vs. IL1+Triacsin+Clari/Roxi (Table 7, mRNA from culture conditions 8 v. 10 or 11). It is important to remember that results of direct competitive hybridizations are a ratio of gene expression changes from one group versus changes from the other group—i.e., a 10-fold increase in gene X in both IL1+Triacsin and IL1+Triacsin+Clari would result in no observed change in the gene expression ratio (ratio=1) when those groups were compared in a direct competitive hybridization.

There were two possible outcomes from these two final hybridizations. Outcome #1 would be that triacsin C and macrolides act on different signaling pathways. In this case, the AA pathway inhibitor and macrolides would have different effects on transcription and the transcriptional response should resemble the response to macrolide alone, because the IL1+Triacsin in both groups would effectively cancel out the response to triacsin.

Outcome #1: IL1+Triacsin/IL1+Triacsin+ML=ML

A second possibility, Outcome #2, would be that the AA pathway inhibitor (triacsin C) and macrolides are acting on the same signaling pathway. In this case, the transcriptional response to IL1+Triacsin+macrolide would resemble the response to IL1+Triacsin alone, because the macrolide effect would be blocked by or overlap the triacsin effect. The overall observed response to the direct competitive hybridization in Outcome #2 would be no transcriptional changes, since the ratio of IL1+Triacsin vs. IL1+Triacsin+macrolide (resembling triacsin alone) would be 1.

In the hybridization of IL1+Triacsin vs. IL1+Triacsin+Clari, there are only 4 differentially expressed genes across the 2 conditions, in contrast to 54 differentially expressed genes in the comparison of IL1 alone to IL1+clarithromycin (Table 7, culture conditions 2 vs. 4). In a similar direct competitive hybridization between IL1+Triacsin and IL1+Triacsin+Roxi, there were only 7 differentially expressed genes (Table 7, conditions 8 v. 10), compared to 65 differentially expressed genes in response to roxithromycin in the absence of triascin (conditions 2 v. 6).

The results of these hybridization experiments are compelling. The macrolide effect is blocked by, or is overlapping, the triacsin C effect. The minimal change in gene expression in these direct competitive hybridizations corresponds to outcome #2. These data imply that triacsin C blocks the macrolide effect or that the two effects are nearly identical, and strongly support the hypothesis that the AA pathway is a target of macrolides. These results further suggest that the molecular target is likely to be upstream of triacsin C in the biosynthetic pathway, which is comprised of just four possible target enzymes and includes FADS1.

FADS1 Antisense and Inhibitor Microarray Experiment

FADS1, also known as Δ5 desaturase, is the enzyme responsible for conversion of dihomo-gamma-linolenic acid (DGLA) to AA. The related gene FADS2 is A6 desaturase, and is responsible for an earlier step in the biosynthesis of AA—the conversion of linoleic acid (from the diet) to gamma-linolenic acid (GLA). The function of a third related gene, FADS3, is unclear, however it is believed to be more closely related to FADS2 than FADS1.

Experiments in which A549 cells are exposed to a compound reported to be a specific inhibitor of FADS1 activity reduced expression of PGE₂ production, as determined by competitive enzyme immunoassay (FIG. 3A). This reduction in PGE₂ has been observed in response to macrolide treatment (FIG. 3B), and further supports the possibility that the specific macrolide target in the AA biosynthetic pathway is FADS1.

To specifically address whether macrolides were specifically targeting the FADS1 enzyme of the arachidonic acid biosynthesis pathway, a microarray experiment was carried out in A549 cells to compare the transcriptional response of macrolides to that of an inhibitor reported to be specific for FADS1 (CP-74006) and to the response of FADS1 mRNA knock-down by antisense oligonucleotides.

A549 cells were transfected with 2 different pairs of FADS1 antisense/reverse control oligonucleotides and incubated for 48 hours. Cells then were pre-incubated overnight (17 hours) with macrolides (50 μM clarithromycin, 50 μM roxithromycin), and 10 μM CP-74006. All cells then were stimulated for 4 hours with IL-1β, because the activation of PLA₂ and downstream signaling events generally requires an inflammatory stimulus. The various treatment conditions are shown below in Table 10. Following macrolide and inhibitor pre-treatment and IL-1β stimulation, the cells were lysed, total RNA was collected, and the poly-A+ mRNA fraction was purified. Competitive hybridizations to the microarray were performed as shown in Table 11. The resulting microarray data was analyzed using the methods described in the Examples above. The transcriptional response to CP74006 (FADS1 inhibitor) is in Appendix D.

The table in Appendix D represents the effects of the FADS1 inhibitor in the absence and presence of macrolides, and represents genes that show differential expression (>1.3-fold) in response to at least one of the conditions. The genes that meet this criterion (≧1.3 min fold change) are indicated in bold.

TABLE 10
Treatments for antisense, FADS1 inhibitor microarray experiment
								FADS1
Culture				AS	RC			(CP-
Con-		AS	RC	262-	262-	Clari	Roxi	74006)
dition	IL1β	262-6	262-6	12	12	(50 μM)	(50 μM)	(10 μM)
1	−	−	−	−	−	−	−	−
2	+	−	−	−	−	−	−	−
3	+	+	−	−	−	−	−	−
4	+	−	+	−	−	−	−	−
5	+	−	−	+	−	−	−	−
6	+	−	−	−	+	−	−	−
7	+	+	−	−	−	+	−	−
8	+	−	+	−	−	+	−	−
9	+	−	−	+	−	+	−	−
10	+	−	−	−	+	+	−	−
11	+	−	−	−	−	+	−	−
12	+	−	−	−	−	−	+	−
13	+	−	−	−	−	−	−	+
14	+	−	−	−	−	+	−	+
15	+	−	−	−	−	−	+	+

TABLE 11
Hybridizations for antisense, FADS1 inhibitor microarray experiment
Treatment Conditions          Hybridization Outcome
Untreated vs. IL-1β           IL-1β effect (Inflammation)
IL1 vs. IL1 + Clari           Clarithromycin effect
IL1 vs. IL1 + Roxi            Roxithromycin effect
IL1 vs. IL1 + FADS1 inhibitor FADS1 inhibitor effect
IL1 + FADS1 inh vs. IL1 +     Clan effect in presence of FADS1 inhib
FADS1 inh + Clari
IL1 + FADS1 inh vs. IL1 +     Roxi effect in presence of FADS1 inhib
FADS1 inh + Roxi
RC-6 vs. RC-6 + Clari         Clari effect w/RC background
RC-12 vs. RC-12 + Clari       Clari effect w/RC background
AS-6 vs. RC-6                 Antisense 6 effect
AS-12 vs. RC-12               Antisense 12 effect
AS-6 vs. AS-6 + Clari         Clari effect in presence of KO
AS-12 vs. AS-12 + Clari       Clari effect in presence of KO

Quantitative analysis was done to determine how well the response to the FADS1 inhibitor correlated with the macrolide response and with the responses to the other inhibitors of the arachidonic acid pathway (triacsin C and indomethacin). The macrolide and arachidonic acid pathway inhibitor data used for the correlations are in Appendix C and the FADS1 inhibitor data are in Appendix D. The correlation analysis was done using the methods described in the Examples above.

The analysis indicates a strong correlation between the FADS1 inhibitor and both arachidonic acid inhibitors triacsin and indomethacin. Using the subset of spots differentially expressed in response to triacsin and indomethacin, the correlation between the FADS1 inhibitor and both triacsin and indomethacin was greater than 0.9 (p-value <0.001). This result was anticipated, since all three of the above inhibitors target the arachidonic acid pathway and therefore should have similar effects on cells.

Significantly, the correlation analysis also demonstrates a strong correlation between the FADS1 inhibitor and the active macrolides. Using a subset of spots differentially expressed in response to clarithromycin and roxithromycin, the correlations between the FADS1 inhibitor and clarithromycin was 0.9 (p-value 0.3), between the FADS1 inhibitor and roxithromycin was greater than 0.9 (p-value 0.03), and between the FADS1 inhibitor and FMA was greater than 0.9 (p-value 0.003). These data suggest that the FADS1 inhibitor and the macrolides are acting on the same pathway.

The correlation analyses demonstrate that the responses to the anti-inflammatory macrolides are highly correlated with the responses to three different inhibitors of the arachidonic acid pathway (triacsin C, indomethacin, and FADS1 inhibitor). These data, in conjunction with the ability of macrolides to inhibit production of PGE2, a product of arachidonic acid activation, strongly support the hypothesis that macrolides are targeting the arachidonic acid pathway.

EXAMPLE 4

In this example, the usefulness of a macrolide compound for inflammatory disease of the lung was evaluated.

PREPARATION EXAMPLE

	clarithromycin	50	mg
	lactose	40	mg
	corn starch	49.75	mg
	crystalline cellulose	17	mg
	carmellose calcium	17	mg
	hydroxypropyl cellulose	5.25	mg
	magnesium stearate	1	mg
	total	180	mg

Clarithromycin, lactose, corn starch, crystalline cellulose, and carmellose calcium were uniformly mixed. To this was added a 10% hydroxypropyl cellulose aqueous solution. After blending the mixture, the granules were dried and sieved with a 30M-screen to make uniform granules. Magnesium stearate was added to the granules and it was compressed to form tablets.

The pharmacological action of clarithromycin (improvement to a pulmonary emphysema condition) will be next explained by way of test examples.

Test Example: Pharmacological effect in model mice with tobacco smoke-induced pulmonary emphysema

The model mice with tobacco smoke-induced pulmonary emphysema mimicking human pulmonary emphysema were constructed according to the method as described in Hautamaki, R. D. et al., Science 1997, 277: 2002-2004 or Shapiro, S. D. et al., Am. J. Pathol (2003) 163: 2329-2335. Specifically, C57black/6 female mice of 12-weeks old were exposed to tobacco smoke at two cigarettes per day, 6 days per week for 6 months.

Administration of clarithromycin was carried out orally at the rate of 25, 50 or 100 mg/body weight twice daily (morning and evening) during the tobacco smoke exposure period. The plasma AUC_0-8 of clarithromycin obtained when 50 mg/kg was singly administered to the mice was 2.677 μg·hr/ml while the plasma AUC_0-8 of clarithromycin obtained when 200 mg of clarithromycin was singly administered to a normal human subject was 8.98 μg·hr/ml. The former concentration was substantially lower than the latter one and was an adequate concentration to be used clinically.

The index of the improvement to the pulmonary emphysema condition followed the mothod as described in Hautamaki, R. D. et al., ibid. or Shapiro, S. D. et al., ibid.

Hematoxylin eosin-stained pathological specimens were prepared from the model mice and ten visual fields under a microscope were randomly selected, where the average sizes of pulmonary alveoli were measured. An increase in the average size of pulmonary alveolus is considered as an index of the destruction of pulmonary alveoli, i.e., the pulmonary emphysema condition.

Table 12 shows the improvement factor of pulmonary emphysema in the model mice with tobacco smoke induced pulmonary emphysema. Six months' smoking (i.e., exposure to tobacco smoke) increased the pulmonary emphysema rate by 20% relative to the non-smoking group (control). The pulmonary emphysema was improved by 47% in the group administered with clarithromycin (25 mg/kg) and by a maximum of up to 87% in the group administered with clarithromycin (50 mg/kg). These results indicate that clarithromysin is effective against pulmonary emphysema (or pulmonary emphysema condition).

	TABLE 12
	pulmonary		pulmonary
	alveolus size	statistical	emphysema	improvement
	(μm)	significance	rate (%)	factor (%)
non-smoking	32.21 ± 0.507		0
smoking +	38.51 ± 0.765	0.0004 (vs.	20	0
solvent		non-
		smoking)
smoking +	35.60 ± 1.425	0.1001 (vs.	10.6	47
CAM		smoking)
(25 mg/kg)
smoking +	33.16 ± 0.890	0.0046 (vs.	3	85
CAM		smoking)
(50 mg/kg)
smoking +	34.35 ± 0.936	0.0092 (vs.	6.7	66.5
CAM		smoking)
(100 mg/kg)
(mean ± SE)

The cell counts of inflammatory cells (microphages and neutrophiles) in the bronchoalveolar lavage fluids after six months' exposure were measured to provide an index of the inflammatory condition in the model mice with tobacco smoke-induced pulmonary emphysema. The results are shown in FIG. 4A and FIG. 4B.

The cell counts of macrophages and neutrophiles increased as the pulmonary emphysema progressed. These cells produce the proteases that are involved in pulmonary emphysema. These cells increase exacerbate the pulmonary emphysema. Administration of clarithromycin reduced the cell counts of macrophages and neutrophiles in a dose-dependant manner. This result indicates that clarithromycin inhibits inflammation reaction and suppresses the progression of pulmonary alveoli destruction.

It has been reported that as pulmonary emphysema progresses, pulmonary functions deteriorate. It has also been known that the pulmonary compliance, which is an index of pulmonary functions, increases in model mice with tobacco smoke-induced pulmonary emphysema. Thus, the pulmonary compliance was measured in the model mice with tobacco smoke-induced pulmonary emphysema after six months' exposure. The result is shown in FIG. 5.

As the pulmonary emphysema progressed, the pulmonary compliance (the index of pulmonary functions) was increasing in the model mice with tobacco smoke-induced pulmonary emphysema; however, the pulmonary compliance recovered upon the administration of clarithromycin. This result was in accord with the improvement of the pulmonary emphysema ratio as well as with the decrease in the number of the inflammatory cells, and it indicates that the clarithromycin administration is useful for the treatment of pulmonary emphysema (or pulmonary emphysema condition).

EXAMPLE 5

In this example, among the genes shown in the above-mentioned Appendixes A to E, the influence of a macrolide compound on the level of expression of a gene of a material related to inflammatory disease of the lung was examined.

The influence of a macrolide compound on the level of expression of the gene of the material related to inflammatory disease of the lung is summarized in Appendix F. In Appendix F, ‘+/−Clari, wtd means’ denotes gene induction (suppression) when clarithromycin is added to THP-1 cells, and the larger the figure, the more the gene is expressed. Furthermore, ‘+LPS+/−Clari, wtd means’ denotes gene induction (suppression) when clarithromycin is added to LSP-stimulated THP-1 cells, and the smaller the figure, the more the gene expression is suppressed.

From Appendix F, it can be seen that clarithromycin acts effectively on the expression of genes of Categories 1 to 3.

The present invention may have the following modes.

1. A method of screening test macrolides to identify potential anti-inflammatory agents, comprising the steps of:

• • contacting a first biological sample with a test macrolide; and
  • detecting a first level of de novo biosynthesis of arachidonic acid in the first biological sample, wherein a test macrolide that alters the first level of de novo arachidonic acid biosynthesis relative to a second level of de novo arachidonic acid biosynthesis in a second biological sample that has not been contacted with the test macrolide identifies the test macrolide as a potential anti-inflammatory agent.

2. The method of embodiment 1 wherein the test macrolide increases the first level of de novo arachidonic acid biosynthesis.

3. The method of embodiment 1 wherein the test macrolide decreases the first level of de novo arachidonic acid biosynthesis.

4. The method of embodiment 1 wherein the biological sample comprises cells.

5. The method of embodiment 1 wherein the biological sample comprises a cellular extract.

6. The method of embodiment 1 wherein the biological sample is in an in vivo system.

7. The method of embodiment 1 wherein the biological sample is in an in vitro system.

8. The method of embodiment 1 wherein the in vitro system is a cell culture.

9. The method of embodiment 1 wherein the first level of de novo arachidonic acid biosynthesis is detected by measuring incorporation of labeled arachidonic acid into phospholipids.

10. The method of embodiment 1 wherein incorporation of label into an intermediate in an arachidonic acid biosynthesis pathway is measured.

11. A method of screening macrolides to identify potential anti-inflammatory agents, comprising the steps of:

• • contacting a first biological sample with a test macrolide; and
  • determining a first level of expression of a gene involved in arachidonic acid biosynthesis or activation, wherein a test macrolide that alters the first level of expression of the gene relative to a second level of expression of the gene in a second biological sample that has not been contacted with the test macrolide identifies the test macrolide as a potential anti-inflammatory agent.

12. The method of embodiment 41 wherein the test macrolide increases the first level of expression.

13. The method of embodiment 11 wherein the test macrolide decreases the first level of expression.

14. The method of embodiment 11 wherein the step of contacting is in vitro.

15. The method of embodiment 11 wherein the step of contacting is in vivo.

16. The method of embodiment 15 wherein the step of contacting is in a cell culture.

17. The method of embodiment 16 wherein the cell culture comprises an epithelial cell line.

18. The method of embodiment 17 wherein the epithelial cell line is a macrophage cell line.

19. The method of embodiment 17 wherein the epithelial cell line is A549.

20. The method of embodiment 17 wherein the epithelial cell line is THP-1.

21. The method of embodiment 11 wherein the gene is A5 fatty acid desaturase (FADS1).

22. The method of embodiment 11 wherein the gene is A6 fatty acid desaturase (FADS2).

23. The method of embodiment 11 wherein the gene is fatty acid elongase.

24. The method of embodiment 11 wherein the gene is arachidonyl CoA synthetase.

25. The method of embodiment 11 wherein the gene is selected from the group consisting of cyclooxygenase 2, prostaglandin E receptor EP4, cytosolic phospholipase A2, fatty acid desaturase, prostaglandin E synthase, prostaglandin E receptor EP1, prostaglandin 12 receptor, and secretory phospholipase A2 receptor 1.

26. The method of embodiment 11 wherein the gene is selected from the group consisting of genes listed in Appendices A-E.

27. The method of embodiment 11 wherein expression of the gene is determined by detecting mRNA.

28. The method of embodiment 11 wherein expression of the gene is determined by detecting protein.

29. The method of embodiment 11 wherein expression of the gene is determined by detecting protein synthesis.

30. A method of screening macrolides to identify potential anti-inflammatory agents, comprising the steps of:

• • contacting a first biological sample with a test macrolide; and
  • determining a first level of activity of an enzyme involved in arachidonic acid biosynthesis, wherein a test macrolide that alters the first level of activity of the enzyme relative to a second level of activity of the enzyme in a second biological sample that has not been contacted with the test macrolide identifies the test macrolide as a potential anti-inflammatory agent.

31. The method of claim 30 wherein the test macrolide increases the first level of activity of the enzyme.

32. The method of claim 30 wherein the test macrolide decreases the first level of activity of the enzyme.

33. The method of embodiment 30 wherein the step of contacting is in vitro.

34. The method of embodiment 30 wherein the step of contacting is in vivo.

35. The method of embodiment 24 wherein the step of contacting is in a cell culture.

36. The method of embodiment 33 wherein the cell culture comprises an epithelial cell line.

37. The method of embodiment 36 wherein the epithelial cell line is a macrophage cell line.

38. The method of embodiment 36 wherein the epithelial cell line is A549.

39. The method of embodiment 36 wherein the epithelial cell line is THP-1.

40. The method of embodiment 30 wherein the enzyme is A5 fatty acid desaturase (FADS1).

41. The method of embodiment 30 wherein the enzyme is A6 fatty acid desaturase (FADS2).

42. The method of embodiment 30 wherein the enzyme is fatty acid elongase.

43. The method of embodiment 30 wherein the enzyme is arachidonyl CoA synthetase.

APPENDIX A
					IL1		Clari		FMA		IL1b +/− clari,		IL1b +/− FMA,
				IL1	treated,	Clari	treated,	FMA	treated,	IL1b +/− clari,	min	IL1b +/− FMA,	min	sum
				treated,	min fold	treated,	min fold	treated,	min fold	wtd	fold	wtd	fold	of min
				wtd mean	change	wtd mean	change	wtd mean	change	mean	change	mean	change	fold
SpotID	GeneSymbol	GeneName	GeneDesc	ratio	(1.5x)	ratio	(1.3x)	ratio	(1.3x)	ratio	(1.3x)	ratio	(1.3x)	change
Total Differentials in A549 Cells (Genes differential in at least 1 hybridization)
Genes in bold - ≧1.5-fold differential expression in response to IL-1β
Genes in italics - ≧1.3-fold differential expression in response to Clari and/or FMA alone
Genes in bold and italics - ≧1.3-fold differential expression in response to IL1 + Clari and/or IL1 + FMA
49276				1.0	1.0	1.3	1.2	0.9	1.0		1.8	1.4	1.2	5.2
49147				1.0	1.0	1.3	1.1	0.9	1.0		1.8	1.4	1.2	5.0
50600				1.0	1.0	0.7	1.4	1.1	1.0	1.0	1.0	1.2	1.1	4.5
49168				3.4	2.8	1.1	1.0	1.1	1.0	1.3	1.0	1.3	1.1	4.1
49491				2.4	1.8	1.0	1.0	1.0	1.0	1.3	1.1	0.9	1.0	4.1
47030				0.6	1.4	0.6	1.3	0.9	1.1		1.5	0.9	1.0	4.8
48063				0.8	1.0	0.6	1.4	0.9	1.0		1.3	0.9	1.0	4.7
50085				2.1	2.0	1.1	1.0	1.1	1.1	1.0	1.0	1.1	1.0	4.1
48739				1.7	1.4	0.8	1.0	1.1	1.0		1.7	1.0	1.0	4.7
46627				1.0	1.0	1.0	1.0	1.0	1.0		1.5	1.0	1.0	4.5
48749				1.0	1.0	1.3	1.1	1.1	1.0		1.4	1.1	1.0	4.5
50278				0.8	1.2	1.0	1.0	1.1	1.0		1.4	1.0	1.0	4.4
47792				1.5	1.4	0.6	1.4	0.9	1.0		1.4	0.9	1.0	4.7
49510				1.6	1.4	1.9	1.5	1.0	1.0		1.3	1.0	1.0	4.7
47373				2.2	1.5	1.2	1.1	1.0	1.0	1.3	1.2	1.1	1.0	4.4
46609				0.9	1.0	0.6	1.4	0.8	1.0	0.8	1.1	1.0	1.0	4.5
47420				1.8	1.7	0.8	1.1	1.0	1.0	0.8	1.1	1.0	1.0	4.2
46704				1.0	1.0	0.9	1.0	0.7	1.3	1.0	1.0	0.9	1.0	4.3
46858				2.0	1.7	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
47210				0.6	1.6	0.8	1.1	0.9	1.0	0.9	1.0	0.9	1.0	4.1
50306				1.6	1.6	0.9	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
49952	1			0.9	1.0	0.6	1.3	0.8	1.3	0.7	1.0	3	1.4	5.0
47089	ACYP2			0.9	1.0	1.6	1.3	1.1	1.0	3	1.3	1.0	1.0	4.6
48442	ADAM17	TACE	a disintegrin and	1.8	1.7	1.1	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
			metalloproteinase
			domain 17 (tum
49421	ADAM17	TACE	a disintegrin and	1.7	1.6	1.2	1.1	1.0	1.0	1.0	1.0	1.0	1.0	4.1
			metalloproteinase
			domain 17 (tum
50627	ADH1A			1.0	1.0	1.1	1.0	1.0	1.0	4	1.3	1.0	1.0	4.3
48600	AGXT	serine-	alanine-glyoxylate	1.0	1.0	1.3	1.3	1.0	1.0	1.0	1.0	1.0	1.0	4.3
		pyruvate	aminotransferase
		aminotransferase	(oxalosis I; h
49620	AKAP1			0.6	1.5	1.0	1.0	1.0	1.0	1.1	1.1	0.9	1.0	4.1
47127	ALAD			4.9	3.2	1.1	1.0	1.0	1.0		1.3	1.4	1.0	4.4
49549	ANXA8			1.2	1.1	0.7	1.2	1.0	1.0		1.3	0.9	1.0	4.5
49935	APOA2			2.7	2.4	1.1	1.1	1.1	1.0	1.0	1.0	1.0	1.0	4.1
46982	AREG	amphiregu-lin	amphiregulin	2.5	2.3	0.9	1.0	1.3	1.1		1.4	1.2	1.0	4.5
			(schwannoma-
			derived growth
			factor)
46986	AREG	amphiregu-lin	amphiregulin	2.4	2.2	0.9	1.1	1.2	1.1		1.4	1.1	1.0	4.6
			(schwannoma-
			derived growth
			factor)
46949	AREG	amphiregu-lin	amphiregulin	2.6	2.4	0.9	1.0	1.3	1.1		1.3	1.1	1.0	4.4
			(schwannoma-
			derived growth
			factor)
46953	AREG	amphiregu-lin	amphiregulin	2.5	2.5	1.0	1.0	1.3	1.1		1.3	1.2	1.0	4.4
			(schwannoma-
			derived growth
			factor)
47617	ARF3			1.0	1.0	1.0	1.0	0.5	1.7	0.8	1.0	0.7	1.0	4.7
49290	ARHB	RhoB	ras homolog gene	1.3	1.2	1.4	1.1	1.4	1.3		1.3	1.2	1.0	4.8
			family, member B
48282	ARHG	RhoG	ras homolog gene	1.8	1.6	1.3	1.2	1.1	1.0		1.4	1.2	1.1	4.7
			family, member G
			(rho G)
48344	ARHG	RhoG	ras homolog gene	1.7	1.5	1.2	1.1	1.1	1.1	4	1.4	1.1	1.1	4.6
			family, member G
			(rho G)
50517	ARHGAP4	ARHGAP4	Rho GTPase	1.1	1.0	1.2	1.1	1.0	1.0		1.4	1.0	1.0	4.5
			activating protein 4
46600	ARHGEF7	P85SPR	PAK-interacting	1.6	1.5	1.0	1.0	0.9	1.0	0.9	1.0	0.9	1.0	4.0
			exchange factor
			beta
49155				0.7	1.3	0.6	1.4	0.9	1.0		1.8	1.0	1.0	5.2
46817	ATF3	ATF3	activating	2.3	2.0	1.3	1.3	1.4	1.1		1.3	1.0	1.0	4.7
			transcription factor 3
50635	B4GALT1			1.9	1.8	1.5	1.1	1.0	1.0	1.3	1.2	1.0	1.0	4.3
49694	BAG3	BAG3	BCL2-associated	1.2	1.0	1.1	1.0	0.9	1.0		1.3	1.0	1.0	4.3
			athanogene 3
48802	BAI3			2.2	2.1	1.3	1.1	1.0	1.0	1.3	1.2	1.1	1.0	4.3
47691	BATF	B-ATF	basic leucine	0.8	1.0	0.8	1.0	0.6	1.5	0.7	1.0	0.7	1.2	4.8
			zipper
			transcription
			factor, ATF-lik
49013	BBC3			2.0	2.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.0	4.0
50033	BCL10	BCL10	B-cell	1.9	1.6	1.0	1.0	1.0	1.0	1.0	1.0	0.9	1.0	4.0
			CLL/lymphoma 10
47738	BCL2A1	BCL2A1	BCL2-related	26.7	14.9	1.3	1.0	1.0	1.0	1.1	1.0	1.0	1.0	4.0
			protein A1
48697	BCL3	Bcl3	B-cell	1.5	1.3	1.1	1.0	0.9	1.0		1.4	1.0	1.0	4.4
			CLL/lymphoma 3
48679	BCL3	Bcl3	B-cell	1.0	1.0	1.1	1.0	0.6	1.5	0.9	1.0	0.8	1.0	4.5
			CLL/lymphoma 3
47979	BDKRB1	BDKRB1	bradykinin	3.3	3.1	1.6	1.5	1.0	1.0	1.3	1.1	0.9	1.0	4.5
			receptor B1
48374	BDKRB1	BDKRB1	bradykinin	4.3	3.5	1.5	1.4	0.9	1.0	1.4	1.1	1.0	1.0	4.4
			receptor B1
46689	BENE			0.7	1.3	1.3	1.0	1.0	1.0	4	1.3	1.1	1.0	4.3
50726	BID	BID	BH3 interacting	2.4	2.2	0.9	1.0	1.0	1.0	1.0	1.0	0.8	1.0	4.0
			domain death
			agonist
48766	BID	BID	BH3 interacting	2.4	2.2	0.9	1.0	0.9	1.1	1.0	1.0	1.0	1.0	4.1
			domain death
			agonist
49310	BID	BID	BH3 interacting	2.4	2.1	0.8	1.0	0.9	1.0	1.0	1.0	1.0	1.0	4.1
			domain death
			agonist
49061	BIRC2	cIAP1	baculoviral IAP	2.3	2.2	1.1	1.0	0.9	1.0	0.9	1.0	0.9	1.1	4.2
			repeat-containing 2
49094	BIRC2	cIAP1	baculoviral IAP	2.3	2.2	1.0	1.0	0.9	1.0	0.9	1.0	0.9	1.1	4.1
			repeat-containing 2
48375	BIRC2	cIAP1	baculoviral IAP	2.1	2.0	1.0	1.0	0.9	1.0	1.0	1.0	0.9	1.1	4.1
			repeat-containing 2
48408	BIRC2	cIAP1	baculoviral IAP	2.0	2.0	1.0	1.0	0.9	1.0	1.0	1.0	1.0	1.0	4.0
			repeat-containing 2
50448	BIRC3	cIAP2	baculoviral IAP	20.3	17.7	1.5	1.3	0.8	1.2	1.2	1.1	1.0	1.0	4.6
			repeat-containing 3
47497	BIRC3	cIAP2	baculoviral IAP	9.9	7.2	1.2	1.0	0.9	1.0	1.1	1.0	0.9	1.0	4.0
			repeat-containing 3
49065	BMP4	BMP4	bone	0.8	1.1	1.3	1.0	0.9	1.0		1.6	1.0	1.0	4.6
			morphogenetic
			protein 4
49098	BMP4	BMP4	bone	0.8	1.1	1.4	1.2	0.9	1.0		1.6	1.0	1.0	4.8
			morphogenetic
			protein 4
49840	BMP4	BMP4	bone	1.2	1.0	1.2	1.0	0.9	1.0		1.4	1.0	1.0	4.4
			morphogenetic
			protein 4
49981	BMP6	BMP6	bone	1.4	1.1	1.5	1.4	0.9	1.0		1.5	0.8	1.1	5.0
			morphogenetic
			protein 6
50319	BMP6	BMP6	bone	1.2	1.2	1.5	1.4	1.0	1.0	4	1.3	0.9	1.1	4.8
			morphogenetic
			protein 6
47516	BTG1			1.2	1.1	1.5	1.3	1.1	1.0		1.4	1.1	1.0	4.7
47930	C21orf4	C21ORF4	chromosome 21	0.9	1.0	0.9	1.0	0.7	1.3	1.0	1.0	0.8	1.1	4.4
			open reading
			frame 4
49509	C3			2.9	2.7	0.9	1.0	1.0	1.0	0.7	1.2	0.9	1.0	4.2
50709	C5	C5	complement	0.6	1.5	1.0	1.0	1.0	1.0	1.1	1.0	0.9	1.0	4.0
			component 5
49928	C6orf5			1.8	1.7	1.0	1.0	1.1	1.0	1.2	1.1	1.0	1.0	4.1
48480	CARS			1.1	1.1	0.8	1.2	0.9	1.0		1.4	0.9	1.0	4.6
47007	CASP4	CASP4	caspase 4,	3.0	2.3	1.4	1.4	1.0	1.0	1.0	1.0	1.1	1.0	4.4
			apoptosis-related
			cysteine protease
49807	CASP4	CASP4	caspase 4,	2.7	2.2	1.4	1.3	1.0	1.0	1.1	1.0	1.0	1.0	4.3
			apoptosis-related
			cysteine protease
50721	CASP4	CASP4	caspase 4,	3.1	2.8	1.3	1.2	1.0	1.0	1.1	1.0	1.0	1.0	4.2
			apoptosis-related
			cysteine protease
49425	CASP7	caspase-7	caspase 7,	4.1	3.7	1.1	1.0	0.9	1.0	1.2	1.1	1.1	1.0	4.1
			apoptosis-related
			cysteine protease
48336	CASP7	caspase-7	caspase 7,	4.3	3.5	1.0	1.0	0.9	1.0	1.1	1.0	1.1	1.0	4.0
			apoptosis-related
			cysteine protease
49909	CASR			1.6	1.5	1.2	1.1	1.1	1.0	1.3	1.2	1.1	1.0	4.3
49773	CCNA2	cyclin A2	cyclin A2	1.0	1.0	0.5	1.4	0.9	1.0	0.6	1.2	0.8	1.1	4.8
49118	CCNA2	cyclin A2	cyclin A2	0.9	1.0	0.6	1.3	0.9	1.0		1.5	0.8	1.0	4.8
49085	CCNA2	cyclin A2	cyclin A2	0.9	1.0	0.7	1.1	1.0	1.0		1.4	0.8	1.0	4.5
48586	CD4	CD4	CD4 antigen (p55)	0.9	1.0	0.9	1.0	0.6	1.4	0.8	1.0	0.7	1.2	4.6
48042	CD4	CD4	CD4 antigen (p55)	0.9	1.0	1.0	1.0	0.6	1.3	0.7	1.0	0.7	1.1	4.4
48166	CDH15			0.8	1.2	1.5	1.3	1.2	1.0	1.3	1.1	1.1	1.0	4.4
50474	CEBPA	C/EBP alpha	CCAAT/en-hancer	0.9	1.0	1.5	1.4	1.1	1.0		1.5	1.0	1.0	4.9
			binding protein
			(C/EBP), alpha
46849	CEBPD	CEBP delta	CCAAT/en-hancer	5.8	4.5	0.8	1.0	0.8	1.1	1.1	1.0	0.9	1.0	4.1
			binding protein
			(C/EBP), delta
47891	CEBPD	CEBP delta	CCAAT/en-hancer	4.5	3.4	1.0	1.0	0.9	1.1	1.1	1.0	0.9	1.0	4.1
			binding protein
			(C/EBP), delta
47135	CHKL			1.2	1.0	0.7	1.0	0.7	1.3	0.8	1.0	0.7	1.2	4.6
47032		CIT	citron (rho-	0.7	1.1	0.6	1.5	0.8	1.1		1.4	0.8	1.2	5.2
			interacting,
			serine/threo-nine
			kinase 2
48972		CIT	citron (rho-	0.7	1.1	0.4	2.1	0.8	1.1	1.0	1.0	1.0	1.0	5.2
			interacting,
			serine/threo-nine
			kinase 2
49854	COCH			24.0	23.8	1.1	1.0	1.0	1.0	1.1	1.0	1.0	1.0	4.0
47563	COL11A1	COL11A1	collagen, type XI,	0.7	1.2	0.7	1.4	0.9	1.0	0.8	1.1	0.8	1.0	4.6
			alpha 1
50087	COL4A1	COL4A1	collagen, type IV,	2.9	2.7	1.4	1.1	1.0	1.0	1.2	1.2	1.1	1.0	4.3
			alpha 1
48068	COL4A1	COL4A1	collagen, type IV,	2.4	1.9	1.1	1.0	0.9	1.0	1.1	1.0	1.0	1.0	4.0
			alpha 1
49315	COL4A2	COL4A2	collagen, type IV,	1.9	1.6	1.5	1.3	1.2	1.0		1.3	1.1	1.0	4.6
			alpha 2
47197	COL4A2	COL4A2	collagen, type IV,	1.9	1.7	1.0	1.0	1.2	1.0	1.0	1.0	1.1	1.0	4.0
			alpha 2
49762	COL4A4	COL4A4	collagen, type IV,	0.7	1.0	1.2	1.1	1.0	1.0		1.4	1.1	1.0	4.5
			alpha 4
50705	COL7A1	COL7A1	collagen, type VII,	2.0	1.6	0.8	1.0	0.8	1.1	0.9	1.0	1.1	1.0	4.1
			alpha 1
			(epidermolysis
			bullosa
50564				0.6	1.5	0.6	1.4	0.7	1.3		1.3	0.7	1.2	5.1
49572	CRMP1			0.7	1.3	1.4	1.1	1.1	1.0		1.5	1.3	1.2	4.7
49149	CSF1	M-CSF,	colony stimulating	3.5	2.0	0.9	1.0	1.1	1.0	0.8	1.0	1.1	1.0	4.0
		macro-phage	factor 1
		colony	(macrophage)
		stimulating
		factor
49278	CSF1	M-CSF,	colony stimulating	3.5	2.0	0.9	1.0	1.1	1.0	0.8	1.0	1.1	1.0	4.0
		macro-phage	factor 1
		colony	(macrophage)
		stimulating
		factor
48596	CSF2	G-CSF,	colony stimulating	5.9	5.4	0.9	1.0	1.0	1.0	1.2	1.1	1.0	1.0	4.1
		granulocyte	factor 2
		colony	(granulocyte-
		stimulating	macrophage
		factor
48052	CSF2	G-CSF,	colony stimulating	4.2	2.3	1.3	1.0	1.0	1.0	1.1	1.0	1.0	1.0	4.0
		granulocyte	factor 2
		colony	(granulocyte-
		stimulating	macrophag
		factor
49266	CSF3	GM-CSF,	colony stimulating	2.1	1.6	1.0	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
		granulocyte-	factor 3
		macrophage	(granulocyte)
		colony
		stimulating
		factor
49137	CSF3	GM-CSF,	colony stimulating	2.1	1.8	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
		granulocyte-	factor 3
		macrophage	(granulocyte)
		colony
		stimulating
		factor
48943	CSF3R	G-CSF	colony stimulating	0.7	1.0	0.5	1.7	1.1	1.0	1.0	1.0	1.1	1.0	4.7
		receptor	factor 3 receptor
			(granulocyte)
48263	CSPG2	CSPG2	chondroitin sulfate	0.6	1.5	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			proteoglycan 2
			(versican)
50282	CSRP1			2.5	1.7	1.6	1.3	1.4	1.3	1.4	1.2	1.2	1.0	4.8
49060	CTGF	CTGF	connective tissue	0.3	2.3	0.8	1.0	1.1	1.0		1.6	0.9	1.0	4.6
			growth factor
48000	CTSH			0.7	1.3	1.4	1.3	1.1	1.0		1.4	1.2	1.0	4.7
47834	CYP1A1			1.0	1.0	1.5	1.4	1.2	1.2	1.3	1.2	1.2	1.0	4.8
48721		CD55	decay	4.0	2.7	2.1	2.0	1.0	1.0		1.6	1.1	1.0	5.6
			accelerating factor
			for complement
			(CD55, Cr
46942		CD55	decay	4.0	3.6	2.0	1.9	1.0	1.0		1.4	1.2	1.0	5.3
			accelerating factor
			for complement
			(CD55, Cr
47976	DDB2			0.6	1.5	0.7	1.3	0.9	1.0		1.5	1.0	1.0	4.8
49903	DDXL			1.0	1.0	0.7	1.4	1.0	1.0		1.3	0.9	1.0	4.7
49922	DHCR24			0.9	1.1	1.4	1.2	1.0	1.0		1.5	1.0	1.0	4.7
47523	DNAJB1	DNAJB1	DnaJ (Hsp40)	1.0	1.0	1.0	1.0	0.9	1.0		1.4	1.2	1.1	4.5
			homolog,
			subfamily B,
			member 1
50745	DNAJB1	DNAJB1	DnaJ (Hsp40)	0.9	1.0	1.0	1.0	1.0	1.0		1.4	1.1	1.0	4.5
			homolog,
			subfamily B,
			member 1
49389	DUSP1	MKP-1,	dual specificity	1.4	1.0	1.5	1.5	1.1	1.0	1.1	1.0	1.0	1.0	4.5
		PTPN10	phosphatase 1
50362	DUSP10	DUSP10	dual specificity	2.9	2.6	1.3	1.1	1.0	1.0	1.3	1.0	1.0	1.0	4.2
			phosphatase 10
46670	DUSP5	DUSP5	dual specificity	2.0	2.0	1.4	1.3	1.2	1.1	1.3	1.2	1.2	1.1	4.8
			phosphatase 5
49777	DUSP6	DUSP6	dual specificity	2.1	2.0	1.5	1.3	1.0	1.0	1.5	1.0	0.8	1.1	4.4
			phosphatase 6
47277	DUSP6	DUSP6	dual specificity	2.8	2.3	1.2	1.0	1.0	1.0	1.4	1.0	0.9	1.1	4.1
			phosphatase 6
49810	DUSP6	DUSP6	dual specificity	2.1	2.0	1.5	1.2	0.9	1.0	1.5	1.0	0.9	1.0	4.2
			phosphatase 6
50140		ECT2	epithelial cell	1.2	1.1	0.5	1.6	0.9	1.1		1.7	0.8	1.2	5.6
			transforming
			sequence 2
			oncogene
48032		ECT2	epithelial cell	1.1	1.0	0.5	1.4	0.8	1.1		1.7	0.8	1.2	5.4
			transforming
			sequence 2
			oncogene
47654	EFEMP1	EFEMP1	EGF-containing	0.8	1.1	1.1	1.0	1.1	1.0	4	1.3	1.2	1.0	4.4
			fibulin-like
			extracellular
			matrix p
49636	EGFR	EGFR, ErbB1	epidermal growth	3.2	3.0	1.4	1.2	1.1	1.0	1.2	1.0	1.1	1.0	4.3
			factor receptor
			(avian erythrobla
49764		EHF	ets homologous	1.2	1.2	0.6	1.4	0.8	1.0		1.6	0.9	1.0	5.1
			factor
47708	EHF	EHF	ets homologous	1.0	1.0	1.0	1.0	1.0	1.0		1.7	1.0	1.0	4.7
			factor
46821	ELA2	elastase-2	elastase 2,	1.0	1.0	0.8	1.0	0.6	1.4	0.8	1.0	0.8	1.0	4.4
			neutrophil
46813	ELK3	ELK3	ELK3, ETS-	1.9	1.6	1.0	1.0	1.0	1.0	0.9	1.1	1.1	1.0	4.1
			domain protein
			(SRF accessory
			protein 2)
46955	EREG	epiregulin	epiregulin	5.4	3.3	1.2	1.0	1.4	1.0		1.3	1.2	1.1	4.4
50126	EREG	epiregulin	epiregulin	3.8	3.6	1.3	1.1	1.4	1.2		1.5	1.1	1.0	4.8
46988	EREG	epiregulin	epiregulin	5.4	3.4	1.1	1.1	1.3	1.0		1.5	1.1	1.0	4.6
47907		ERG	v-ets avian	4.7	4.1	1.0	1.0	1.0	1.0	1.3	1.2	2.2		5.3
			erythroblastosis
			virus E26
			oncogene re
47554	ERG	ERG	v-ets avian	1.0	1.0	1.0	1.0	0.9	1.0		1.3	1.9	1.4	4.7
			erythroblastosis
			virus E26
			oncogene re
50339	ETV6	ETV6	ets variant gene 6	2.5	2.1	1.3	1.1	1.0	1.0	1.2	1.2	1.1	1.0	4.4
			(TEL oncogene)
49695	ETV6	ETV6	ets variant gene 6	2.2	2.1	1.0	1.0	1.0	1.0	1.2	1.2	1.0	1.0	4.2
			(TEL oncogene)
47539	F2	F2	coagulation factor	5.6	3.7	1.2	1.1	1.1	1.1	1.0	1.0	1.3	1.1	4.3
			II (thrombin)
48998				0.8	1.0	2.1	2.0	1.1	1.1		2.0	1.0	1.0	6.0
49529	FGA			0.4	2.1	1.5	1.3	0.9	1.0		1.3	0.8	1.1	4.7
46993	FOSL1	FOSL1, Fra1	FOS-like antigen-1	2.8	2.0	1.1	1.0	1.2	1.0	0.9	1.0	1.1	1.0	4.0
50475	FOSL1	FOSL1, Fra1	FOS-like antigen-1	2.7	1.9	1.1	1.0	1.1	1.0	1.0	1.0	1.2	1.0	4.1
50508	FOSL1	FOSL1, Fra1	FOS-like antigen-1	2.7	2.0	1.0	1.0	1.1	1.0	1.0	1.0	1.1	1.0	4.0
48969	FOSL2	FOSL2, Fra2	FOS-like antigen 2	2.3	2.0	1.3	1.2	1.0	1.0	4	1.3	1.1	1.0	4.5
48270	FOSL2	FOSL2, Fra2	FOS-like antigen 2	2.3	2.2	1.2	1.1	1.0	1.0		1.3	1.1	1.0	4.4
49798	FRAG1	FRAG1	FGF receptor	0.7	1.4	1.2	1.1	1.1	1.1	4	1.4	1.2	1.2	4.7
			activating protein 1
49793	FRAG1	FRAG1	FGF receptor	0.7	1.3	1.2	1.0	1.1	1.1	4	1.3	1.1	1.1	4.5
			activating protein 1
49765	FRAG1	FRAG1	FGF receptor	0.6	1.5	1.2	1.1	1.1	1.0	1.3	1.2	1.1	1.1	4.4
			activating protein 1
48137	FRDA			2.3	2.0	0.8	1.1	1.0	1.0	0.7	1.1	0.8	1.0	4.2
49862	FUT8			0.7	1.4	1.4	1.2	1.0	1.0	4	1.4	1.0	1.0	4.5
49883	FVT1			1.1	1.0	1.4	1.2	1.1	1.0	4	1.3	1.0	1.0	4.6
48615	GADD45B	MyD118	growth arrest and	0.4	2.1	1.2	1.0	0.6	1.3		1.3	1.0	1.0	4.6
			DNA-damage-
			inducible, beta
50142	GBP1	IFN induced	guanylate binding	10.3	6.1	1.0	1.0	1.0	1.0	0.7	1.2	1.1	1.0	4.2
		GBP-1	protein 1,
			interferon-
			inducible,
49059	GCH1	GTP	GTP	6.9	6.1	1.2	1.1	0.9	1.0	1.3	1.0	0.9	1.0	4.2
		cyclohydrolase I	cyclohydrolase 1
			(dopa-responsive
			dystonia)
49092	GCH1	GTP	GTP	6.8	6.3	1.4	1.3	0.9	1.0	1.2	1.0	0.9	1.0	4.3
		cyclohydrolase I	cyclohydrolase 1
			(dopa-responsive
			dystonia)
46977	GCH1	GTP	GTP	8.1	4.9	1.2	1.0	0.9	1.0	1.2	1.0	1.0	1.0	4.0
		cyclohydrolase I	cyclohydrolase 1
			(dopa-responsive
			dystonia)
50653	GM2A			1.0	1.0	1.2	1.1	1.1	1.0		1.4	1.0	1.0	4.4
50689	GNB5	G protein, beta 5	guanine	0.9	1.0	1.3	1.2	1.1	1.0		1.3	1.2	1.0	4.5
			nucleotide binding
			protein (G
			protein), be
50671	GNG3	G protein,	guanine	0.9	1.0	1.6	1.3	1.0	1.0	0.8	1.0	1.0	1.0	4.3
		gamma 3	nucleotide binding
			protein (G
			protein), ga
48713	GPRK7	MNK2	G protein-coupled	0.6	1.4	1.7	1.4	1.1	1.0	1.3	1.2	1.1	1.0	4.6
			receptor kinase 7
46825	GPRK7	MNK2	G protein-coupled	0.7	1.1	1.5	1.4	1.1	1.0	1.2	1.1	1.1	1.0	4.5
			receptor kinase 7
48548	GRAP2	GRAP2	GRB2-related	1.2	1.0	1.0	1.0	0.7	1.4	0.8	1.1	1.0	1.0	4.5
			adaptor protein 2
46936	GRB10	GRB10	growth factor	1.4	1.2	1.6	1.3	1.1	1.1	1.3	1.0	1.1	1.0	4.4
			receptor-bound
			protein 10
46962	GRB10	GRB10	growth factor	1.5	1.4	1.6	1.5	1.1	1.0	1.2	1.0	1.1	1.0	4.5
			receptor-bound
			protein 10
49586	GRIN2C			39.1	25.1	1.2	1.1	0.9	1.0	1.0	1.0	0.9	1.0	4.1
49754	GRO1	GRO1	GRO1 oncogene	65.9	48.3	1.4	1.2	0.9	1.0	1.1	1.1	1.0	1.0	4.3
			(melanoma growth
			stimulating activit
50462	GRO1	GRO1	GRO1 oncogene	83.9	45.6	1.5	1.3	1.0	1.0	1.1	1.0	1.0	1.0	4.3
			(melanoma growth
			stimulating activit
47632	GRO2	GRO2	GRO2 oncogene	68.5	50.8	1.5	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
47558	GRO2	GRO2	GRO2 oncogene	28.9	21.2	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
49692	GRO3	GRO3	GRO3 oncogene	97.5	64.4	1.6	1.2	1.0	1.0	1.1	1.0	1.0	1.0	4.3
48330	GRO3	GRO3	GRO3 oncogene	79.2	47.5	1.6	1.2	0.9	1.0	1.1	1.0	1.1	1.0	4.2
49688	GSK3B	GSK3B	glycogen synthase	1.5	1.4	1.4	1.4	1.0	1.0	4	1.3	0.9	1.0	4.7
			kinase 3 beta
49032	GSK3B	GSK3B	glycogen synthase	1.4	1.2	1.4	1.3	1.0	1.0	1.4	1.2	1.1	1.0	4.5
			kinase 3 beta
47492	HDGF			2.3	2.0	0.8	1.1	1.0	1.0	0.9	1.0	1.0	1.0	4.1
47831	HEC			1.1	1.0	0.6	1.4	0.9	1.0		1.3	1.0	1.0	4.8
46778	HMG2			1.1	1.0	0.6	1.1	0.8	1.1		1.4	0.8	1.0	4.6
49347				0.9	1.0	0.5	1.6	1.0	1.0		1.5	1.0	1.0	5.0
47922	HS3ST3A1	HS3ST3A1	heparan sulfate	1.0	1.0	1.0	1.0	1.0	1.0		1.5	1.2	1.1	4.6
			(glucosamine) 3-
			O-sulfotransferase
49113	HS3ST3A1	HS3ST3A1	heparan sulfate	2.9	2.4	1.4	1.2	1.0	1.0		1.5	1.1	1.1	4.8
			(glucosamine) 3-
			O-sulfotransferase
47414	HSF4			0.7	1.3	0.7	1.1	0.7	1.3	0.8	1.1	1.0	1.0	4.4
49417		HSPA1B	heat shock 70 kD	1.0	1.0	1.5	1.3	1.0	1.0		2.0		1.3	5.6
			protein 1B
49064		HSPA1B	heat shock 70 kD	1.0	1.0	1.5	1.3	1.0	1.0		1.9		1.3	5.6
			protein 1B
48618		HSPA1B	heat shock 70 kD	1.1	1.0	1.5	1.3	1.0	1.0		1.9		1.3	5.5
			protein 1B
47185		HSPA1B	heat shock 70 kD	1.2	1.0	1.3	1.1	1.0	1.0		1.9	1.4	1.2	5.3
			protein 1B
49516	HSPA5	HSPA5	heat shock 70 kD	1.1	1.0	1.6	1.3	1.2	1.1	1.2	1.1	1.2	1.0	4.6
			protein 5 (glucose-
			regulated prote
48094	HSPA6	HSPA6	heat shock 70 kD	1.0	1.0	1.1	1.0	1.0	1.0		1.6	1.2	1.0	4.7
			protein 6
			(HSP70B′)
49436	HSPB1	HSPB1	heat shock 27 kD	0.6	1.5	1.0	1.0	1.2	1.1	1.3	1.0	1.2	1.0	4.1
			protein 1
48550	HSPB2	HSPB2	heat shock 27 kD	2.5	2.1	1.0	1.0	1.0	1.0	1.1	1.0	1.0	1.0	4.1
			protein 2
48421	HSPB2	HSPB2	heat shock 27 kD	2.6	2.4	1.2	1.0	0.9	1.0	1.0	1.0	1.1	1.0	4.0
			protein 2
48515	HYA22			0.6	1.6	1.0	1.0	1.0	1.0	1.1	1.0	1.3	1.2	4.2
49804	ICAM1	ICAM1	intercellular	46.2	31.4	1.2	1.1	0.9	1.0	0.8	1.1	1.0	1.0	4.2
			adhesion
			molecule 1
			(CD54), human rh
49771	ICAM1	ICAM1	intercellular	49.6	33.2	1.2	1.1	0.9	1.0	0.8	1.0	1.1	1.0	4.1
			adhesion
			molecule 1
			(CD54), human rh
49140	ICAM1	ICAM1	intercellular	16.2	12.4	1.1	1.0	1.0	1.0	0.8	1.0	1.1	1.0	4.0
			adhesion
			molecule 1
			(CD54), human rh
50084				0.7	1.0	1.7	1.6	0.8	1.1		1.4	0.9	1.1	5.2
49222	IFNAR1	IFN alpha,	interferon (alpha,	1.9	1.8	1.3	1.2	1.0	1.0	1.1	1.1	1.1	1.0	4.3
		beta, omega	beta and omega)
		receptor 1	receptor 1
49265	IFNAR2	IFN alpha,	interferon (alpha,	3.0	2.5	1.2	1.2	1.0	1.0	1.1	1.0	1.0	1.0	4.2
		beta, omega	beta and omega)
		receptor 2	receptor 2
48913	IFNAR2	IFN alpha,	interferon (alpha,	3.0	2.7	1.2	1.2	1.0	1.0	1.1	1.0	1.0	1.0	4.2
		beta, omega	beta and omega)
		receptor 2	receptor 2
47903	IFNGR1	IFN gamma	interferon gamma	4.6	4.0	1.0	1.0	0.9	1.0	0.8	1.0	0.9	1.0	4.0
		receptor 1	receptor 1
50311	IFNGR1	IFN gamma	interferon gamma	4.6	4.5	1.0	1.0	0.9	1.0	1.1	1.0	0.9	1.0	4.0
		receptor 1	receptor 1
47225	IFNGR2	IFN gamma	interferon gamma	4.1	3.8	1.1	1.1	0.9	1.0	1.0	1.0	1.2	1.0	4.1
		receptor 2	receptor 2
			(interferon gamma
			tran
47582	IFNGR2	IFN gamma	interferon gamma	3.9	3.7	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
		receptor 2	receptor 2
			(interferon gamma
			tran
48725	IKKE	IKK-related K	IKK-related kinase	4.1	3.2	1.0	1.0	0.9	1.0	0.9	1.0	0.9	1.1	4.1
		epsilon, IKK-I	epsilon; inducible
			IkappaB kina
50342	IKKE	IKK-related K	IKK-related kinase	5.9	4.0	1.2	1.1	1.0	1.0	1.1	1.0	1.1	1.0	4.1
		epsilon, IKK-I	epsilon; inducible
			IkappaB kina
48961	IL10RB	IL-10R beta	interleukin 10	1.8	1.5	1.1	1.1	1.0	1.0	1.1	1.1	1.1	1.1	4.2
			receptor, beta
50013	IL13RA1	IL-13Ralpha′	interleukin 13	0.6	1.2	1.3	1.2	1.1	1.1	4	1.3	1.0	1.0	4.6
			receptor, alpha 1
48423	IL1A	IL-1, alpha	interleukin 1,	1.9	1.8	1.1	1.0	1.0	1.0	1.1	1.0	1.0	1.0	4.0
			alpha
48552	IL1A	IL-1, alpha	interleukin 1,	1.9	1.9	1.1	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			alpha
46970	IL1B	IL-1, beta	interleukin 1, beta	29.3	23.7	1.0	1.0	1.0	1.0	1.1	1.0	4	1.3	4.3
47656	IL1B	IL-1, beta	interleukin 1, beta	15.9	14.8	1.0	1.0	1.0	1.0	1.2	1.0	4	1.3	4.3
48637	IL1R1	IL-1RI	interleukin 1	0.6	1.6	1.1	1.0	0.8	1.2	1.4	1.1	0.9	1.0	4.3
			receptor, type I
47204	IL1RL1LG	T1/ST2 R	putative T1/ST2	0.9	1.0	0.7	1.4	0.9	1.0	0.9	1.0	1.0	1.0	4.4
		binding protein	receptor binding
			protein
48324	IL3RA	IL-3R alpha	interleukin 3	1.7	1.2	1.9	1.5	1.0	1.0	1.3	1.0	1.0	1.0	4.5
			receptor, alpha
			(low affinity)
46856	IL8	interleukin-8	interleukin 8	239.5	161.1	2.2	1.9	0.8	1.0	1.0	1.0	1.1	1.0	4.9
49873				0.6	1.1	2.1	1.3	0.9	1.0		1.9	1.0	1.0	5.2
46642	IRAK2	IRAK-2	interleukin-1	8.9	7.4	1.0	1.0	1.0	1.0	0.9	1.0	1.2	1.0	4.0
			receptor-
			associated kinase 2
46618	ISG15	ISG15, IFN	interferon-	5.6	4.1	1.3	1.0	1.5	1.0	1.2	1.2	1.6	1.0	4.2
		stimulated	stimulated protein,
		protein	15 kDa
49054	ITGA2	integrin, alpha	integrin, alpha 2	1.7	1.3	1.5	1.3	1.0	1.0	1.3	1.2	1.1	1.0	4.6
		2, CD49B,	(CD49B, alpha 2
		VLA-2	subunit of VLA-2
46686	ITGAV	integrin alpha	integrin, alpha V	2.4	1.9	0.8	1.1	1.0	1.0	0.9	1.1	1.0	1.0	4.3
		V, CD51	(vitronectin
			receptor, alpha pol
50607	ITGB3BP			0.8	1.0	0.6	1.0	0.9	1.1		1.4	0.8	1.2	4.7
48228	JAK1	Jak1	Janus kinase 1 (a	1.7	1.5	1.1	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			protein tyrosine
			kinase)
49322	JUNB	JunB	jun B proto-	1.2	1.1	1.7	1.6	0.9	1.0	1.3	1.0	0.8	1.1	4.7
			oncogene
49319	JUNB	JunB	jun B proto-	1.2	1.1	1.6	1.4	1.0	1.0	1.3	1.0	0.9	1.0	4.4
			oncogene
49167	KDELR3			0.9	1.0	1.5	1.1	1.1	1.0		1.6	1.1	1.0	4.8
48663	KIAA0089			0.6	1.3	1.5	1.3	1.2	1.1		1.3	1.0	1.0	4.7
46911	KIAA0170			1.0	1.0	0.6	1.5	0.9	1.0		1.4	0.9	1.0	4.9
50052	KIAA0171			1.9	1.8	0.9	1.0	0.9	1.0	0.9	1.1	0.9	1.0	4.2
47775	KIAA0365			0.9	1.0	0.7	1.3	0.8	1.0	0.8	1.2	0.9	1.0	4.5
47944	KIAA0395			0.9	1.0	0.9	1.0	1.1	1.0	1.0	1.0		1.4	4.4
47762	KIAA0414			0.9	1.0	0.7	1.3	0.8	1.0	0.8	1.2	0.9	1.0	4.5
48520	KIAA0418			1.2	1.0	1.4	1.3	1.0	1.0		1.5	1.2	1.0	4.8
48918	KIAA0514			0.8	1.2	1.4	1.3	1.1	1.0	4	1.3	1.1	1.0	4.7
48162	KNSL2			0.9	1.0	0.7	1.2	0.9	1.0		1.3	1.0	1.0	4.5
50568	KNSL5			1.1	1.0	0.5	1.2	0.8	1.1		0.6	0.8	1.1	4.8
48856	KRT2A			0.7	1.2	0.6	1.4	1.0	1.0	0.6	1.0	1.0	1.0	4.4
47437	KRT4			0.8	1.1	0.7	1.4	1.0	1.0	0.8	1.0	1.2	1.1	4.4
50042	LAMB3	LAMB3	laminin, beta 3	13.3	11.0	0.7	1.3	0.9	1.0		1.4	0.8	1.1	4.8
			(nicein (125 kD),
			kalinin (140 kD),
50037		LAMC2	laminin, gamma 2	1.0	1.0	2.0	1.5	1.0	1.0	0	1.5	1.2	1.0	5.0
			(nicein (100 kD),
			kalinin (105 kD),
50393	LAMC2	LAMC2	laminin, gamma 2	6.5	6.1	1.3	1.0	1.3	1.0		1.4	1.1	1.0	4.4
			(nicein (100 kD),
			kalinin (105 kD),
49163	LGALS3			1.0	1.0	1.3	1.2	1.2	1.1	4	1.3	1.2	1.1	4.7
50025	LIFR	LIFR	leukemia inhibitory	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0		1.6	4.6
			factor receptor
47191	LIFR	LIFR	leukemia inhibitory	1.0	1.0	1.4	1.3	1.1	1.0	1.1	1.0	1.2	1.2	4.5
			factor receptor
49857	LLGL2			0.6	1.6	1.0	1.0	1.0	1.0	1.2	1.0	1.0	1.0	4.0
50349	LOC51295	ECSIT	ECSIT	0.9	1.1	0.6	1.4	1.1	1.0		1.4	1.1	1.0	4.8
46875				1.0	1.0	2.1	1.9	1.1	1.1	1.1	1.0	1.0	1.0	5.0
48673	LRDD	LRDD	leucine rich repeat	0.9	1.0	0.7	1.3	0.8	1.1		1.4	1.0	1.0	4.7
			and death domain
			containing pr
48748	LTB	LT, beta	lymphotoxin beta	1.0	1.0	1.0	1.0	1.0	1.0		1.3		1.3	4.6
			(TNF superfamily,
			member 3)
49292	LTB	LT, beta	lymphotoxin beta	4.6	2.7	1.0	1.0	1.0	1.0		1.6	1.3	1.0	4.7
			(TNF superfamily,
			member 3)
46676	LYN	Lyn	v-yes-1	2.1	2.0	1.3	1.2	1.0	1.0	1.2	1.2	1.0	1.0	4.3
			Yamaguchi
			sarcoma viral
			related oncogene h
46605	LYN	Lyn	v-yes-1	2.5	2.2	1.3	1.1	1.0	1.0	1.2	1.1	1.0	1.0	4.2
			Yamaguchi
			sarcoma viral
			related oncogene h
47158	MAD	MAD	MAX dimerization	2.0	1.8	1.3	1.1	0.9	1.0	1.0	1.0	1.1	1.0	4.1
			protein
47029	MAD	MAD	MAX dimerization	1.9	1.6	1.1	1.0	0.9	1.0	1.1	1.0	1.1	1.0	4.0
			protein
46776	MAD2L1			0.9	1.0	0.7	1.1	0.8	1.1		1.4	0.9	1.0	4.6
47705	MAD4	MAD4	Mad4 homolog	1.0	1.0	1.5	1.1	1.0	1.0	0	1.4	1.1	1.0	4.5
47087	MADH3			2.3	1.9	0.8	1.1	1.0	1.0	0.9	1.1	1.0	1.0	4.3
49678	MAP2K1	MEK1, MKK1	mitogen-activated	2.3	2.2	1.2	1.1	1.0	1.0	1.2	1.0	0.9	1.0	4.1
			protein kinase
			kinase 1
50482	MAP2K2	MAP2K2	mitogen-activated	2.2	2.1	1.0	1.0	1.1	1.0	0.9	1.0	0.9	1.0	4.0
			protein kinase
			kinase 2
48028	MAP2K3	MKK3	mitogen-activated	3.0	2.7	1.0	1.0	1.0	1.0	1.1	1.0	1.1	1.1	4.1
			protein kinase
			kinase 3
48278	MAP2K3	MKK3	mitogen-activated	3.2	2.8	1.1	1.0	1.0	1.0	1.1	1.0	1.0	1.0	4.0
			protein kinase
			kinase 3
48740	MAP2K6	MKK6	mitogen-activated	0.6	1.4	1.5	1.5	0.9	1.1	1.3	1.2	1.0	1.0	4.7
			protein kinase
			kinase 6
49284	MAP2K6	MKK6	mitogen-activated	0.6	1.2	1.5	1.4	0.9	1.1	1.3	1.0	1.0	1.0	4.5
			protein kinase
			kinase 6
50045	MAP3K5	MKK5, ASK1	mitogen-activated	1.0	1.0	1.0	1.0	1.5	1.0		1.4	1.0	1.0	4.4
			protein kinase
			kinase kinase 5
47969	MAP3K8	c-cot	mitogen-activated	5.2	3.7	0.8	1.1	0.7	1.4	1.1	1.0	1.0	1.0	4.6
			protein kinase
			kinase kinase 8
48424	MAP4K4	GCK-like,	mitogen-activated	2.3	2.1	1.2	1.2	1.1	1.0	1.3	1.2	1.1	1.0	4.4
		HPK, HGK,	protein kinase
		NIK	kinase kinase kin
46998	MAPK6	MAPK6	mitogen-activated	2.0	1.7	1.0	1.0	0.9	1.0	0.9	1.0	0.9	1.1	4.1
			protein kinase 6
46965	MAPK6	MAPK6	mitogen-activated	2.0	1.7	1.0	1.0	0.9	1.0	0.9	1.0	0.9	1.0	4.1
			protein kinase 6
48377	MAPK6	MAPK6	mitogen-activated	2.1	1.9	1.1	1.0	0.9	1.0	1.0	1.0	0.9	1.0	4.0
			protein kinase 6
48410	MAPK6	MAPK6	mitogen-activated	2.1	2.0	1.1	1.0	1.0	1.0	1.0	1.0	0.9	1.0	4.0
			protein kinase 6
48992	MAPKAPK2	MAPKAPK2	mitogen-activated	1.0	1.0	1.4	1.3	1.1	1.0	1.2	1.1	1.0	1.0	4.4
			protein kinase-
			activated protein
50118	MAPKAPK3	MAPKAPK3	mitogen-activated	0.8	1.1	1.2	1.0	1.1	1.1		1.4	1.3	1.0	4.5
			protein kinase-
			activated protein
49511	MATN2			0.6	1.3	1.5	1.4	0.9	1.0	1.5	1.2	0.9	1.0	4.7
48470				0.8	1.2	0.6	1.7	1.0	1.0		1.6	1.0	1.0	5.2
50742	MGEA5	MGEA5	meningioma	0.9	1.0	1.2	1.1	1.0	1.0		1.4	0.9	1.0	4.5
			expressed antigen
			5 (hyaluronidase)
48933	MMP2	MMP2,	matrix	1.0	1.0	1.3	1.0	1.2	1.0		1.3	1.3	1.2	4.5
		gelatinase A	metalloproteinase
			2 (gelatinase A,
			72 kD gel
48949	MMP2	MMP2,	matrix	0.8	1.0	1.9	1.6	1.4	1.0	1.0	1.0	1.0	1.0	4.6
		gelatinase A	metalloproteinase
			2 (gelatinase A,
			72 kD gel
48334	2	MMP7	matrix	4.3	3.9	0.4	2.3	0.9	1.1		1.6	0.9	1.0	6.0
			metalloproteinase
			7 (matrilysin,
			uterine)
49124	MMP7	MMP7	matrix	3.2	3.1	0.6	1.6	0.9	1.0	0.7	1.0	1.0	1.0	4.6
			metalloproteinase
			7 (matrilysin,
			uterine)
46716	MPHOSPH9			0.9	1.0	0.5	1.6	1.0	1.0	0.7	1.2	0.9	1.1	4.8
49860	MSX1			1.2	1.1	1.2	1.1	1.0	1.0		1.6	1.1	1.1	4.8
47106	MT1L			2.0	1.7	1.5	1.0	0.8	1.0	4	1.3	0.8	1.0	4.3
46766	MT3			2.5	2.4	1.1	1.0	0.8	1.1	1.1	1.0	0.9	1.0	4.1
47772	5			1.4	1.4	0.7	1.4	0.9	1.0		1.7	0.8	1.0	5.1
48399	MUC1	mucin1	mucin 1,	1.6	1.6	1.0	1.0	0.9	1.0	0.9	1.1	0.8	1.1	4.2
			transmem-brane
50460	MUC1	mucin1	mucin 1,	2.0	1.8	1.0	1.0	0.8	1.1	0.9	1.0	0.8	1.1	4.2
			transmem-brane
48332	MUC4	mucin4	mucin 4,	1.9	1.5	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			tracheobronchial
50406	MX1			1.7	1.0	1.0	1.0	1.0	1.0	1.0	1.0		1.3	4.3
47754	NBS1			2.4	1.7	0.9	1.0	1.1	1.0	0.9	1.0	1.1	1.1	4.1
47875	NCK1	Nck	NCK adaptor	2.5	2.3	1.0	1.0	0.9	1.0	0.9	1.0	0.9	1.0	4.0
			protein 1
48719	NCK1	Nck	NCK adaptor	2.1	1.9	1.0	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
			protein 1
48290	NEDD4L			1.8	1.6	1.1	1.0	1.1	1.0	1.1	1.0	1.0	1.0	4.0
46799	NFE2L1	NFE2L1	nuclear factor	2.1	1.5	1.0	1.0	1.0	1.0	1.5	1.2	1.0	1.0	4.2
			(erythroid-derived
			2)-like 1
47201	NFIA	NFAT 3	nuclear factor I/A	0.6	1.5	1.3	1.2	1.0	1.0		1.4	1.0	1.0	4.6
47173	NFKB1	NFkappaB,	nuclear factor of	6.3	6.1	1.2	1.0	1.0	1.0	1.0	1.0	0.9	1.0	4.0
		p105	kappa light
			polypeptide gene
			enh
47877	NFKB1	NFkappaB,	nuclear factor of	6.3	6.2	1.1	1.0	0.9	1.0	1.0	1.0	0.9	1.0	4.0
		p105	kappa light
			polypeptide gene
			enh
50547	NFKB2	NFkappaB,	nuclear factor of	5.3	3.1	1.1	1.1	1.0	1.0	1.1	1.0	0.9	1.0	4.1
		p49/p100	kappa light
			polypeptide gene
			enh
50676	NFKB2	NFkappaB,	nuclear factor of	4.6	2.4	1.1	1.0	1.0	1.0	1.1	1.0	0.9	1.0	4.0
		p49/p100	kappa light
			polypeptide gene
			enh
49046	NFKBIA	IkB, alpha	nuclear factor of	9.4	6.3	1.6	1.4	0.9	1.1	1.1	1.1	1.0	1.0	4.5
			kappa light
			polypeptide gene
			enh
47147	NFKBIB	IkB, beta	nuclear factor of	1.8	1.7	0.8	1.1	0.9	1.0	0.9	1.0	0.9	1.0	4.1
			kappa light
			polypeptide gene
			enh
48923	NFKBIB	IkB, beta	nuclear factor of	1.7	1.7	0.9	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
			kappa light
			polypeptide gene
			enh
50542	NFKBIE	IkB, epsilon	nuclear factor of	2.6	2.0	1.3	1.3	1.0	1.0	1.2	1.2	1.0	1.0	4.4
			kappa light
			polypeptide gene
			enh
48405	NFKBIE	IkB, epsilon	nuclear factor of	2.8	2.7	1.3	1.3	1.1	1.0	1.3	1.1	1.1	1.0	4.4
			kappa light
			polypeptide gene
			enh
49783	6	NFYB	nuclear	0.9	1.0	0.6	1.5	0.8	1.1	0.7	1.1		1.4	5.0
			transcription factor
			Y, beta
49816	6	NFYB	nuclear	0.9	1.0	0.6	1.4	0.7	1.2	0.8	1.1		1.4	5.2
			transcription factor
			Y, beta
48712	NFYB	NFYB	nuclear	0.8	1.1	0.7	1.0	0.8	1.1	0.7	1.1		1.3	4.6
			transcription factor
			Y, beta
49690	NID	NID	nidogen (enactin)	0.9	1.0	1.8	1.5	1.3	1.0	0	1.4	1.0	1.0	4.9
49014	NINJ1			3.5	2.9	1.1	1.0	1.1	1.1	1.2	1.0	1.2	1.0	4.2
48029	NOL3	NOL3	nucleolar protein 3	0.5	2.0	0.8	1.1	0.9	1.0	1.0	1.0	1.1	1.0	4.2
			(apoptosis
			repressor with
			CARD
47679	NR4A2	TINUR	nuclear receptor	1.3	1.0	1.7	1.6	0.8	1.0	1.3	1.0	0.8	1.1	4.7
			subfamily 4, group
			A, member 2
47897	NR4A2	TINUR	nuclear receptor	1.6	1.1	1.9	1.4	0.9	1.0	1.5	1.1	0.9	1.0	4.5
			subfamily 4, group
			A, member 2
47712	NR4A2	TINUR	nuclear receptor	1.4	1.0	1.7	1.5	0.7	1.1	1.5	1.1	1.0	1.0	4.7
			subfamily 4, group
			A, member 2
48227	7	neuregulin1,	neuregulin 1	1.3	1.1	0.6	1.5	0.9	1.1		1.4	0.9	1.1	5.0
		neu diff.
		Factor,
		heregulin
48454	NRP1			0.5	1.6	1.1	1.0	1.1	1.0	1.1	1.0	1.1	1.0	4.0
47416	NTS			0.7	1.2	0.6	1.4	0.9	1.0	1.0	1.0	0.9	1.0	4.4
49778	OSMR	oncostatin MR	oncostatin M	2.2	1.8	1.4	1.2	1.1	1.0		1.3	1.0	1.0	4.5
			receptor
47183	OSMR	oncostatin MR	oncostatin M	2.6	2.5	1.5	1.5	1.0	1.0	1.3	1.1	1.1	1.0	4.6
			receptor
48545	P2RY1	P2RY1	purinergic	0.8	1.1	1.0	1.0	1.3	1.2	0.9	1.0		1.4	4.6
			receptor P2Y, G-
			protein coupled, 1
48193	P2RY1	P2RY1	purinergic	1.0	1.0	0.8	1.0	1.1	1.0	1.2	1.0		1.4	4.4
			receptor P2Y, G-
			protein coupled, 1
46650	P2RY6	P2RY6	pyrimidinergic	0.6	1.7	1.1	1.1	0.9	1.0	1.3	1.2	0.8	1.0	4.3
			receptor P2Y, G-
			protein coupled, 6
47194	P2RY6	P2RY6	pyrimidinergic	0.5	1.7	1.2	1.1	0.9	1.0	1.5	1.2	1.0	1.0	4.4
			receptor P2Y, G-
			protein coupled, 6
48707	P4HA1	P4HA1, prolyl-	procollagen-	1.0	1.0	1.6	1.1	0.9	1.0		1.5	0.9	1.0	4.7
		4-hydroxylase	proline, 2-
		alpha1	oxoglutarate 4-
			dioxygenase
47935	P4HA1	P4HA1, prolyl-	procollagen-	0.9	1.0	1.5	1.2	0.8	1.1		1.4	1.0	1.0	4.7
		4-hydroxylase	proline, 2-
		alpha1	oxoglutarate 4-
			dioxygenase
48971	8	P4HA2	procollagen-	1.1	1.0	2.1	1.4	1.0	1.0		1.6	1.2	1.1	5.2
			proline, 2-
			oxoglutarate 4-
			dioxygenase
49905	PAX3			1.9	1.6	1.1	1.0	0.9	1.0	1.1	1.0	1.0	1.0	4.0
49705	PCYT2			0.5	1.7	0.9	1.0	1.0	1.0	1.2	1.0	0.9	1.0	4.0
48556	PDE4B	phosphodiesterase	phosphodiesterase	2.6	2.5	1.2	1.1	1.0	1.0	1.0	1.0	1.1	1.0	4.2
		4B	4B, cAMP-
			specific (dunce
			(Drosop
48427	PDE4B	phosphodiesterase	phosphodiesterase	2.7	2.3	1.2	1.2	1.0	1.0	1.1	1.0	1.2	1.0	4.2
		4B	4B, cAMP-
			specific (dunce
			(Drosop
49671	9	PDEF	prostate	1.0	1.0	1.5	1.2	1.0	1.0		1.9	1.0	1.0	5.1
			epithelium-specific
			Ets transcription
			fac
48370	PDGFA	PDGF, alpha	platelet-derived	0.9	1.0	1.1	1.0	1.2	1.0		1.4	1.3	1.1	4.5
			growth factor
			alpha polypeptide
48824	PDK2			0.5	1.6	0.8	1.2	1.0	1.0	0.8	1.0	1.1	1.0	4.2
49965	PF4	platelet factor 4	platelet factor 4	2.3	1.5	1.0	1.0	1.2	1.0	1.1	1.0	1.0	1.0	4.0
47320	PI3	PI3	protease inhibitor	18.5	17.4	1.0	1.0	1.0	1.0	0.9	1.0	1.2	1.0	4.0
			3, skin-derived
			(SKALP)
49975	PIM1	pim-1	pim-1 oncogene	1.5	1.4	0.8	1.2	1.0	1.0		1.3	0.9	1.0	4.5
46818	PIM2	Pim-2	pim-2 oncogene	3.7	1.7	1.1	1.1	0.9	1.0		1.5	1.2	1.1	4.6
50338	PIM2	Pim-2	pim-2 oncogene	2.4	1.8	1.2	1.1	0.9	1.0		1.4	1.0	1.0	4.5
48547	PLA2G1B	phospholipase	phospholipase A2,	1.0	1.0	1.0	1.0	0.6	1.7	0.8	1.0	0.8	1.0	4.7
		A2	group IB
			(pancreas)
46577	PLA2G4B	phospholipase	phospholipase A2,	1.2	1.1	0.6	1.5	0.9	1.0	0.7	1.2	0.9	1.0	4.7
		A2	group IVB
			(cytosolic)
48624	PLA2R1	phospholipase	phospholipase A2	1.0	1.0	1.4	1.0	0.9	1.0	0	1.5	1.0	1.0	4.5
		A2	receptor 1, 180 kD
48023	PLAB	PLAB	prostate	2.4	2.1	1.2	1.1	1.2	1.1	1.2	1.1	1.2	1.0	4.2
			differentiation
			factor
50434	PLAB	PLAB	prostate	2.0	1.7	1.2	1.1	1.1	1.1	1.1	1.0	1.0	1.0	4.2
			differentiation
			factor
49424	PLAU	urokinase-type	plasminogen	7.9	6.6	1.5	1.3	1.4	1.3	1.1	1.0	1.3	1.0	4.6
		plasminogen	activator,
		activator	urokinase
47537	PLAU	urokinase-type	plasminogen	9.1	7.2	1.4	1.2	1.3	1.3	1.0	1.0	1.2	1.0	4.5
		plasminogen	activator,
		activator	urokinase
48138				2.2	2.0	1.4	1.2	1.0	1.0		1.7	1.2	1.2	5.1
49422	PLCG1	PLC gamma	phospholipase C,	0.6	1.5	0.9	1.1	0.9	1.0	0.9	1.0	1.0	1.0	4.2
		1,	gamma 1
		phopholipase	(formerly subtype
		C, gamma 1	148)
49073		PLOD	procollagen-	0.8	1.2	1.7	1.6	1.0	1.0		1.5	1.0	1.0	5.1
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
47704		PLOD	procollagen-	0.8	1.2	1.6	1.5	1.1	1.0		1.5	1.1	1.0	5.0
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
49106	PLOD	PLOD	procollagen-	0.8	1.1	1.7	1.5	1.0	1.0		1.4	1.0	1.0	4.9
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
47671	PLOD	PLOD	procollagen-	0.8	1.2	1.6	1.4	1.0	1.0		1.3	1.0	1.0	4.7
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
50313	PLOD2	PLOD2	procollagen-	1.0	1.0	1.5	1.1	0.8	1.0	4	1.3	1.0	1.0	4.5
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
49325	PLOD2	PLOD2	procollagen-	1.1	1.0	1.5	1.0	0.8	1.0		1.3	1.0	1.0	4.4
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
49809	PLXNB1	PLXNB1	plexin B1	0.6	1.6	0.8	1.0	0.9	1.1	0.8	1.0		1.3	4.3
49950	PPAP2B			3.0	2.3	1.0	1.0	1.1	1.0	1.3	1.0	1.0	1.0	4.0
46862	PPIF	cyclophilin F	peptidylprolyl	1.9	1.7	1.1	1.0	1.1	1.1	1.1	1.0	1.0	1.0	4.2
			isomerase F
			(cyclophilin F)
48616	PPIH	cyclophilin H	peptidyl prolyl	0.8	1.1	0.6	1.4	0.9	1.0	0.8	1.1	1.0	1.0	4.5
			isomerase H
			(cyclophilin H)
49738	PRKCA	PKC alpha	protein kinase C,	0.9	1.0	1.5	1.4	1.0	1.0		1.3	1.1	1.0	4.8
			alpha
48579	PRKCBP1	PRKCBP1	protein kinase C	1.3	1.3	0.7	1.2	0.8	1.1		1.5	0.8	1.1	4.9
			binding protein 1
47190	PRKCE	PKC epsilon	protein kinase C,	1.0	1.0	1.5	1.3	1.0	1.0	1.0	1.0	1.0	1.0	4.3
			epsilon
49921	PRKR			1.8	1.6	1.3	1.1	1.0	1.0		1.3	1.4	1.0	4.4
50401	PROL3			0.9	1.0	1.0	1.0	1.0	1.0	0.9	1.0		1.3	4.3
50096	PRSS11			0.7	1.5	1.6	1.3	1.1	1.1		1.4	1.2	1.1	4.9
49475	PSA			0.8	1.1	0.9	1.0	1.0	1.0		1.3	0.8	1.2	4.5
49219	PSMB10			2.8	2.2	0.9	1.0	1.1	1.0	1.0	1.0	1.2	1.0	4.0
47998	PSMB9			2.6	1.7	1.1	1.0	1.2	1.0	1.3	1.0	1.2	1.0	4.0
50625	PSMC6			1.3	1.1	0.6	1.4	0.9	1.0	0.8	1.0	0.8	1.1	4.6
47830	PSME1			1.6	1.6	1.1	1.0	1.1	1.0	0.9	1.1	1.0	1.0	4.1
49846	PTEN	PTEN	phosphatase and	0.7	1.3	1.4	1.2	1.0	1.0	4	1.3	0.9	1.0	4.6
			tensin homolog
			(mutated in multipl
47995		PTGER1	prostaglandin E	1.2	1.0	0.7	1.4	0.9	1.1		1.4	0.8	1.1	5.0
			receptor 1
			(subtype EP1),
			42 kD
50200	PTGER4	EP2	prostaglandin E	1.1	1.0	1.0	1.0	1.2	1.0	4	1.3	1.1	1.0	4.3
			receptor 4
			(subtype EP4)
46632		PTGES	prostaglandin E	3.2	3.1	2.4	1.9	1.2	1.0		1.6	1.2	1.0	5.5
			synthase
47176		PTGES	prostaglandin E	3.5	3.4	2.6	2.0	1.2	1.1	0	1.3	1.1	1.0	5.4
			synthase
50010	PTGIR	PTGIR	prostaglandin I2	0.7	1.0	0.7	1.1	1.0	1.0		1.3	0.8	1.0	4.5
			(prostacyclin)
			receptor (IP)
47499	PTGS2	PTGS2, COX2	prostaglandin-	14.9	7.0	1.2	1.1	0.9	1.0	0.9	1.0	0.9	1.0	4.1
			endoperoxide
			synthase 2
			(prostagland
50665	PTGS2	PTGS2, COX2	prostaglandin-	20.4	10.9	1.1	1.0	0.9	1.0	0.9	1.0	0.9	1.0	4.0
			endoperoxide
			synthase 2
			(prostagland
50376	PTPN1	PTP1B	protein tyrosine	2.0	1.8	1.1	1.0	1.1	1.0	1.2	1.1	1.1	1.0	4.2
			phosphatase, non-
			receptor type 1
48259	PTPN1	PTP1B	protein tyrosine	2.1	2.1	1.1	1.0	1.0	1.0	1.3	1.2	0.9	1.0	4.2
			phosphatase, non-
			receptor type 1
47208	PTPN3	PTPN3	protein tyrosine	0.9	1.0	1.4	1.3	1.0	1.0	1.4	1.2	1.0	1.0	4.6
			phosphatase, non-
			receptor type 3
50395	PTPRF	PTPRF	protein tyrosine	0.9	1.1	1.4	1.3	1.4	1.2	1.4	1.1	1.3	1.1	4.7
			phosphatase,
			receptor type, F
49533	PTPRG	PTPRG	protein tyrosine	0.9	1.0	1.5	1.3	1.1	1.0		1.5	1.0	1.0	4.8
			phosphatase,
			receptor type, G
50348	PTPRG	PTPRG	protein tyrosine	0.9	1.0	1.7	1.6	1.3	1.1	1.0	1.0	1.0	1.0	4.7
			phosphatase,
			receptor type, G
47698	PTPRJ	PTPRJ	protein tyrosine	1.7	1.6	1.6	1.5	1.0	1.0	1.3	1.2	1.0	1.0	4.7
			phosphatase,
			receptor type, J
47308	PTPRJ	PTPRJ	protein tyrosine	1.5	1.4	1.6	1.4	1.0	1.0	1.3	1.2	1.1	1.0	4.6
			phosphatase,
			receptor type, J
50632	PTPRJ	PTPRJ	protein tyrosine	1.6	1.4	1.5	1.4	1.0	1.0		1.3	1.0	1.0	4.7
			phosphatase,
			receptor type, J
47665	PTPRJ	PTPRJ	protein tyrosine	2.0	1.8	1.6	1.5	1.0	1.0	1.2	1.0	1.0	1.0	4.5
			phosphatase,
			receptor type, J
47983	PTPRN2	PTPRN2	protein tyrosine	0.9	1.0	0.5	1.4	1.0	1.0	0.6	1.0	1.0	1.0	4.4
			phosphatase,
			receptor type, N
			pol
46924	RAB9	RAB9	RAB9, member	2.3	2.0	1.2	1.2	1.0	1.0	1.1	1.0	1.0	1.0	4.2
			RAS oncogene
			family
47002	RAC1	Rac-1	ras-related C3	2.4	2.2	1.1	1.0	1.1	1.1	1.0	1.0	1.0	1.0	4.1
			botulinum toxin
			substrate 1 (rho fa
46969	RAC1	Rac-1	ras-related C3	2.4	2.2	1.1	1.1	1.1	1.0	1.0	1.0	1.0	1.0	4.1
			botulinum toxin
			substrate 1 (rho fa
47319	RAC1	Rac-1	ras-related C3	2.5	2.3	1.2	1.0	1.1	1.0	0.9	1.0	1.1	1.0	4.0
			botulinum toxin
			substrate 1 (rho fa
48542	RAP1GA1			0.4	1.9	1.0	1.0	1.0	1.0	1.2	1.0	1.2	1.0	4.0
47707	RASA2	RasGAP	RAS p21 protein	1.6	1.5	0.9	1.0	0.9	1.0	1.0	1.0	1.1	1.0	4.0
			activator 2
47652	RELA	p65, NFKB3	v-rel avian	2.4	2.0	0.8	1.1	1.0	1.0	1.0	1.0	1.0	1.0	4.1
			reticuloendotheliosis
			viral oncogene h
47672	RELA	p65, NFKB3	v-rel avian	2.5	2.0	0.9	1.0	1.1	1.0	0.9	1.0	1.1	1.0	4.0
			reticuloendotheliosis
			viral oncogene h
49087	RELB	l-rel	v-rel avian	7.1	6.4	1.3	1.0	1.1	1.0	0.9	1.0	1.0	1.0	4.0
			reticuloendotheliosis
			viral oncogene h
49120	RELB	l-rel	v-rel avian	7.1	6.2	1.3	1.0	1.1	1.0	1.0	1.0	1.1	1.0	4.0
			reticuloendotheliosis
			viral oncogene h
46658	RELB	l-rel	v-rel avian	2.7	2.3	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			reticuloendotheliosis
			viral oncogene h
49813	RGS14	RGS14	regulator of G-	0.3	2.7	0.9	1.0	1.0	1.0	1.2	1.1	1.1	1.0	4.1
			protein signalling
			14
47933	RIPK2	RIP2, RICK	receptor-	4.7	3.9	1.2	1.1	1.1	1.0	1.1	1.0	1.1	1.0	4.1
			interacting serine-
			threonine kinase 2
48244	RPS6KA5	RPS6KA5	ribosomal protein	0.8	1.1	0.8	1.1	1.0	1.0		1.3	1.0	1.0	4.5
			S6 kinase, 90 kD,
			polypeptide 5
50666	S100A12	S100A12	S100 calcium-	4.1	3.3	0.8	1.0	1.0	1.0	0.9	1.0	1.1	1.0	4.0
			binding protein
			A12 (calgranulin
			C)
46891	SAA2			1.0	1.0	1.6	1.4	1.0	1.0	1.4	1.0	0.9	1.0	4.4
49076		KIAA0524	KIAA0524 protein	0.8	1.1	0.7	1.3	0.7	1.4	0.8	1.0		1.4	5.1
50441	SAT			3.3	3.2	0.7	1.4	0.7	1.2	0.8	1.0	0.8	1.0	4.6
49507	SCNN1A			0.6	1.6	0.8	1.0	0.9	1.0	1.0	1.0	0.9	1.0	4.0
50026	SCYA2	MCP1	small inducible	100.5	99.1	1.0	1.0	1.0	1.0		1.4	1.1	1.0	4.4
			cytokine A2
			(monocyte
			chemotactic
47916	SCYA2	MCP1	small inducible	1.0	1.0	1.0	1.0	1.0	1.0		1.4	1.0	1.0	4.4
			cytokine A2
			(monocyte
			chemotactic
48830	SCYA2	MCP1	small inducible	16.0	8.8	1.1	1.0	0.9	1.0		1.3	1.0	1.0	4.3
			cytokine A2
			(monocyte
			chemotactic
46596	SCYA20	MIP-3a	small inducible	1.8	1.7	0.9	1.0	1.0	1.0	0.8	1.0	1.0	1.0	4.0
			cytokine subfamily
			A (Cys—Cys), me
48190	SCYA20	MIP-3a	small inducible	328.2	325.5	1.6	1.5	1.0	1.0	0.9	1.0	0.8	1.0	4.5
			cytokine subfamily
			A (Cys—Cys), me
46598	SCYA20	MIP-3a	small inducible	275.9	218.3	1.0	1.0	1.0	1.0	0.8	1.0	1.0	1.0	4.0
			cytokine subfamily
			A (Cys—Cys), me
47893	SCYA4	MIP-1beta	small inducible	5.1	2.5	1.0	1.0	1.0	1.0	0.9	1.0	1.1	1.0	4.0
			cytokine A4
			(homologous to
			mouse M
48257	SCYA4	MIP-1beta	small inducible	4.4	3.7	1.0	1.0	1.0	1.0	0.9	1.0	1.1	1.0	4.0
			cytokine A4
			(homologous to
			mouse M
49839	SCYB5	ENA-78	small inducible	27.5	18.0	0.9	1.0	1.0	1.0	1.1	1.0	0.9	1.0	4.0
			cytokine subfamily
			B (Cys-X-Cys),
49968	SCYB5	ENA-78	small inducible	26.3	16.6	1.1	1.0	1.0	1.0	1.1	1.0	0.9	1.0	4.0
			cytokine subfamily
			B (Cys-X-Cys),
49645	SCYD1	fractalkine	small inducible	14.5	5.8	1.0	1.0	1.0	1.0		1.3	1.4	1.2	4.5
			cytokine subfamily
			D (Cys-X3-Cys),
49492	SCYD1	fractalkine	small inducible	4.5	2.3	1.1	1.0	1.2	1.0	0.8	1.0	1.4	1.2	4.2
			cytokine subfamily
			D (Cys-X3-Cys),
48646	SDCBP			2.6	2.5	1.2	1.1	1.0	1.0	1.2	1.0	1.0	1.0	4.1
49498			serine (or	11.3	9.5	0.7	1.1	0.9	1.0		2.2	0.9	1.0	5.3
			cysteine)
			proteinase
			inhibitor, clade A
46950			serine (or	20.4	14.0	0.6	1.6	0.9	1.1		2.0	0.9	1.0	5.7
			cysteine)
			proteinase
			inhibitor, clade A
48415	SERPINB1		serine (or	1.0	1.0	1.8	1.7	1.3	1.0	1.0	1.0	1.0	1.0	4.7
			cysteine)
			proteinase
			inhibitor, clade B
47876	SERPINB3		serine (or	4.9	4.8	1.2	1.1	1.0	1.0	1.1	1.0	0.9	1.0	4.1
			cysteine)
			proteinase
			inhibitor, clade B
47332	SERPINB3		serine (or	4.7	4.1	1.1	1.0	1.0	1.0	1.0	1.0	1.2	1.0	4.0
			cysteine)
			proteinase
			inhibitor, clade B
49963	SERPINB8		serine (or	3.7	3.4	1.6	1.5	1.0	1.0	1.2	1.0	1.0	1.0	4.5
			cysteine)
			proteinase
			inhibitor, clade B
48205	SERPINB8		serine (or	3.3	2.4	1.6	1.5	1.0	1.0	1.2	1.0	1.0	1.0	4.5
			cysteine)
			proteinase
			inhibitor, clade B
49991	SERPINE1		serine (or	2.0	1.9	1.4	1.2	1.2	1.1	0.7	1.0	4	1.3	4.6
			cysteine)
			proteinase
			inhibitor, clade E
48269	SERPINE1		serine (or	1.9	1.8	1.3	1.1	1.1	1.1	0.9	1.0		1.3	4.5
			cysteine)
			proteinase
			inhibitor, clade E
48400	SERPINE2		serine (or	3.3	2.7	1.3	1.2	1.1	1.1	1.0	1.0	1.0	1.0	4.3
			cysteine)
			proteinase
			inhibitor, clade E
48367	SERPINE2		serine (or	3.5	2.7	1.4	1.2	1.1	1.0	1.0	1.0	1.1	1.0	4.2
			cysteine)
			proteinase
			inhibitor, clade E
48281	SERPINE2		serine (or	3.7	2.9	1.4	1.2	1.1	1.0	1.0	1.0	1.1	1.0	4.2
			cysteine)
			proteinase
			inhibitor, clade E
50577	SIAT4C			2.0	1.8	1.0	1.0	0.9	1.0	1.2	1.1	1.0	1.0	4.1
47211	SLC26A2	SLC26A2	solute carrier	0.9	1.0	1.5	1.0	1.0	1.0		1.5	1.1	1.0	4.5
			family 26 (sulfate
			transporter), me
50378	SLC26A2	SLC26A2	solute carrier	0.7	1.0	1.6	1.1	1.0	1.0		1.4	1.0	1.0	4.5
			family 26 (sulfate
			transporter), me
47310	SLC29A1	ENT1	solute carrier	0.6	1.5	1.0	1.0	1.0	1.0	1.1	1.0	1.1	1.0	4.0
			family 29
			(nucleoside
			transporters)
50641	SLC5A1			0.7	1.3	1.4	1.3	1.1	1.1	1.2	1.1	1.1	1.0	4.5
46678	SLPI	SLPI	secretory	3.1	1.9	0.7	1.0	0.8	1.1	0.7	1.0	0.9	1.0	4.1
			leukocyte
			protease inhibitor
			(antileukop
47300	SLPI	SLPI	secretory	2.9	1.9	0.8	1.1	0.9	1.0	0.8	1.0	1.2	1.0	4.1
			leukocyte
			protease inhibitor
			(antileukop
48182	SNAPC1			2.0	1.7	0.9	1.0	0.9	1.0	0.8	1.0	0.8	1.1	4.1
47418	SNK			2.3	2.0	0.8	1.1	1.0	1.0	0.8	1.1	1.1	1.0	4.2
50706	SP110	IFI41,	interferon-induced	3.5	2.0	1.1	1.0	1.0	1.0	1.2	1.1	1.3	1.0	4.1
		interferon	protein 41, 30 kD
		induced
		protein 41
50162	SP110	IFI41,	interferon-induced	2.6	2.2	1.2	1.1	1.0	1.0	1.2	1.0	1.2	1.0	4.1
		interferon	protein 41, 30 kD
		induced
		protein 41
49990	SRC	Src	v-src avian	1.5	1.3	1.4	1.3	1.0	1.0	1.3	1.1	0.9	1.0	4.5
			sarcoma
			(Schmidt-Ruppin
			A-2) viral onc
49446	SRC	Src	v-src avian	1.5	1.4	1.4	1.4	0.9	1.0	1.3	1.1	0.9	1.0	4.5
			sarcoma
			(Schmidt-Ruppin
			A-2) viral onc
50003	STAT5A	STAT5a	signal transducer	4.8	3.9	1.2	1.1	1.0	1.0	1.0	1.0	1.1	1.1	4.2
			and activator of
			transcription 5
48987	STAT5A	STAT5a	signal transducer	5.0	4.6	1.1	1.0	1.1	1.0	1.0	1.0	1.1	1.0	4.0
			and activator of
			transcription 5
47323	STAT5B	STAT5b	signal transducer	1.2	1.0	0.9	1.0	1.0	1.0	1.0	1.0		1.3	4.3
			and activator of
			transcription 5
46796				2.8	2.3	1.8	1.3	1.0	1.0		2.2	1.2	1.0	5.6
48769	SUV39H1			1.0	1.0	0.7	1.0	0.9	1.0		1.6	1.0	1.0	4.6
46754	TAF1A			1.1	1.0	0.6	1.4	0.8	1.1	0.8	1.0	1.0	1.0	4.5
50071	TAF1C			1.1	1.0	0.8	1.0	0.8	1.1	0.8	1.1		1.4	4.6
49372	TAP1			2.6	2.4	1.2	1.2	1.1	1.0	1.4	1.2	1.3	1.2	4.5
46975	TBK1	TANK binding	TANK-binding	1.6	1.5	0.9	1.0	0.8	1.0	0.8	1.0	0.9	1.0	4.1
		kinase, NAK	kinase 1
46613	TCF12	TCF12	transcription factor	1.8	1.7	1.1	1.0	1.0	1.0	1.3	1.2	1.0	1.0	4.2
			12 (HTF4, helix-
			loop-helix tr
50370	TCFL5	TCFL5	transcription	0.6	1.6	1.0	1.0	0.9	1.0	1.0	1.0	1.0	1.0	4.0
			factor-like 5 (basic
			helix-loop-heli
46991	TFPI2	TFPI2	tissue factor	2.1	1.9	0.8	1.3	1.0	1.0		1.3	1.0	1.0	4.6
			pathway inhibitor 2
47987		THBS1	thrombospondin 1	1.0	1.0	0.6	1.4	0.9	1.0		1.6	0.8	1.1	5.1
46859	TIEG	TGF beta-	TGFB inducible	1.9	1.6	1.3	1.3	1.1	1.0	1.1	1.0	1.0	1.0	4.3
		inducible early	early growth
		growth	response
		response
48457	TIF1			0.6	1.5	0.9	1.1	0.9	1.1	0.9	1.1	0.9	1.0	4.3
49818	TIMP2	TIMP2	tissue inhibitor of	0.8	1.0	1.4	1.1	1.3	1.2		1.5	1.1	1.0	4.8
			metalloproteinase 2
49420		TIMP2	tissue inhibitor of	0.9	1.0	2.0	1.4	1.2	1.0		1.5	1.1	1.0	5.0
			metalloproteinase 2
49785	TIMP2	TIMP2	tissue inhibitor of	0.9	1.0	1.5	1.1	1.3	1.2		1.4	1.1	1.0	4.6
			metalloproteinase 2
48239	TLN1	TLN1	talin 1	1.0	1.0	1.1	1.0	0.6	1.3	0.8	1.0	0.7	1.0	4.3
47918	TNFAIP1	TNFAIP1	tumor necrosis	1.7	1.6	1.2	1.1	1.0	1.0	1.0	1.0	1.0	1.0	4.2
			factor, alpha-
			induced protein 1
			(en
47936	TNFAIP1	TNFAIP1	tumor necrosis	1.7	1.6	1.1	1.1	1.0	1.0	1.0	1.0	1.0	1.0	4.1
			factor, alpha-
			induced protein 1
			(en
47993	TNFAIP2	TNFAIP2	tumor necrosis	19.5	19.3	0.9	1.0	0.8	1.1	0.9	1.0	0.9	1.0	4.1
			factor, alpha-
			induced protein 2
47642	TNFAIP3	A20,	tumor necrosis	35.5	34.5	1.2	1.0	1.0	1.0	0.8	1.1	1.1	1.0	4.1
		TNFAIP2, Zn	factor, alpha-
		finger	induced protein 3
48770	TNFAIP3	A20,	tumor necrosis	2.2	1.8	1.0	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
		TNFAIP2, Zn	factor, alpha-
		finger	induced protein 3
47155	TNFAIP6	TNFAIP6	tumor necrosis	11.8	8.3	0.9	1.0	1.1	1.0	0.7	1.0	0.9	1.0	4.0
			factor, alpha-
			induced protein 6
46803	TNFAIP6	TNFAIP6	tumor necrosis	10.6	7.0	1.0	1.0	1.1	1.0	0.7	1.0	0.9	1.0	4.0
			factor, alpha-
			induced protein 6
49143	TNFRSF10B	DR5	tumor necrosis	2.2	2.0	1.2	1.1	1.1	1.0	1.3	1.1	0.9	1.0	4.2
			factor receptor
			superfamily,
			member
49272	TNFRSF10B	DR5	tumor necrosis	2.2	2.0	1.2	1.1	1.1	1.0	1.2	1.1	1.0	1.0	4.2
			factor receptor
			superfamily,
			member
47143	TNFRSF10C	DcR1	tumor necrosis	1.2	1.1	1.2	1.1	1.0	1.0	4	1.3	1.3	1.1	4.5
			factor receptor
			superfamily,
			member
50365	TNFRSF1A	TNFR1	tumor necrosis	0.5	1.6	1.1	1.1	1.0	1.0	1.2	1.1	0.9	1.0	4.1
			factor receptor
			superfamily,
			member
47697	TNFRSF6B	DcR3	tumor necrosis	1.1	1.1	0.6	1.3	0.9	1.0		1.5	0.9	1.0	4.8
			factor receptor
			superfamily,
			member
50524	TNFRSF6B	DcR3	tumor necrosis	1.1	1.0	0.7	1.4	0.9	1.0		1.4	0.9	1.0	4.8
			factor receptor
			superfamily,
			member
47517	TNFRSF9	4-1BB, CD137	tumor necrosis	3.4	1.9	1.0	1.0	0.9	1.0	0.9	1.0	1.0	1.0	4.1
			factor receptor
			superfamily,
			member
49303	TNFSF12	TWEAK	tumor necrosis	0.5	1.5	1.1	1.0	1.1	1.0	1.3	1.1	1.0	1.0	4.1
			factor (ligand)
			superfamily,
			member
48626	TNNT1			0.9	1.0	0.6	1.5	0.8	1.1	0.8	1.2	0.9	1.0	4.7
48275	TRAF2	TRAF2	TNF receptor-	1.5	1.5	0.9	1.0	0.9	1.0	0.9	1.0	1.0	1.0	4.1
			associated factor 2
48078	TRIP	TRIP	TRAF interacting	0.9	1.0	0.7	1.2	1.0	1.0		1.5	1.0	1.0	4.7
			protein
46947	TRIP	TRIP	TRAF interacting	0.8	1.0	0.6	1.3	0.9	1.0		1.5	1.0	1.0	4.8
			protein
46980	TRIP	TRIP	TRAF interacting	0.9	1.0	0.6	1.4	0.9	1.0	0.5	1.2	1.0	1.0	4.6
			protein
49901	TROAP			1.0	1.0	0.5	1.0	0.9	1.0		1.6	0.7	1.2	4.8
49402	TWIST			0.8	1.0	0.7	1.0	1.0	1.0	4	1.3	1.2	1.0	4.4
50575	UBD			8.6	3.9	1.0	1.0	1.0	1.0	0.7	1.0	0.8	1.1	4.1
50592	VARS2			1.0	1.0	0.6	1.4	1.3	1.0		1.3	1.0	1.0	4.6
47298	VAV3	Vav3	vav 3 oncogene	1.0	1.0	0.6	1.4	0.9	1.0	1.0	1.0	1.0	1.0	4.5
48262	VAV3	Vav3	vav 3 oncogene	0.2	5.1	0.8	1.0	0.9	1.0	1.0	1.0	1.0	1.0	4.0
49899	WWOX			1.2	1.0	1.2	1.2	1.1	1.0	4	1.3	1.3	1.1	4.6
50466		tristetrapro-lin	zinc finger protein	1.8	1.4	1.8	1.3	1.1	1.1		1.7	1.1	1.0	5.1
			homologous to
			Zfp-36 in mouse
48979		tristetrapro-lin	zinc finger protein	1.7	1.2	2.0	1.7	1.1	1.1	0	1.4	1.0	1.0	5.1
			homologous to
			Zfp-36 in mouse
47758	ZNF184			2.3	2.0	1.3	1.0	1.3	1.2	1.1	1.0	1.3	1.2	4.4
50586	ZNF263			1.4	1.2	0.7	1.2	0.9	1.0		1.4	0.9	1.0	4.6
49723	ZNF76			0.9	1.1	0.7	1.4	0.9	1.0		1.3	0.9	1.0	4.6
Drug Effects in A549 Cells, sum min fold change >=4.5
Genes in bold - ≧1.5-fold differential expression in response to IL-1β
Genes in italics - ≧1.3-fold differential expression in response to Clari and/or FMA alone
Genes in bold and italics - ≧1.3-fold differential expression in response to IL1 + Clari and/or IL1 + FMA
48998	FADS1		fatty acid	0.8	1.0	2.1	2.0	1.1	1.1		2.0	1.0	1.0	6.0
			desaturase 1
48334	MMP7	MMP7	matrix	4.3	3.9	0.4	2.3	0.9	1.1		1.6	0.9	1.0	6.0
			metalloproteinase
			7 (matrilysin,
			uterine)
46950	SERPINA3		serine (or	20.4	14.0	0.6	1.6	0.9	1.1		2.0	0.9	1.0	5.7
			cysteine)
			proteinase
			inhibitor, clade A
49417	HSPA1B	HSPA1B	heat shock 70 kD	1.0	1.0	1.5	1.3	1.0	1.0		2.0		1.3	5.6
			protein 1B
50140	ECT2	ECT2	epithelial cell	1.2	1.1	0.5	1.6	0.9	1.1		1.7	0.8	1.2	5.6
			transforming
			sequence 2
			oncogene
49064	HSPA1B	HSPA1B	heat shock 70 kD	1.0	1.0	1.5	1.3	1.0	1.0		1.9		1.3	5.6
			protein 1B
48721	DAF	CD55	decay	4.0	2.7	2.1	2.0	1.0	1.0		1.6	1.1	1.0	5.6
			accelerating factor
			for complement
			(CD55, Cr
46796	STC1		stanniocalcin 1	2.8	2.3	1.8	1.3	1.0	1.0		2.2	1.2	1.0	5.6
48618	HSPA1B	HSPA1B	heat shock 70 kD	1.1	1.0	1.5	1.3	1.0	1.0		1.9		1.3	5.5
			protein 1B
46632	PTGES	PTGES	prostaglandin E	3.2	3.1	2.4	1.9	1.2	1.0		1.6	1.2	1.0	5.5
			synthase
48032	ECT2	ECT2	epithelial cell	1.1	1.0	0.5	1.4	0.8	1.1		1.7	0.8	1.2	5.4
			transforming
			sequence 2
			oncogene
47176	PTGES	PTGES	prostaglandin E	3.5	3.4	2.6	2.0	1.2	1.1	0	1.3	1.1	1.0	5.4
			synthase
46942	DAF	CD55	decay	4.0	3.6	2.0	1.9	1.0	1.0		1.4	1.2	1.0	5.3
			accelerating factor
			for complement
			(CD55, Cr
47185	HSPA1B	HSPA1B	heat shock 70 kD	1.2	1.0	1.3	1.1	1.0	1.0		1.9	1.4	1.2	5.3
			protein 1B
49498	SERPINA3		serine (or	11.3	9.5	0.7	1.1	0.9	1.0		2.2	0.9	1.0	5.3
			cysteine)
			proteinase
			inhibitor, clade A
47907	ERG	ERG	v-ets avian	4.7	4.1	1.0	1.0	1.0	1.0	1.3	1.2		2.0	5.3
			erythroblastosis
			virus E26
			oncogene re
48470	MCM5			0.8	1.2	0.6	1.7	1.0	1.0		1.6	1.0	1.0	5.2
50084	IDI1		isopentyl	0.7	1.0	1.7	1.6	0.8	1.1		1.4	0.9	1.1	5.2
			diphosphate delta
			isomerase
49276				1.0	1.0	1.3	1.2	0.9	1.0		1.8	1.4	1.2	5.2
49816	NFYB	NFYB	nuclear	0.9	1.0	0.6	1.4	0.7	1.2	0.8	1.1		1.4	5.2
			transcription factor
			Y, beta
47032	CIT	CIT	citron (rho-	0.7	1.1	0.6	1.5	0.8	1.1		1.4	0.8	1.2	5.2
			interacting,
			serine/threonine
			kinase 2
49155	ARTS-1			0.7	1.3	0.6	1.4	0.9	1.0		1.8	1.0	1.0	5.2
49873	INSIG1			0.6	1.1	2.1	1.3	0.9	1.0		1.9	1.0	1.0	5.2
48972	CIT	CIT	citron (rho-	0.7	1.1	0.4	2.1	0.8	1.1	1.0	1.0	1.0	1.0	5.2
			interacting,
			serine/threonine
			kinase 2
48971	P4HA2	P4HA2	procollagen-	1.1	1.0	2.1	1.4	1.0	1.0		1.6	1.2	1.1	5.2
			proline, 2-
			oxoglutarate 4-
			dioxygenase
48979	ZFP36	tristetraprolin	zinc finger protein	1.7	1.2	2.0	1.7	1.1	1.1	0	1.4	1.0	1.0	5.1
			homologous to
			Zfp-36 in mouse
50564	CRA			0.6	1.5	0.6	1.4	0.7	1.3		1.3	0.7	1.2	5.1
49671	PDEF	PDEF	prostate	1.0	1.0	1.5	1.2	1.0	1.0		1.9	1.0	1.0	5.1
			epithelium-specific
			Ets transcription
			fac
49764	EHF	EHF	ets homologous	1.2	1.2	0.6	1.4	0.8	1.0		1.6	0.9	1.0	5.1
			factor
48138	PLAUR		urokinase	2.2	2.0	1.4	1.2	1.0	1.0		1.7	1.2	1.2	5.1
			plasminogen
			activator receptor
47772	MTHFD2		methylene	1.4	1.4	0.7	1.4	0.9	1.0		1.7	0.8	1.0	5.1
			tetrahydrofolate
			dehydrogenase
47987	THBS1	THBS1	thrombospondin 1	1.0	1.0	0.6	1.4	0.9	1.0		1.6	0.8	1.1	5.1
49073	PLOD	PLOD	procollagen-	0.8	1.2	1.7	1.6	1.0	1.0		1.5	1.0	1.0	5.1
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
49076	SARM	KIAA0524	KIAA0524 protein	0.8	1.1	0.7	1.3	0.7	1.4	0.8	1.0		1.4	5.1
50466	ZFP36	tristetrapro-lin	zinc finger protein	1.8	1.4	1.8	1.3	1.1	1.1		1.7	1.1	1.0	5.1
			homologous to
			Zfp-36 in mouse
49347	HNRPA3			0.9	1.0	0.5	1.6	1.0	1.0		1.5	1.0	1.0	5.0
48227	NRG1	neuregulin1,	neuregulin 1	1.3	1.1	0.6	1.5	0.9	1.1		1.4	0.9	1.1	5.0
		neu diff.
		Factor,
		heregulin
50037	LAMC2	LAMC2	laminin, gamma 2	1.0	1.0	2.0	1.5	1.0	1.0	0	1.5	1.2	1.0	5.0
			(nicein (100 kD),
			kalinin (105 kD),
49783	NFYB	NFYB	nuclear	0.9	1.0	0.6	1.5	0.8	1.1	0.7	1.1		1.4	5.0
			transcription factor
			Y, beta
49147				1.0	1.0	1.3	1.1	0.9	1.0		1.8	1.4	1.2	5.0
49952	AADAC			0.9	1.0	0.6	1.3	0.8	1.3	0.7	1.0		1.4	5.0
49981	BMP6	BMP6	bone	1.4	1.1	1.5	1.4	0.9	1.0		1.5	0.8	1.1	5.0
			morphogenetic
			protein 6
49420	TIMP2	TIMP2	tissue inhibitor of	0.9	1.0	2.0	1.4	1.2	1.0		1.5	1.1	1.0	5.0
			metalloproteinase 2
46875	LOC94105			1.0	1.0	2.1	1.9	1.1	1.1	1.1	1.0	1.0	1.0	5.0
47995	PTGER1	PTGER1	prostaglandin E	1.2	1.0	0.7	1.4	0.9	1.1		1.4	0.8	1.1	5.0
			receptor 1
			(subtype EP1),
			42 kD
47704	PLOD	PLOD	procollagen-	0.8	1.2	1.6	1.5	1.1	1.0		1.5	1.1	1.0	5.0
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
48579	PRKCBP1	PRKCBP1	protein kinase C	1.3	1.3	0.7	1.2	0.8	1.1		1.5	0.8	1.1	4.9
			binding protein 1
49106	PLOD	PLOD	procollagen-	0.8	1.1	1.7	1.5	1.0	1.0		1.4	1.0	1.0	4.9
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
46911	KIAA0170			1.0	1.0	0.6	1.5	0.9	1.0		1.4	0.9	1.0	4.9
50474	CEBPA	C/EBP alpha	CCAAT/enhancer	0.9	1.0	1.5	1.4	1.1	1.0		1.5	1.0	1.0	4.9
			binding protein
			(C/EBP), alpha
49690	NID	NID	nidogen (enactin)	0.9	1.0	1.8	1.5	1.3	1.0	0	1.4	1.0	1.0	4.9
46856	IL8	interleukin-8	interleukin 8	239.5	161.1	2.2	1.9	0.8	1.0	1.0	1.0	1.1	1.0	4.9
50096	PRSS11			0.7	1.5	1.6	1.3	1.1	1.1		1.4	1.2	1.1	4.9
49860	MSX1			1.2	1.1	1.2	1.1	1.0	1.0		1.6	1.1	1.1	4.8
47030				0.6	1.4	0.6	1.3	0.9	1.1		1.5	0.9	1.0	4.8
49118	CCNA2	cyclin A2	cyclin A2	0.9	1.0	0.6	1.3	0.9	1.0		1.5	0.8	1.0	4.8
47691	BATF	B-ATF	basic leucine	0.8	1.0	0.8	1.0	0.6	1.5	0.7	1.0	0.7	1.2	4.8
			zipper
			transcription
			factor, ATF-lik
48520	KIAA0418			1.2	1.0	1.4	1.3	1.0	1.0		1.5	1.2	1.0	4.8
49818	TIMP2	TIMP2	tissue inhibitor of	0.8	1.0	1.4	1.1	1.3	1.2		1.5	1.1	1.0	4.8
			metalloproteinase 2
50282	CSRP1			2.5	1.7	1.6	1.3	1.4	1.3	1.4	1.2	1.2	1.0	4.8
49901	TROAP			1.0	1.0	0.5	1.0	0.9	1.0		1.6	0.7	1.2	4.8
46947	TRIP	TRIP	TRAF interacting	0.8	1.0	0.6	1.3	0.9	1.0		1.5	1.0	1.0	4.8
			protein
49098	BMP4	BMP4	bone	0.8	1.1	1.4	1.2	0.9	1.0		1.6	1.0	1.0	4.8
			morphogenetic
			protein 4
50126	EREG	epiregulin	epiregulin	3.8	3.6	1.3	1.1	1.4	1.2		1.5	1.1	1.0	4.8
50042	LAMB3	LAMB3	laminin, beta 3	13.3	11.0	0.7	1.3	0.9	1.0		1.4	0.8	1.1	4.8
			(nicein (125 kD),
			kalinin (140 kD),
46716	MPHOSPH9			0.9	1.0	0.5	1.6	1.0	1.0	0.7	1.2	0.9	1.1	4.8
50568	KNSL5			1.1	1.0	0.5	1.2	0.8	1.1		1.4	0.8	1.1	4.8
47976	DDB2			0.6	1.5	0.7	1.3	0.9	1.0		1.5	1.0	1.0	4.8
49533	PTPRG	PTPRG	protein tyrosine	0.9	1.0	1.5	1.3	1.1	1.0		1.5	1.0	1.0	4.8
			phosphatase,
			receptor type, G
49290	ARHB	RhoB	ras homolog gene	1.3	1.2	1.4	1.1	1.4	1.3		1.3	1.2	1.0	4.8
			family, member B
47831	HEC			1.1	1.0	0.6	1.4	0.9	1.0		1.3	1.0	1.0	4.8
49738	PRKCA	PKC alpha	protein kinase C,	0.9	1.0	1.5	1.4	1.0	1.0		1.3	1.1	1.0	4.8
			alpha
50319	BMP6	BMP6	bone	1.2	1.2	1.5	1.4	1.0	1.0	4	1.3	0.9	1.1	4.8
			morphogenetic
			protein 6
50349	LOC51295	ECSIT	ECSIT	0.9	1.1	0.6	1.4	1.1	1.0		1.4	1.1	1.0	4.8
50524	TNFRSF6B	DcR3	tumor necrosis	1.1	1.0	0.7	1.4	0.9	1.0		1.4	0.9	1.0	4.8
			factor receptor
			superfamily,
			member
49773	CCNA2	cyclin A2	cyclin A2	1.0	1.0	0.5	1.4	0.9	1.0	0.6	1.2	0.8	1.1	4.8
46670	DUSP5	DUSP5	dual specificity	2.0	2.0	1.4	1.3	1.2	1.1	1.3	1.2	1.2	1.1	4.8
			phosphatase 5
49113	HS3ST3A1	HS3ST3A1	heparan sulfate	2.9	2.4	1.4	1.2	1.0	1.0		1.5	1.1	1.1	4.8
			(glucosamine) 3-
			O-sulfotransferase
47697	TNFRSF6B	DcR3	tumor necrosis	1.1	1.1	0.6	1.3	0.9	1.0		1.5	0.9	1.0	4.8
			factor receptor
			superfamily,
			member
49167	KDELR3			0.9	1.0	1.5	1.1	1.1	1.0		1.6	1.1	1.0	4.8
47834	CYP1A1			1.0	1.0	1.5	1.4	1.2	1.2	1.3	1.2	1.2	1.0	4.8
49798	FRAG1	FRAG1	FGF receptor	0.7	1.4	1.2	1.1	1.1	1.1	4	1.4	1.2	1.2	4.7
			activating protein 1
48063				0.8	1.0	0.6	1.4	0.9	1.0		1.3	0.9	1.0	4.7
47792				1.5	1.4	0.6	1.4	0.9	1.0		1.4	0.9	1.0	4.7
48626	TNNT1			0.9	1.0	0.6	1.5	0.8	1.1	0.8	1.2	0.9	1.0	4.7
49510				1.6	1.4	1.9	1.5	1.0	1.0		1.3	1.0	1.0	4.7
49572	CRMP1			0.7	1.3	1.4	1.1	1.1	1.0		1.5	1.3	1.2	4.7
49688	GSK3B	GSK3B	glycogen synthase	1.5	1.4	1.4	1.4	1.0	1.0	4	1.3	0.9	1.0	4.7
			kinase 3 beta
48547	PLA2G1B	phospholipase	phospholipase A2,	1.0	1.0	1.0	1.0	0.6	1.7	0.8	1.0	0.8	1.0	4.7
		A2	group IB
			(pancreas)
49322	JUNB	JunB	jun B proto-	1.2	1.1	1.7	1.6	0.9	1.0	1.3	1.0	0.8	1.1	4.7
			oncogene
49529	FGA			0.4	2.1	1.5	1.3	0.9	1.0		1.3	0.8	1.1	4.7
48673	LRDD	LRDD	leucine rich repeat	0.9	1.0	0.7	1.3	0.8	1.1		1.4	1.0	1.0	4.7
			and death domain
			containing pr
47671	PLOD	PLOD	procollagen-	0.8	1.2	1.6	1.4	1.0	1.0		1.3	1.0	1.0	4.7
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
49511	MATN2			0.6	1.3	1.5	1.4	0.9	1.0	1.5	1.2	0.9	1.0	4.7
49922	DHCR24			0.9	1.1	1.4	1.2	1.0	1.0		1.5	1.0	1.0	4.7
49903	DDXL			1.0	1.0	0.7	1.4	1.0	1.0		1.3	0.9	1.0	4.7
48740	MAP2K6	MKK6	mitogen-activated	0.6	1.4	1.5	1.5	0.9	1.1	1.3	1.2	1.0	1.0	4.7
			protein kinase
			kinase 6
46577	PLA2G4B	phospholipase	phospholipase A2,	1.2	1.1	0.6	1.5	0.9	1.0	0.7	1.2	0.9	1.0	4.7
		A2	group IVB
			(cytosolic)
48707	P4HA1	P4HA1, prolyl-	procollagen-	1.0	1.0	1.6	1.1	0.9	1.0		1.5	0.9	1.0	4.7
		4-hydroxylase	proline, 2-
		alpha1	oxoglutarate 4-
			dioxygenase
49163	LGALS3			1.0	1.0	1.3	1.2	1.2	1.1	4	1.3	1.2	1.1	4.7
50348	PTPRG	PTPRG	protein tyrosine	0.9	1.0	1.7	1.6	1.3	1.1	1.0	1.0	1.0	1.0	4.7
			phosphatase,
			receptor type, G
48000	CTSH			0.7	1.3	1.4	1.3	1.1	1.0		1.4	1.2	1.0	4.7
48282	ARHG	RhoG	ras homolog gene	1.8	1.6	1.3	1.2	1.1	1.0		1.4	1.2	1.1	4.7
			family, member G
			(rho G)
48094	HSPA6	HSPA6	heat shock 70 kD	1.0	1.0	1.1	1.0	1.0	1.0		1.6	1.2	1.0	4.7
			protein 6
			(HSP70B′)
47708	EHF	EHF	ets homologous	1.0	1.0	1.0	1.0	1.0	1.0		1.7	1.0	1.0	4.7
			factor
48663	KIAA0089			0.6	1.3	1.5	1.3	1.2	1.1		1.3	1.0	1.0	4.7
47698	PTPRJ	PTPRJ	protein tyrosine	1.7	1.6	1.6	1.5	1.0	1.0	1.3	1.2	1.0	1.0	4.7
			phosphatase,
			receptor type, J
47712	NR4A2	TINUR	nuclear receptor	1.4	1.0	1.7	1.5	0.7	1.1	1.5	1.1	1.0	1.0	4.7
			subfamily 4, group
			A, member 2
50395	PTPRF	PTPRF	protein tyrosine	0.9	1.1	1.4	1.3	1.4	1.2	1.4	1.1	1.3	1.1	4.7
			phosphatase,
			receptor type, F
48078	TRIP	TRIP	TRAF interacting	0.9	1.0	0.7	1.2	1.0	1.0		1.5	1.0	1.0	4.7
			protein
47935	P4HA1	P4HA1, prolyl-	procollagen-	0.9	1.0	1.5	1.2	0.8	1.1		1.4	1.0	1.0	4.7
		4-hydroxylase	proline, 2-
		alpha1	oxoglutarate 4-
			dioxygenase
47679	NR4A2	TINUR	nuclear receptor	1.3	1.0	1.7	1.6	0.8	1.0	1.3	1.0	0.8	1.1	4.7
			subfamily 4, group
			A, member 2
48918	KIAA0514			0.8	1.2	1.4	1.3	1.1	1.0	4	1.3	1.1	1.0	4.7
48415	SERPINB1		serine (or	1.0	1.0	1.8	1.7	1.3	1.0	1.0	1.0	1.0	1.0	4.7
			cysteine)
			proteinase
			inhibitor, clade B
46817	ATF3	ATF3	activating	2.3	2.0	1.3	1.3	1.4	1.1		1.3	1.0	1.0	4.7
			transcription factor 3
47516	BTG1			1.2	1.1	1.5	1.3	1.1	1.0		1.4	1.1	1.0	4.7
48739				1.7	1.4	0.8	1.0	1.1	1.0		1.7	1.0	1.0	4.7
48943	CSF3R	G-CSF	colony stimulating	0.7	1.0	0.5	1.7	1.1	1.0	1.0	1.0	1.1	1.0	4.7
		receptor	factor 3 receptor
			(granulocyte)
50632	PTPRJ	PTPRJ	protein tyrosine	1.6	1.4	1.5	1.4	1.0	1.0		1.3	1.0	1.0	4.7
			phosphatase,
			receptor type, J
49292	LTB	LT, beta	lymphotoxin beta	4.6	2.7	1.0	1.0	1.0	1.0		1.6	1.3	1.0	4.7
			(TNF superfamily,
			member 3)
50607	ITGB3BP			0.8	1.0	0.6	1.0	0.9	1.1		1.4	0.8	1.2	4.7
47554	ERG	ERG	v-ets avian	1.0	1.0	1.0	1.0	0.9	1.0		1.3		1.4	4.7
			erythroblastosis
			virus E26
			oncogene re
47617	ARF3			1.0	1.0	1.0	1.0	0.5	1.7	0.8	1.0	0.7	1.0	4.7
48713	GPRK7	MNK2	G protein-coupled	0.6	1.4	1.7	1.4	1.1	1.0	1.3	1.2	1.1	1.0	4.6
			receptor kinase 7
46980	TRIP	TRIP	TRAF interacting	0.9	1.0	0.6	1.4	0.9	1.0	0.5	1.2	1.0	1.0	4.6
			protein
49424	PLAU	urokinase-type	plasminogen	7.9	6.6	1.5	1.3	1.4	1.3	1.1	1.0	1.3	1.0	4.6
		plasminogen	activator,
		activator	urokinase
48712	NFYB	NFYB	nuclear	0.8	1.1	0.7	1.0	0.8	1.1	0.7	1.1		1.3	4.6
			transcription factor
			Y, beta
49723	ZNF76			0.9	1.1	0.7	1.4	0.9	1.0		1.3	0.9	1.0	4.6
50592	VARS2			1.0	1.0	0.6	1.4	1.3	1.0		1.3	1.0	1.0	4.6
49991	SERPINE1		serine (or	2.0	1.9	1.4	1.2	1.2	1.1	0.7	1.0	4	1.3	4.6
			cysteine)
			proteinase
			inhibitor, clade E
46818	PIM2	Pim-2	pim-2 oncogene	3.7	1.7	1.1	1.1	0.9	1.0		1.5	1.2	1.1	4.6
46776	MAD2L1			0.9	1.0	0.7	1.1	0.8	1.1		1.4	0.9	1.0	4.6
49846	PTEN	PTEN	phosphatase and	0.7	1.3	1.4	1.2	1.0	1.0	4	1.3	0.9	1.0	4.6
			tensin homolog
			(mutated in multipl
50071	TAF1C			1.1	1.0	0.8	1.0	0.8	1.1	0.8	1.1		1.4	4.6
50586	ZNF263			1.4	1.2	0.7	1.2	0.9	1.0		1.4	0.9	1.0	4.6
49315	COL4A2	COL4A2	collagen, type IV,	1.9	1.6	1.5	1.3	1.2	1.0		1.3	1.1	1.0	4.6
			alpha 2
48949	MMP2	MMP2,	matrix	0.8	1.0	1.9	1.6	1.4	1.0	1.0	1.0	1.0	1.0	4.6
		gelatinase A	metalloproteinase
			2 (gelatinase A,
			72 kD gel
49785	TIMP2	TIMP2	tissue inhibitor of	0.9	1.0	1.5	1.1	1.3	1.2		1.4	1.1	1.0	4.6
			metalloproteinase 2
46778	HMG2			1.1	1.0	0.6	1.1	0.8	1.1		1.4	0.8	1.0	4.6
47183	OSMR	oncostatin MR	oncostatin M	2.6	2.5	1.5	1.5	1.0	1.0	1.3	1.1	1.1	1.0	4.6
			receptor
49065	BMP4	BMP4	bone	0.8	1.1	1.3	1.0	0.9	1.0		1.6	1.0	1.0	4.6
			morphogenetic
			protein 4
48748	LTB	LT, beta	lymphotoxin beta	1.0	1.0	1.0	1.0	1.0	1.0		1.3		1.3	4.6
			(TNF superfamily,
			member 3)
48615	GADD45B	MyD118	growth arrest and	0.4	2.1	1.2	1.0	0.6	1.3		1.3	1.0	1.0	4.6
			DNA-damage-
			inducible, beta
48545	P2RY1	P2RY1	purinergic	0.8	1.1	1.0	1.0	1.3	1.2	0.9	1.0		1.4	4.6
			receptor P2Y, G-
			protein coupled, 1
47308	PTPRJ	PTPRJ	protein tyrosine	1.5	1.4	1.6	1.4	1.0	1.0	1.3	1.2	1.1	1.0	4.6
			phosphatase,
			receptor type, J
48480	CARS			1.1	1.1	0.8	1.2	0.9	1.0		1.4	0.9	1.0	4.6
48769	SUV39H1			1.0	1.0	0.7	1.0	0.9	1.0		1.6	1.0	1.0	4.6
47135	CHKL			1.2	1.0	0.7	1.0	0.7	1.3	0.8	1.0	0.7	1.2	4.6
50441	SAT			3.3	3.2	0.7	1.4	0.7	1.2	0.8	1.0	0.8	1.0	4.6
49124	MMP7	MMP7	matrix	3.2	3.1	0.6	1.6	0.9	1.0	0.7	1.0	1.0	1.0	4.6
			metalloproteinase
			7 (matrilysin,
			uterine)
50625	PSMC6			1.3	1.1	0.6	1.4	0.9	1.0	0.8	1.0	0.8	1.1	4.6
46991	TFPI2	TFPI2	tissue factor	2.1	1.9	0.8	1.3	1.0	1.0		1.3	1.0	1.0	4.6
			pathway inhibitor 2
48586	CD4	CD4	CD4 antigen (p55)	0.9	1.0	0.9	1.0	0.6	1.4	0.8	1.0	0.7	1.2	4.6
48344	ARHG	RhoG	ras homolog gene	1.7	1.5	1.2	1.1	1.1	1.1	4	1.4	1.1	1.1	4.6
			family, member G
			(rho G)
50025	LIFR	LIFR	leukemia inhibitory	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0		1.6	4.6
			factor receptor
49060	CTGF	CTGF	connective tissue	0.3	2.3	0.8	1.0	1.1	1.0		1.6	0.9	1.0	4.6
			growth factor
47089	ACYP2			0.9	1.0	1.6	1.3	1.1	1.0	3	1.3	1.0	1.0	4.6
49883	FVT1			1.1	1.0	1.4	1.2	1.1	1.0	4	1.3	1.0	1.0	4.6
49516	HSPA5	HSPA5	heat shock 70 kD	1.1	1.0	1.6	1.3	1.2	1.1	1.2	1.1	1.2	1.0	4.6
			protein 5 (glucose-
			regulated prote
50013	IL13RA1	IL-13Ralpha′	interleukin 13	0.6	1.2	1.3	1.2	1.1	1.1	4	1.3	1.0	1.0	4.6
			receptor, alpha 1
47563	COL11A1	COL11A1	collagen, type XI,	0.7	1.2	0.7	1.4	0.9	1.0	0.8	1.1	0.8	1.0	4.6
			alpha 1
49899	WWOX			1.2	1.0	1.2	1.2	1.1	1.0	4	1.3	1.3	1.1	4.6
47201	NFIA	NFAT 3	nuclear factor I/A	0.6	1.5	1.3	1.2	1.0	1.0		1.4	1.0	1.0	4.6
46986	AREG	amphiregulin	amphiregulin	2.4	2.2	0.9	1.1	1.2	1.1		1.4	1.1	1.0	4.6
			(schwannoma-
			derived growth
			factor)
46988	EREG	epiregulin	epiregulin	5.4	3.4	1.1	1.1	1.3	1.0		1.5	1.1	1.0	4.6
50448	BIRC3	cIAP2	baculoviral IAP	20.3	17.7	1.5	1.3	0.8	1.2	1.2	1.1	1.0	1.0	4.6
			repeat-containing 3
47208	PTPN3	PTPN3	protein tyrosine	0.9	1.0	1.4	1.3	1.0	1.0	1.4	1.2	1.0	1.0	4.6
			phosphatase, non-
			receptor type 3
47922	HS3ST3A1	HS3ST3A1	heparan sulfate	1.0	1.0	1.0	1.0	1.0	1.0		1.5	1.2	1.1	4.6
			(glucosamine) 3-
			O-sulfotransferase
49054	ITGA2	integrin, alpha	integrin, alpha 2	1.7	1.3	1.5	1.3	1.0	1.0	1.3	1.2	1.1	1.0	4.6
		2, CD49B,	(CD49B, alpha 2
		VLA-2	subunit of VLA-2
47969	MAP3K8	c-cot	mitogen-activated	5.2	3.7	0.8	1.1	0.7	1.4	1.1	1.0	1.0	1.0	4.6
			protein kinase
			kinase kinase 8
47979	BDKRB1	BDKRB1	bradykinin	3.3	3.1	1.6	1.5	1.0	1.0	1.3	1.1	0.9	1.0	4.5
			receptor B1
49975	PIM1	pim-1	pim-1 oncogene	1.5	1.4	0.8	1.2	1.0	1.0		1.3	0.9	1.0	4.5
47523	DNAJB1	DNAJB1	DnaJ (Hsp40)	1.0	1.0	1.0	1.0	0.9	1.0		1.4	1.2	1.1	4.5
			homolog,
			subfamily B,
			member 1
49046	NFKBIA	IkB, alpha	nuclear factor of	9.4	6.3	1.6	1.4	0.9	1.1	1.1	1.1	1.0	1.0	4.5
			kappa light
			polypeptide gene
			enh
46825	GPRK7	MNK2	G protein-coupled	0.7	1.1	1.5	1.4	1.1	1.0	1.2	1.1	1.1	1.0	4.5
			receptor kinase 7
49372	TAP1			2.6	2.4	1.2	1.2	1.1	1.0	1.4	1.2	1.3	1.2	4.5
47191	LIFR	LIFR	leukemia inhibitory	1.0	1.0	1.4	1.3	1.1	1.0	1.1	1.0	1.2	1.2	4.5
			factor receptor
50689	GNB5	G protein, beta 5	guanine	0.9	1.0	1.3	1.2	1.1	1.0		1.3	1.2	1.0	4.5
			nucleotide binding
			protein (G
			protein), be
49793	FRAG1	FRAG1	FGF receptor	0.7	1.3	1.2	1.0	1.1	1.1	4	1.3	1.1	1.1	4.5
			activating protein 1
46982	AREG	amphiregulin	amphiregulin	2.5	2.3	0.9	1.0	1.3	1.1		1.4	1.2	1.0	4.5
			(schwannoma-
			derived growth
			factor)
49549	ANXA8			1.2	1.1	0.7	1.2	1.0	1.0		1.3	0.9	1.0	4.5
49645	SCYD1	fractalkine	small inducible	14.5	5.8	1.0	1.0	1.0	1.0		1.3	1.4	1.2	4.5
			cytokine subfamily
			D (Cys-X3-Cys),
47762	KIAA0414			0.9	1.0	0.7	1.3	0.8	1.0	0.8	1.2	0.9	1.0	4.5
50517	ARHGAP4	ARHGAP4	Rho GTPase	1.1	1.0	1.2	1.1	1.0	1.0		1.4	1.0	1.0	4.5
			activating protein 4
48370	PDGFA	PDGF, alpha	platelet-derived	0.9	1.0	1.1	1.0	1.2	1.0		1.4	1.3	1.1	4.5
			growth factor
			alpha polypeptide
48324	IL3RA	IL-3R alpha	interleukin 3	1.7	1.2	1.9	1.5	1.0	1.0	1.3	1.0	1.0	1.0	4.5
			receptor, alpha
			(low affinity)
49475	PSA			0.8	1.1	0.9	1.0	1.0	1.0		1.3	0.8	1.2	4.5
49862	FUT8			0.7	1.4	1.4	1.2	1.0	1.0	4	1.4	1.0	1.0	4.5
48749				1.0	1.0	1.3	1.1	1.1	1.0		1.4	1.1	1.0	4.5
48616	PPIH	cyclophilin H	peptidyl prolyl	0.8	1.1	0.6	1.4	0.9	1.0	0.8	1.1	1.0	1.0	4.5
			isomerase H
			(cyclophilin H)
47775	KIAA0365			0.9	1.0	0.7	1.3	0.8	1.0	0.8	1.2	0.9	1.0	4.5
48933	MMP2	MMP2,	matrix	1.0	1.0	1.3	1.0	1.2	1.0		1.3	1.3	1.2	4.5
		gelatinase A	metalloproteinase
			2 (gelatinase A,
			72 kD gel
49446	SRC	Src	v-src avian	1.5	1.4	1.4	1.4	0.9	1.0	1.3	1.1	0.9	1.0	4.5
			sarcoma
			(Schmidt-Ruppin
			A-2) viral onc
50338	PIM2	Pim-2	pim-2 oncogene	2.4	1.8	1.2	1.1	0.9	1.0		1.4	1.0	1.0	4.5
48190	SCYA20	MIP-3a	small inducible	328.2	325.5	1.6	1.5	1.0	1.0	0.9	1.0	0.8	1.0	4.5
			cytokine subfamily
			A (Cys—Cys), me
47665	PTPRJ	PTPRJ	protein tyrosine	2.0	1.8	1.6	1.5	1.0	1.0	1.2	1.0	1.0	1.0	4.5
			phosphatase,
			receptor type, J
50118	MAPKAPK3	MAPKAPK3	mitogen-activated	0.8	1.1	1.2	1.0	1.1	1.1		1.4	1.3	1.0	4.5
			protein kinase-
			activated protein
47897	NR4A2	TINUR	nuclear receptor	1.6	1.1	1.9	1.4	0.9	1.0	1.5	1.1	0.9	1.0	4.5
			subfamily 4, group
			A, member 2
50641	SLC5A1			0.7	1.3	1.4	1.3	1.1	1.1	1.2	1.1	1.1	1.0	4.5
49284	MAP2K6	MKK6	mitogen-activated	0.6	1.2	1.5	1.4	0.9	1.1	1.3	1.0	1.0	1.0	4.5
			protein kinase
			kinase 6
49389	DUSP1	MKP-1,	dual specificity	1.4	1.0	1.5	1.5	1.1	1.0	1.1	1.0	1.0	1.0	4.5
		PTPN10	phosphatase 1
48162	KNSL2			0.9	1.0	0.7	1.2	0.9	1.0		1.3	1.0	1.0	4.5
48624	PLA2R1	phospholipase	phospholipase A2	1.0	1.0	1.4	1.0	0.9	1.0	0	1.5	1.0	1.0	4.5
		A2	receptor 1, 180 kD
49963	SERPINB8		serine (or	3.7	3.4	1.6	1.5	1.0	1.0	1.2	1.0	1.0	1.0	4.5
			cysteine)
			proteinase
			inhibitor, clade B
50600				1.0	1.0	0.7	1.4	1.1	1.0	1.0	1.0	1.2	1.1	4.5
49085	CCNA2	cyclin A2	cyclin A2	0.9	1.0	0.7	1.1	1.0	1.0		1.4	0.8	1.0	4.5
47298	VAV3	Vav3	vav 3 oncogene	1.0	1.0	0.6	1.4	0.9	1.0	1.0	1.0	1.0	1.0	4.5
48205	SERPINB8		serine (or	3.3	2.4	1.6	1.5	1.0	1.0	1.2	1.0	1.0	1.0	4.5
			cysteine)
			proteinase
			inhibitor, clade B
47537	PLAU	urokinase-type	plasminogen	9.1	7.2	1.4	1.2	1.3	1.3	1.0	1.0	1.2	1.0	4.5
		plasminogen	activator,
		activator	urokinase
46609				0.9	1.0	0.6	1.4	0.8	1.0	0.8	1.1	1.0	1.0	4.5
46962	GRB10	GRB10	growth factor	1.5	1.4	1.6	1.5	1.1	1.0	1.2	1.0	1.1	1.0	4.5
			receptor-bound
			protein 10
48548	GRAP2	GRAP2	GRB2-related	1.2	1.0	1.0	1.0	0.7	1.4	0.8	1.1	1.0	1.0	4.5
			adaptor protein 2
46627				1.0	1.0	1.0	1.0	1.0	1.0		1.5	1.0	1.0	4.5
49778	OSMR	oncostatin MR	oncostatin M	2.2	1.8	1.4	1.2	1.1	1.0		1.3	1.0	1.0	4.5
			receptor
47143	TNFRSF10C	DcR1	tumor necrosis	1.2	1.1	1.2	1.1	1.0	1.0	4	1.3	1.3	1.1	4.5
			factor receptor
			superfamily,
			member
48969	FOSL2	FOSL2, Fra2	FOS-like antigen 2	2.3	2.0	1.3	1.2	1.0	1.0	4	1.3	1.1	1.0	4.5
49762	COL4A4	COL4A4	collagen, type IV,	0.7	1.0	1.2	1.1	1.0	1.0		1.4	1.1	1.0	4.5
			alpha 4
48269	SERPINE1		serine (or	1.9	1.8	1.3	1.1	1.1	1.1	0.9	1.0		1.3	4.5
			cysteine)
			proteinase
			inhibitor, clade E
50378	SLC26A2	SLC26A2	solute carrier	0.7	1.0	1.6	1.1	1.0	1.0		1.4	1.0	1.0	4.5
			family 26 (sulfate
			transporter), me
50313	PLOD2	PLOD2	procollagen-	1.0	1.0	1.5	1.1	0.8	1.0	4	1.3	1.0	1.0	4.5
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
50010	PTGIR	PTGIR	prostaglandin I2	0.7	1.0	0.7	1.1	1.0	1.0		1.3	0.8	1.0	4.5
			(prostacyclin)
			receptor (IP)
49032	GSK3B	GSK3B	glycogen synthase	1.4	1.2	1.4	1.3	1.0	1.0	1.4	1.2	1.1	1.0	4.5
			kinase 3 beta
47211	SLC26A2	SLC26A2	solute carrier	0.9	1.0	1.5	1.0	1.0	1.0		1.5	1.1	1.0	4.5
			family 26 (sulfate
			transporter), me
50742	MGEA5	MGEA5	meningioma	0.9	1.0	1.2	1.1	1.0	1.0		1.4	0.9	1.0	4.5
			expressed antigen
			5 (hyaluronidase)
46754	TAF1A			1.1	1.0	0.6	1.4	0.8	1.1	0.8	1.0	1.0	1.0	4.5
50745	DNAJB1	DNAJB1	DnaJ (Hsp40)	0.9	1.0	1.0	1.0	1.0	1.0		1.4	1.1	1.0	4.5
			homolog,
			subfamily B,
			member 1
48679	BCL3	Bcl3	B-cell	1.0	1.0	1.1	1.0	0.6	1.5	0.9	1.0	0.8	1.0	4.5
			CLL/lymphoma 3
47705	MAD4	MAD4	Mad4 homolog	1.0	1.0	1.5	1.1	1.0	1.0	0	1.4	1.1	1.0	4.5
49990	SRC	Src	v-src avian	1.5	1.3	1.4	1.3	1.0	1.0	1.3	1.1	0.9	1.0	4.5
			sarcoma
			(Schmidt-Ruppin
			A-2) viral onc
48244	RPS6KA5	RPS6KA5	ribosomal protein	0.8	1.1	0.8	1.1	1.0	1.0		1.3	1.0	1.0	4.5
			S6 kinase, 90 kD,
			polypeptide 5

APPENDIX B
					LPS		Clari		FMA	LPS +/−	LPS +/− clari,	LPS +/−	LPS +/− FMA,
				LPS	treated,	Clari	treated,	FMA	treated,	clari,	min	FMA,	min	sum of
				treated,	min fold	treated,	min fold	treated,	min fold	wtd	fold	wtd	fold	min
				wtd mean	change	wtd mean	change	wtd mean	change	mean	change	mean	change	fold
SpotID	GeneSymbol	GeneName	GeneDesc	ratio	(2x)	ratio	(1.5x)	ratio	(1.3x)	ratio	(1.5x)	ratio	(1.3x)	change
Total Differentials in THP1 Cells
Genes in bold - ≧2-fold differential expression in response to LPS
Genes in italics - ≧1.5-fold differential expression in response to Clari and/or ≧1.3-fold differential expression in response to FMA alone
Genes in bold and italics - ≧1.5-fold differential expression in response to IL1 + Clari and/or ≧1.3-fold differential in response to IL1 + FMA
47030				1.3	1.2	1.9	1.7	1.1	1.1	1.5	1.3		1.4	5.4
48097				3.8	3.1	1.0	1.0	1.0	1.0		1.7		1.3	4.9
49208				0.5	1.7	0.6	1.4	0.8	1.1		1.8	0.8	1.2	5.5
48074				1.4	1.1	1.8	1.6	1.1	1.1		1.8	1.1	1.1	5.6
49168				5.1	4.8	1.4	1.3	1.0	1.0	1.1	1.0	1.1	1.1	4.4
49351				0.4	2.4	1.1	1.0	1.0	1.0	1.2	1.1	0.9	1.1	4.2
49411				3.1	2.2	1.2	1.0	0.9	1.1	1.4	1.2	1.2	1.0	4.4
49147				1.9	1.3	1.4	1.3	1.0	1.0	1.6	1.3	1.2	1.0	4.6
49276				1.9	1.3	1.4	1.3	1.1	1.0	1.6	1.3	1.2	1.0	4.7
49838				1.0	1.0	1.9	1.7	1.1	1.0		1.9	1.1	1.0	5.7
49056				1.2	1.0	0.7	1.3	0.9	1.0	0.9	1.0	0.9	1.0	4.4
48252				3.8	3.3	0.8	1.0	0.8	1.1	1.1	1.0	1.1	1.0	4.2
49594				1.4	1.4	1.5	1.3	1.0	1.0		1.5	1.1	1.0	4.9
48659				2.4	2.4	1.2	1.1	1.0	1.0	1.2	1.0	1.1	1.0	4.2
50285				0.8	1.2	1.2	1.1	1.1	1.0	1.4	1.4	1.1	1.0	4.5
48364				1.3	1.0	1.3	1.1	0.9	1.0	1.4	1.3	0.9	1.0	4.5
50380				0.9	1.0	1.9	1.7	1.2	1.0		1.8	1.1	1.0	5.5
49752				2.0	1.8	0.5	2.0	0.9	1.0	0.7	1.2	1.1	1.0	5.2
50199				1.1	1.0	1.9	1.8	1.0	1.0	1.5	1.2	1.0	1.0	5.0
48771				0.9	1.1	1.5	1.4	0.9	1.0		1.5	1.0	1.0	5.0
48167				2.0	1.8	1.8	1.7	1.1	1.1	1.2	1.1	1.1	1.0	4.9
48957				1.0	1.0	1.4	1.3	1.0	1.0		1.5	1.1	1.0	4.8
49510				1.5	1.1	1.5	1.3	1.0	1.0		1.5	1.0	1.0	4.8
50408				1.3	1.1	0.7	1.4	1.0	1.0	0.7	1.2	1.0	1.0	4.7
50728				0.6	1.7	1.4	1.3	1.1	1.1	1.3	1.2	1.0	1.0	4.6
49378				1.4	1.3	1.5	1.0	1.2	1.1	1.9	1.3	1.0	1.0	4.5
48639				0.6	1.3	1.5	1.3	1.0	1.0	1.4	1.1	0.8	1.0	4.5
46578				0.7	1.2	0.6	1.5	1.0	1.0	0.7	1.0	0.8	1.0	4.5
46651				1.1	1.0	0.8	1.1	1.0	1.0	0.7	1.3	1.0	1.0	4.4
48129				1.6	1.6	0.8	1.1	1.0	1.0	0.7	1.3	1.0	1.0	4.4
49491				1.8	1.3	1.1	1.0	0.9	1.0	1.5	1.4	1.2	1.0	4.4
48060				0.7	1.2	0.9	1.0	1.0	1.0	0.7	1.3	0.9	1.0	4.3
49920				1.0	1.0	0.8	1.0	0.7	1.3	0.9	1.0	0.8	1.0	4.3
48183				3.3	2.9	1.4	1.3	1.0	1.0	1.0	1.0	1.1	1.0	4.3
48534				2.9	2.7	0.9	1.0	1.0	1.0	0.8	1.1	1.1	1.0	4.1
50155				0.5	2.0	0.9	1.0	1.1	1.0	1.0	1.0	1.0	1.0	4.0
48120				2.6	2.1	1.0	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
50633	ABL2			1.8	1.3	1.1	1.0	1.0	1.0	1.6	1.4	0.9	1.0	4.4
50259	ACE			0.7	1.3	1.6	1.4	1.0	1.0		1.5	1.0	1.0	4.9
48835	ACOX1			1.0	1.0	1.2	1.1	1.0	1.0	1.4	1.3	1.0	1.0	4.5
47896	ADAM11	ADAM11	a disintegrin and	0.9	1.0	1.5	1.3	1.2	1.1	1.0	1.0	1.0	1.0	4.4
			metalloproteinase
			domain 11
47352	ADAM11	ADAM11	a disintegrin and	0.9	1.0	1.5	1.4	1.0	1.0	1.0	1.0	1.0	1.0	4.4
			metalloproteinase
			domain 11
49421	ADAM17	TACE	a disintegrin and	1.1	1.0	1.0	1.0	0.9	1.0	1.5	1.4	1.1	1.0	4.4
			metalloproteinase
			domain 17 (tum
48442	ADAM17	TACE	a disintegrin and	1.2	1.0	0.9	1.0	0.9	1.0		1.5	1.1	1.0	4.5
			metalloproteinase
			domain 17 (tum
47217	ADAMTS1	ADAMTS1	a disintegrin-like	1.9	1.6	2.3	2.0	1.1	1.0	1.5	1.4	1.1	1.0	5.4
			and
			metalloprotease
			(reprolysin
47913	ADAMTS1	ADAMTS1	a disintegrin-like	0.5	1.3	1.0	1.0	0.5	1.5	1.0	1.0	0.8	1.0	4.5
			and
			metalloprotease
			(reprolysin
48271	ADCY7	adenylate	adenylate cyclase 7	1.1	1.0	1.8	1.3	1.2	1.2		1.8	1.3	1.2	5.5
		cyclase
49287	ADCY7	adenylate	adenylate cyclase 7	1.1	1.0	1.9	1.6	1.2	1.1		1.7	1.2	1.1	5.5
		cyclase
47329	ADRB2			0.8	1.1	1.5	1.4	1.0	1.0.	1.3	1.1	0.9	1.0	4.5
50412	AGPAT1			0.9	1.0	1.3	1.2	1.1	1.0	1.4	1.3	1.1	1.0	4.6
50345	AGT		serine (or	0.7	1.1	2.1	1.7	1.1	1.1		2.2	1.1	1.0	6.0
			cysteine)
			proteinase
			inhibitor, clade A
49478	AIM1	AIM1	absent in	1.1	1.0	1.5	1.4	1.3	1.2	1.1	1.0	1.2	1.0	4.5
			melanoma 1
49638	AKT3	AKT3, PKB	v-akt murine	16.2	14.6	1.7	1.5	1.1	1.0	1.6	1.3	1.2	1.1	4.9
			thymoma viral
			oncogene
			homolog 3 (pro
47127	ALAD			25.9	15.0	1.3	1.2	1.2	1.1	1.0	1.0	1.3	1.1	4.5
50435	AMPD2			0.9	1.0	1.3	1.2	1.0	1.0	1.5	1.4	0.9	1.0	4.6
48530	APLP2			0.9	1.1	1.7	1.7	1.0	1.0		1.6	1.0	1.0	5.3
46986	AREG	amphiregulin	amphiregulin	1.8	1.5	0.8	1.0	0.5	1.8		2.0		1.6	6.5
			(schwannoma-
			derived growth
			factor)
46953	AREG	amphiregulin	amphiregulin	1.8	1.5	0.8	1.0	0.5	1.9		2.0		1.5	6.4
			(schwannoma-
			derived growth
			factor)
46982	AREG	amphiregulin	amphiregulin	1.8	1.6	0.8	1.1	0.5	1.8		2.2		1.5	6.5
			(schwannoma-
			derived growth
			factor)
46949	AREG	amphiregulin	amphiregulin	1.9	1.4	0.8	1.0	0.5	1.8		2.4		1.4	6.6
			(schwannoma-
			derived growth
			factor)
48357	ARF6	ARF6	ADP-ribosylation	1.4	1.3	1.2	1.1	1.1	1.1	1.4	1.3	1.1	1.1	4.5
			factor 6
50502	ARF6	ARF6	ADP-ribosylation	1.3	1.1	1.3	1.2	1.2	1.2	1.4	1.4	1.1	1.0	4.8
			factor 6
50469	ARF6	ARF6	ADP-ribosylation	1.3	1.1	1.3	1.2	1.2	1.1	1.4	1.4	1.1	1.0	4.7
			factor 6
50242	ARHG	RhoG	ras homolog gene	4.5	3.5	1.2	1.1	1.1	1.0	1.0	1.0	1.2	1.1	4.2
			family, member G
			(rho G)
49317	ARHGEF9	ARHGEF9	Cdc42 guanine	0.8	1.2	0.6	1.3	1.0	1.0	0.9	1.0	0.8	1.0	4.3
			exchange factor
			(GEF) 9
47456	ASB1			0.5	1.6	0.6	1.5	0.9	1.0	0.7	1.2	0.9	1.0	4.7
46817	ATF3	ATF3	activating	2.2	2.1	1.1	1.0	0.9	1.1	1.6	1.4	1.1	1.0	4.5
			transcription factor 3
50635	B4GALT1			2.6	2.1	1.0	1.0	1.1	1.1	0.9	1.0	1.0	1.0	4.1
48802	BAI3			4.7	4.6	1.2	1.1	1.1	1.1	1.5	1.4	1.3	1.2	4.8
50557	BCL2	Bcl2	B-cell	1.6	1.5	0.7	1.2	1.0	1.0		1.5	1.2	1.2	4.8
			CLL/lymphoma 2
50686	BCL2	Bcl2	B-cell	1.5	1.4	0.8	1.0	1.0	1.0	1.5	1.3	1.2	1.1	4.5
			CLL/lymphoma 2
47738	BCL2A1	BCL2A1	BCL2-related	3.1	2.7	0.9	1.0	1.0	1.0	1.6	1.0	1.1	1.0	4.1
			protein A1
48697	BCL3	Bcl3	B-cell	4.1	4.0	0.6	1.5	0.8	1.2	1.1	1.0	1.1	1.0	4.8
			CLL/lymphoma 3
49927	BCRP1			0.8	1.2	0.8	1.2	1.0	1.0	0.7	1.3	0.9	1.0	4.5
47396	BHLHB2			2.9	2.7	1.0	1.0	1.0	1.0	1.2	1.1	1.1	1.0	4.1
48408	BIRC2	cIAP1	baculoviral IAP	3.2	3.0	1.0	1.0	0.9	1.0	0.9	1.0	1.1	1.0	4.0
			repeat-containing 2
49061	BIRC2	cIAP1	baculoviral IAP	3.4	3.0	1.0	1.0	1.0	1.0	0.9	1.0	1.1	1.0	4.0
			repeat-containing 2
48375	BIRC2	cIAP1	baculoviral IAP	3.3	3.3	0.9	1.0	1.0	1.0	0.9	1.0	1.1	1.0	4.0
			repeat-containing 2
49094	BIRC2	cIAP1	baculoviral IAP	3.3	3.1	1.0	1.0	1.0	1.0	0.9	1.0	1.1	1.0	4.0
			repeat-containing 2
50448	BIRC3	cIAP2	baculoviral IAP	22.0	21.6	0.9	1.0	0.9	1.1	1.0	1.0	0.9	1.0	4.1
			repeat-containing 3
47497	BIRC3	cIAP2	baculoviral IAP	11.3	7.4	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			repeat-containing 3
49871	BLZF1			3.5	3.3	1.2	1.0	1.0	1.0	1.1	1.0	1.1	1.0	4.0
49098	BMP4	BMP4	bone	2.8	2.3	1.0	1.0	1.0	1.0	1.0	1.0	0.9	1.0	4.0
			morphogenetic
			protein 4
49981	BMP6	BMP6	bone	11.2	6.0	0.9	1.0	0.9	1.0	1.1	1.1	1.2	1.1	4.1
			morphogenetic
			protein 6
46586	C12orf8			0.9	1.0	1.7	1.3	1.2	1.1		1.8	1.2	1.1	5.2
48543	C2			1.9	1.7	2.0	1.6	1.3	1.2	1.3	1.1	1.2	1.2	5.1
46616	C2orf3	GCF, TCF-9	chromosome 2	1.1	1.0	1.6	1.5	1.1	1.0	1.5	1.2	1.2	1.1	4.9
			open reading
			frame 3
49928	C6orf5			3.6	3.1	1.0	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
49034	CARD4	NOD1	caspase	2.3	2.2	1.2	1.0	1.0	1.0	1.2	1.0	1.0	1.0	4.0
			recruitment
			domain 4
48267	CASP1	caspase 1,	caspase 1,	5.9	4.1	2.2	1.9	1.2	1.0	1.3	1.1	1.3	1.2	5.3
		ICE	apoptosis-related
			cysteine protease
			(in
49132	CASP1	caspase 1,	caspase 1,	4.1	3.0	1.9	1.4	1.1	1.1	1.5	1.3	1.2	1.2	5.0
		ICE	apoptosis-related
			cysteine protease
			(in
47007	CASP4	CASP4	caspase 4,	4.4	3.2	1.0	1.0	1.0	1.0	1.1	1.0	1.2	1.2	4.2
			apoptosis-related
			cysteine protease
49807	CASP4	CASP4	caspase 4,	3.4	3.2	1.0	1.0	1.1	1.0	1.1	1.0	1.2	1.1	4.1
			apoptosis-related
			cysteine protease
50721	CASP4	CASP4	caspase 4,	3.3	2.8	1.0	1.0	1.1	1.0	1.0	1.0	1.0	1.0	4.0
			apoptosis-related
			cysteine protease
50188	CASP4	CASP4	caspase 4,	3.0	2.4	1.0	1.0	1.1	1.0	1.0	1.0	1.0	1.0	4.0
			apoptosis-related
			cysteine protease
48336	CASP7	caspase-7	caspase 7,	3.2	3.1	0.8	1.0	0.9	1.0	0.8	1.1	1.1	1.0	4.1
			apoptosis-related
			cysteine protease
49425	CASP7	caspase-7	caspase 7,	3.8	3.5	0.9	1.0	1.0	1.0	0.8	1.1	1.1	1.0	4.1
			apoptosis-related
			cysteine protease
49909	CASR			3.4	2.5	1.0	1.0	0.9	1.0	1.3	1.2	1.0	1.0	4.2
48117	CAST			1.2	1.1	1.5	1.4	1.1	1.1	1.5	1.3	1.2	1.1	4.9
49698	CAT			0.9	1.0	1.5	1.4	1.2	1.1	1.2	1.2	1.1	1.0	4.7
50473	CBL	Cbl	Cas-Br-M (murine)	0.5	2.2	1.2	1.1	1.0	1.0	1.1	1.0	0.9	1.0	4.1
			ecotropic retroviral
			transformin
49773	CCNA2	cyclin A2	cyclin A2	0.9	1.0	0.5	1.5	1.0	1.0	0.6	1.4	1.1	1.1	4.9
49806	CCNA2	cyclin A2	cyclin A2	0.7	1.2	0.5	1.6	1.1	1.0	0.5	1.0	1.2	1.0	4.7
49118	CCNA2	cyclin A2	cyclin A2	0.7	1.3	0.5	1.3	1.0	1.0	0.6	1.0	1.0	1.0	4.3
48015	CCND3	Cyclin D3	cyclin D3	1.2	1.1	1.6	1.5	1.1	1.0	1.0	1.0	1.1	1.0	4.6
47926	CCNE2	cyclin E2	cyclin E2	1.6	1.2	0.5	1.8	1.0	1.0	0.6	1.2	1.2	1.0	5.0
48683	CCR1	CCR1	chemokine (C—C	1.0	1.0	1.4	1.4	1.1	1.0	1.4	1.3	0.9	1.0	4.8
			motif) receptor 1
48790	CCR1	CCR1	chemokine (C—C	1.2	1.0	1.5	1.3	1.1	1.0	1.4	1.3	0.9	1.0	4.6
			motif) receptor 1
47154	CCR7	CCR7	chemokine (C—C	41.5	39.4	1.2	1.0	1.0	1.0	1.1	1.0	1.7	1.2	4.2
			motif) receptor 7
47025	CCR7	CCR7	chemokine (C—C	49.6	47.7	1.1	1.0	1.0	1.0	1.1	1.0	1.6	1.1	4.1
			motif) receptor 7
50091	CCRL2	CCRL2	chemokine (C—C	5.3	4.1	1.2	1.1	1.1	1.1	1.4	1.2	1.2	1.0	4.5
			motif) receptor-like 2
46930	CD14	CD14	CD14 antigen	0.6	1.2	2.4	2.0	1.1	1.1	1.2	1.0	0.8	1.0	5.1
47927	CD14	CD14	CD14 antigen	0.6	1.4	1.8	1.6	1.0	1.0	1.0	1.0	0.9	1.0	4.6
47424	CD36L1			0.5	2.0	1.6	1.3	1.0	1.0		1.5	1.1	1.0	4.8
48460	CD48			2.6	2.3	1.0	1.0	1.2	1.0	1.2	1.0	1.0	1.0	4.0
48573	CD69	CD69	CD69 antigen	2.8	2.4	1.0	1.0	1.0	1.0	1.1	1.0	0.9	1.0	4.0
			(p60, early T-cell
			activation antigen
49410	CD97	CD97	CD97 antigen	3.4	2.6	1.5	1.4	1.1	1.1	0.9	1.1	1.2	1.0	4.6
50392	CD97	CD97	CD97 antigen	3.4	2.9	1.4	1.3	1.0	1.0	0.8	1.2	1.1	1.0	4.5
49656	CDK6	cyclin	cyclin-dependent	1.2	1.0	1.3	1.2	1.0	1.0		1.6	1.0	1.0	4.8
		dependent	kinase 6
		kinase 6
47521	CDK6	cyclin	cyclin-dependent	1.2	1.0	1.3	1.1	1.0	1.0		1.5	1.1	1.0	4.6
		dependent	kinase 6
		kinase 6
50474	CEBPA	C/EBP alpha	CCAAT/enhancer	0.2	4.4	1.6	1.4	1.1	1.0	1.4	1.3	0.9	1.0	4.7
			binding protein
			(C/EBP), alpha
47891	CEBPD	CEBP delta	CCAAT/enhancer	3.8	2.9	1.3	1.2	1.0	1.0	1.2	1.1	1.3	1.2	4.4
			binding protein
			(C/EBP), delta
46849	CEBPD	CEBP delta	CCAAT/enhancer	3.8	2.5	1.3	1.0	1.0	1.0	1.5	1.1	1.2	1.0	4.2
			binding protein
			(C/EBP), delta
48013	CEP3	CEP3	Cdc42 effector	1.4	1.3	1.4	1.2	1.0	1.0		1.8	1.2	1.1	5.1
			protein 3
48493	CG018			7.0	5.5	1.1	1.0	1.0	1.0	1.5	1.3	1.1	1.0	4.3
49031	CKB			3.3	3.1	1.0	1.0	1.0	1.0		1.7	1.2	1.0	4.7
49434	CKLF1	chemokine-	chemokine-like	0.5	2.0	1.4	1.3	1.1	1.0	1.6	1.2	1.0	1.0	4.5
		like factor 3	factor,
			alternatively
			spliced
48373	CKLF1	chemokine-	chemokine-like	0.5	2.0	1.4	1.2	1.0	1.0	1.6	1.2	1.0	1.0	4.4
		like factor 3	factor,
			alternatively
			spliced
49345	CLU			1.1	1.0	1.4	1.2	1.1	1.0		1.5	1.0	1.0	4.7
50087	COL4A1	COL4A1	collagen, type IV,	1.5	1.2	0.6	1.4	1.2	1.1	1.0	1.0	1.3	1.1	4.6
			alpha 1
47197	COL4A2	COL4A2	collagen, type IV,	1.2	1.1	0.6	1.3	1.0	1.0	0.9	1.0	1.3	1.2	4.5
			alpha 2
49315	COL4A2	COL4A2	collagen, type IV,	1.2	1.0	0.7	1.5	1.1	1.0	1.0	1.0	1.2	1.0	4.5
			alpha 2
50705	COL7A1	COL7A1	collagen, type VII,	1.0	1.0	0.3	2.0	0.6	1.4		2.6		1.4	7.4
			alpha 1
			(epidermolysis
			bullosa
50125	COL7A1	COL7A1	collagen, type VII,	1.0	1.0	0.3	2.3	0.6	1.4		2.6		1.4	7.7
			alpha 1
			(epidermolysis
			bullosa
47505	COL9A2	COL9A2	collagen, type IX,	1.0	1.0	1.8	1.5	1.2	1.1		1.5	1.1	1.1	5.2
			alpha 2
47857	COL9A2	COL9A2	collagen, type IX,	1.0	1.0	1.9	1.7	1.2	1.1		1.5	1.1	1.1	5.4
			alpha 2
50437	COMT			0.9	1.0	1.4	1.3	1.0	1.0		1.5	1.0	1.0	4.8
47070	CPD			1.7	1.6	1.5	1.4	1.1	1.0		1.6	1.1	1.1	5.0
50564	CRA			1.0	1.0	1.3	1.0	1.0	1.0		1.6	1.0	1.0	4.6
47895	CRADD	RAIDD	CASP2 and	1.5	1.4	0.4	2.2	0.8	1.1		3.3	0.8	1.2	7.7
			RIPK1 domain
			containing adaptor
			with dea
49665	CRADD	RAIDD	CASP2 and	1.6	1.2	0.4	1.9	0.8	1.1		3.2	0.7	1.0	7.3
			RIPK1 domain
			containing adaptor
			with dea
46684	CREB1	CREB-1	cAMP responsive	2.5	2.2	0.8	1.0	0.9	1.0	1.1	1.0	1.0	1.0	4.0
			element binding
			protein 1
50652	CRIP1			0.8	1.2	1.5	1.3	1.1	1.1	1.4	1.1	1.1	1.1	4.6
49278	CSF1	M-CSF,	colony stimulating	1.1	1.0	0.7	1.2	1.0	1.0	0.7	1.3	1.1	1.0	4.6
		macrophage	factor 1
		colony	(macrophage)
		stimulating
		factor
49149	CSF1	M-CSF,	colony stimulating	1.1	1.0	0.7	1.3	1.0	1.0	0.7	1.3	1.1	1.0	4.6
		macrophage	factor 1
		colony	(macrophage)
		stimulating
		factor
48596	CSF2	G-CSF,	colony stimulating	11.4	10.3	0.9	1.0	0.9	1.0	0.7	1.3	1.0	1.0	4.3
		granulocyte	factor 2
		colony	(granulocyte-
		stimulating	macrophag
		factor
48052	CSF2	G-CSF,	colony stimulating	12.7	10.0	0.9	1.0	1.0	1.0	0.8	1.3	1.0	1.0	4.3
		granulocyte	factor 2
		colony	(granulocyte-
		stimulating	macrophag
		factor
49266	CSF3	GM-CSF,	colony stimulating	4.3	4.0	1.0	1.0	1.0	1.0	0.4	1.8	0.9	1.0	4.9
		granulocyte-	factor 3
		macrophage	(granulocyte)
		colony
		stimulating
		factor
49137	CSF3	GM-CSF,	colony stimulating	4.8	3.9	1.0	1.0	1.0	1.0	0.5	1.4	0.9	1.0	4.5
		granulocyte-	factor 3
		macrophage	(granulocyte)
		colony
		stimulating
		factor
48943	CSF3R	G-CSF	colony stimulating	1.0	1.0	1.5	1.3	1.2	1.0	1.8	1.2	1.0	1.0	4.6
		receptor	factor 3 receptor
			(granulocyte)
49060	CTGF	CTGF	connective tissue	108.1	106.7	1.0	1.0	1.3	1.0		4.9	1.1	1.0	7.9
			growth factor
47937	CTSB			1.0	1.0	1.6	1.3	1.2	1.1	1.5	1.4	1.1	1.1	4.9
47226	CTSD	cathepsin D	cathepsin D	0.6	1.6	1.1	1.0	1.1	1.1	1.2	1.0		1.4	4.5
			(lysosomal
			aspartyl protease)
49651	CTSD	cathepsin D	cathepsin D	0.6	1.4	1.2	1.2	1.3	1.2	1.5	1.3	1.5	1.2	4.9
			(lysosomal
			aspartyl protease)
47837	CTSG			1.2	1.0	1.5	1.3	0.9	1.0	1.5	1.3	1.0	1.0	4.7
48000	CTSH			0.8	1.1	1.7	1.6	1.1	1.1	1.6	1.4	1.1	1.0	5.1
49052	CXCR4	CXCR4	chemokine (C—X—C	2.0	1.7	0.4	2.2	0.9	1.0	0.7	1.3	1.1	1.0	5.5
			motif), receptor 4
			(fusin)
50763	CYBB			1.1	1.0	1.5	1.3	1.2	1.1	1.1	1.1	1.2	1.1	4.5
49787	CYC1	cytochrome c-1	cytochrome c-1	1.0	1.0	0.8	1.2	1.0	1.0	0.7	1.4	1.0	1.0	4.5
49820	CYC1	cytochrome c-1	cytochrome c-1	1.0	1.0	0.8	1.2	1.0	1.0	0.7	1.3	1.0	1.0	4.5
47834	CYP1A1			0.9	1.1	1.8	1.7	1.1	1.0	1.3	1.1	1.2	1.2	4.9
48650	DAB2			0.3	2.6	1.0	1.0	1.1	1.1	0.9	1.0	0.9	1.0	4.2
47335	DAPP1			2.4	1.8	1.5	1.2	1.0	1.0		1.5	1.2	1.1	4.8
49903	DDXL			1.0	1.0	0.7	1.4	0.9	1.0	0.7	1.4	0.9	1.0	4.8
49162	DKFZP761N09121			1.0	1.0	1.9	1.6	1.1	1.0		1.7	1.1	1.0	5.3
50693	DKFZp762A227			1.2	1.1	1.1	1.0	1.1	1.0	1.5	1.4	1.0	1.0	4.5
47553	DKFZp762A227			1.2	1.1	1.0	1.0	1.0	1.0	1.4	1.4	1.0	1.0	4.4
48333	DNMT1			0.6	1.5	0.7	1.4	1.0	1.0	0.7	1.3	0.9	1.0	4.7
48131	DSCR1			0.9	1.0	0.7	1.4	0.9	1.0	0.7	1.2	0.9	1.0	4.6
46877	DTR	HB-EGF,	diphtheria toxin	2.4	2.0	0.5	1.4	0.7	1.1		1.6		1.4	5.5
		diptheria toxin	receptor (heparin-
		receptor	binding epiderm
50383	DTR	HB-EGF,	diphtheria toxin	1.7	1.3	0.6	1.5	0.7	1.2		1.5		1.3	5.5
		diptheria toxin	receptor (heparin-
		receptor	binding epiderm
49389	DUSP1	MKP-1,	dual specificity	5.5	5.4	0.6	1.6	0.9	1.1	0.7	1.3	0.8	1.2	5.1
		PTPN10	phosphatase 1
50046	DUSP1	MKP-1,	dual specificity	5.6	5.0	0.5	1.8	0.9	1.0	0.7	1.2	0.9	1.0	5.0
		PTPN10	phosphatase 1
47279	DUSP10	DUSP10	dual specificity	1.4	1.2	0.6	1.5	1.0	1.0	0.6	1.3	1.0	1.0	4.8
			phosphatase 10
50362	DUSP10	DUSP10	dual specificity	1.2	1.0	0.7	1.5	1.1	1.0	0.7	1.2	1.0	1.0	4.7
			phosphatase 10
50109	DUSP4	DUSP4	dual specificity	1.8	1.6	0.9	1.0	1.0	1.0	0.7	1.3	0.8	1.1	4.4
			phosphatase 4
46575	DUSP4	DUSP4	dual specificity	2.1	2.0	0.9	1.0	1.0	1.0	0.7	1.4	0.9	1.1	4.5
			phosphatase 4
46670	DUSP5	DUSP5	dual specificity	3.1	2.6	0.9	1.0	0.9	1.0	1.3	1.2	1.1	1.1	4.3
			phosphatase 5
47888	DUSP7	DUSP7	dual specificity	0.2	3.4	1.2	1.0	0.9	1.1	1.0	1.0	0.9	1.1	4.2
			phosphatase 7
47344	DUSP7	DUSP7	dual specificity	0.2	3.4	1.2	1.1	0.9	1.0	1.1	1.0	0.9	1.1	4.2
			phosphatase 7
46619	DUSP9	DUSP9	dual specificity	2.3	2.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			phosphatase 9
46804	EBI3			6.2	5.8	0.9	1.1	0.9	1.0	1.0	1.0	1.1	1.0	4.1
47626	ECE1	ECE1	endothelin	6.3	5.7	0.8	1.0	0.8	1.0	0.8	1.2	0.8	1.1	4.3
			converting
			enzyme 1
47209	ECE1	ECE1	endothelin	3.8	3.4	0.9	1.0	1.0	1.0	0.8	1.1	0.9	1.0	4.1
			converting
			enzyme 1
48911	ECM1	ECM1	extracellular	0.9	1.0	1.9	1.7	1.1	1.0		1.8	1.2	1.1	5.7
			matrix protein 1
50669	ECM1	ECM1	extracellular	0.9	1.0	2.0	1.8	1.1	1.0		1.9	1.2	1.1	5.8
			matrix protein 1
46841	EDG1	EDG-1	endothelial	3.1	2.8	0.4	1.1	1.2	1.1		1.6	1.1	1.0	4.8
			differentiation,
			sphingolipid G-
			protei
47152	EDN1	EDN1	endothelin 1	1.4	1.3	1.7	1.7	1.2	1.1	0.9	1.1	1.1	1.1	4.9
47023	EDN1	EDN1	endothelin 1	1.4	1.3	1.7	1.5	1.2	1.1	0.8	1.1	1.1	1.0	4.7
47675	EHF	EHF	ets homologous	3.3	2.8	1.0	1.0	1.0	1.0	0.7	1.0	1.2	1.0	4.0
			factor
47708	EHF	EHF	ets homologous	4.1	3.5	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.0	4.0
			factor
48728	EIF4EBP1	PHAS-1	eukaryotic	0.4	2.1	0.8	1.2	1.1	1.0	0.7	1.4	1.0	1.0	4.5
			translation
			initiation factor 4E
			bindin
47530	ELK1	Elk-1	ELK1, member of	3.3	2.8	1.6	1.5	1.0	1.0	1.3	1.1	1.1	1.0	4.6
			ETS oncogene
			family
50170	EMILIN	EMILIN	elastin microfibril	0.8	1.1	1.4	1.4	1.1	1.1		1.6	1.2	1.2	5.2
			interface located
			protein
50714	EMILIN	EMILIN	elastin microfibril	0.8	1.1	1.3	1.2	1.1	1.0		1.5	1.3	1.0	4.7
			interface located
			protein
47580	EMS1	cortactin	ems1 sequence	0.8	1.1	0.6	1.5	1.0	1.0		1.6	1.0	1.0	5.1
			(mammary tumor
			and squamous
			cell car
48587	EMS1	cortactin	ems1 sequence	0.9	1.0	0.6	1.4	1.0	1.0	0.7	1.4	1.0	1.0	4.8
			(mammary tumor
			and squamous
			cell car
49392	EPHA2			1.6	1.4	0.7	1.4	1.1	1.0	0.7	1.3	1.0	1.0	4.7
46988	EREG	epiregulin	epiregulin	4.5	3.9	1.0	1.0	1.0	1.0		2.2	0.8	1.1	5.3
50126	EREG	epiregulin	epiregulin	6.6	6.2	1.0	1.0	0.7	1.0		1.9	0.8	1.1	5.0
46955	EREG	epiregulin	epiregulin	3.8	3.5	1.0	1.0	1.0	1.0		2.1	0.8	1.0	5.1
47907	ERG	ERG	v-ets avian	27.1	10.3	2.7	1.7	1.2	1.0	1.3	1.0	1.2	1.1	4.9
			erythroblastosis
			virus E26
			oncogene re
47554	ERG	ERG	v-ets avian	12.8	12.2	2.5	1.7	1.2	1.0	1.2	1.0	1.1	1.0	4.8
			erythroblastosis
			virus E26
			oncogene re
49672	ETS2	Ets-2	v-ets avian	6.4	4.8	0.9	1.0	0.9	1.0	0.9	1.0	1.1	1.0	4.0
			erythroblastosis
			virus E26
			oncogene ho
49674	ETS2	Ets-2	v-ets avian	7.6	2.9	1.1	1.0	0.9	1.0	0.9	1.0	1.1	1.0	4.0
			erythroblastosis
			virus E26
			oncogene ho
50382	ETV4	ETV4	ets variant gene 4	0.3	3.0	1.5	1.3	1.1	1.0	1.0	1.0	1.0	1.0	4.3
			(E1A enhancer-
			binding protein,
46951	ETV5	ETV5	ets variant gene 5	0.3	2.9	1.6	1.5	1.1	1.1	1.4	1.0	0.9	1.0	4.6
			(ets-related
			molecule)
50540	ETV5	ETV5	ets variant gene 5	0.8	1.0	1.5	1.4	1.1	1.0	1.3	1.2	1.0	1.0	4.5
			(ets-related
			molecule)
46984	ETV5	ETV5	ets variant gene 5	0.3	3.7	1.7	1.4	1.1	1.0	1.6	1.0	0.9	1.0	4.4
			(ets-related
			molecule)
47539	F2	F2	coagulation factor	1.7	1.5	0.7	1.2	0.8	1.1		2.1	0.8	1.2	5.6
			II (thrombin)
50758	F8A			2.1	1.7	1.2	1.1	1.1	1.0	1.4	1.3	1.2	1.0	4.5
49295	FAF1	CGI-03	Fas (TNFRSF6)	0.9	1.0	1.5	1.4	1.1	1.0	1.4	1.4	1.2	1.2	4.9
			associated factor 1
47756	FAP			1.2	1.1	0.6	1.5	0.9	1.0	0.9	1.0	1.0	1.0	4.6
48362	FBN2	FBN2	fibrillin 2	0.9	1.0	1.5	1.4	1.0	1.0	1.3	1.3	0.9	1.0	4.6
			(congenital
			contractural
			arachnodactyl
48839	FCGR1A			0.8	1.1	2.2	2.1	1.2	1.2	1.4	1.3	1.1	1.0	5.5
48273	FCGR2A	CD32	Fc fragment of	2.0	1.9	3.8	2.5	1.0	1.0		2.3		1.3	7.0
			IgG, low affinity
			Ila, receptor for
50715	FCGR2A	CD32	Fc fragment of	1.7	1.7	3.8	3.1	1.1	1.1		2.5	1.3	1.2	7.8
			IgG, low affinity
			Ila, receptor for
48977	FCGR2A	CD32	Fc fragment of	2.1	1.9	3.0	2.1	1.0	1.0		2.5	1.2	1.2	6.9
			IgG, low affinity
			Ila, receptor for
49995	FCGR2A	CD32	Fc fragment of	2.4	2.0	3.6	2.7	1.1	1.0		2.5	1.2	1.2	7.4
			IgG, low affinity
			Ila, receptor for
49326	FCGR2A	CD32	Fc fragment of	2.5	2.1	3.2	2.1	1.0	1.0		1.9	1.2	1.1	6.0
			IgG, low affinity
			Ila, receptor for
49649	FGF2	FGF-2	fibroblast growth	3.0	2.8	1.0	1.0	0.9	1.0		2.1	0.9	1.0	5.1
			factor 2 (basic)
50729	FGF7	FGF7	fibroblast growth	3.2	2.7	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			factor 7
			(keratinocyte
			growth fa
48946	FGFR1	FGF receptor 1	fibroblast growth	0.7	1.3	1.7	1.6	1.0	1.0		1.5	1.0	1.0	5.1
			factor receptor 1
			(fms-related t
49493	FLJ10430			0.9	1.0	0.7	1.4	0.9	1.1	1.0	1.0	0.9	1.0	4.4
47385	FLJ10718			3.2	2.7	0.4	1.9	0.7	1.3	0.8	1.0	1.0	1.0	5.2
48328	FN1	FN1	fibronectin 1	0.9	1.1	0.0	10.1	0.7	1.4		12.4		1.3	25.2
48348	FN1	FN1	fibronectin 1	0.8	1.1	0.0	9.6	0.6	1.4		7.6	0.8	1.2	19.9
47566	FOS	c-fos	v-fos FBJ murine	0.8	1.2	1.4	1.3	0.9	1.0	0.8	1.2	0.7	1.1	4.7
			osteosarcoma
			viral oncogene
			homol
49617	FOXF1	FOXF1	forkhead box F1	3.3	1.7	1.4	1.1	1.0	1.0		1.8	1.3	1.2	5.1
49969	FOXF1	FOXF1	forkhead box F1	3.4	1.7	1.4	1.1	1.0	1.0		1.7	1.3	1.1	4.9
46564	FYB			2.3	1.7	1.3	1.2	1.0	1.0	1.6	1.3	1.3	1.0	4.5
48467	GAA			0.8	1.2	1.3	1.2	1.1	1.0	1.6	1.4	1.2	1.1	4.7
47169	GAB1	Gab1	GRB2-associated	3.5	3.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.0	4.0
			binding protein 1
47386	GALNAC4S-6ST	BRAG	B cell RAG	0.7	1.0	0.6	1.5	1.0	1.0	0.6	1.4	0.8	1.1	5.0
			associated protein
49669	GALNAC4S-6ST	BRAG	B cell RAG	0.5	1.5	0.5	1.7	1.0	1.0		1.8	0.7	1.0	5.5
			associated protein
49626	GARP			3.2	2.5	1.0	1.0	1.0	1.0	0.8	1.0	1.0	1.0	4.0
50142	GBP1	IFN induced	guanylate binding	26.3	17.4	1.4	1.3	1.2	1.1	1.0	1.0	1.2	1.1	4.6
		GBP-1	protein 1,
			interferon-
			inducible,
48066	GBP2	IFN induced	guanylate binding	13.0	12.4	1.3	1.0	1.1	1.0	0.9	1.0	1.2	1.1	4.1
		GBP-2	protein 2,
			interferon-
			inducible
50373	GBP2	IFN induced	guanylate binding	30.2	29.9	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.0	4.0
		GBP-2	protein 2,
			interferon-
			inducible
49092	GCH1	GTP	GTP	20.6	20.1	1.0	1.0	0.9	1.0	0.9	1.0		1.3	4.3
		cyclohydrolase I	cyclohydrolase 1
			(dopa-responsive
			dystonia)
46977	GCH1	GTP	GTP	15.5	14.6	0.5	1.4	1.0	1.0	0.8	1.0		1.3	4.7
		cyclohydrolase I	cyclohydrolase 1
			(dopa-responsive
			dystonia)
49059	GCH1	GTP	GTP	18.7	18.2	1.0	1.0	0.8	1.0	0.9	1.0	1.3	1.1	4.1
		cyclohydrolase I	cyclohydrolase 1
			(dopa-responsive
			dystonia)
49023	GGA2			0.5	2.1	1.0	1.0	1.0	1.0	0.8	1.1	0.9	1.0	4.1
48293	GGT1			0.9	1.0	1.6	1.3	1.1	1.0		1.5	1.2	1.1	4.9
48651	GLA			1.3	1.2	1.4	1.3	1.0	1.0	1.4	1.2	1.1	1.0	4.6
50653	GM2A			0.9	1.0	1.7	1.6	1.1	1.0		1.6	1.2	1.1	5.3
49017	GMPR			2.8	2.1	1.3	1.1	1.0	1.0	1.1	1.0	1.1	1.0	4.2
48722	GNA13	G protein,	guanine	2.5	2.1	0.9	1.0	1.0	1.0	1.1	1.0	1.1	1.0	4.1
		alpha 13	nucleotide binding
			protein (G
			protein), al
50020	GNAI1	G protein,	guanine	0.4	2.2	0.6	1.3	1.0	1.0	1.0	1.0	1.0	1.0	4.3
		alpha i1	nucleotide binding
			protein (G
			protein), al
50433	GNAS	G protein,	guanine	0.9	1.1	1.6	1.4	1.1	1.0		1.7	1.1	1.0	5.1
		alpha s1	nucleotide binding
			protein (G
			protein), al
47648	GNAS	G protein,	guanine	0.8	1.1	1.5	1.3	1.0	1.0		1.6	1.1	1.0	4.9
		alpha s1	nucleotide binding
			protein (G
			protein), al
50746	GNAS	G protein,	guanine	0.9	1.1	1.5	1.3	1.1	1.0		1.5	1.0	1.0	4.9
		alpha s1	nucleotide binding
			protein (G
			protein), al
50743	GNB1	G protein, beta 1	guanine	0.9	1.0	0.7	1.4	1.1	1.1	0.7	1.4	1.0	1.0	4.9
			nucleotide binding
			protein (G
			protein), be
49769	GNG10	G protein,	guanine	1.1	1.0	1.3	1.1	1.1	1.0	1.4	1.3	1.1	1.0	4.4
		gamma 10	nucleotide binding
			protein 10
46876	GNG11	G protein,	guanine	1.2	1.0	0.4	2.6	0.8	1.1		2.8	0.9	1.0	7.5
		gamma 11	nucleotide binding
			protein 11
49277	GNG11	G protein,	guanine	1.1	1.0	0.5	1.6	0.8	1.1		1.9	1.0	1.0	5.6
		gamma 11	nucleotide binding
			protein 11
47511	GNLY	NKG5	granulysin	1.2	1.0	0.6	1.3	0.8	1.1	0.7	1.0	1.0	1.0	4.5
46780	GPA33			11.3	7.9	0.9	1.0	1.0	1.0	1.5	1.2		1.4	4.6
46936	GRB10	GRB10	growth factor	3.9	2.8	0.9	1.0	0.9	1.0	0.9	1.0	1.2	1.0	4.0
			receptor-bound
			protein 10
50674	GRF2	C3G	guanine	0.9	1.0	1.2	1.1	1.1	1.0		1.5	1.1	1.0	4.6
			nucleotide-
			releasing factor 2
			(specific fo
50545	GRF2	C3G	guanine	0.9	1.0	1.2	1.1	1.0	1.0	1.5	1.4	1.1	1.0	4.5
			nucleotide-
			releasing factor 2
			(specific fo
49586	GRIN2C			7.9	7.7	0.2	4.4	0.7	1.4	0.5	1.3	0.8	1.0	8.1
49754	GRO1	GRO1	GRO1 oncogene	44.5	27.1	0.4	2.2	0.7	1.3	0.8	1.0	1.0	1.0	5.5
			(melanoma growth
			stimulating activit
50462	GRO1	GRO1	GRO1 oncogene	33.8	21.0	0.4	2.1	0.8	1.2	0.7	1.0	1.0	1.0	5.3
			(melanoma growth
			stimulating activit
47558	GRO2	GRO2	GRO2 oncogene	44.6	15.5	1.0	1.0	0.8	1.0	0.7	1.1	0.9	1.1	4.3
47632	GRO2	GRO2	GRO2 oncogene	25.4	16.7	0.4	2.5	0.7	1.4	0.7	1.0	0.9	1.0	5.9
48330	GRO3	GRO3	GRO3 oncogene	36.2	17.9	0.4	2.2	0.7	1.2	0.8	1.0	0.9	1.1	5.5
49692	GRO3	GRO3	GRO3 oncogene	33.5	17.1	0.4	2.2	0.7	1.4	0.7	1.0	1.0	1.0	5.6
48455	GRP58			0.9	1.0	1.3	1.2	1.0	1.0	1.4	1.3	1.2	1.1	4.7
46895	GS3686			6.6	6.0	1.6	1.5	1.1	1.0	0.9	1.1	1.1	1.0	4.5
49688	GSK3B	GSK3B	glycogen synthase	1.0	1.0	1.3	1.2	1.0	1.0	1.3	1.3	1.1	1.0	4.5
			kinase 3 beta
47982	GSTA4			0.9	1.0	1.6	1.4	1.1	1.0	1.4	1.1	0.9	1.0	4.5
47753	GTF2B			3.2	2.9	1.0	1.0	1.0	1.0	1.3	1.0	1.1	1.0	4.0
48780	GZMA	granzyme A	granzyme A	3.4	3.0	1.2	1.0	1.0	1.0	1.4	1.2	1.0	1.0	4.2
			(granzyme 1,
			cytotoxic T-
			lymphocyte-ass
46882	HEXA			0.9	1.0	1.4	1.1	1.1	1.1	1.6	1.4	1.1	1.1	4.7
48397	HIF1A	HIF-1 alpha	hypoxia-inducible	4.1	3.9	0.8	1.2	1.1	1.0	1.0	1.0	1.1	1.0	4.2
			factor 1, alpha
			subunit (basic h
50022	HIF1A	HIF-1 alpha	hypoxia-inducible	3.9	3.4	0.9	1.1	1.1	1.0	1.0	1.0	1.1	1.0	4.2
			factor 1, alpha
			subunit (basic h
50381	HLA-DQB1	MHCII, DQ	major	1.0	1.0	2.0	1.7	1.2	1.0		1.6	1.0	1.0	5.3
		beta 1	histocompatibility
			complex, class II,
			DQ bet
47179	HLA-DRB1	MHCII, DR	major	0.9	1.0	2.0	1.7	1.2	1.1		1.8	1.3	1.2	5.8
		beta 1	histocompatibility
			complex, class II,
			DR bet
49305	HLA-DRB1	MHCII, DR	major	0.9	1.0	2.1	1.8	1.1	1.1		1.8	1.2	1.2	6.0
		beta 1	histocompatibility
			complex, class II,
			DR bet
47887	HLA-DRB1	MHCII, DR	major	1.1	1.0	1.8	1.7	1.1	1.0		1.7	1.2	1.2	5.6
		beta 1	histocompatibility
			complex, class II,
			DR bet
46926	HLA-DRB1	MHCII, DR	major	1.0	1.0	2.0	1.5	1.2	1.1		1.7	1.3	1.2	5.6
		beta 1	histocompatibility
			complex, class II,
			DR bet
48589	HLA-DRB1	MHCII, DR	major	1.0	1.0	2.0	1.8	1.1	1.1		1.7	1.2	1.2	5.7
		beta 1	histocompatibility
			complex, class II,
			DR bet
50385	HLA-DRB1	MHCII, DR	major	0.9	1.1	1.9	1.7	1.1	1.0		1.8	1.2	1.0	5.5
		beta 1	histocompatibility
			complex, class II,
			DR bet
49293	HLA-DRB3	MHCII, DR	major	0.9	1.0	2.0	1.8	1.1	1.1		1.7	1.1	1.1	5.8
		beta 3	histocompatibility
			complex, class II,
			DR bet
47855	HM74	GPGR	putative	1.8	1.7	1.2	1.2	1.1	1.0	1.4	1.3	1.2	1.1	4.6
			chemokine
			receptor; GTP-
			binding protein
49217	HMGIC			0.6	1.1	0.7	1.3	0.9	1.0		1.8		1.3	5.4
50361	HMGIY	HMG-I/Y	high-mobility	0.7	1.3	0.5	1.7	0.9	1.1		1.5	0.8	1.1	5.4
			group (nonhistone
			chromosomal)
			prote
50526	HMGIY	HMG-I/Y	high-mobility	0.7	1.4	0.5	1.6	0.9	1.1	0.6	1.4	0.8	1.1	5.2
			group (nonhistone
			chromosomal)
			prote
50493	HMGIY	HMG-I/Y	high-mobility	0.7	1.4	0.6	1.4	0.9	1.1	0.6	1.4	0.8	1.1	5.0
			group (nonhistone
			chromosomal)
			prote
49347	HNRPA3			0.9	1.1	0.5	1.7	1.0	1.0		1.7	1.0	1.0	5.4
47605	HRMT1L2			1.3	1.2	0.5	1.8	0.8	1.1	0.6	1.4	0.9	1.0	5.3
47922	HS3ST3A1	HS3ST3A1	heparan sulfate	2.3	2.1	0.6	1.3	0.6	1.2	1.1	1.0	1.0	1.0	4.5
			(glucosamine) 3-
			O-sulfotransferase
47185	HSPA1B	HSPA1B	heat shock 70 kD	2.0	1.7	1.6	1.5	1.1	1.0		1.5	1.3	1.2	5.1
			protein 1B
49417	HSPA1B	HSPA1B	heat shock 70 kD	2.2	1.4	1.7	1.5	1.1	1.0		1.6	1.3	1.1	5.2
			protein 1B
48618	HSPA1B	HSPA1B	heat shock 70 kD	2.2	1.5	1.6	1.5	1.1	1.0	1.8	1.4	1.3	1.1	4.9
			protein 1B
49064	HSPA1B	HSPA1B	heat shock 70 kD	2.4	1.6	1.6	1.4	1.1	1.0	1.8	1.4	1.2	1.0	4.7
			protein 1B
48421	HSPB2	HSPB2	heat shock 27 kD	4.1	3.4	1.0	1.0	1.0	1.0	0.8	1.0	1.1	1.0	4.0
			protein 2
48550	HSPB2	HSPB2	heat shock 27 kD	4.1	3.2	1.1	1.0	1.0	1.0	1.0	1.0	1.1	1.0	4.0
			protein 2
48693	HSPBP1	HSPBP1	hsp70-interacting	0.9	1.0	0.7	1.2	0.9	1.0	0.7	1.3	1.0	1.0	4.5
			protein
49681	HSXIAPAF1	XIAP assoc	XIAP associated	9.5	9.3	2.8	2.6	1.1	1.0	1.0	1.0	0.9	1.0	5.6
		factor 1	factor-1
48605	HSXIAPAF1	XIAP assoc	XIAP associated	13.2	8.9	2.7	2.5	1.2	1.0	1.1	1.0	1.0	1.0	5.6
		factor 1	factor-1
47611	HTATIP			1.2	1.1	0.7	1.3	1.0	1.0	0.8	1.2	1.0	1.0	4.5
48199	HXB	HXB	hexabrachion	3.0	2.3	1.2	1.0	1.0	1.0	1.2	1.0	0.9	1.0	4.0
			(tenascin C,
			cytotactin)
49140	ICAM1	ICAM1	intercellular	6.0	4.2	0.7	1.2	0.9	1.0	1.0	1.0	1.1	1.0	4.2
			adhesion
			molecule 1
			(CD54), human rh
49771	ICAM1	ICAM1	intercellular	6.3	4.5	0.7	1.3	0.9	1.1	0.9	1.0	1.1	1.0	4.4
			adhesion
			molecule 1
			(CD54), human rh
49804	ICAM1	ICAM1	intercellular	6.0	4.4	0.7	1.3	0.9	1.1	1.0	1.0	1.1	1.0	4.4
			adhesion
			molecule 1
			(CD54), human rh
50084	IDI1			0.8	1.2	1.1	1.0	0.8	1.2	0.9	1.1		1.3	4.6
47803	IFI16			4.2	3.3	1.1	1.1	1.0	1.0	1.1	1.0	1.1	1.0	4.1
48436	IFI35	IFN-induced	interferon-induced	5.2	4.5	1.7	1.5	1.1	1.0	0.9	1.0	1.1	1.0	4.5
		protein 35	protein 35
46595	IFI35	IFN-induced	interferon-induced	6.3	4.8	1.6	1.2	1.2	1.1	1.0	1.0	1.1	1.0	4.3
		protein 35	protein 35
49870	IFIT4			10.9	6.3	1.1	1.0	0.7	1.2		1.7	1.2	1.2	5.2
48115	IFITM3			4.3	3.1	1.7	1.6	1.1	1.1	1.2	1.1	1.1	1.1	4.9
50311	IFNGR1	IFN gamma	interferon gamma	0.7	1.2	2.3	1.8	1.2	1.0	1.3	1.1	0.9	1.0	5.0
		receptor 1	receptor 1
47903	IFNGR1	IFN gamma	interferon gamma	0.7	1.0	2.0	1.5	1.1	1.0	1.4	1.3	1.0	1.0	4.9
		receptor 1	receptor 1
47225	IFNGR2	IFN gamma	interferon gamma	1.3	1.0	0.7	1.3	0.9	1.0	1.0	1.0	1.0	1.0	4.3
		receptor 2	receptor 2
			(interferon gamma
			tran
47582	IFNGR2	IFN gamma	interferon gamma	1.3	1.0	0.7	1.3	0.9	1.0	1.1	1.0	1.0	1.0	4.3
		receptor 2	receptor 2
			(interferon gamma
			tran
50403	IGFBP3			2.8	2.2	0.2	4.2	0.9	1.0		3.8	0.7	1.1	10.1
50342	IKKE	IKK-related K	IKK-related kinase	1.1	1.0	1.5	1.3	1.0	1.0	1.3	1.0	1.0	1.0	4.3
		epsilon, IKK-I	epsilon; inducible
			IkappaB kina
49758	IL10RA	IL-10R alpha	interleukin 10	9.5	7.9	2.0	1.8	1.2	1.0		2.1	1.4	1.2	6.1
			receptor, alpha
47040	IL10RA	IL-10R alpha	interleukin 10	11.8	10.6	2.1	1.7	1.1	1.0		1.8	1.5	1.2	5.8
			receptor, alpha
48581	IL13RA1	IL-13Ralpha′	interleukin 13	1.9	1.6	1.7	1.5	1.0	1.0	1.1	1.1	0.9	1.0	4.6
			receptor, alpha 1
50013	IL13RA1	IL-13Ralpha′	interleukin 13	1.7	1.5	1.5	1.4	1.1	1.0	1.1	1.0	1.0	1.0	4.5
			receptor, alpha 1
48909	IL15RA	IL-15R alpha	interleukin 15	11.9	9.5	0.9	1.0	1.0	1.0	1.0	1.0	1.3	1.2	4.2
			receptor, alpha
50667	IL15RA	IL-15R alpha	interleukin 15	13.9	13.4	1.0	1.0	1.0	1.0	1.1	1.1	1.3	1.2	4.3
			receptor, alpha
47656	IL1B	IL-1, beta	interleukin 1, beta	2.5	2.4	0.3	3.5	0.7	1.1	1.3	1.1	1.2	1.1	6.8
46970	IL1B	IL-1, beta	interleukin 1, beta	3.3	2.3	0.2	3.9	0.7	1.2	1.2	1.2	1.2	1.1	7.3
48637	IL1R1	IL-1RI	interleukin 1	2.8	2.5	0.7	1.4	0.9	1.0	1.1	1.1	1.2	1.1	4.6
			receptor, type I
47659	IL1RAP	IL-1RAP	interleukin 1	5.6	5.2	1.0	1.0	1.0	1.0	0.9	1.0	0.9	1.0	4.0
			receptor
			accessory protein
47692	IL1RAP	IL-1RAP	interleukin 1	5.1	4.6	1.0	1.0	1.0	1.0	0.9	1.0	1.1	1.0	4.0
			receptor
			accessory protein
48324	IL3RA	IL-3R alpha	interleukin 3	3.4	3.1	1.4	1.2	1.0	1.0	0.8	1.0	0.8	1.1	4.2
			receptor, alpha
			(low affinity)
49135	IL6	interleukin-6,	interleukin 6	13.6	11.3	1.3	1.2	1.0	1.0	1.3	1.0		1.4	4.6
		IFNbeta2	(interferon, beta 2)
49264	IL6	interleukin-6,	interleukin 6	13.5	9.7	1.4	1.2	1.0	1.0	1.3	1.0		1.4	4.6
		IFNbeta2	(interferon, beta 2)
49289	IL6R	IL-6R	interleukin 6	0.9	1.0	1.4	1.3	1.0	1.0	1.5	1.3	1.0	1.0	4.6
			receptor
47844	IL7R	IL-7R	interleukin 7	20.6	16.8	0.9	1.0	1.0	1.0	0.7	1.2	1.4	1.2	4.5
			receptor
47715	IL7R	IL-7R	interleukin 7	19.9	19.3	1.0	1.0	1.0	1.0	0.8	1.3	1.4	1.2	4.5
			receptor
46856	IL8	interleukin-8	interleukin 8	7.2	6.7	0.2	3.8	0.6	1.4	1.2	1.2	1.2	1.0	7.4
50455	IMPDH1			1.5	1.3	1.3	1.1	1.1	1.0	1.4	1.3	1.0	1.0	4.5
46724	INDO			47.1	35.0	1.0	1.0	1.0	1.0	0.9	1.0	1.4	1.2	4.3
49873	INSIG1			1.5	1.4	0.6	1.4	0.7	1.4	1.0	1.0		1.3	5.1
49763	IQGAP2	IQGAP2	IQ motif	2.2	1.8	1.2	1.0	1.1	1.0	0.7	1.4	1.0	1.0	4.4
			containing
			GTPase activating
			protein 2
46642	IRAK2	IRAK-2	interleukin-1	5.7	5.2	0.7	1.0	1.1	1.0	1.1	1.0	1.0	1.0	4.0
			receptor-
			associated kinase 2
47186	IRAK2	IRAK-2	interleukin-1	5.3	4.4	0.8	1.0	1.2	1.0	1.1	1.0	1.0	1.0	4.0
			receptor-
			associated kinase 2
49335	IRF7	IRF-7A	interferon	6.9	4.5	1.4	1.2	1.0	1.0	0.9	1.1	1.0	1.0	4.3
			regulatory factor 7
47149	IRF7	IRF-7A	interferon	4.2	3.9	1.2	1.1	1.0	1.0	1.0	1.0	1.1	1.0	4.1
			regulatory factor 7
48371	IRS1	IRS1	insulin receptor	1.0	1.0	0.5	1.3	1.0	1.0	1.0	1.0	1.0	1.0	4.3
			substrate 1
50580	ISG15	ISG15, IFN	interferon-	17.1	15.2	1.5	1.3	1.0	1.0	1.2	1.1	1.2	1.1	4.5
		stimulated	stimulated protein,
		protein	15 kDa
46618	ISG15	ISG15, IFN	interferon-	32.0	24.1	1.9	1.7	1.2	1.1	1.2	1.0	1.2	1.1	4.8
		stimulated	stimulated protein,
		protein	15 kDa
50089	ISG15	ISG15, IFN	interferon-	16.8	13.5	1.7	1.5	1.1	1.0	1.3	1.2	1.1	1.0	4.7
		stimulated	stimulated protein,
		protein	15 kDa
49054	ITGA2	integrin, alpha	integrin, alpha 2	0.9	1.0	0.6	1.4	0.9	1.0		1.6	1.0	1.0	5.0
		2, CD49B,	(CD49B, alpha 2
		VLA-2	subunit of VLA-2
48617	ITGA4	VLA4a,	integrin, alpha 4	0.7	1.2	1.7	1.6	1.1	1.1	1.3	1.2	1.1	1.0	4.8
		integrin, alpha 5	(antigen CD49D,
			alpha 4 subunit
48426	ITGA4	VLA4a,	integrin, alpha 4	0.5	1.7	1.5	1.4	1.2	1.0	1.4	1.3	1.1	1.0	4.7
		integrin, alpha 5	(antigen CD49D,
			alpha 4 subunit
47138	ITGAM	Mac-1,	integrin, alpha M	0.7	1.2	1.4	1.3	1.0	1.0	1.7	1.4	1.1	1.0	4.8
		CD11b,	(complement
		integrin alpha M	component
			receptor 3
47009	ITGAM	Mac-1,	integrin, alpha M	0.7	1.1	1.4	1.3	1.0	1.0	1.6	1.4	1.1	1.0	4.7
		CD11b,	(complement
		integrin alpha M	component
			receptor 3
48628	ITGB2	CD18	integrin, beta 2	0.9	1.0	1.2	1.1	1.0	1.0	1.5	1.4	1.1	1.0	4.5
			(antigen CD18
			(p95), lymphocyte f
50343	JAK2	JAK2	Janus kinase 2 (a	4.6	4.2	1.4	1.2	1.0	1.0		1.5	1.3	1.2	5.0
			protein tyrosine
			kinase)
48929	JAK2	JAK2	Janus kinase 2 (a	4.5	4.3	1.0	1.0	1.0	1.0	1.4	1.4	1.3	1.2	4.6
			protein tyrosine
			kinase)
46749	JM1			2.2	2.1	0.8	1.1	1.0	1.0	0.9	1.0	1.1	1.0	4.1
49322	JUNB	JunB	jun B proto-	2.4	2.1	0.9	1.0	0.9	1.1	1.1	1.1	1.0	1.0	4.2
			oncogene
49319	JUNB	JunB	Jun B proto-	2.3	2.0	0.9	1.0	0.9	1.1	1.2	1.1	1.0	1.0	4.1
			oncogene
47770	KIAA0062			3.8	3.1	0.8	1.0	0.8	1.1	0.9	1.0	1.0	1.0	4.1
50052	KIAA0171			1.1	1.0	1.1	1.0	1.0	1.0	1.4	1.4	0.9	1.0	4.4
49552	KIAA0173			0.9	1.0	1.3	1.2	1.0	1.0	1.4	1.4	1.0	1.0	4.6
48643	KIAA0184			1.0	1.0	0.8	1.2	1.1	1.0	0.7	1.3	1.1	1.0	4.6
50764	KIAA0212			1.7	1.4	1.3	1.2	1.1	1.1		1.5	1.0	1.0	4.8
50304	KIAA0226			2.2	2.1	1.2	1.1	1.1	1.0	1.3	1.1	1.1	1.0	4.2
48896	KIAA0227			0.1	7.3	0.8	1.1	1.0	1.0	0.9	1.0	0.9	1.0	4.1
48668	KIAA0247			2.6	2.4	1.2	1.1	1.0	1.0	1.0	1.0	1.0	1.0	4.1
48294	KIAA0286			3.5	2.8	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.1	4.1
50582	KIAA0534			2.4	2.0	1.0	1.0	1.1	1.0	1.0	1.0	1.0	1.0	4.0
49904	KIAA1557			2.3	1.7	2.3	2.1	1.1	1.0	1.2	1.1	0.9	1.0	5.2
48479	KIF3C			0.5	1.4	1.6	1.4	1.0	1.0	1.1	1.0	0.9	1.0	4.4
49225	KMO			2.8	2.3	1.1	1.0	1.1	1.1	1.0	1.0	1.2	1.1	4.2
48990	KRAS2	K-Ras	v-Ki-ras2 Kirsten	1.0	1.0	0.9	1.1	1.0	1.0	0.7	1.3	1.1	1.0	4.5
			rat sarcoma 2 viral
			oncogene hom
47062	LAIR1			0.4	2.1	1.1	1.0	1.1	1.0	0.9	1.1	1.1	1.0	4.1
50042	LAMB3	LAMB3	laminin, beta 3	4.7	3.6	1.7	1.5	1.1	1.0	0.6	1.3	0.8	1.1	4.9
			(nicein (125 kD),
			kalinin (140 kD),
48692	LAMC1	LAMC1	laminin, gamma 1	0.8	1.3	1.3	1.2	0.9	1.0		1.5	0.9	1.0	4.7
			(formerly LAMB2)
49882	LAMP2			0.9	1.0	1.5	1.3	1.1	1.0	1.5	1.4	1.2	1.1	4.9
47033	LCP2	SLP-76	lymphocyte	3.8	3.3	0.7	1.2	0.9	1.0	1.0	1.0	1.2	1.1	4.3
			cytosolic protein 2
			(SH2 domain-
			contain
47162	LCP2	SLP-76	lymphocyte	3.7	3.2	0.7	1.2	0.9	1.0	1.1	1.0	1.2	1.1	4.3
			cytosolic protein 2
			(SH2 domain-
			contain
49163	LGALS3			1.4	1.3	1.4	1.2	1.2	1.1	1.5	1.3	1.1	1.0	4.6
49016	LIPA			1.1	1.0	1.4	1.3	1.1	1.0		1.6	1.2	1.1	5.0
50303	LMO2			0.9	1.0	1.9	1.4	1.2	1.1	1.4	1.3	1.0	1.0	4.8
50349	LOC51295	ECSIT	ECSIT	0.7	1.3	0.6	1.5	1.0	1.0		1.5	0.9	1.0	5.0
50618	LOC51339			0.4	1.9	0.7	1.0	0.7	1.3	1.0	1.0	1.0	1.0	4.3
49577	LOC54543			1.1	1.0	1.2	1.1	1.0	1.0	1.4	1.3	1.0	1.0	4.4
47114	LPP			1.0	1.0	1.6	1.5	1.2	1.1	1.1	1.0	1.2	1.2	4.9
47585	LRPAP1			0.9	1.0	1.5	1.2	1.0	1.0	1.4	1.3	1.1	1.0	4.5
49560	LY117			1.0	1.0	1.5	1.4	1.0	1.0	1.7	1.4	1.0	1.0	4.9
46676	LYN	Lyn	v-yes-1	5.7	4.6	1.0	1.0	1.0	1.0	1.4	1.4	1.2	1.2	4.5
			Yamaguchi
			sarcoma viral
			related oncogene h
46605	LYN	Lyn	v-yes-1	5.0	3.9	0.9	1.0	1.0	1.0	1.4	1.4	1.2	1.0	4.4
			Yamaguchi
			sarcoma viral
			related oncogene h
46776	MAD2L1			0.7	1.2	0.4	1.6	1.0	1.0	0.6	1.1	1.0	1.0	4.6
47705	MAD4	MAD4	Mad4 homolog	0.7	1.3	1.6	1.4	0.9	1.0	1.6	1.4	1.0	1.0	4.8
47267	MAD4	MAD4	Mad4 homolog	0.4	2.1	0.7	1.1	1.0	1.0	0.7	1.0	0.9	1.0	4.1
48028	MAP2K3	MKK3	mitogen-activated	2.1	2.0	0.9	1.0	0.9	1.0	1.1	1.0	1.1	1.0	4.0
			protein kinase
			kinase 3
48278	MAP2K3	MKK3	mitogen-activated	2.2	2.1	0.9	1.0	0.9	1.0	1.1	1.0	0.9	1.0	4.0
			protein kinase
			kinase 3
49650	MAP3K10	MLK2	mitogen-activated	0.9	1.0	1.4	1.3	1.0	1.0	1.4	1.3	1.0	1.0	4.6
			protein kinase
			kinase kinase 10
50694	MAP3K4	MEKK4	mitogen-activated	1.0	1.0	0.8	1.1	0.9	1.0		1.8	0.8	1.1	4.9
			protein kinase
			kinase kinase 4
50150	MAP3K4	MEKK4	mitogen-activated	0.9	1.0	0.7	1.2	0.9	1.0		2.1	0.8	1.0	5.4
			protein kinase
			kinase kinase 4
50043	MAP3K5	MKK5, ASK1	mitogen-activated	4.5	3.4	1.3	1.2	1.0	1.0	0.9	1.0	1.0	1.0	4.2
			protein kinase
			kinase kinase 5
50045	MAP3K5	MKK5, ASK1	mitogen-activated	4.1	3.4	1.2	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
			protein kinase
			kinase kinase 5
47145	MAP3K7	TAK1	mitogen-activated	1.1	1.0	1.0	1.0	1.0	1.0	1.3	1.3	1.1	1.0	4.3
			protein kinase
			kinase kinase 7
47969	MAP3K8	c-cot	mitogen-activated	4.9	4.8	0.9	1.0	0.8	1.0		1.8	1.4	1.1	5.0
			protein kinase
			kinase kinase 8
48424	MAP4K4	GCK-like,	mitogen-activated	1.5	1.4	1.3	1.2	1.0	1.0	1.4	1.3	1.2	1.2	4.6
		HPK, HGK,	protein kinase
		NIK	kinase kinase kin
49437	MAPK13	SAPK4, p38,	mitogen-activated	0.6	1.6	0.7	1.3	1.0	1.0	0.7	1.4	0.8	1.1	4.8
		delta	protein kinase 13
50569	MBNL			2.2	1.8	1.4	1.3	1.0	1.0	1.6	1.4	1.3	1.1	4.8
47123	MCM2			0.6	1.7	0.5	1.3	1.0	1.0	0.7	1.2	1.1	1.0	4.5
48470	MCM5			0.7	1.5	0.6	1.3	0.9	1.1		1.5	1.0	1.0	4.9
47137	MD-2	MD-2	MD-2 protein	1.0	1.0	2.1	1.7	1.1	1.0	1.6	1.4	1.2	1.2	5.2
46785	MD-2	MD-2	MD-2 protein	1.0	1.0	1.9	1.3	1.1	1.1	1.6	1.4	1.1	1.1	4.8
46691	MEF2C	MEF2C	MADS box	0.8	1.0	0.9	1.1	1.0	1.0	0.7	1.4	1.0	1.0	4.5
			transcription
			enhancer factor 2,
			polypept
50742	MGEA5	MGEA5	meningioma	0.7	1.3	1.4	1.2	1.1	1.0	1.6	1.4	0.9	1.0	4.6
			expressed antigen
			5 (hyaluronidase)
48411	MGEA5	MGEA5	meningioma	0.8	1.1	1.4	1.3	1.0	1.0	1.2	1.1	1.0	1.0	4.4
			expressed antigen
			5 (hyaluronidase)
47799	MGLL			1.8	1.7	1.0	1.0	1.0	1.0		1.5	1.1	1.0	4.5
50404	MIC2			1.2	1.1	1.5	1.3	1.2	1.1	1.5	1.4	1.2	1.0	4.7
48570	MIG	monokine	monokine induced	15.7	10.8	0.6	1.3	0.9	1.0	1.0	1.0	1.4	1.4	4.7
		induced by	by gamma
		gamma	interferon
		interferon
48441	MIG	monokine	monokine induced	13.7	7.6	0.6	1.2	0.8	1.1	0.9	1.0	1.4	1.3	4.6
		induced by	by gamma
		gamma	interferon
		interferon
48465	MIG2			1.0	1.0	0.5	1.5	1.0	1.0	0.6	1.2	1.0	1.0	4.6
49224	MITF			0.4	1.9	1.4	1.3	1.1	1.0	1.1	1.0	1.2	1.0	4.3
48966	MMP10	MMP10	matrix	1.7	1.6	0.5	1.8	0.6	1.6		2.3		1.5	7.2
			metalloproteinase
			10 (stromelysin 2)
47380	MMP12	MMP12	matrix	2.8	1.4	0.7	1.0	0.8	1.0	0.6	1.4	1.1	1.0	4.4
			metalloproteinase
			12 (macrophage
			elastase)
48038	MMP13	MMP13	matrix	0.9	1.0	1.6	1.4	1.1	1.0		1.7	1.1	1.0	5.2
			metalloproteinase
			13 (collagenase 3)
48582	MMP13	MMP13	matrix	0.9	1.1	1.6	1.5	1.1	1.1		1.7	1.2	1.0	5.3
			metalloproteinase
			13 (collagenase 3)
50739	MMP14	MT1-MMP	matrix	0.9	1.1	1.2	1.1	1.1	1.0	1.4	1.3	1.1	1.0	4.4
			metalloproteinase
			14 (membrane-
			inserted)
48949	MMP2	MMP2,	matrix	0.7	1.3	1.6	1.3	1.0	1.0		1.6	1.1	1.0	4.9
		gelatinase A	metalloproteinase
			2 (gelatinase A,
			72 kD gel
48933	MMP2	MMP2,	matrix	0.8	1.1	1.3	1.1	1.1	1.0		1.6	1.1	1.0	4.7
		gelatinase A	metalloproteinase
			2 (gelatinase A,
			72 kD gel
50755	MMP2	MMP2,	matrix	0.8	1.0	1.4	1.3	1.1	1.0	1.5	1.4	1.1	1.0	4.7
		gelatinase A	metalloproteinase
			2 (gelatinase A,
			72 kD gel
47174	MMP3	MMP3	matrix	3.9	3.6	1.0	1.0	0.6	1.6	1.0	1.0	0.7	1.1	4.7
			metalloproteinase
			3 (stromelysin 1,
			progela
46630	MMP3	MMP3	matrix	3.8	3.2	1.0	1.0	0.6	1.5		6.8	0.7	1.1	10.4
			metalloproteinase
			3 (stromelysin 1,
			progela
49124	MMP7	MMP7	matrix	1.4	1.3	0.4	1.5	0.9	1.0		2.1	0.9	1.0	5.6
			metalloproteinase
			7 (matrilysin,
			uterine)
48334	MMP7	MMP7	matrix	1.5	1.4	0.1	4.3	0.9	1.1		4.4	0.9	1.0	10.8
			metalloproteinase
			7 (matrilysin,
			uterine)
48187	MRPL27			1.1	1.0	0.7	1.4	1.0	1.0	0.6	1.2	1.0	1.0	4.6
47106	MT1L			12.3	10.0	0.7	1.4	0.9	1.0	0.8	1.0	1.1	1.1	4.5
46766	MT3			9.4	5.6	1.2	1.1	1.2	1.1	1.4	1.3	1.1	1.0	4.5
47772	MTHFD2			2.8	2.7	0.8	1.1	0.9	1.1	1.0	1.0	1.1	1.0	4.2
48399	MUC1	mucin1	mucin 1,	2.6	2.5	1.1	1.0	0.9	1.0	0.7	1.2	0.9	1.0	4.3
			transmembrane
50460	MUC1	mucin1	mucin 1,	3.0	2.3	1.2	1.0	1.0	1.0	0.7	1.3	0.9	1.0	4.3
			transmembrane
50390	MUC13	mucin13	mucin 13,	2.3	2.0	1.0	1.0	1.0	1.0	1.0	1.0	0.8	1.0	4.0
			epithelial
			transmembrane
50406	MX1			13.2	10.4	1.8	1.7	1.2	1.1	1.3	1.1	1.1	1.0	4.9
47450	MX2			18.3	14.2	2.2	1.6	1.2	1.1	1.1	1.0	1.0	1.0	4.7
46860	MYB	c-myb	v-myb avian	2.4	2.1	0.8	1.0	0.9	1.0	1.1	1.0	0.9	1.0	4.0
			myeloblastosis
			viral oncogene
			homolog
47968	MYLK			0.8	1.2	0.6	1.4	1.0	1.0	0.7	1.3	0.9	1.0	4.7
47754	NBS1			3.7	3.0	0.7	1.4	1.1	1.0	0.7	1.3	1.2	1.1	4.7
48487	NDN			3.0	1.7	1.1	1.0	0.8	1.1	1.6	1.4	1.0	1.0	4.5
48290	NEDD4L			1.6	1.5	0.6	1.4	0.8	1.1		1.5	0.8	1.1	5.0
48866	NEO1			1.0	1.0	1.6	1.4	1.1	1.0	1.4	1.1	1.1	1.0	4.5
47584	NFAT5	NFAT 5	nuclear factor of	3.0	2.8	0.9	1.0	0.9	1.0	1.3	1.2	1.1	1.0	4.2
			activated T-cells
			5, tonicity-re
50442	NFATC3	NFAT 4	nuclear factor of	0.5	1.9	1.6	1.4	1.0	1.0	1.2	1.0	0.9	1.1	4.5
			activated T-cells,
			cytoplasmic,
46799	NFE2L1	NFE2L1	nuclear factor	2.7	2.6	1.3	1.2	1.0	1.0	0.7	1.3	0.9	1.0	4.5
			(erythroid-derived
			2)-like 1
47201	NFIA	NFAT 3	nuclear factor I/A	6.8	6.2	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
47877	NFKB1	NFkappaB,	nuclear factor of	5.7	4.3	0.7	1.2	0.9	1.1	1.2	1.1	1.1	1.0	4.5
		p105	kappa light
			polypeptide gene
			enh
47173	NFKB1	NFkappaB,	nuclear factor of	4.7	3.5	0.7	1.2	0.9	1.0	1.2	1.1	1.1	1.0	4.3
		p105	kappa light
			polypeptide gene
			enh
50676	NFKB2	NFkappaB,	nuclear factor of	3.6	2.3	1.0	1.0	1.0	1.0	1.3	1.3	1.0	1.0	4.3
		p49/p100	kappa light
			polypeptide gene
			enh
50547	NFKB2	NFkappaB,	nuclear factor of	3.5	2.3	1.0	1.0	0.9	1.0	1.3	1.2	1.0	1.0	4.2
		p49/p100	kappa light
			polypeptide gene
			enh
49046	NFKBIA	IkB, alpha	nuclear factor of	7.0	6.3	0.7	1.4	0.9	1.0	1.1	1.0	1.0	1.0	4.4
			kappa light
			polypeptide gene
			enh
47056	NFRKB			0.8	1.2	0.6	1.5	0.9	1.0	0.6	1.4	0.9	1.1	5.0
49690	NID	NID	nidogen (enactin)	1.0	1.0	1.4	1.3	1.1	1.0	1.4	1.3	1.2	1.0	4.6
49014	NINJ1			5.1	5.0	0.7	1.3	1.1	1.0	0.8	1.1	1.0	1.0	4.4
49872	NMA			4.3	2.6	1.6	1.2	0.9	1.0		1.6	1.1	1.1	4.9
48289	NR1H3			1.3	1.1	0.6	1.3	1.0	1.0		1.5	1.0	1.0	4.7
49383	NR4A1	NAK1	nuclear receptor	3.3	2.8	1.1	1.0	1.1	1.0	1.4	1.2	1.1	1.0	4.3
			subfamily 4, group
			A, member 1
48941	NR4A1	NAK1	nuclear receptor	20.4	5.2	0.8	1.0	0.7	1.1	0.7	1.0	0.9	1.0	4.1
			subfamily 4, group
			A, member 1
47897	NR4A2	TINUR	nuclear receptor	7.0	6.0	0.9	1.0	0.9	1.0	1.8	1.1	0.8	1.0	4.1
			subfamily 4, group
			A, member 2
47712	NR4A2	TINUR	nuclear receptor	8.1	4.9	1.1	1.0	0.9	1.0	1.4	1.1	1.2	1.0	4.1
			subfamily 4, group
			A, member 2
47679	NR4A2	TINUR	nuclear receptor	4.8	2.6	1.2	1.0	1.0	1.0	1.3	1.2	1.1	1.0	4.2
			subfamily 4, group
			A, member2
48227	NRG1	neuregulin1,	neuregulin 1	5.8	3.5	0.4	1.9	0.7	1.2		1.5	0.8	1.1	5.8
		neu diff.
		Factor,
		heregulin
48468	NRG1	neuregulin1,	neuregulin 1	5.3	4.1	0.5	1.6	0.7	1.3	0.7	1.0	0.8	1.1	5.1
		neu diff.
		Factor,
		heregulin
46661	ORC6L			2.7	2.5	0.9	1.0	1.0	1.0	1.0	1.0		1.3	4.3
47183	OSMR	oncostatin MR	oncostatin M	2.8	2.5	1.0	1.0	1.0	1.0	0.4	1.2	0.7	1.2	4.5
			receptor
49778	OSMR	oncostatin MR	oncostatin M	3.2	2.6	0.8	1.0	0.9	1.0	0.4	1.4	0.7	1.0	4.4
			receptor
48707	P4HA1	P4HA1, prolyl-	procollagen-	1.1	1.0	1.5	1.4	1.0	1.0	1.4	1.2	1.0	1.0	4.6
		4-hydroxylase	proline, 2-
		alpha1	oxoglutarate 4-
			dioxygenase
47935	P4HA1	P4HA1, prolyl-	procollagen-	1.2	1.0	1.5	1.4	0.9	1.0	1.7	1.2	1.0	1.0	4.7
		4-hydroxylase	proline, 2-
		alpha1	oxoglutarate 4-
			dioxygenase
48971	P4HA2	P4HA2	procollagen-	1.2	1.1	2.0	1.7	1.0	1.0	1.7	1.4	1.0	1.0	5.1
			proline, 2-
			oxoglutarate 4-
			dioxygenase
47366	P4HB	P4HB	procollagen-	1.0	1.0	1.4	1.4	1.0	1.0	1.4	1.4	1.1	1.1	4.8
			proline, 2-
			oxoglutarate 4-
			dioxygenase
47699	PAK1	Pak1	p21/Cdc42/Rac1-	0.9	1.1	2.0	1.8	1.0	1.0	1.4	1.3	1.0	1.0	5.1
			activated kinase 1
			(yeast Ste20-rel
47688	PAK1	Pak1	p21/Cdc42/Rac1-	0.7	1.3	1.8	1.5	1.0	1.0	1.3	1.2	0.9	1.0	4.6
			activated kinase 1
			(yeast Ste20-rel
47655	PAK1	Pak1	p21/Cdc42/Rac1-	0.7	1.0	1.9	1.5	1.0	1.0	1.2	1.0	0.9	1.0	4.5
			activated kinase 1
			(yeast Ste20-rel
46834	PAK4	Pak4	protein kinase	2.1	1.7	0.8	1.1	1.0	1.0		1.5	1.0	1.0	4.5
			related to S. cerevisiae
			STE20,
			eff
49104	PARG1	PARG1	PTPL1-associated	1.1	1.0	1.5	1.3	1.1	1.0	1.0	1.0	1.1	1.0	4.3
			RhoGAP 1
48827	PBX3			0.9	1.0	2.1	1.8	1.1	1.0		1.8	1.1	1.0	5.7
47050	PCDH17			4.9	4.1	1.0	1.0	1.0	1.0	0.7	1.0	1.1	1.0	4.0
49705	PCYT2			0.4	2.5	1.0	1.0	1.0	1.0	1.0	1.0	0.9	1.0	4.0
48556	PDE4B	phosphodiesterase	phosphodiesterase	9.8	9.4	1.0	1.0	1.1	1.0	0.8	1.1	1.1	1.1	4.1
		4B	4B, cAMP-
			specific (dunce
			(Drosop
48427	PDE4B	phosphodiesterase	phosphodiesterase	9.4	8.8	1.0	1.0	1.0	1.0	0.8	1.1	1.1	1.1	4.2
		4B	4B, cAMP-
			specific (dunce
			(Drosop
50597	PDE7A			0.9	1.0	1.8	1.7	1.0	1.0		1.7	0.9	1.0	5.4
48370	PDGFA	PDGF, alpha	platelet-derived	0.4	2.3	0.6	1.6	0.9	1.0	0.9	1.0	1.0	1.0	4.7
			growth factor
			alpha polypeptide
47014	PDGFA	PDGF, alpha	platelet-derived	0.5	1.6	0.6	1.4	1.0	1.0	0.8	1.2	1.1	1.0	4.6
			growth factor
			alpha polypeptide
49625	PDGFB	PDGF, beta	platelet-derived	3.4	2.2	0.9	1.0	1.0	1.0	0.7	1.2	0.9	1.0	4.2
			growth factor beta
			polypeptide (s
48824	PDK2			0.3	2.8	1.3	1.2	1.1	1.0	1.0	1.0	1.0	1.0	4.2
49745	PFKP			0.8	1.0	1.3	1.2	1.1	1.0	1.4	1.4	1.1	1.0	4.6
46890	PHKA1			0.9	1.0	1.7	1.5	1.1	1.1	1.3	1.2	1.2	1.1	4.8
50038	PIK3R3	PI3K	phosphoinositide-	2.2	2.0	1.0	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
		regulatory	3-kinase,
		subunit, p55	regulatory subunit,
			pol
48759	PILR(ALPHA)			1.3	1.1	1.8	1.6	1.0	1.0	1.6	1.3	1.0	1.0	4.9
49975	PIM1	pim-1	pim-1 oncogene	2.4	2.0	1.1	1.0	1.1	1.1	1.8	1.4	1.1	1.0	4.5
46818	PIM2	Pim-2	pim-2 oncogene	4.8	3.3	1.1	1.0	0.9	1.0		1.7	1.1	1.1	4.8
50338	PIM2	Pim-2	pim-2 oncogene	4.7	2.8	1.3	1.2	1.0	1.0		1.8	1.1	1.0	5.0
48920	PKM2			1.0	1.0	1.3	1.2	0.9	1.0	1.5	1.3	1.0	1.0	4.6
47118	PLA2G4A	phospholipase	phospholipase A2,	2.0	1.6	1.3	1.2	1.0	1.0		1.6		1.3	5.1
		A2	group IVA
			(cytosolic,
			calcium-de
46577	PLA2G4B	phospholipase	phospholipase A2,	0.7	1.2	0.7	1.3	1.0	1.0	0.6	1.2	0.9	1.0	4.5
		A2	group IVB
			(cytosolic)
48607	PLA2G7	phospholipase	phospholipase A2,	2.2	2.0	1.5	1.3	1.2	1.1	1.2	1.1	1.3	1.1	4.6
		A2	group VII (platelet-
			activating f
50434	PLAB	PLAB	prostate	0.3	3.3	0.5	1.7	0.9	1.0	1.0	1.0	0.8	1.0	4.7
			differentiation
			factor
48023	PLAB	PLAB	prostate	0.3	3.3	0.5	1.9	0.8	1.0	0.9	1.0	0.9	1.0	4.9
			differentiation
			factor
49424	PLAU	urokinase-type	plasminogen	1.8	1.5	0.7	1.1	0.7	1.3		2.5	0.8	1.2	6.1
		plasminogen	activator,
		activator	urokinase
47537	PLAU	urokinase-type	plasminogen	1.9	1.7	0.6	1.3	0.8	1.3		2.6	0.8	1.2	6.3
		plasminogen	activator,
		activator	urokinase
49422	PLCG1	PLC gamma	phospholipase C,	0.4	2.4	0.8	1.1	1.1	1.0	0.7	1.2	0.9	1.0	4.4
		1,	gamma 1
		phopholipase	(formerly subtype
		C, gamma 1	148)
50490	PLD1	phospholipase	phospholipase D1,	3.4	3.2	1.9	1.7	1.3	1.0	1.2	1.0	1.1	1.0	4.7
		D1	phophatidylcholine-
			specific
49106	PLOD	PLOD	procollagen-	0.6	1.7	1.9	1.7	1.0	1.0		1.6	0.9	1.0	5.3
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
47704	PLOD	PLOD	procollagen-	0.6	1.5	1.9	1.7	0.9	1.0		1.7	1.0	1.0	5.4
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
49073	PLOD	PLOD	procollagen-	0.7	1.4	1.9	1.7	1.0	1.0		1.6	1.0	1.0	5.3
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
47671	PLOD	PLOD	procollagen-	0.6	1.5	1.9	1.7	0.9	1.0		1.6	1.1	1.0	5.3
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
49111	PLOD3	PLOD3	procollagen-	0.7	1.2	1.3	1.2	1.0	1.0	1.5	1.4	1.0	1.0	4.6
			lysine, 2-
			oxoglutarate 5-
			dioxygenase 3
48675	PLOD3	PLOD3	procollagen-	0.9	1.0	1.3	1.2	1.0	1.0	1.5	1.4	1.1	1.0	4.5
			lysine, 2-
			oxoglutarate 5-
			dioxygenase 3
47419	PLS3			1.6	1.4	0.6	1.4	0.9	1.0	0.8	1.0	1.1	1.1	4.5
49809	PLXNB1	PLXNB1	plexin B1	0.9	1.0	0.6	1.5	0.9	1.0	0.7	1.2	0.8	1.0	4.7
50073	PM5			0.9	1.1	1.3	1.2	1.1	1.0	1.5	1.4	1.2	1.1	4.7
50534	PPBP	NAP-2	pro-platelet basic	1.1	1.1	0.6	1.4	0.8	1.1	0.5	1.2	0.8	1.1	4.8
			protein (includes
			platelet basi
49832	PPFIBP1	PPFIBP1	PTPRF interacting	0.6	1.5	0.7	1.3	0.9	1.1	0.7	1.2	0.9	1.0	4.6
			protein, binding
			protein 1 (lipr
47328	PPFIBP1	PPFIBP1	PTPRF interacting	0.6	1.5	0.6	1.6	0.9	1.0	0.7	1.3	0.9	1.0	5.0
			protein, binding
			protein 1 (lipr
49142	PPIB	cyclophilin B	peptidylprolyl	0.9	1.0	1.5	1.3	1.1	1.0	1.2	1.1	1.0	1.0	4.4
			isomerase B
			(cyclophilin B)
46983	PPIC	cyclophilin C	peptidylprolyl	1.0	1.0	2.0	1.5	1.2	1.2		1.6	1.4	1.2	5.6
			isomerase C
			(cyclophilin C)
50387	PPIC	cyclophilin C	peptidylprolyl	0.9	1.0	2.0	1.9	1.2	1.1		1.9	1.2	1.0	5.9
			isomerase C
			(cyclophilin C)
46862	PPIF	cyclophilin F	peptidylprolyl	1.3	1.2	0.8	1.0	0.9	1.1		1.9		1.3	5.4
			isomerase F
			(cyclophilin F)
48616	PPIH	cyclophilin H	peptidyl prolyl	0.8	1.1	0.8	1.2	0.9	1.0	0.7	1.4	0.9	1.1	4.6
			isomerase H
			(cyclophilin H)
46624	PPP3CC	calcineurin A	protein	3.5	2.7	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
		gamma	phosphatase 3
			(formerly 2B),
			catalytic sub
49079	PPP3CC	calcineurin A	protein	3.2	2.4	1.0	1.0	1.0	1.0	1.1	1.0	1.0	1.0	4.0
		gamma	phosphatase 3
			(formerly 2B),
			catalytic sub
49331	PRKAR1A	PKA,	protein kinase,	0.8	1.2	0.8	1.2	1.0	1.0	0.7	1.3	1.0	1.0	4.5
		regulatory	cAMP-dependent,
		subunit, type I	regulatory, type I
		alpha
47513	PRKCB1	PKC, beta	protein kinase C,	1.0	1.0	2.0	1.8	1.1	1.0		1.7	1.2	1.1	5.5
			beta 1
47528	PRKCN	PKC, nu	protein kinase C,	1.8	1.6	0.7	1.3	0.9	1.0	0.8	1.1	0.9	1.1	4.6
			nu
49921	PRKR			4.4	4.3	1.8	1.5	1.1	1.0	1.3	1.2	1.2	1.1	4.7
50643	PROS1			0.9	1.0	1.5	1.4	1.0	1.0	1.5	1.4	1.1	1.0	4.8
49006	PRSS25			1.0	1.0	1.4	1.4	1.1	1.0	1.2	1.1	1.0	1.0	4.5
47998	PSMB9			4.3	3.6	1.4	1.3	1.2	1.1	0.9	1.0	1.1	1.0	4.4
47690	PTEN	PTEN	phosphatase and	1.9	1.7	1.6	1.5	1.0	1.0	1.3	1.2	1.1	1.0	4.7
			tensin homolog
			(mutated in multipl
49846	PTEN	PTEN	phosphatase and	1.2	1.1	1.3	1.2	1.0	1.0	1.4	1.4	1.1	1.0	4.6
			tensin homolog
			(mutated in multipl
47657	PTEN	PTEN	phosphatase and	3.9	3.1	1.2	1.1	0.9	1.0	1.1	1.0	1.0	1.0	4.1
			tensin homolog
			(mutated in multipl
47198	PTGER2	PTGER2	prostaglandin E	5.3	4.7	1.0	1.0	1.0	1.0	1.4	1.1	1.0	1.0	4.1
			receptor 2
			(subtype EP2),
			53 kD
46654	PTGER2	PTGER2	prostaglandin E	4.0	3.1	1.0	1.0	0.9	1.0	1.2	1.0	1.0	1.0	4.0
			receptor 2
			(subtype EP2),
			53 kD
48422	PTGER2	PTGER2	prostaglandin E	3.3	2.8	0.8	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0
			receptor 2
			(subtype EP2),
			53 kD
47551	PTGER4	EP2	prostaglandin E	1.4	1.3	0.7	1.3	1.1	1.0		1.5		1.3	5.1
			receptor 4
			(subtype EP4)
50200	PTGER4	EP2	prostaglandin E	1.4	1.0	0.7	1.3	1.1	1.1		1.6	1.3	1.2	5.1
			receptor 4
			(subtype EP4)
50010	PTGIR	PTGIR	prostaglandin I2	2.8	2.7	0.8	1.1	0.9	1.1	0.8	1.2	0.8	1.1	4.4
			(prostacyclin)
			receptor (IP)
49466	PTGIR	PTGIR	prostaglandin I2	2.5	2.2	0.8	1.0	0.9	1.0	0.8	1.1	0.9	1.0	4.2
			(prostacyclin)
			receptor (IP)
48809	PTGS1	PTGS1	prostaglandin-	0.3	2.9	0.6	1.4	1.0	1.0		1.5	0.9	1.0	4.9
			endoperoxide
			synthase 1
			(prostagland
48625	PTGS1	PTGS1	prostaglandin-	0.6	1.5	1.4	1.3	1.0	1.0		1.5	1.1	1.0	4.9
			endoperoxide
			synthase 1
			(prostagland
47499	PTGS2	PTGS2, COX2	prostaglandin-	28.8	28.0	0.7	1.0	0.9	1.0		1.9	1.3	1.1	5.1
			endoperoxide
			synthase 2
			(prostagland
50665	PTGS2	PTGS2, COX2	prostaglandin-	32.8	31.2	1.0	1.0	0.8	1.2		2.3	1.3	1.1	5.6
			endoperoxide
			synthase 2
			(prostagland
49036	PTK2B	PYK2	protein tyrosine	1.1	1.0	1.5	1.4	1.0	1.0	1.3	1.2	0.9	1.0	4.6
			kinase 2 beta
47997	PTPN3	PTPN3	protein tyrosine	1.5	1.4	1.6	1.5	1.1	1.1	1.2	1.1	1.2	1.1	4.7
			phosphatase, non-
			receptor type 3
48940	PTPRC	CD45	protein tyrosine	1.0	1.0	1.6	1.5	1.1	1.1	1.2	1.0	1.1	1.1	4.8
			phosphatase,
			receptor type, C
48685	PTPRC	CD45	protein tyrosine	1.1	1.0	1.7	1.5	1.2	1.1	1.3	1.0	1.2	1.1	4.7
			phosphatase,
			receptor type, C
47308	PTPRJ	PTPRJ	protein tyrosine	1.7	1.4	1.0	1.0	1.0	1.0	1.5	1.4	1.1	1.0	4.4
			phosphatase,
			receptor type, J
50632	PTPRJ	PTPRJ	protein tyrosine	1.5	1.3	1.2	1.0	1.0	1.0		1.5	1.1	1.0	4.6
			phosphatase,
			receptor type, J
47698	PTPRJ	PTPRJ	protein tyrosine	1.7	1.3	1.0	1.0	1.0	1.0	1.5	1.3	1.0	1.0	4.3
			phosphatase,
			receptor type, J
47548	PTPRK	PTPRK	protein tyrosine	3.8	3.1	0.7	1.2	0.8	1.1	1.1	1.0	1.1	1.0	4.3
			phosphatase,
			receptor type, K
48687	PTPRM	PTPRM	protein tyrosine	3.1	2.7	0.8	1.0	0.9	1.0	1.0	1.0	0.9	1.0	4.1
			phosphatase,
			receptor type, M
49684	PTPRO	PTPRO	protein tyrosine	0.5	1.3	1.7	1.6	1.1	1.0	1.0	1.0	1.0	1.0	4.6
			phosphatase,
			receptor type, O
46748	PTX3			8.7	3.4	1.4	1.3	1.0	1.0		1.5		1.3	5.2
49876	RAD54L			0.9	1.0	0.6	1.1	1.0	1.0	0.6	1.3	1.0	1.0	4.5
47446	RANBP1			0.8	1.1	0.6	1.4	0.9	1.0	0.7	1.2	1.0	1.0	4.6
47231	RASA1	RasGAP	RAS p21 protein	0.4	2.4	1.0	1.0	1.0	1.0	0.8	1.2	0.9	1.0	4.2
			activator (GTPase
			activating prote
50122	RASA1	RasGAP	RAS p21 protein	0.4	2.6	1.1	1.0	1.1	1.0	1.0	1.0	1.0	1.0	4.0
			activator (GTPase
			activating prote
48031	RASA2	RasGAP	RAS p21 protein	1.4	1.3	1.0	1.0	0.9	1.0		1.5	0.9	1.0	4.5
			activator 2
47707	RASA2	RasGAP	RAS p21 protein	1.4	1.2	1.0	1.0	0.9	1.0		1.5	0.9	1.0	4.5
			activator 2
50244	RBL1			2.6	2.3	1.0	1.0	1.1	1.0	1.2	1.0	1.2	1.0	4.0
48471	RBM3			1.1	1.0	0.7	1.5	1.0	1.0	0.8	1.2	1.1	1.1	4.7
48843	RBMS1			1.3	1.2	0.9	1.1	1.1	1.0		1.5	1.0	1.0	4.6
48132	RCN2			0.8	1.2	1.4	1.2	1.0	1.0	1.4	1.4	1.0	1.0	4.6
49957	REL	c-rel	v-rel avian	4.4	2.2	1.0	1.0	0.9	1.1	1.4	1.1	1.1	1.0	4.2
			reticuloendotheliosis
			viral oncogene h
47672	RELA	p65, NFKB3	v-rel avian	2.6	2.5	0.8	1.2	0.9	1.0	1.0	1.0	1.1	1.1	4.3
			reticuloendotheliosis
			viral oncogene h
47652	RELA	p65, NFKB3	v-rel avian	2.4	2.1	0.8	1.2	1.0	1.0	1.0	1.0	1.1	1.0	4.2
			reticuloendotheliosis
			viral oncogene h
49120	RELB	I-rel	v-rel avian	2.5	2.2	0.7	1.2	1.0	1.0	1.0	1.0	1.0	1.0	4.2
			reticuloendotheliosis
			viral oncogene h
49087	RELB	I-rel	v-rel avian	2.5	2.1	0.7	1.2	1.0	1.0	1.0	1.0	1.0	1.0	4.2
			reticuloendotheliosis
			viral oncogene h
50499	RGS14	RGS14	regulator of G-	0.4	2.3	2.0	1.7	1.3	1.2	1.4	1.3	1.0	1.0	5.2
			protein signalling
			14
49813	RGS14	RGS14	regulator of G-	0.3	2.4	1.7	1.2	1.3	1.2	1.1	1.0	1.1	1.0	4.4
			protein signalling
			14
49786	RGS16	Rgs-16	regulator of G-	4.0	3.4	0.2	4.1	0.7	1.4		2.1	0.8	1.2	8.8
			protein signalling
			16
48784	RGS16	Rgs-16	regulator of G-	3.5	3.2	0.4	2.0	0.7	1.3		2.1	0.9	1.0	6.4
			protein signalling
			16
47933	RIPK2	RIP2, RICK	receptor-	8.5	6.4	0.9	1.1	0.9	1.0	0.9	1.0	1.1	1.0	4.1
			interacting serine-
			threonine kinase 2
46938	ROCK2	ROCK2	Rho-associated,	1.4	1.0	0.8	1.2	1.0	1.0	0.7	1.4	1.0	1.0	4.6
			coiled-coil
			containing protein
			kin
50344	RPS6KA4	RPS6KA4	ribosomal protein	0.4	2.1	1.2	1.1	1.1	1.0	1.0	1.0	1.0	1.0	4.1
			S6 kinase, 90 kD,
			polypeptide 4
50354	RPS6KC1	RPS6KC1	ribosomal protein	1.8	1.8	1.1	1.0	1.0	1.0		1.5	1.1	1.0	4.5
			S6 kinase, 52 kD,
			polypeptide 1
47224	RPS6KC1	RPS6KC1	ribosomal protein	2.1	1.7	1.1	1.1	0.9	1.0	1.5	1.3	1.1	1.0	4.4
			S6 kinase, 52 kD,
			polypeptide 1
49416	S100A10	S100A10	S100 calcium-	1.2	1.0	1.9	1.5	1.1	1.0	1.9	1.4	1.2	1.1	5.1
			binding protein
			A10 (annexin II
			ligan
50130	S100A10	S100A10	S100 calcium-	1.2	1.1	1.9	1.5	1.1	1.0	1.7	1.4	1.1	1.0	4.8
			binding protein
			A10 (annexin II
			ligan
50120	S100A4	S100A4	S100 calcium-	1.0	1.0	2.2	2.0	1.2	1.1		1.9	1.2	1.1	6.2
			binding protein A4
			(calcium protein,
47318	S100A4	S100A4	S100 calcium-	1.0	1.0	2.0	1.8	1.2	1.0		1.6	1.2	1.1	5.6
			binding protein A4
			(calcium protein,
50144	S100A6	S100A6	S100 calcium-	0.9	1.0	1.4	1.3	1.2	1.1	1.5	1.1	1.1	1.0	4.5
			binding protein A6
			(calcyclin)
50138	S100A6	S100A6	S100 calcium-	1.0	1.0	1.4	1.3	1.1	1.1	1.5	1.0	1.1	1.0	4.4
			binding protein A6
			(calcyclin)
49076	SARM	KIAA0524	KIAA0524 protein	1.0	1.0	1.3	1.2	0.6	1.4	1.8	1.0	0.8	1.0	4.6
50441	SAT			7.2	5.4	1.0	1.0	0.9	1.0	0.9	1.0	0.8	1.1	4.1
49261	SCYA1	I-309	small inducible	2.9	2.7	0.8	1.0	1.0	1.0	0.8	1.1	1.1	1.0	4.1
			cytokine A1 (I-
			309, homologous
			to
47503	SCYA1	I-309	small inducible	2.7	2.3	1.0	1.0	1.2	1.0	0.9	1.0	1.1	1.0	4.0
			cytokine A1 (I-
			309, homologous
			to
49412	SCYA15	MIP-5	small inducible	2.4	2.2	1.0	1.0	1.1	1.0	1.2	1.1	1.1	1.0	4.1
			cytokine subfamily
			A (Cys—Cys), me
49044	SCYA18	DC-CK1	small inducible	26.3	23.0	0.4	1.7	0.6	1.4	1.3	1.1	1.0	1.0	5.2
			cytokine subfamily
			A (Cys—Cys), me
48001	SCYA18	DC-CK1	small inducible	31.7	24.7	0.5	1.4	0.7	1.3	1.2	1.1	1.0	1.0	4.8
			cytokine subfamily
			A (Cys—Cys), me
48830	SCYA2	MCP1	small inducible	8.2	5.2	0.7	1.3	1.0	1.0	0.7	1.1	1.1	1.0	4.4
			cytokine A2
			(monocyte
			chemotactic
47916	SCYA2	MCP1	small inducible	16.9	10.7	0.3	2.1	1.2	1.1	0.7	1.0	1.1	1.0	5.2
			cytokine A2
			(monocyte
			chemotactic
50026	SCYA2	MCP1	small inducible	24.1	13.0	0.4	2.4	1.2	1.0	0.6	1.3	1.1	1.0	5.8
			cytokine A2
			(monocyte
			chemotactic
46598	SCYA20	MIP-3a	small inducible	8.6	7.8	0.2	4.0	0.7	1.4	0.6	1.3	1.0	1.0	7.7
			cytokine subfamily
			A (Cys—Cys), me
48190	SCYA20	MIP-3a	small inducible	8.1	5.6	0.1	6.1	0.7	1.4	0.6	1.0	1.1	1.0	9.5
			cytokine subfamily
			A (Cys—Cys), me
46596	SCYA20	MIP-3a	small inducible	3.7	3.2	0.6	1.5	0.9	1.0	0.6	1.0	1.0	1.0	4.5
			cytokine subfamily
			A (Cys—Cys), me
46945	SCYA28	SCYA28	CC chemokine	1.3	1.0	0.5	1.4	1.2	1.0	1.0	1.0	1.0	1.0	4.4
			CCL28
50009	SCYA3	MIP1, alpha	small inducible	7.8	5.0	0.4	1.8	0.8	1.0	1.2	1.2	1.2	1.1	5.1
		homolog	cytokine A3
			(homologous to
			mouse M
49742	SCYA3	MIP1, alpha	small inducible	9.0	8.7	0.4	1.6	0.8	1.0	1.2	1.2	1.2	1.0	4.8
		homolog	cytokine A3
			(homologous to
			mouse M
50369	SCYA3	MIP1, alpha	small inducible	8.5	8.4	0.4	2.0	0.8	1.0	1.2	1.1	1.2	1.0	5.2
		homolog	cytokine A3
			(homologous to
			mouse M
48585	SCYA3	MIP1, alpha	small inducible	9.5	8.6	0.5	1.8	0.8	1.1	1.2	1.2	1.2	1.0	5.1
		homolog	cytokine A3
			(homologous to
			mouse M
47893	SCYA4	MIP-1beta	small inducible	48.7	24.7	0.3	2.8	0.8	1.0	1.2	1.2	1.2	1.1	6.0
			cytokine A4
			(homologous to
			mouse M
48257	SCYA4	MIP-1beta	small inducible	40.5	17.9	0.3	1.8	0.9	1.0	1.2	1.2	1.2	1.0	5.0
			cytokine A4
			(homologous to
			mouse M
47575	SCYA8	MCP-2	small inducible	47.8	46.5	1.0	1.0	1.1	1.0	0.8	1.0	1.3	1.1	4.1
			cytokine subfamily
			A (Cys—Cys), me
48338	SCYB11	I-TAC	small inducible	38.0	37.8	0.8	1.0	0.9	1.1	1.5	1.1	1.4	1.3	4.5
			cytokine subfamily
			B (Cys-X-Cys),
47726	SCYB11	I-TAC	small inducible	38.7	37.6	1.2	1.0	1.0	1.0	1.5	1.0		1.3	4.3
			cytokine subfamily
			B (Cys-X-Cys),
49968	SCYB5	ENA-78	small inducible	2.6	2.0	0.7	1.1	0.8	1.0	0.6	1.2		1.5	4.8
			cytokine subfamily
			B (Cys-X-Cys),
49839	SCYB5	ENA-78	small inducible	2.6	1.9	0.8	1.2	0.8	1.0	0.5	1.3		1.4	5.0
			cytokine subfamily
			B (Cys-X-Cys),
50117	SDBCAG84			0.9	1.0	1.4	1.3	1.0	1.0	1.4	1.4	1.0	1.0	4.6
47729	SELPLG	selectin P	selectin P ligand	1.1	1.0	1.5	1.4	1.1	1.0	1.1	1.0	1.1	1.1	4.5
		ligand
47858	SELPLG	selectin P	selectin P ligand	1.0	1.0	1.4	1.3	1.1	1.0	1.1	1.0	1.1	1.1	4.4
		ligand
49117	SERPINB1		serine (or	3.8	2.9	0.7	1.2	1.0	1.0		1.9	1.2	1.0	5.2
			cysteine)
			proteinase
			inhibitor, clade B
46682	SERPINB2		serine (or	4.2	3.4	1.0	1.0	1.1	1.0	0.6	1.3	0.8	1.2	4.5
			cysteine)
			proteinase
			inhibitor, clade B
48269	SERPINE1		serine (or	1.1	1.0	0.6	1.3	0.7	1.2	0.7	1.0	0.7	1.2	4.7
			cysteine)
			proteinase
			inhibitor, clade E
48281	SERPINE2		serine (or	34.6	17.3	0.4	2.2	1.0	1.0	0.6	1.1	1.1	1.0	5.3
			cysteine)
			proteinase
			inhibitor, clade E
48400	SERPINE2		serine (or	26.7	13.2	0.4	2.2	1.0	1.0	0.7	1.1	1.0	1.0	5.3
			cysteine)
			proteinase
			inhibitor, clade E
48367	SERPINE2		serine (or	27.1	12.5	0.4	2.1	1.0	1.0	0.7	1.2	1.1	1.0	5.3
			cysteine)
			proteinase
			inhibitor, clade E
48609	SERPINF1		serine (or	0.8	1.1	1.5	1.3	1.1	1.0		1.7	1.1	1.0	5.0
			cysteine)
			proteinase
			inhibitor, clade F
49679	SERPINF1		serine (or	0.8	1.2	1.6	1.4	1.1	1.1		1.5	1.1	1.0	5.0
			cysteine)
			proteinase
			inhibitor, clade F
48309	SERPINF1		serine (or	0.9	1.1	1.5	1.5	1.1	1.0	1.6	1.3	1.1	1.0	4.8
			cysteine)
			proteinase
			inhibitor, clade F
46579	SERPING1		serine (or	2.7	2.5	0.8	1.1	1.0	1.0	0.7	1.3	1.0	1.0	4.4
			cysteine)
			proteinase
			inhibitor, clade G
50083	SERPING1		serine (or	11.1	7.2	1.3	1.1	1.1	1.0	0.7	1.2	1.1	1.0	4.2
			cysteine)
			proteinase
			inhibitor, clade G
46621	SERPINH2		serine (or	0.7	1.1	0.8	1.2	1.0	1.0	0.6	1.4	0.9	1.0	4.5
			cysteine)
			proteinase
			inhibitor, clade H
47577	SERPINH2		serine (or	1.0	1.0	0.9	1.0	0.9	1.0	0.7	1.4	0.9	1.0	4.4
			cysteine)
			proteinase
			inhibitor, clade H
46787	SERPINI1		serine (or	1.1	1.0	2.6	1.8	1.1	1.1		1.6	1.1	1.1	5.5
			cysteine)
			proteinase
			inhibitor, clade I
47139	SERPINI1		serine (or	1.0	1.0	2.2	1.4	1.1	1.1		1.6	1.1	1.0	5.1
			cysteine)
			proteinase
			inhibitor, clade I
49880	SLC25A13			0.8	1.2	0.7	1.2	0.9	1.0	0.7	1.3	0.8	1.0	4.6
50621	SLC4A7			0.6	1.6	0.5	1.4	0.9	1.0	0.7	1.4	0.8	1.1	4.9
47960	SLC7A5			1.7	1.6	1.1	1.1	0.9	1.0	0.6	1.4	1.0	1.0	4.5
49423	SMPD1	acid	sphingomyelin	0.7	1.3	1.7	1.4	1.1	1.1	1.5	1.2	1.1	1.1	4.8
		sphingomylinase	phosphodiesterase
			1, acid
			lysosomal
50548	SMPD1	acid	sphingomyelin	0.8	1.0	1.5	1.4	1.1	1.1	1.4	1.3	1.1	1.0	4.8
		sphingomylinase	phosphodiesterase
			1, acid
			lysosomal
47418	SNK			2.4	2.1	0.8	1.0	1.2	1.1		1.6	1.1	1.0	4.8
50162	SP110	IFI41,	interferon-induced	5.3	3.4	1.5	1.4	1.2	1.1	1.1	1.1	1.1	1.0	4.6
		interferon	protein 41, 30 kD
		induced
		protein 41
50706	SP110	IFI41,	interferon-induced	5.4	3.2	1.5	1.4	1.2	1.1	1.1	1.1	1.1	1.0	4.6
		interferon	protein 41, 30 kD
		induced
		protein 41
48711	SPP1	SPP1	secreted	0.5	1.7	0.4	2.0	1.1	1.0		1.6	1.2	1.0	5.7
			phosphoprotein 1
			(osteopontin, bone
			sialo
50397	SPP1	SPP1	secreted	0.5	1.6	0.4	2.3	1.1	1.0		1.5	1.1	1.0	5.7
			phosphoprotein 1
			(osteopontin, bone
			sialo
49446	SRC	Src	v-src avian	10.4	9.7	1.1	1.0	0.9	1.0		1.7	1.2	1.0	4.7
			sarcoma
			(Schmidt-Ruppin
			A-2) viral onc
49990	SRC	Src	v-src avian	10.7	10.2	1.1	1.0	1.0	1.0		1.7	1.2	1.0	4.7
			sarcoma
			(Schmidt-Ruppin
			A-2) viral onc
47195	SRF	SRF	serum response	0.7	1.1	0.7	1.3	1.0	1.0	0.7	1.4	1.1	1.0	4.6
			factor (c-fos
			serum response
			elemen
47101	SSA1			3.6	3.3	1.1	1.0	1.0	1.0	0.9	1.0	1.0	1.0	4.0
48009	ST14	ST14	suppression of	0.4	1.9	1.6	1.4	1.2	1.1		1.6	1.2	1.1	5.1
			tumorigenicity 14
			(colon carcinoma,
50341	ST14	ST14	suppression of	0.4	1.8	1.6	1.5	1.2	1.1		1.6	1.1	1.0	5.1
			tumorigenicity 14
			(colon carcinoma,
49746	STAT1	STAT1	signal transducer	4.7	4.3	1.9	1.6	1.2	1.0	1.2	1.1	1.1	1.0	4.7
			and activator of
			transcription 1
50450	STAT1	STAT1	signal transducer	5.2	4.0	2.1	2.0	1.2	1.1	1.3	1.2	1.1	1.0	5.3
			and activator of
			transcription 1
47727	STAT2	Stat2	signal transducer	4.3	4.1	1.1	1.1	0.9	1.1	0.9	1.0	1.1	1.0	4.1
			and activator of
			transcription 2
47856	STAT2	Stat2	signal transducer	4.3	4.0	1.1	1.0	0.9	1.0	0.9	1.0	1.1	1.0	4.1
			and activator of
			transcription 2
48987	STAT5A	STAT5a	signal transducer	3.4	2.7	1.1	1.0	1.1	1.0	1.2	1.2	1.1	1.1	4.3
			and activator of
			transcription 5
50003	STAT5A	STAT5a	signal transducer	3.3	2.6	1.1	1.0	1.1	1.0	1.3	1.3	1.1	1.0	4.3
			and activator of
			transcription 5
47634	STATI2	SOCS-2	STAT induced	3.1	2.6	1.0	1.0	1.0	1.0	0.7	1.2	1.1	1.0	4.2
			STAT inhibitor-2
50732	STATI2	SOCS-2	STAT induced	3.5	2.8	1.0	1.0	1.0	1.0	1.0	1.0	0.8	1.0	4.0
			STAT inhibitor-2
46796	STC1			2.3	1.7	0.8	1.1	0.8	1.0		1.5		1.3	5.0
48769	SUV39H1			0.8	1.2	0.6	1.4	1.0	1.0	1.0	1.0	1.0	1.0	4.4
48970	SYK	Syk	spleen tyrosine	0.6	1.3	1.5	1.4	1.1	1.0	1.4	1.3	1.0	1.0	4.7
			kinase
49134	SYK	Syk	spleen tyrosine	0.6	1.5	1.5	1.4	1.1	1.0	1.4	1.2	0.9	1.0	4.6
			kinase
47695	TANK	I-TRAF, TANK	TRAF family	2.5	2.4	1.0	1.0	0.9	1.0	1.3	1.0	1.0	1.0	4.0
			member-
			associated NFKB
			activator
49372	TAP1			6.9	6.0	1.4	1.2	1.1	1.0	1.0	1.0	1.1	1.0	4.2
48635	TAX1BP1	Tax1 BP,	Tax1 (human T-	1.4	1.2	1.4	1.3	1.0	1.0	1.4	1.3	1.1	1.1	4.6
		T6BP, A20	cell leukemia virus
		inhibitor	type I) binding
46907	TBL1			1.2	1.0	1.7	1.5	1.1	1.0	1.3	1.0	1.0	1.0	4.5
49538	TBXAS1			0.9	1.0	1.7	1.3	0.9	1.0		1.6	1.0	1.0	4.9
46613	TCF12	TCF12	transcription factor	2.0	1.8	1.3	1.3	1.0	1.0	1.1	1.1	1.0	1.0	4.4
			12 (HTF4, helix-
			loop-helix tr
47324	TCF7L2	TCF7L2	transcription factor	1.3	1.1	0.6	1.4	0.9	1.0	0.8	1.1	0.9	1.1	4.6
			7-like 2 (T-cell
			specific, HM
50172	TCF8	TCF8	transcription factor	0.5	1.8	0.6	1.3	1.0	1.0	0.7	1.3	0.9	1.1	4.6
			8 (represses
			interleukin 2 ex
50139	TCFL4	TCFL4	transcription	0.6	1.6	0.9	1.1	1.0	1.0	0.7	1.3	0.9	1.0	4.4
			factor-like 4
50001	TCFL4	TCFL4	transcription	0.6	1.6	0.8	1.2	1.0	1.0	0.7	1.3	0.9	1.0	4.5
			factor-like 4
50370	TCFL5	TCFL5	transcription	5.6	2.5	0.8	1.0	1.0	1.0	1.1	1.0	1.0	1.0	4.0
			factor-like 5 (basic
			helix-loop-heli
49291	TEAD4	TEAD4	TEA domain	1.8	1.5	0.9	1.0	0.9	1.0	0.7	1.3	0.9	1.0	4.4
			family member 4
50587	TEKT2			1.1	1.0	1.6	1.3	1.1	1.0	1.6	1.0	1.0	1.0	4.3
50529	TFEC	TFEC	transcription factor	2.5	2.3	1.4	1.4	1.1	1.0	1.5	1.4	1.0	1.0	4.8
			EC
50658	TFEC	TFEC	transcription factor	2.5	2.2	1.5	1.4	1.1	1.0	1.5	1.3	1.0	1.0	4.7
			EC
46991	TFPI2	TFPI2	tissue factor	4.2	3.9	0.1	5.1	0.7	1.2		4.2	0.9	1.0	11.5
			pathway inhibitor 2
48907	TGFB3	TGF, beta3	transforming	0.8	1.1	0.4	2.0	0.8	1.1	0.6	1.0	0.7	1.1	5.3
			growth factor, beta 3
47865	TGFB3	TGF, beta3	transforming	0.8	1.1	0.4	1.7	0.7	1.3		1.8	0.8	1.1	6.0
			growth factor, beta 3
48513	TGFBR3			1.1	1.0	1.0	1.0	1.1	1.0		1.9	1.0	1.0	4.9
47593	THBD			0.5	1.6	0.6	1.8	0.8	1.1		3.5		1.4	7.8
47987	THBS1	THBS1	thrombospondin 1	2.4	1.7	0.2	2.2	1.0	1.0		2.8	0.9	1.0	7.0
46857	THBS1	THBS1	thrombospondin 1	5.0	2.4	0.6	1.5	0.8	1.0	0.8	1.2	0.9	1.0	4.7
47885	THBS2	THBS2	thrombospondin 2	2.8	2.2	0.8	1.0	1.0	1.0	1.1	1.0	0.7	1.0	4.0
48627	TIAM2	TIAM2	T-cell lymphoma	2.9	2.5	1.0	1.0	1.0	1.0	1.0	1.0	0.9	1.0	4.0
			invasion and
			metastasis 2
50035	TIAM2	TIAM2	T-cell lymphoma	2.5	2.1	1.0	1.0	1.0	1.0	0.9	1.0	0.9	1.0	4.0
			invasion and
			metastasis 2
49420	TIMP2	TIMP2	tissue inhibitor of	0.8	1.1	2.2	2.0	1.2	1.2		1.8		1.3	6.3
			metalloproteinase 2
49785	TIMP2	TIMP2	tissue inhibitor of	0.8	1.1	2.0	1.9	1.2	1.2		1.7	1.3	1.2	5.9
			metalloproteinase 2
49818	TIMP2	TIMP2	tissue inhibitor of	0.8	1.1	1.9	1.8	1.2	1.2		1.6	1.3	1.1	5.7
			metalloproteinase 2
48754	TIMP3			1.4	1.3	0.7	1.4	0.8	1.1	0.9	1.0	0.9	1.0	4.6
49298	TIMP3			1.4	1.3	0.6	1.5	0.8	1.1	0.9	1.0	0.9	1.0	4.7
50294	TM7SF2			0.6	1.3	1.3	1.1	0.7	1.2	1.7	1.3	0.7	1.1	4.8
49613	TNF	TNFSF2, TNF,	tumor necrosis	14.9	14.6	1.0	1.0	0.8	1.1		1.5	1.2	1.1	4.7
		alpha, tumor	factor (TNF
		necrosis	superfamily,
		factor, alpha	member 2)
47163	TNF	TNFSF2, TNF,	tumor necrosis	16.6	15.0	0.9	1.0	0.8	1.1	1.6	1.4	1.2	1.0	4.6
		alpha, tumor	factor (TNF
		necrosis	superfamily,
		factor, alpha	member 2)
47918	TNFAIP1	TNFAIP1	tumor necrosis	1.4	1.2	1.0	1.0	1.0	1.0	0.7	1.3	1.0	1.0	4.3
			factor, alpha-
			induced protein 1
			(en
47993	TNFAIP2	TNFAIP2	tumor necrosis	69.9	51.6	1.4	1.3	0.9	1.0	1.0	1.0	1.1	1.1	4.3
			factor, alpha-
			induced protein 2
47642	TNFAIP3	A20,	tumor necrosis	8.2	6.3	1.1	1.0	0.9	1.0	1.1	1.0	1.2	1.0	4.0
		TNFAIP2, Zn	factor, alpha-
		finger	induced protein 3
47155	TNFAIP6	TNFAIP6	tumor necrosis	56.8	35.7	0.9	1.0	1.0	1.0	0.8	1.0	1.1	1.0	4.0
			factor, alpha-
			induced protein 6
46803	TNFAIP6	TNFAIP6	tumor necrosis	62.1	44.9	0.7	1.0	1.0	1.0	0.8	1.0	1.1	1.0	4.0
			factor, alpha-
			induced protein 6
47651	TNFRSF21	DR6	death receptor 6	0.5	1.6	1.2	1.1	1.2	1.1	0.6	1.4	1.3	1.1	4.7
50458	TNFRSF21	DR6	death receptor 6	0.5	1.7	1.2	1.0	1.2	1.2		1.5	1.2	1.0	4.6
47156	TNFRSF5	CD40	tumor necrosis	6.0	5.7	1.1	1.0	0.9	1.0	1.5	1.3	1.2	1.1	4.4
			factor receptor
			superfamily,
			member
47027	TNFRSF5	CD40	tumor necrosis	5.7	5.5	1.1	1.0	1.0	1.0	1.4	1.3	1.1	1.0	4.3
			factor receptor
			superfamily,
			member
48446	TNFRSF6	FAS	tumor necrosis	5.4	5.0	1.2	1.0	1.0	1.0	1.2	1.0	1.2	1.1	4.1
			factor receptor
			superfamily,
			member
50491	TNFRSF6B	DcR3	tumor necrosis	0.7	1.3	0.6	1.2	0.9	1.1		1.6	0.9	1.0	4.9
			factor receptor
			superfamily,
			member
47697	TNFRSF6B	DcR3	tumor necrosis	0.8	1.2	0.5	1.7	0.9	1.0		1.9	0.9	1.0	5.6
			factor receptor
			superfamily,
			member
50524	TNFRSF6B	DcR3	tumor necrosis	0.7	1.2	0.7	1.1	0.9	1.0		1.5	0.9	1.0	4.6
			factor receptor
			superfamily,
			member
49275	TNFRSF9	4-1BB, CD137	tumor necrosis	4.0	2.2	1.1	1.0	1.0	1.0		1.5	1.4	1.2	4.7
			factor receptor
			superfamily,
			member
47517	TNFRSF9	4-1BB, CD137	tumor necrosis	3.8	2.1	1.1	1.0	0.9	1.0	1.4	1.3	1.5	1.1	4.4
			factor receptor
			superfamily,
			member
47223	TNFSF10	TRAIL	tumor necrosis	34.7	26.9	1.0	1.0	1.0	1.0	1.3	1.0	1.2	1.0	4.0
			factor (ligand)
			superfamily,
			member
50533	TNFSF9	4-1BBL	tumor necrosis	3.0	2.3	1.0	1.0	1.0	1.0		1.8	1.3	1.2	4.9
			factor (ligand)
			superfamily,
			member
50662	TNFSF9	4-1BBL	tumor necrosis	3.4	2.2	0.9	1.0	0.9	1.0		1.9	1.3	1.1	4.9
			factor (ligand)
			superfamily,
			member
48111	TP53BP1			0.8	1.3	0.8	1.1	1.0	1.0	0.7	1.3	0.9	1.1	4.5
48501	TPST1			0.3	3.0	0.5	1.7	0.8	1.2	0.9	1.0	0.8	1.0	4.9
46819	TRADD	TRADD	TNFRSF1A-	2.5	2.3	1.2	1.0	1.1	1.0	1.1	1.0	1.2	1.1	4.1
			associated via
			death domain
48574	TRAF1	TRAF1	TNF receptor-	12.2	9.7	0.8	1.2	0.9	1.0	1.3	1.1	1.2	1.1	4.4
			associated factor 1
48445	TRAF1	TRAF1	TNF receptor-	11.8	9.0	0.7	1.2	0.9	1.0	1.3	1.1	1.2	1.1	4.4
			associated factor 1
50347	TRAP1	TRAP1, hsp90	heat shock protein	0.7	1.3	0.6	1.4	0.9	1.0		1.6	0.9	1.0	5.0
		related	75
47622	TRAP1	TRAP1, hsp90	heat shock protein	0.8	1.1	0.7	1.4	1.0	1.0	0.7	1.3	1.0	1.0	4.7
		related	75
47339	TREM2			0.5	2.0	2.0	1.9	1.2	1.2		1.7	1.3	1.2	6.1
46941	TUBA3			0.7	1.1	0.7	1.3	1.0	1.0	0.6	1.2	1.0	1.0	4.5
49402	TWIST			0.8	1.1	0.6	1.4	1.0	1.0		1.5	0.9	1.0	4.9
46574	TXN			1.5	1.3	1.2	1.1	1.0	1.0	1.6	1.4	1.2	1.1	4.5
49779	TXNIP	VDUP1	upregulated by	0.6	1.4	1.5	1.2	1.2	1.1		1.6	1.1	1.1	5.0
			1,25-
			dihydroxyvitamin
			D-3
49812	TXNIP	VDUP1	upregulated by	0.6	1.2	1.5	1.2	1.2	1.2		1.7	1.1	1.0	5.1
			1,25-
			dihydroxyvitamin
			D-3
47470	TXNIP	VDUP1	upregulated by	0.8	1.0	1.4	1.1	1.1	1.1		1.6	1.1	1.0	4.8
			1,25-
			dihydroxyvitamin
			D-3
49584	TYRO3			4.3	3.7	1.1	1.0	1.0	1.0	0.9	1.0	0.9	1.0	4.0
48315	U3-55K			0.8	1.2	0.6	1.4	1.0	1.0	0.6	1.4	0.8	1.1	4.8
49522	UCP2			0.6	1.5	1.8	1.7	1.3	1.2		1.6	1.2	1.1	5.5
49258	UP	uridine	uridine	1.4	1.2	0.5	1.6	0.9	1.1		1.5	0.8	1.2	5.4
		phosphorylase	phosphorylase
49129	UP	uridine	uridine	1.4	1.2	0.6	1.6	0.9	1.1		1.6	0.8	1.1	5.5
		phosphorylase	phosphorylase
46874	VAV1	Vav1	vav 1 oncogene	0.9	1.0	1.2	1.0	1.0	1.0	1.6	1.3	0.9	1.0	4.4
47298	VAV3	Vav3	vav 3 oncogene	0.5	2.1	0.7	1.3	1.1	1.0	0.6	1.2	0.9	1.0	4.6
48262	VAV3	Vav3	vav 3 oncogene	0.5	2.0	0.8	1.2	1.1	1.0		1.5	1.0	1.0	4.7
48185	XAGE-1			1.0	1.0	1.4	1.3	1.0	1.0		1.7	1.2	1.1	5.1
50028	XBP1	XBP-1	X-box binding	3.0	2.7	1.2	1.1	1.0	1.0	1.4	1.3	1.3	1.2	4.5
			protein 1
46956	YWHAQ	14-3-3 theta,	tyrosine 3-	1.1	1.0	1.0	1.0	1.0	1.0	1.6	1.4	1.1	1.0	4.5
		14-3-3 tau,	monooxygenase/tryptophan
		HS1	5-
			monooxygenas
50466	ZFP36	tristetrapro-lin	zinc finger protein	2.0	1.0	1.6	1.5	1.1	1.0		1.5	1.1	1.0	4.9
			homologous to
			Zfp-36 in mouse
47836	ZNF140			0.9	1.0	1.5	1.5	1.2	1.0	1.1	1.0	1.2	1.1	4.6
Drug Effects in THP1 Cells, Sum min fold change >=4.5
Genes in bold - ≧2-fold differential expression in response to LPS
Genes in italics - ≧1.5-fold differential expression in response to Clari and/or ≧1.3-fold differential expression in response to FMA alone
Genes in bold and italics - ≧1.5-fold differential expression in response to IL1 + Clari and/or ≧1.3-fold differential in response to IL1 + FMA
48328	FN1	FN1	fibronectin 1	0.9	1.1	0.0	10.1	0.7	1.4		12.4		1.3	25.2
48348	FN1	FN1	fibronectin 1	0.8	1.1	0.0	9.6	0.6	1.4		7.6	0.8	1.2	19.9
46991	TFPI2	TFPI2	tissue factor	4.2	3.9	0.1	5.1	0.7	1.2		4.2	0.9	1.0	11.5
			pathway inhibitor 2
48334	MMP7	MMP7	matrix	1.5	1.4	0.1	4.3	0.9	1.1		4.4	0.9	1.0	10.8
			metalloproteinase
			7 (matrilysin,
			uterine)
46630	MMP3	MMP3	matrix	3.8	3.2	1.0	1.0	0.6	1.5		6.8	0.7	1.1	10.4
			metalloproteinase
			3 (stromelysin 1,
			progela
50403	IGFBP3			2.8	2.2	0.2	4.2	0.9	1.0		3.8	0.7	1.1	10.1
48190	SCYA20	MIP-3a	small inducible	8.1	5.6	0.1	6.1	0.7	1.4	0.6	1.0	1.1	1.0	9.5
			cytokine subfamily
			A (Cys—Cys), me
49786	RGS16	Rgs-16	regulator of G-	4.0	3.4	0.2	4.1	0.7	1.4		2.1	0.8	1.2	8.8
			protein signalling
			16
49586	GRIN2C			7.9	7.7	0.2	4.4	0.7	1.4	0.5	1.3	0.8	1.0	8.1
49060	CTGF	CTGF	connective tissue	108.1	106.7	1.0	1.0	1.3	1.0		4.9	1.1	1.0	7.9
			growth factor
50715	FCGR2A	CD32	Fc fragment of	1.7	1.7	3.8	3.1	1.1	1.1		2.5	1.3	1.2	7.8
			IgG, low affinity
			IIa, receptor for
47593	THBD			0.5	1.6	0.6	1.8	0.8	1.1		3.5		1.4	7.8
47895	CRADD	RAIDD	CASP2 and	1.5	1.4	0.4	2.2	0.8	1.1		3.3	0.8	1.2	7.7
			RIPK1 domain
			containing adaptor
			with dea
46598	SCYA20	MIP-3a	small inducible	8.6	7.8	0.2	4.0	0.7	1.4	0.6	1.3	1.0	1.0	7.7
			cytokine subfamily
			A (Cys—Cys), me
50125	COL7A1	COL7A1	collagen, type VII,	1.0	1.0	0.3	2.3	0.6	1.4		2.6		1.4	7.7
			alpha 1
			(epidermolysis
			bullosa
46876	GNG11	G protein,	guanine	1.2	1.0	0.4	2.6	0.8	1.1		2.8	0.9	1.0	7.5
		gamma 11	nucleotide binding
			protein 11
46856	IL8	interleukin-8	interleukin 8	7.2	6.7	0.2	3.8	0.6	1.4	1.2	1.2	1.2	1.0	7.4
49995	FCGR2A	CD32	Fc fragment of	2.4	2.0	3.6	2.7	1.1	1.0		2.5	1.2	1.2	7.4
			IgG, low affinity
			IIa, receptor for
50705	COL7A1	COL7A1	collagen, type VII,	1.0	1.0	0.3	2.0	0.6	1.4		2.6		1.4	7.4
			alpha 1
			(epidermolysis
			bullosa
46970	IL1B	IL-1, beta	interleukin 1, beta	3.3	2.3	0.2	3.9	0.7	1.2	1.2	1.2	1.2	1.1	7.3
49665	CRADD	RAIDD	CASP2 and	1.6	1.2	0.4	1.9	0.8	1.1		3.2	0.7	1.0	7.3
			RIPK1 domain
			containing adaptor
			with dea
48966	MMP10	MMP10	matrix	1.7	1.6	0.5	1.8	0.6	1.6		2.3		1.5	7.2
			metalloproteinase
			10 (stromelysin 2)
48273	FCGR2A	CD32	Fc fragment of	2.0	1.9	3.8	2.5	1.0	1.0		2.3		1.3	7.0
			IgG, low affinity
			IIa, receptor for
47987	THBS1	THBS1	thrombospondin 1	2.4	1.7	0.2	2.2	1.0	1.0		2.8	0.9	1.0	7.0
48977	FCGR2A	CD32	Fc fragment of	2.1	1.9	3.0	2.1	1.0	1.0		2.5	1.2	1.2	6.9
			IgG, low affinity
			IIa, receptor for
47656	IL1B	IL-1, beta	interleukin 1, beta	2.5	2.4	0.3	3.5	0.7	1.1	1.3	1.1	1.2	1.1	6.8
46949	AREG	amphiregulin	amphiregulin	1.9	1.4	0.8	1.0	0.5	1.8		2.4		1.4	6.6
			(schwannoma-
			derived growth
			factor)
46982	AREG	amphiregulin	amphiregulin	1.8	1.6	0.8	1.1	0.5	1.8		2.2		1.5	6.5
			(schwannoma-
			derived growth
			factor)
46986	AREG	amphiregulin	amphiregulin	1.8	1.5	0.8	1.0	0.5	1.8		2.0		1.6	6.5
			(schwannoma-
			derived growth
			factor)
46953	AREG	amphiregulin	amphiregulin	1.8	1.5	0.8	1.0	0.5	1.9		2.0		1.5	6.4
			(schwannoma-
			derived growth
			factor)
48784	RGS16	Rgs-16	regulator of G-	3.5	3.2	0.4	2.0	0.7	1.3		2.1	0.9	1.0	6.4
			protein signalling
			16
47537	PLAU	urokinase-type	plasminogen	1.9	1.7	0.6	1.3	0.8	1.3		2.6	0.8	1.2	6.3
		plasminogen	activator,
		activator	urokinase
49420	TIMP2	TIMP2	tissue inhibitor of	0.8	1.1	2.2	2.0	1.2	1.2		1.8		1.3	6.3
			metalloproteinase 2
50120	S100A4	S100A4	S100 calcium-	1.0	1.0	2.2	2.0	1.2	1.1		1.9	1.2	1.1	6.2
			binding protein A4
			(calcium protein,
49424	PLAU	urokinase-type	plasminogen	1.8	1.5	0.7	1.1	0.7	1.3		2.5	0.8	1.2	6.1
		plasminogen	activator,
		activator	urokinase
49758	IL10RA	IL-10R alpha	interleukin 10	9.5	7.9	2.0	1.8	1.2	1.0		2.1	1.4	1.2	6.1
			receptor, alpha
47339	TREM2			0.5	2.0	2.0	1.9	1.2	1.2		1.7	1.3	1.2	6.1
50345	AGT		serine (or	0.7	1.1	2.1	1.7	1.1	1.1		2.2	1.1	1.0	6.0
			cysteine)
			proteinase
			inhibitor, clade A
47893	SCYA4	MIP-1beta	small inducible	48.7	24.7	0.3	2.8	0.8	1.0	1.2	1.2	1.2	1.1	6.0
			cytokine A4
			(homologous to
			mouse M
49326	FCGR2A	CD32	Fc fragment of	2.5	2.1	3.2	2.1	1.0	1.0		1.9	1.2	1.1	6.0
			IgG, low affinity
			IIa, receptor for
47865	TGFB3	TGF, beta3	transforming	0.8	1.1	0.4	1.7	0.7	1.3		1.8	0.8	1.1	6.0
			growth factor, beta 3
49305	HLA-DRB1	MHCII, DR	major	0.9	1.0	2.1	1.8	1.1	1.1		1.8	1.2	1.2	6.0
		beta 1	histocompatibility
			complex, class II,
			DR bet
49785	TIMP2	TIMP2	tissue inhibitor of	0.8	1.1	2.0	1.9	1.2	1.2		1.7	1.3	1.2	5.9
			metalloproteinase 2
47632	GRO2	GRO2	GRO2 oncogene	25.4	16.7	0.4	2.5	0.7	1.4	0.7	1.0	0.9	1.0	5.9
50387	PPIC	cyclophilin C	peptidylprolyl	0.9	1.0	2.0	1.9	1.2	1.1		1.9	1.2	1.0	5.9
			isomerase C
			(cyclophilin C)
50669	ECM1	ECM1	extracellular	0.9	1.0	2.0	1.8	1.1	1.0		1.9	1.2	1.1	5.8
			matrix protein 1
47179	HLA-DRB1	MHCII, DR	major	0.9	1.0	2.0	1.7	1.2	1.1		1.8	1.3	1.2	5.8
		beta 1	histocompatibility
			complex, class II,
			DR bet
47040	IL10RA	IL-10R alpha	interleukin 10	11.8	10.6	2.1	1.7	1.1	1.0		1.8	1.5	1.2	5.8
			receptor, alpha
50026	SCYA2	MCP1	small inducible	24.1	13.0	0.4	2.4	1.2	1.0	0.6	1.3	1.1	1.0	5.8
			cytokine A2
			(monocyte
			chemotactic
48227	NRG1	neuregulin1,	neuregulin 1	5.8	3.5	0.4	1.9	0.7	1.2		1.5	0.8	1.1	5.8
		neu diff.
		Factor,
		heregulin
49293	HLA-DRB3	MHCII, DR	major	0.9	1.0	2.0	1.8	1.1	1.1		1.7	1.1	1.1	5.8
		beta 3	histocompatibility
			complex, class II,
			DR bet
49818	TIMP2	TIMP2	tissue inhibitor of	0.8	1.1	1.9	1.8	1.2	1.2		1.6	1.3	1.1	5.7
			metalloproteinase 2
50397	SPP1	SPP1	secreted	0.5	1.6	0.4	2.3	1.1	1.0		1.5	1.1	1.0	5.7
			phosphoprotein 1
			(osteopontin, bone
			sialo
48711	SPP1	SPP1	secreted	0.5	1.7	0.4	2.0	1.1	1.0		1.6	1.2	1.0	5.7
			phosphoprotein 1
			(osteopontin, bone
			sialo
48911	ECM1	ECM1	extracellular	0.9	1.0	1.9	1.7	1.1	1.0		1.8	1.2	1.1	5.7
			matrix protein 1
48827	PBX3			0.9	1.0	2.1	1.8	1.1	1.0		1.8	1.1	1.0	5.7
48589	HLA-DRB1	MHCII, DR	major	1.0	1.0	2.0	1.8	1.1	1.1		1.7	1.2	1.2	5.7
		beta 1	histocompatibility
			complex, class II,
			DR bet
49838				1.0	1.0	1.9	1.7	1.1	1.0		1.9	1.1	1.0	5.7
47887	HLA-DRB1	MHCII, DR	major	1.1	1.0	1.8	1.7	1.1	1.0		1.7	1.2	1.2	5.6
		beta 1	histocompatibility
			complex, class II,
			DR bet
47539	F2	F2	coagulation factor	1.7	1.5	0.7	1.2	0.8	1.1		2.1	0.8	1.2	5.6
			II (thrombin)
49124	MMP7	MMP7	matrix	1.4	1.3	0.4	1.5	0.9	1.0		2.1	0.9	1.0	5.6
			metalloproteinase
			7 (matrilysin,
			uterine)
49681	HSXIAPAF1	XIAP assoc	XIAP associated	9.5	9.3	2.8	2.6	1.1	1.0	1.0	1.0	0.9	1.0	5.6
		factor 1	factor-1
47697	TNFRSF6B	DcR3	tumor necrosis	0.8	1.2	0.5	1.7	0.9	1.0		1.9	0.9	1.0	5.6
			factor receptor
			superfamily,
			member
46926	HLA-DRB1	MHCII, DR	major	1.0	1.0	2.0	1.5	1.2	1.1		1.7	1.3	1.2	5.6
		beta 1	histocompatibility
			complex, class II,
			DR bet
49277	GNG11	G protein,	guanine	1.1	1.0	0.5	1.6	0.8	1.1		1.9	1.0	1.0	5.6
		gamma 11	nucleotide binding
			protein 11
47318	S100A4	S100A4	S100 calcium-	1.0	1.0	2.0	1.8	1.2	1.0		1.6	1.2	1.1	5.6
			binding protein A4
			(calcium protein,
46983	PPIC	cyclophilin C	peptidylprolyl	1.0	1.0	2.0	1.5	1.2	1.2		1.6	1.4	1.2	5.6
			isomerase C
			(cyclophilin C)
50665	PTGS2	PTGS2, COX2	prostaglandin-	32.8	31.2	1.0	1.0	0.8	1.2		2.3	1.3	1.1	5.6
			endoperoxide
			synthase 2
			(prostagland
48605	HSXIAPAF1	XIAP assoc	XIAP associated	13.2	8.9	2.7	2.5	1.2	1.0	1.1	1.0	1.0	1.0	5.6
		factor 1	factor-1
48074				1.4	1.1	1.8	1.6	1.1	1.1		1.8	1.1	1.1	5.6
49692	GRO3	GRO3	GRO3 oncogene	33.5	17.1	0.4	2.2	0.7	1.4	0.7	1.0	1.0	1.0	5.6
48330	GRO3	GRO3	GRO3 oncogene	36.2	17.9	0.4	2.2	0.7	1.2	0.8	1.0	0.9	1.1	5.5
49754	GRO1	GRO1	GRO1 oncogene	44.5	27.1	0.4	2.2	0.7	1.3	0.8	1.0	1.0	1.0	5.5
			(melanoma growth
			stimulating activit
47513	PRKCB1	PKC, beta	protein kinase C,	1.0	1.0	2.0	1.8	1.1	1.0		1.7	1.2	1.1	5.5
			beta 1
48839	FCGR1A			0.8	1.1	2.2	2.1	1.2	1.2	1.4	1.3	1.1	1.0	5.5
49129	UP	uridine	uridine	1.4	1.2	0.6	1.6	0.9	1.1		1.6	0.8	1.1	5.5
		phosphorylase	phosphorylase
49669	GALNAC4S-6ST	BRAG	B cell RAG	0.5	1.5	0.5	1.7	1.0	1.0		1.8	0.7	1.0	5.5
			associated protein
46787	SERPINI1		serine (or	1.1	1.0	2.6	1.8	1.1	1.1		1.6	1.1	1.1	5.5
			cysteine)
			proteinase
			inhibitor, clade I
49052	CXCR4	CXCR4	chemokine (C—X—C	2.0	1.7	0.4	2.2	0.9	1.0	0.7	1.3	1.1	1.0	5.5
			motif), receptor 4
			(fusin)
48271	ADCY7	adenylate	adenylate cyclase 7	1.1	1.0	1.8	1.3	1.2	1.2		1.8	1.3	1.2	5.5
		cyclase
49522	UCP2			0.6	1.5	1.8	1.7	1.3	1.2		1.6	1.2	1.1	5.5
50385	HLA-DRB1	MHCII, DR	major	0.9	1.1	1.9	1.7	1.1	1.0		1.8	1.2	1.0	5.5
		beta 1	histocompatibility
			complex, class II,
			DR bet
46877	DTR	HB-EGF,	diphtheria toxin	2.4	2.0	0.5	1.4	0.7	1.1		1.6		1.4	5.5
		diptheria toxin	receptor (heparin-
		receptor	binding epiderm
49208				0.5	1.7	0.6	1.4	0.8	1.1		1.8	0.8	1.2	5.5
49287	ADCY7	adenylate	adenylate cyclase 7	1.1	1.0	1.9	1.6	1.2	1.1		1.7	1.2	1.1	5.5
		cyclase
50380				0.9	1.0	1.9	1.7	1.2	1.0		1.8	1.1	1.0	5.5
50383	DTR	HB-EGF,	diphtheria toxin	1.7	1.3	0.6	1.5	0.7	1.2		1.5		1.3	5.5
		diptheria toxin	receptor (heparin-
		receptor	binding epiderm
47030				1.3	1.2	1.9	1.7	1.1	1.1	1.5	1.3		1.4	5.4
50597	PDE7A			0.9	1.0	1.8	1.7	1.0	1.0		1.7	0.9	1.0	5.4
47217	ADAMTS1	ADAMTS1	a disintegrin-like	1.9	1.6	2.3	2.0	1.1	1.0	1.5	1.4	1.1	1.0	5.4
			and
			metalloprotease
			(reprolysin
49217	HMGIC			0.6	1.1	0.7	1.3	0.9	1.0		1.8		1.3	5.4
50361	HMGIY	HMG-I/Y	high-mobility	0.7	1.3	0.5	1.7	0.9	1.1		1.5	0.8	1.1	5.4
			group (nonhistone
			chromosomal)
			prote
49258	UP	uridine	uridine	1.4	1.2	0.5	1.6	0.9	1.1		1.5	0.8	1.2	5.4
		phosphorylase	phosphorylase
49347	HNRPA3			0.9	1.1	0.5	1.7	1.0	1.0		1.7	1.0	1.0	5.4
47704	PLOD	PLOD	procollagen-	0.6	1.5	1.9	1.7	0.9	1.0		1.7	1.0	1.0	5.4
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
47857	COL9A2	COL9A2	collagen, type IX,	1.0	1.0	1.9	1.7	1.2	1.1		1.5	1.1	1.1	5.4
			alpha 2
46862	PPIF	cyclophilin F	peptidylprolyl	1.3	1.2	0.8	1.0	0.9	1.1		1.9		1.3	5.4
			isomerase F
			(cyclophilin F)
50150	MAP3K4	MEKK4	mitogen-activated	0.9	1.0	0.7	1.2	0.9	1.0		2.1	0.8	1.0	5.4
			protein kinase
			kinase kinase 4
49106	PLOD	PLOD	procollagen-	0.6	1.7	1.9	1.7	1.0	1.0		1.6	0.9	1.0	5.3
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
48582	MMP13	MMP13	matrix	0.9	1.1	1.6	1.5	1.1	1.1		1.7	1.2	1.0	5.3
			metalloproteinase
			13 (collagenase 3)
50462	GRO1	GRO1	GRO1 oncogene	33.8	21.0	0.4	2.1	0.8	1.2	0.7	1.0	1.0	1.0	5.3
			(melanoma growth
			stimulating activit
49162	DKFZP761N09121			1.0	1.0	1.9	1.6	1.1	1.0		1.7	1.1	1.0	5.3
48281	SERPINE2		serine (or	34.6	17.3	0.4	2.2	1.0	1.0	0.6	1.1	1.1	1.0	5.3
			cysteine)
			proteinase
			inhibitor, clade E
46988	EREG	epiregulin	epiregulin	4.5	3.9	1.0	1.0	1.0	1.0		2.2	0.8	1.1	5.3
48400	SERPINE2		serine (or	26.7	13.2	0.4	2.2	1.0	1.0	0.7	1.1	1.0	1.0	5.3
			cysteine)
			proteinase
			inhibitor, clade E
49073	PLOD	PLOD	procollagen-	0.7	1.4	1.9	1.7	1.0	1.0		1.6	1.0	1.0	5.3
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
48907	TGFB3	TGF, beta3	transforming	0.8	1.1	0.4	2.0	0.8	1.1	0.6	1.0	0.7	1.1	5.3
			growth factor, beta 3
47671	PLOD	PLOD	procollagen-	0.6	1.5	1.9	1.7	0.9	1.0		1.6	1.1	1.0	5.3
			lysine, 2-
			oxoglutarate 5-
			dioxygenase (
48530	APLP2			0.9	1.1	1.7	1.7	1.0	1.0		1.6	1.0	1.0	5.3
48267	CASP1	caspase 1,	caspase 1,	5.9	4.1	2.2	1.9	1.2	1.0	1.3	1.1	1.3	1.2	5.3
		ICE	apoptosis-related
			cysteine protease
			(in
50450	STAT1	STAT1	signal transducer	5.2	4.0	2.1	2.0	1.2	1.1	1.3	1.2	1.1	1.0	5.3
			and activator of
			transcription 1
50381	HLA-DQB1	MHCII, DQ	major	1.0	1.0	2.0	1.7	1.2	1.0		1.6	1.0	1.0	5.3
		beta 1	histocompatibility
			complex, class II,
			DQ bet
50653	GM2A			0.9	1.0	1.7	1.6	1.1	1.0		1.6	1.2	1.1	5.3
47605	HRMT1L2			1.3	1.2	0.5	1.8	0.8	1.1	0.6	1.4	0.9	1.0	5.3
48367	SERPINE2		serine (or	27.1	12.5	0.4	2.1	1.0	1.0	0.7	1.2	1.1	1.0	5.3
			cysteine)
			proteinase
			inhibitor, clade E
50526	HMGIY	HMG-I/Y	high-mobility	0.7	1.4	0.5	1.6	0.9	1.1	0.6	1.4	0.8	1.1	5.2
			group (nonhistone
			chromosomal)
			prote
50170	EMILIN	EMILIN	elastin microfibril	0.8	1.1	1.4	1.4	1.1	1.1		1.6	1.2	1.2	5.2
			interface located
			protein
47916	SCYA2	MCP1	small inducible	16.9	10.7	0.3	2.1	1.2	1.1	0.7	1.0	1.1	1.0	5.2
			cytokine A2
			(monocyte
			chemotactic
49117	SERPINB1		serine (or	3.8	2.9	0.7	1.2	1.0	1.0		1.9	1.2	1.0	5.2
			cysteine)
			proteinase
			inhibitor, clade B
47137	MD-2	MD-2	MD-2 protein	1.0	1.0	2.1	1.7	1.1	1.0	1.6	1.4	1.2	1.2	5.2
49752				2.0	1.8	0.5	2.0	0.9	1.0	0.7	1.2	1.1	1.0	5.2
47385	FLJ10718			3.2	2.7	0.4	1.9	0.7	1.3	0.8	1.0	1.0	1.0	5.2
47505	COL9A2	COL9A2	collagen, type IX,	1.0	1.0	1.8	1.5	1.2	1.1		1.5	1.1	1.1	5.2
			alpha 2
48038	MMP13	MMP13	matrix	0.9	1.0	1.6	1.4	1.1	1.0		1.7	1.1	1.0	5.2
			metalloproteinase
			13 (collagenase 3)
49904	KIAA1557			2.3	1.7	2.3	2.1	1.1	1.0	1.2	1.1	0.9	1.0	5.2
46586	C12orf8			0.9	1.0	1.7	1.3	1.2	1.1		1.8	1.2	1.1	5.2
49417	HSPA1B	HSPA1B	heat shock 70 kD	2.2	1.4	1.7	1.5	1.1	1.0		1.6	1.3	1.1	5.2
			protein 1B
49044	SCYA18	DC-CK1	small inducible	26.3	23.0	0.4	1.7	0.6	1.4	1.3	1.1	1.0	1.0	5.2
			cytokine subfamily
			A (Cys—Cys), me
49870	IFIT4			10.9	6.3	1.1	1.0	0.7	1.2		1.7	1.2	1.2	5.2
46748	PTX3			8.7	3.4	1.4	1.3	1.0	1.0		1.5		1.3	5.2
50499	RGS14	RGS14	regulator of G-	0.4	2.3	2.0	1.7	1.3	1.2	1.4	1.3	1.0	1.0	5.2
			protein signalling
			14
50369	SCYA3	MIP1, alpha	small inducible	8.5	8.4	0.4	2.0	0.8	1.0	1.2	1.1	1.2	1.0	5.2
		homolog	cytokine A3
			(homologous to
			mouse M
49649	FGF2	FGF-2	fibroblast growth	3.0	2.8	1.0	1.0	0.9	1.0		2.1	0.9	1.0	5.1
49873	INSIG1			1.5	1.4	0.6	1.4	0.7	1.4	1.0	1.0		1.3	5.1
47185	HSPA1B	HSPA1B	heat shock 70 kD	2.0	1.7	1.6	1.5	1.1	1.0		1.5	1.3	1.2	5.1
			protein 1B
48971	P4HA2	P4HA2	procollagen-	1.2	1.1	2.0	1.7	1.0	1.0	1.7	1.4	1.0	1.0	5.1
			proline, 2-
			oxoglutarate 4-
			dioxygenase
48946	FGFR1	FGF receptor 1	fibroblast growth	0.7	1.3	1.7	1.6	1.0	1.0		1.5	1.0	1.0	5.1
			factor receptor 1
			(fms-related t
49812	TXNIP	VDUP1	upregulated by	0.6	1.2	1.5	1.2	1.2	1.2		1.7	1.1	1.0	5.1
			1,25-
			dihydroxyvitamin
			D-3
48000	CTSH			0.8	1.1	1.7	1.6	1.1	1.1	1.6	1.4	1.1	1.0	5.1
50433	GNAS	G protein,	guanine	0.9	1.1	1.6	1.4	1.1	1.0		1.7	1.1	1.0	5.1
		alpha s1	nucleotide binding
			protein (G
			protein), al
50200	PTGER4	EP2	prostaglandin E	1.4	1.0	0.7	1.3	1.1	1.1		1.6	1.3	1.2	5.1
			receptor 4
			(subtype EP4)
46930	CD14	CD14	CD14 antigen	0.6	1.2	2.4	2.0	1.1	1.1	1.2	1.0	0.8	1.0	5.1
49389	DUSP1	MKP-1,	dual specificity	5.5	5.4	0.6	1.6	0.9	1.1	0.7	1.3	0.8	1.2	5.1
		PTPN10	phosphatase 1
48185	XAGE-1			1.0	1.0	1.4	1.3	1.0	1.0		1.7	1.2	1.1	5.1
48009	ST14	ST14	suppression of	0.4	1.9	1.6	1.4	1.2	1.1		1.6	1.2	1.1	5.1
			tumorigenicity 14
			(colon carcinoma,
50009	SCYA3	MIP1, alpha	small inducible	7.8	5.0	0.4	1.8	0.8	1.0	1.2	1.2	1.2	1.1	5.1
		homolog	cytokine A3
			(homologous to
			mouse M
47551	PTGER4	EP2	prostaglandin E	1.4	1.3	0.7	1.3	1.1	1.0		1.5		1.3	5.1
			receptor 4
			(subtype EP4)
47118	PLA2G4A	phospholipase	phospholipase A2,	2.0	1.6	1.3	1.2	1.0	1.0		1.6		1.3	5.1
		A2	group IVA
			(cytosolic,
			calcium-de
48013	CEP3	CEP3	Cdc42 effector	1.4	1.3	1.4	1.2	1.0	1.0		1.8	1.2	1.1	5.1
			protein 3
46955	EREG	epiregulin	epiregulin	3.8	3.5	1.0	1.0	1.0	1.0		2.1	0.8	1.0	5.1
50341	ST14	ST14	suppression of	0.4	1.8	1.6	1.5	1.2	1.1		1.6	1.1	1.0	5.1
			tumorigenicity 14
			(colon carcinoma,
47699	PAK1	Pak1	p21/Cdc42/Rac1-	0.9	1.1	2.0	1.8	1.0	1.0	1.4	1.3	1.0	1.0	5.1
			activated kinase 1
			(yeast Ste20-rel
47499	PTGS2	PTGS2, COX2	prostaglandin-	28.8	28.0	0.7	1.0	0.9	1.0		1.9	1.3	1.1	5.1
			endoperoxide
			synthase 2
			(prostagland
48543	C2			1.9	1.7	2.0	1.6	1.3	1.2	1.3	1.1	1.2	1.2	5.1
49617	FOXF1	FOXF1	forkhead box F1	3.3	1.7	1.4	1.1	1.0	1.0		1.8	1.3	1.2	5.1
47580	EMS1	cortactin	ems1 sequence	0.8	1.1	0.6	1.5	1.0	1.0		1.6	1.0	1.0	5.1
			(mammary tumor
			and squamous
			cell car
48468	NRG1	neuregulin1,	neuregulin 1	5.3	4.1	0.5	1.6	0.7	1.3	0.7	1.0	0.8	1.1	5.1
		neu diff.
		Factor,
		heregulin
48585	SCYA3	MIP1, alpha	small inducible	9.5	8.6	0.5	1.8	0.8	1.1	1.2	1.2	1.2	1.0	5.1
		homolog	cytokine A3
			(homologous to
			mouse M
49416	S100A10	S100A10	S100 calcium-	1.2	1.0	1.9	1.5	1.1	1.0	1.9	1.4	1.2	1.1	5.1
			binding protein
			A10 (annexin II
			ligan
47139	SERPINI1		serine (or	1.0	1.0	2.2	1.4	1.1	1.1		1.6	1.1	1.0	5.1
			cysteine)
			proteinase
			inhibitor, clade I
48257	SCYA4	MIP-1beta	small inducible	40.5	17.9	0.3	1.8	0.9	1.0	1.2	1.2	1.2	1.0	5.0
			cytokine A4
			(homologous to
			mouse M
50126	EREG	epiregulin	epiregulin	6.6	6.2	1.0	1.0	0.7	1.0		1.9	0.8	1.1	5.0
47056	NFRKB			0.8	1.2	0.6	1.5	0.9	1.0	0.6	1.4	0.9	1.1	5.0
47070	CPD			1.7	1.6	1.5	1.4	1.1	1.0		1.6	1.1	1.1	5.0
49054	ITGA2	integrin, alpha	integrin, alpha 2	0.9	1.0	0.6	1.4	0.9	1.0		1.6	1.0	1.0	5.0
		2, CD49B,	(CD49B, alpha 2
		VLA-2	subunit of VLA-2
50338	PIM2	Pim-2	pim-2 oncogene	4.7	2.8	1.3	1.2	1.0	1.0		1.8	1.1	1.0	5.0
48290	NEDD4L			1.6	1.5	0.6	1.4	0.8	1.1		1.5	0.8	1.1	5.0
50349	LOC51295	ECSIT	ECSIT	0.7	1.3	0.6	1.5	1.0	1.0		1.5	0.9	1.0	5.0
49016	LIPA			1.1	1.0	1.4	1.3	1.1	1.0		1.6	1.2	1.1	5.0
48609	SERPINF1		serine (or	0.8	1.1	1.5	1.3	1.1	1.0		1.7	1.1	1.0	5.0
			cysteine)
			proteinase
			inhibitor, clade F
46796	STC1			2.3	1.7	0.8	1.1	0.8	1.0		1.5		1.3	5.0
47926	CCNE2	cyclin E2	cyclin E2	1.6	1.2	0.5	1.8	1.0	1.0	0.6	1.2	1.2	1.0	5.0
50493	HMGIY	HMG-I/Y	high-mobility	0.7	1.4	0.6	1.4	0.9	1.1	0.6	1.4	0.8	1.1	5.0
			group (nonhistone
			chromosomal)
			prote
49839	SCYB5	ENA-78	small inducible	2.6	1.9	0.8	1.2	0.8	1.0	0.5	1.3		1.4	5.0
			cytokine subfamily
			B (Cys-X-Cys),
50199				1.1	1.0	1.9	1.8	1.0	1.0	1.5	1.2	1.0	1.0	5.0
49679	SERPINF1		serine (or	0.8	1.2	1.6	1.4	1.1	1.1		1.5	1.1	1.0	5.0
			cysteine)
			proteinase
			inhibitor, clade F
50311	IFNGR1	IFN gamma	interferon gamma	0.7	1.2	2.3	1.8	1.2	1.0	1.3	1.1	0.9	1.0	5.0
		receptor 1	receptor 1
50347	TRAP1	TRAP1, hsp90	heat shock protein	0.7	1.3	0.6	1.4	0.9	1.0		1.6	0.9	1.0	5.0
		related	75
50343	JAK2	JAK2	Janus kinase 2 (a	4.6	4.2	1.4	1.2	1.0	1.0		1.5	1.3	1.2	5.0
			protein tyrosine
			kinase)
49132	CASP1	caspase 1,	caspase 1,	4.1	3.0	1.9	1.4	1.1	1.1	1.5	1.3	1.2	1.2	5.0
		ICE	apoptosis-related
			cysteine protease
			(in
47328	PPFIBP1	PPFIBP1	PTPRF interacting	0.6	1.5	0.6	1.6	0.9	1.0	0.7	1.3	0.9	1.0	5.0
			protein, binding
			protein 1 (lipr
48771				0.9	1.1	1.5	1.4	0.9	1.0		1.5	1.0	1.0	5.0
50046	DUSP1	MKP-1,	dual specificity	5.6	5.0	0.5	1.8	0.9	1.0	0.7	1.2	0.9	1.0	5.0
		PTPN10	phosphatase 1
49779	TXNIP	VDUP1	upregulated by	0.6	1.4	1.5	1.2	1.2	1.1		1.6	1.1	1.1	5.0
			1,25-
			dihydroxyvitamin
			D-3
47969	MAP3K8	c-cot	mitogen-activated	4.9	4.8	0.9	1.0	0.8	1.0		1.8	1.4	1.1	5.0
			protein kinase
			kinase kinase 8
47386	GALNAC4S-6ST	BRAG	B cell RAG	0.7	1.0	0.6	1.5	1.0	1.0	0.6	1.4	0.8	1.1	5.0
			associated protein

APPENDIX C
AA Pathway Inhibitors
Genes differentially expressed (≧1.3-fold) in A549 cells in response to at least one arachidonic acid pathway inhibitor, in presence of IL-1β
Genes in bold have min fold change ≧1.3
							+IL1b +/− Triac,		+IL1b +/− Indo,
				+IL1b +/− Dexa,	+IL1b +/− Dexa,	+IL1b +/− Triac,	min	+IL1b +/− Indo,	min
				wtd	min fold	wtd	fold	wtd	fold
SpotID	GeneSymbol	GeneName	GeneAssignment	means	change	means	change	means	change
48626				1.89	1.67	2.09	1.79	1.86	1.77
47003				1.81	1.41	2.01	1.59	1.84	1.68
47624				1.61	1.48	1.97	1.74	1.80	1.64
50456				1.54	1.24	1.90	1.53	1.70	1.59
46987				2.82	2.22	2.05	1.57	1.77	1.53
50468				1.45	1.23	1.74	1.47	1.72	1.52
46609				1.65	1.30	1.82	1.67	1.71	1.52
49817				1.47	1.26	2.06	1.75	1.76	1.48
49343				1.76	1.62	1.94	1.60	1.77	1.45
46594				1.64	1.05	1.73	1.62	1.77	1.38
47206				1.79	1.12	1.91	1.60	1.58	1.35
48580				1.69	1.44	1.50	1.47	1.47	1.32
47048				2.19	1.26	2.17	1.66	1.58	1.31
48763				1.72	1.47	1.54	1.31	1.25	1.17
48036				1.63	1.38	1.68	1.51	1.39	1.13
50596				2.04	1.75	0.81	1.07	0.77	1.12
49612				1.63	1.34	1.98	1.54	1.37	1.11
47315				1.50	1.21	1.70	1.47	1.52	1.09
50250			putative methyltransferase	1.48	1.03	1.41	1.36	1.13	1.09
48260				1.72	1.23	2.14	1.75	1.56	1.07
49348			KIAA1085 protein	1.19	1.04	1.39	1.34	1.11	1.05
47016		LBC, lymphoid	lymphoid blast crisis oncogene	1.51	1.36	1.19	1.10	1.17	1.05
		blast crisis
		oncogene
46753				1.38	1.00	1.44	1.36	1.08	1.05
48924				0.96	1.00	1.58	1.40	1.19	1.05
46769				1.53	1.10	1.83	1.70	1.41	1.02
47233				1.72	1.53	0.46	1.71	0.98	1.00
48039				0.76	1.25	1.73	1.54	0.92	1.00
46783				0.84	1.08	2.02	1.46	1.09	1.00
50624				2.08	1.46	2.27	1.43	1.08	1.00
48604				0.30	2.29	1.48	1.40	1.00	1.00
46580				1.30	1.00	1.52	1.39	1.24	1.00
48060				0.23	2.64	1.39	1.27	1.04	1.00
50375		LBC, lymphoid	lymphoid blast crisis oncogene	3.55	3.24	1.25	1.24	1.06	1.00
		blast crisis
		oncogene
49276				0.48	1.69	0.67	1.23	0.90	1.00
49147				0.47	1.83	0.69	1.20	0.83	1.00
50287				0.51	1.76	0.78	1.18	0.85	1.00
48336				0.44	1.35	1.22	1.15	1.02	1.00
49908				1.74	1.59	1.94	1.12	1.22	1.00
49425				0.49	1.67	1.23	1.10	1.06	1.00
46627				1.58	1.37	1.30	1.04	1.13	1.00
48775				0.71	1.32	0.91	1.02	0.97	1.00
50562				2.46	2.01	1.14	1.00	0.84	1.00
50782				1.68	1.58	0.95	1.00	1.02	1.00
48047				1.78	1.45	1.10	1.00	1.06	1.00
50151				0.63	1.31	0.99	1.00	0.94	1.00
49051	A2M		alpha-2-macroglobulin	0.51	1.54	1.00	1.00	1.00	1.00
49952	AADAC		arylacetamide deacetylase (esterase)	0.52	1.41	1.50	1.40	0.91	1.00
50633	ABL2		v-abl Abelson murine leukemia viral oncogene	1.27	1.00	1.73	1.49	1.09	1.00
			homolog 2 (arg, Abelson-related gene)
47263	ACVR2		activin A receptor, type II	1.51	1.24	1.67	1.58	1.27	1.16
48251	ADAM15	ADAM15	a disintegrin and metalloproteinase domain 15	1.40	1.33	0.77	1.21	0.92	1.00
			(metargidin)
49237	ADORA2B		adenosine A2b receptor	0.63	1.33	1.08	1.00	0.88	1.00
47060	AF1Q		ALL1-fused gene from chromosome 1q	0.43	2.17	1.36	1.30	0.91	1.00
50345	AGT		angiotensinogen (serine (or cysteine)	2.59	2.45	1.00	1.00	0.98	1.00
			proteinase inhibitor, clade A (alpha-1
			antiproteinase, antitrypsin), member 8)
49620	AKAP1		A kinase (PRKA) anchor protein 1	1.61	1.38	0.85	1.06	1.02	1.00
48794	ANXA3	annexin III	annexin A3	1.14	1.00	1.36	1.31	1.09	1.00
49549	ANXA8		annexin A8	1.60	1.39	1.20	1.11	0.89	1.00
49524	AP1G2		adaptor-related protein complex 1, gamma 2	1.10	1.00	1.39	1.30	0.99	1.00
			subunit
49935	APOA2		apolipoprotein A-II	0.28	2.55	1.03	1.00	0.90	1.00
46949	AREG	amphiregulin	amphiregulin (schwannoma-derived growth	0.09	10.54	0.75	1.17	0.90	1.09
			factor)
46953	AREG	amphiregulin	amphiregulin (schwannoma-derived growth	0.09	10.74	0.76	1.19	0.89	1.08
			factor)
46982	AREG	amphiregulin	amphiregulin (schwannoma-derived growth	0.09	10.64	0.75	1.22	0.94	1.00
			factor)
47617	ARF3		ADP-ribosylation factor 3	1.08	1.00	1.62	1.44	1.01	1.00
50502	ARF6	ARF6	ADP-ribosylation factor 6	1.50	1.32	0.88	1.07	0.93	1.00
48357	ARF6	ARF6	ADP-ribosylation factor 6	1.63	1.41	0.95	1.00	0.90	1.00
50469	ARF6	ARF6	ADP-ribosylation factor 6	1.47	1.30	0.94	1.00	0.93	1.00
47192	ARHGAP1	ARHGAP1	Rho GTPase activating protein 1	1.44	1.36	1.54	1.44	1.21	1.07
46648	ARHGAP1	ARHGAP1	Rho GTPase activating protein 1	1.41	1.35	1.54	1.41	1.24	1.02
46873	ARHGAP4	ARHGAP4	Rho GTPase activating protein 4	0.85	1.00	1.65	1.40	1.12	1.00
48984	ARHGDIB	ARHGDIB	Rho GDP dissociation inhibitor (GDI) beta	0.48	1.47	1.22	1.05	0.99	1.00
48287	ARHGEF15	ARHGEF15	Rho guanine nucleotide exchange factor (GEF)	1.63	1.32	1.87	1.45	1.83	1.37
			15
48322	ARHGEF16	ARHGEF16	Rho guanine exchange factor (GEF) 16	1.43	1.00	1.73	1.53	1.46	1.00
48277	ARHGEF2	ARHGEF2	rho/rac guanine nucleotide exchange factor	0.41	2.22	1.18	1.05	0.91	1.00
			(GEF) 2
48346	ARHGEF2	ARHGEF2	rho/rac guanine nucleotide exchange factor	0.48	1.81	1.18	1.00	0.97	1.00
			(GEF) 2
48516	ARL6IP		ADP-ribosylation factor-like 6 interacting	0.84	1.07	0.62	1.41	0.86	1.04
			protein
50440	ATF5	ATF5	activating transcription factor 5	1.37	1.00	1.53	1.49	1.14	1.06
47568	ATF7	ATF7	activating transcription factor 7	1.73	1.24	1.92	1.53	1.66	1.42
50635	B4GALT1		UDP-Gal: betaGlcNAc beta 1,4-	1.58	1.49	1.10	1.00	0.98	1.00
			galactosyltransferase, polypeptide 1
49146	BAG4	BAG-4, SODD	BCL2-associated athanogene 4	0.60	1.38	0.89	1.00	1.16	1.00
49307	BAG5	BAG5	BCL2-associated athanogene 5	1.40	1.00	1.57	1.36	1.19	1.00
48802	BAI3		brain-specific angiogenesis inhibitor 3	0.69	1.38	0.93	1.03	0.95	1.01
47691	BATF	B-ATF	basic leucine zipper transcription factor, ATF-	1.30	1.00	1.54	1.35	1.15	1.00
			like
49013	BBC3		Bcl-2 binding component 3	0.66	1.34	0.99	1.00	0.97	1.00
47650	BBS2	BBS2	Bardet-Biedl syndrome 2	1.44	1.34	1.05	1.00	0.97	1.00
50686	BCL2	Bcl2	B-cell CLL/lymphoma 2	1.31	1.00	1.62	1.37	1.17	1.00
50019	BCL2A1	BCL2A1	BCL2-related protein A1	1.10	1.00	1.43	1.34	1.13	1.07
47738	BCL2A1	BCL2A1	BCL2-related protein A1	0.25	3.26	1.29	1.19	1.06	1.00
48679	BCL3	Bcl3	B-cell CLL/lymphoma 3	1.48	1.20	1.50	1.45	1.43	1.21
48374	BDKRB1	BDKRB1	bradykinin receptor B1	0.16	4.59	1.18	1.13	0.93	1.02
47979	BDKRB1	BDKRB1	bradykinin receptor B1	0.27	3.24	1.21	1.09	0.95	1.00
46689	BENE		BENE protein	1.01	1.00	0.62	1.36	0.97	1.00
47396	BHLHB2		basic helix-loop-helix domain containing, class	0.53	1.60	0.99	1.00	0.96	1.00
			B, 2
50726	BID	BID	BH3 interacting domain death agonist	0.69	1.33	0.80	1.12	0.97	1.01
48408	BIRC2	cIAP1	baculoviral IAP repeat-containing 2	0.64	1.43	0.91	1.05	1.02	1.00
49061	BIRC2	cIAP1	baculoviral IAP repeat-containing 2	0.60	1.41	0.93	1.03	0.99	1.00
49094	BIRC2	cIAP1	baculoviral IAP repeat-containing 2	0.60	1.47	0.92	1.00	1.05	1.00
49840	BMP4	BMP4	bone morphogenetic protein 4	0.24	3.58	0.49	1.92	0.98	1.00
49098	BMP4	BMP4	bone morphogenetic protein 4	0.33	1.65	0.38	1.90	0.94	1.00
49065	BMP4	BMP4	bone morphogenetic protein 4	0.18	3.21	0.40	1.79	0.98	1.00
49148	BMP7	BMP7	bone morphogenetic protein 7 (osteogenic	0.43	1.71	0.90	1.00	0.81	1.00
			protein 1)
49058	BNIP3	BNIP3	BCL2/adenovirus E1B 19 kD interacting protein 3	0.56	1.47	1.25	1.14	0.95	1.00
46916	BNIP3	BNIP3	BCL2/adenovirus E1B 19 kD interacting protein 3	0.56	1.75	1.36	1.13	0.92	1.00
49028	BNIP3L	BNIP3L	BCL2/adenovirus E1B 19 kD interacting protein	0.44	2.11	1.20	1.14	0.95	1.03
			3-like
49301	BPAG1	BPAG1	bullous pemphigoid antigen 1 (230/240 kD)	0.96	1.00	1.62	1.50	1.36	1.15
50489	BPAG1	BPAG1	bullous pemphigoid antigen 1 (230/240 kD)	0.88	1.00	1.91	1.58	1.25	1.00
50522	BPAG1	BPAG1	bullous pemphigoid antigen 1 (230/240 kD)	0.84	1.00	1.63	1.35	1.20	1.00
47795	BPHL		biphenyl hydrolase-like (serine hydrolase;	1.55	1.01	1.70	1.60	1.20	1.14
			breast epithelial mucin-associated antigen)
47516	BTG1		B-cell translocation gene 1, anti-proliferative	0.64	1.43	1.36	1.31	1.07	1.00
46854	BTN3A2	BTN3A2	butyrophilin, subfamily 3, member A2	1.70	1.29	2.12	1.99	1.76	1.54
49509	C3		complement component 3	2.75	2.65	0.86	1.00	1.02	1.00
49513	CA3		carbonic anhydrase III, muscle specific	0.55	1.47	0.99	1.00	1.09	1.00
48299	CALM2		calmodulin 2 (phosphorylase kinase, delta)	1.61	1.52	0.86	1.04	1.09	1.00
47637	CALM2		calmodulin 2 (phosphorylase kinase, delta)	1.61	1.55	0.85	1.02	1.04	1.00
49750	CARD14	CARD14	caspase recruitment domain protein 14	0.97	1.00	1.61	1.38	0.97	1.00
49807	CASP4	CASP4	caspase 4, apoptosis-related cysteine protease	0.73	1.04	1.42	1.35	1.15	1.12
47007	CASP4	CASP4	caspase 4, apoptosis-related cysteine protease	0.81	1.08	1.45	1.37	1.15	1.09
50721	CASP4	CASP4	caspase 4, apoptosis-related cysteine protease	0.82	1.04	1.45	1.35	1.00	1.00
50372	CASP6	caspase-6	caspase 6, apoptosis-related cysteine protease	1.57	1.22	1.80	1.53	1.60	1.20
49909	CASR		calcium-sensing receptor (hypocalciuric	0.54	1.65	1.42	1.33	1.14	1.12
			hypercalcemia 1, severe neonatal
			hyperparathyroidism)
49836	CCL19	MIP-3b	small inducible cytokine subfamily A (Cys—Cys),	0.61	1.35	1.03	1.00	1.05	1.00
			member 19
48830	CCL2	MCP1	small inducible cytokine A2 (monocyte	0.23	4.02	0.60	1.40	1.01	1.00
			chemotactic protein 1)
50026	CCL2	MCP1	small inducible cytokine A2 (monocyte	0.15	4.46	0.57	1.24	1.00	1.00
			chemotactic protein 1)
47916	CCL2	MCP1	small inducible cytokine A2 (monocyte	0.13	5.80	0.68	1.12	1.04	1.00
			chemotactic protein 1)
46596	CCL20	MIP-3a	small inducible cytokine subfamily A (Cys—Cys),	0.60	1.59	0.91	1.04	0.92	1.03
			member 20
48190	CCL20	MIP-3a	small inducible cytokine subfamily A (Cys—Cys),	0.14	7.04	0.70	1.25	1.03	1.00
			member 20
46598	CCL20	MIP-3a	small inducible cytokine subfamily A (Cys—Cys),	0.10	9.88	0.76	1.18	0.95	1.00
			member 20
49742	CCL3	MIP1, alpha	small inducible cytokine A3	0.57	1.00	2.15	1.88	1.13	1.00
		homolog
47893	CCL4	MIP-1beta	small inducible cytokine A4	0.58	1.31	1.11	1.00	0.79	1.04
47575	CCL8	MCP-2	small inducible cytokine subfamily A (Cys—Cys),	0.18	2.04	0.54	1.40	1.11	1.00
			member 8 (monocyte chemotactic protein 2)
49725	CCM1		cerebral cavernous malformations 1	1.53	1.18	1.44	1.31	1.37	1.21
49085	CCNA2	cyclin A2	cyclin A2	0.77	1.17	0.32	1.42	0.74	1.18
49806	CCNA2	cyclin A2	cyclin A2	0.84	1.10	0.24	3.30	0.83	1.13
49773	CCNA2	cyclin A2	cyclin A2	0.87	1.02	0.25	3.51	0.81	1.08
49118	CCNA2	cyclin A2	cyclin A2	0.75	1.10	0.23	3.12	0.84	1.00
49732	CCND1		cyclin D1 (PRAD1: parathyroid adenomatosis	1.79	1.63	0.91	1.00	1.15	1.04
			1)
50503	CCND1		cyclin D1 (PRAD1: parathyroid adenomatosis	1.90	1.73	0.91	1.02	1.17	1.04
			1)
48015	CCND3	Cyclin D3	cyclin D3	0.48	2.03	0.41	2.05	0.87	1.09
46608	CCND3	Cyclin D3	cyclin D3	0.48	1.96	0.40	2.15	0.89	1.07
47926	CCNE2	cyclin E2	cyclin E2	1.00	1.00	0.54	1.40	0.91	1.00
49967	CCNE2	cyclin E2	cyclin E2	0.59	1.52	0.80	1.13	0.95	1.00
47927	CD14	CD14	CD14 antigen	1.61	1.40	1.65	1.13	1.23	1.00
49123	CD38	CD38	CD38 antigen (p45)	1.63	1.53	0.99	1.00	0.98	1.00
49252	CD38	CD38	CD38 antigen (p45)	1.60	1.52	1.02	1.00	0.97	1.00
48814	CDC14A		CDC14 cell division cycle 14 homolog A (S. cerevisiae)	0.57	1.46	1.39	1.00	1.00	1.00
50229	CDC2		cell division cycle 2, G1 to S and G2 to M	0.83	1.16	0.27	3.07	0.89	1.00
48013	CDC42EP3	CEP3	Cdc42 effector protein 3	4.01	3.12	1.09	1.04	0.95	1.00
46699	CDKN1B	p27	cyclin-dependent kinase inhibitor 1B (p27,	0.62	1.49	0.76	1.24	0.81	1.16
			Kip1)
49801	CDKN1B	p27	cyclin-dependent kinase inhibitor 1B (p27,	0.48	1.91	0.68	1.42	0.85	1.06
			Kip1)
49815	CDKN2C	p18	cyclin-dependent kinase inhibitor 2C (p18,	1.43	1.31	0.82	1.04	1.06	1.00
			inhibits CDK4)
46842	CDKN3	cyclin dependent	cyclin-dependent kinase inhibitor 3 (CDK2-	0.92	1.02	0.35	2.61	1.01	1.00
		kinase inhibitor 3	associated dual specificity phosphatase)
49105	CDKN3	cyclin dependent	cyclin-dependent kinase inhibitor 3 (CDK2-	0.89	1.08	0.47	1.64	1.01	1.00
		kinase inhibitor 3	associated dual specificity phosphatase)
46849	CEBPD	CEBP delta	CCAAT/enhancer binding protein (C/EBP),	1.00	1.00	0.80	1.10	0.68	1.41
			delta
47891	CEBPD	CEBP delta	CCAAT/enhancer binding protein (C/EBP),	0.95	1.00	0.82	1.12	0.71	1.32
			delta
48313	CENPA		centromere protein A (17 kD)	0.92	1.00	0.23	4.00	0.93	1.00
49737	CHAF1B		chromatin assembly factor 1, subunit B (p60)	0.83	1.04	0.68	1.39	1.02	1.00
48672	CHK		choline kinase	1.62	1.59	1.01	1.00	0.98	1.00
47032	CIT	CIT	citron (rho-interacting, serine/threonine kinase	1.11	1.00	0.51	1.59	0.95	1.00
			21)
49031	CKB		creatine kinase, brain	2.04	1.97	0.85	1.09	0.88	1.07
50590	CKS2		CDC28 protein kinase 2	0.92	1.06	0.53	1.69	1.00	1.00
47064	CLGN		calmegin	1.02	1.00	1.69	1.61	1.03	1.00
50087	COL4A1	COL4A1	collagen, type IV, alpha 1	0.58	1.55	0.96	1.00	0.94	1.00
48068	COL4A1	COL4A1	collagen, type IV, alpha 1	0.61	1.44	0.96	1.00	0.99	1.00
49315	COL4A2	COL4A2	collagen, type IV, alpha 2	0.63	1.44	0.91	1.01	0.85	1.02
47197	COL4A2	COL4A2	collagen, type IV, alpha 2	0.63	1.33	0.89	1.01	0.88	1.00
48283	COL5A1	COL5A1	collagen, type V, alpha 1	0.74	1.09	1.50	1.34	0.78	1.00
50125	COL7A1	COL7A1	collagen, type VII, alpha 1 (epidermolysis	0.54	1.60	2.14	1.91	1.05	1.00
			bullosa, dystrophic, dominant and recessive)
50705	COL7A1	COL7A1	collagen, type VII, alpha 1 (epidermolysis	0.52	1.57	2.13	1.82	0.99	1.00
			bullosa, dystrophic, dominant and recessive)
49384	CPS1		carbamoyl-phosphate synthetase 1,	1.29	1.22	0.67	1.36	1.01	1.00
			mitochondrial
48953	CSDA	CSDA	cold shock domain protein A	0.69	1.36	1.02	1.00	0.84	1.17
47549	CSDA	CSDA	cold shock domain protein A	0.64	1.36	1.06	1.00	0.86	1.09
48596	CSF2	G-CSF,	colony stimulating factor 2 (granulocyte-	0.20	4.11	0.72	1.14	1.01	1.00
		granulocyte colony	macrophage)
		stimulating factor
48052	CSF2	G-CSF,	colony stimulating factor 2 (granulocyte-	0.20	4.31	0.63	1.09	0.92	1.00
		granulocyte colony	macrophage)
		stimulating factor
50282	CSRP1		cysteine and glycine-rich protein 1	0.50	1.73	1.06	1.00	1.00	1.00
50462	CXCL1	GRO1	GRO1 oncogene (melanoma growth	0.15	6.10	1.24	1.16	0.94	1.00
			stimulating activity, alpha)
49754	CXCL1	GRO1	GRO1 oncogene (melanoma growth	0.16	5.65	1.15	1.00	1.18	1.00
			stimulating activity, alpha)
47558	CXCL2	GRO2	GRO2 oncogene	0.16	4.98	0.92	1.00	0.93	1.01
47632	CXCL2	GRO2	GRO2 oncogene	0.14	5.79	1.04	1.00	0.94	1.00
49692	CXCL3	GRO3	GRO3 oncogene	0.11	8.67	0.92	1.00	0.96	1.00
48330	CXCL3	GRO3	GRO3 oncogene	0.13	7.42	0.86	1.00	0.91	1.00
49839	CXCL5	ENA-78	small inducible cytokine subfamily B (Cys-X-	0.21	4.52	1.27	1.13	0.90	1.00
			Cys), member 5 (epithelial-derived neutrophil-
			activating peptide 78)
49968	CXCL5	ENA-78	small inducible cytokine subfamily B (Cys-X-	0.20	4.83	1.22	1.00	0.83	1.00
			Cys), member 5 (epithelial-derived neutrophil-
			activating peptide 78)
49752	CXCR4	CXCR4	chemokine (C—X—C motif), receptor 4 (fusin)	0.40	1.70	1.08	1.00	0.96	1.00
49820	CYC1	cytochrome c-1	cytochrome c-1	1.47	1.34	0.79	1.12	1.13	1.03
47834	CYP1A1		cytochrome P450, subfamily I (aromatic	1.74	1.48	1.01	1.00	0.99	1.00
			compound-inducible), polypeptide 1
47412	CYP24A1		cytochrome P450, subfamily XXIV (vitamin D	0.33	2.41	0.72	1.30	1.45	1.00
			24-hydroxylase)
50237	CYR61		cysteine-rich, angiogenic inducer, 61	1.23	1.03	1.46	1.31	0.89	1.00
48650	DAB2		disabled homolog 2, mitogen-responsive	0.71	1.31	0.95	1.00	1.00	1.00
			phosphoprotein (Drosophila)
46942	DAF	CD55	decay accelerating factor for complement	0.28	3.35	1.18	1.08	0.98	1.00
			(CD55, Cromer blood group system)
48721	DAF	CD55	decay accelerating factor for complement	0.27	3.62	1.12	1.05	1.03	1.00
			(CD55, Cromer blood group system)
48235	DAXX	Daxx	death-associated protein 6	0.58	1.52	1.01	1.00	0.96	1.00
49433	DDIT3	CHOP	DNA-damage-inducible transcript 3	1.25	1.06	2.05	1.86	1.08	1.00
50132	DDIT3	CHOP	DNA-damage-inducible transcript 3	1.18	1.04	1.88	1.64	1.01	1.00
48320	DEFB1		defensin, beta 1	0.67	1.41	0.93	1.00	1.00	1.00
49922	DHCR24		24-dehydrocholesterol reductase	1.84	1.66	0.96	1.00	0.94	1.00
46700	DISPB		KIAA1742 protein	1.38	1.36	1.03	1.00	1.00	1.00
50409	DNAJB4		DnaJ (Hsp40) homolog, subfamily B, member 4	0.67	1.31	0.71	1.32	0.86	1.00
48333	DNMT1		DNA (cytosine-5-)-methyltransferase 1	0.93	1.00	0.66	1.43	0.97	1.00
47122	DSG2		desmoglein 2	2.17	2.05	1.15	1.12	0.99	1.00
50383	DTR	HB-EGF, diptheria	diphtheria toxin receptor (heparin-binding	0.43	2.17	1.02	1.00	0.89	1.00
		toxin receptor	epidermal growth factor-like growth factor)
50046	DUSP1	MKP-1, PTPN10	dual specificity phosphatase 1	2.54	1.90	0.79	1.04	0.79	1.09
49389	DUSP1	MKP-1, PTPN10	dual specificity phosphatase 1	2.25	1.60	0.88	1.00	0.87	1.00
50362	DUSP10	DUSP10	dual specificity phosphatase 10	0.24	3.05	0.85	1.08	0.86	1.04
48736	DUSP5	DUSP5	dual specificity phosphatase 5	1.22	1.00	1.60	1.36	1.44	1.14
46670	DUSP5	DUSP5	dual specificity phosphatase 5	0.48	2.00	1.57	1.53	1.08	1.02
49777	DUSP6	DUSP6	dual specificity phosphatase 6	0.46	1.88	1.38	1.32	1.03	1.00
49810	DUSP6	DUSP6	dual specificity phosphatase 6	0.46	1.51	1.44	1.29	1.11	1.00
47277	DUSP6	DUSP6	dual specificity phosphatase 6	0.44	1.84	1.29	1.15	1.22	1.00
50140	ECT2	ECT2	epithelial cell transforming sequence 2	0.61	1.53	0.53	1.47	0.82	1.14
			oncogene
48032	ECT2	ECT2	epithelial cell transforming sequence 2	0.47	1.96	0.41	2.16	0.84	1.10
			oncogene
47654	EFEMP1	EFEMP1	EGF-containing fibulin-like extracellular matrix	0.66	1.32	0.87	1.00	1.19	1.00
			protein 1
49636	EGFR	EGFR, ErbB1	epidermal growth factor receptor (erythroblastic	0.44	1.84	1.08	1.00	0.94	1.00
			leukemia viral (v-erb-b) oncogene homolog,
			avian)
50182	ELA2	elastase-2	elastase 2, neutrophil	1.41	1.20	1.65	1.34	1.41	1.29
47811	ENTPD6		ectonucleoside triphosphate	1.83	1.54	1.04	1.00	0.92	1.01
			diphosphohydrolase 6 (putative function)
49179	EPAS1		endothelial PAS domain protein 1	0.65	1.44	0.80	1.16	1.02	1.00
49696	EPOR	erythropoietin R	erythropoietin receptor	0.40	1.72	1.04	1.00	0.96	1.00
47730	ERBB3	ErbB3	v-erb-b2 erythroblastic leukemia viral	1.83	1.30	1.80	1.73	1.30	1.12
			oncogene homolog 3 (avian)
46599	ERBB3	ErbB3	v-erb-b2 erythroblastic leukemia viral	2.04	1.31	1.97	1.54	1.43	1.00
			oncogene homolog 3 (avian)
46955	EREG	epiregulin	epiregulin	0.11	8.09	1.19	1.14	0.98	1.00
50126	EREG	epiregulin	epiregulin	0.15	4.79	1.18	1.05	1.06	1.00
46988	EREG	epiregulin	epiregulin	0.21	1.77	1.18	1.00	0.96	1.00
50382	ETV4	ETV4	ets variant gene 4 (E1A enhancer binding	0.47	1.56	0.82	1.07	0.80	1.14
			protein, E1AF)
49430	ETV4	ETV4	ets variant gene 4 (E1A enhancer binding	0.57	1.46	0.83	1.09	0.86	1.06
			protein, E1AF)
46984	ETV5	ETV5	ets variant gene 5 (ets-related molecule)	0.69	1.39	1.10	1.00	1.09	1.00
50339	ETV6	ETV6	ets variant gene 6 (TEL oncogene)	0.61	1.30	1.19	1.09	0.95	1.00
48998	FADS1		fatty acid desaturase 1	1.20	1.09	1.57	1.38	1.04	1.00
49721	FANCG		Fanconi anemia, complementation group G	0.93	1.00	0.59	1.60	1.00	1.00
48825	FARP1		FERM, RhoGEF (ARHGEF) and pleckstrin	1.89	1.48	0.95	1.00	0.87	1.00
			domain protein 1 (chondrocyte-derived)
48350	FBLN1	FBLN1	fibulin 1	0.73	1.13	0.43	2.17	0.90	1.00
46932	FBN1	FBN1	fibrillin 1 (Marfan syndrome)	0.60	1.38	1.13	1.00	0.86	1.10
50717	FCER1G	FCER1G	Fc fragment of IgE, high affinity I, receptor for;	0.64	1.34	1.04	1.00	0.84	1.00
			gamma polypeptide
47748	FEZ1		fasciculation and elongation protein zeta 1	0.77	1.01	1.77	1.65	1.00	1.00
			(zygin I)
49529	FGA		fibrinogen, A alpha polypeptide	1.84	1.60	0.58	1.33	0.98	1.00
50006	FGF11	FGF11	fibroblast growth factor 11	0.96	1.00	1.79	1.66	0.79	1.00
49462	FGF11	FGF11	fibroblast growth factor 11	1.00	1.00	1.68	1.51	0.89	1.00
48520	FISH		KIAA0418 gene product	0.53	1.70	1.16	1.03	1.10	1.00
48793	FLJ10535		hypothetical protein FLJ10535	1.52	1.32	0.80	1.18	1.01	1.00
48328	FN1	FN1	fibronectin 1	0.77	1.28	0.70	1.36	0.96	1.00
50475	FOSL1	FOSL1, Fra1	FOS-like antigen 1	0.47	1.94	1.45	1.40	1.06	1.00
50508	FOSL1	FOSL1, Fra1	FOS-like antigen 1	0.41	2.07	1.43	1.34	1.03	1.00
46993	FOSL1	FOSL1, Fra1	FOS-like antigen 1	0.42	2.06	1.44	1.33	1.04	1.00
48969	FOSL2	FOSL2, Fra2	FOS-like antigen 2	1.77	1.71	1.34	1.13	1.13	1.02
48270	FOSL2	FOSL2, Fra2	FOS-like antigen 2	1.84	1.73	1.29	1.09	1.11	1.02
48219	FOXM1	FOXM1	forkhead box M1	0.94	1.01	0.39	2.35	0.97	1.00
50681	FOXM1	FOXM1	forkhead box M1	0.95	1.00	0.41	1.99	0.93	1.00
50701	FOXO3A	FOXO3A	forkhead box O3A	2.03	1.92	1.31	1.10	0.96	1.00
47923	FRAP1	FRAP1, MTOR	FK506 binding protein 12-rapamycin	1.58	1.42	1.38	1.23	1.76	1.25
			associated protein 1
48137	FRDA		Friedreich ataxia	0.56	1.35	0.71	1.32	1.07	1.00
49883	FVT1		follicular lymphoma variant translocation 1	0.75	1.31	1.12	1.08	0.97	1.00
46564	FYB		FYN binding protein (FYB-120/130)	1.05	1.00	1.56	1.32	1.14	1.00
46824	FYN	Fyn	FYN oncogene related to SRC, FGR, YES	0.60	1.41	0.94	1.00	1.05	1.00
47526	FYN	Fyn	FYN oncogene related to SRC, FGR, YES	0.62	1.39	1.05	1.00	0.98	1.00
50580	G1P2	ISG15, IFN	interferon-stimulated protein, 15 kDa	1.51	1.14	1.95	1.60	1.63	1.38
		stimulated protein
46618	G1P2	ISG15, IFN	interferon-stimulated protein, 15 kDa	0.60	1.33	1.26	1.11	0.87	1.00
		stimulated protein
50129	GAB1	Gab1	GRB2-associated binding protein 1	0.63	1.31	1.06	1.00	1.00	1.00
49675	GAB2	GAB2	GRB2-associated binding protein 2	1.73	1.60	2.04	1.58	1.94	1.65
49419	GABPA	GABPA	GA binding protein transcription factor, alpha	0.58	1.53	0.88	1.10	0.95	1.00
			subunit (60 kD)
48615	GADD45B	MyD118	growth arrest and DNA-damage-inducible, beta	0.54	1.50	0.40	2.30	1.00	1.00
50142	GBP1	IFN induced GBP-1	guanylate binding protein 1, interferon-	0.67	1.30	1.22	1.15	0.90	1.09
			inducible, 67 kD
47432	GCS1		glucosidase I	1.71	1.53	0.99	1.00	0.92	1.00
48651	GLA		galactosidase, alpha	0.51	1.89	0.87	1.11	1.02	1.00
48681	GNB2	G protein, beta 2	guanine nucleotide binding protein (G protein),	0.57	1.38	1.58	1.42	0.95	1.00
			beta polypeptide 2
48007	GNB5	G protein, beta 5	guanine nucleotide binding protein (G protein),	0.65	1.37	0.90	1.00	1.00	1.00
			beta 5
47111	GOLGB1		golgi autoantigen, golgin subfamily b,	1.03	1.00	1.43	1.32	1.05	1.00
			macrogolgin (with transmembrane signal), 1
49485	GPR126		hypothetical protein DKFZp564D0462	2.48	2.31	0.55	1.63	0.97	1.00
48854	GPR4		G protein-coupled receptor 4	1.43	1.08	1.52	1.34	1.35	1.22
50141	GRAF	GRAF	GTPase regulator associated with the focal	1.51	1.06	1.51	1.31	1.20	1.15
			adhesion kinase pp125
49069	GRAF	GRAF	GTPase regulator associated with the focal	2.90	2.67	0.77	1.18	0.90	1.00
			adhesion kinase pp125
49102	GRAF	GRAF	GTPase regulator associated with the focal	2.87	2.39	0.79	1.12	0.92	1.00
			adhesion kinase pp125
46936	GRB10	GRB10	growth factor receptor-bound protein 10	0.41	2.26	1.71	1.63	1.18	1.11
46962	GRB10	GRB10	growth factor receptor-bound protein 10	0.33	2.48	1.70	1.66	1.06	1.00
50018	GRB2	Grb2	growth factor receptor-bound protein 2	1.37	1.09	1.67	1.58	1.49	1.19
48110	GREB1		KIAA0575 gene product	1.92	1.35	2.00	1.72	1.65	1.50
49586	GRIN2C		glutamate receptor, ionotropic, N-methyl D-	0.14	6.71	0.72	1.11	0.96	1.00
			aspartate 2C
49032	GSK3B	GSK3B	glycogen synthase kinase 3 beta	0.69	1.31	1.19	1.02	1.05	1.00
49535	GTF2F2		general transcription factor IIF, polypeptide 2	0.68	1.34	0.67	1.28	0.85	1.07
			(30 kD subunit)
46792	HAT1		histone acetyltransferase 1	0.83	1.12	0.65	1.43	0.87	1.06
47502	HBB		hemoglobin, beta	0.70	1.33	0.92	1.02	0.98	1.00
50565	HBP1		HMG-box containing protein 1	0.64	1.45	0.94	1.00	0.99	1.00
47492	HDGF		hepatoma-derived growth factor (high-mobility	0.71	1.33	0.79	1.09	0.85	1.05
			group protein 1-like)
49838	HLA-DRB1	MHCII, DR beta 1	major histocompatibility complex, class II, DR	0.30	2.15	1.02	1.00	0.90	1.00
			beta 1
50526	HMGA1	HMG-I/Y	high-mobility group (nonhistone chromosomal)	0.69	1.37	1.07	1.01	0.88	1.08
			protein isoforms I and Y
50493	HMGA1	HMG-I/Y	high-mobility group (nonhistone chromosomal)	0.69	1.39	1.07	1.04	0.88	1.03
			protein isoforms I and Y
50361	HMGA1	HMG-I/Y	high-mobility group (nonhistone chromosomal)	0.70	1.35	1.09	1.02	0.90	1.02
			protein isoforms I and Y
47045	HMGB1		high-mobility group (nonhistone chromosomal)	0.90	1.03	0.65	1.51	0.92	1.02
			protein 1
46778	HMGB2		high-mobility group (nonhistone chromosomal)	0.85	1.09	0.37	2.27	0.96	1.00
			protein 2
48642	HPGD		hydroxyprostaglandin dehydrogenase 15-	2.55	2.26	0.55	1.39	0.83	1.14
			(NAD)
49113	HS3ST3A1	HS3ST3A1	heparan sulfate (glucosamine) 3-O-	0.47	1.52	1.01	1.00	0.97	1.00
			sulfotransferase 3A1
47185	HSPA1A	HSPA1A	heat shock 70 kD protein 1A	0.45	1.71	0.67	1.29	0.87	1.01
48618	HSPA1A	HSPA1A	heat shock 70 kD protein 1A	0.46	1.82	0.67	1.33	0.93	1.00
49064	HSPA1A	HSPA1A	heat shock 70 kD protein 1A	0.42	1.87	0.66	1.30	0.89	1.00
49417	HSPA1A	HSPA1A	heat shock 70 kD protein 1A	0.44	1.74	0.67	1.28	0.85	1.00
48094	HSPA6	HSPA6	heat shock 70 kD protein 6 (HSP70B′)	0.51	1.52	0.71	1.22	0.90	1.00
49436	HSPB1	HSPB1	heat shock 27 kD protein 1	1.90	1.62	0.86	1.07	0.87	1.06
48550	HSPB2	HSPB2	heat shock 27 kD protein 2	0.41	2.30	1.21	1.16	0.97	1.00
48421	HSPB2	HSPB2	heat shock 27 kD protein 2	0.41	2.14	1.19	1.12	0.95	1.00
48341	HSPCB		heat shock 90 kD protein 1, beta	0.68	1.33	0.83	1.13	1.01	1.00
49804	ICAM1	ICAM1	intercellular adhesion molecule 1 (CD54),	0.74	1.00	1.72	1.50	1.11	1.08
			human rhinovirus receptor
49771	ICAM1	ICAM1	intercellular adhesion molecule 1 (CD54),	0.75	1.00	1.71	1.54	1.10	1.06
			human rhinovirus receptor
49140	ICAM1	ICAM1	intercellular adhesion molecule 1 (CD54),	0.77	1.00	1.71	1.57	1.11	1.05
			human rhinovirus receptor
47245	ID1		inhibitor of DNA binding 1, dominant negative	1.37	1.29	0.74	1.30	0.98	1.00
			helix-loop-helix protein
48913	IFNAR2	IFN alpha, beta,	interferon (alpha, beta and omega) receptor 2	0.73	1.33	1.08	1.03	1.09	1.00
		omega receptor 2
49265	IFNAR2	IFN alpha, beta,	interferon (alpha, beta and omega) receptor 2	0.70	1.33	1.07	1.05	1.06	1.00
		omega receptor 2
47582	IFNGR2	IFN gamma	interferon gamma receptor 2 (interferon	0.48	1.61	1.37	1.32	1.00	1.00
		receptor 2	gamma transducer 1)
47225	IFNGR2	IFN gamma	interferon gamma receptor 2 (interferon	0.45	2.04	1.37	1.25	0.97	1.00
		receptor 2	gamma transducer 1)
50583	IGF2		insulin-like growth factor 2 (somatomedin A)	0.69	1.00	1.76	1.59	0.90	1.00
50403	IGFBP3		insulin-like growth factor binding protein 3	0.15	6.13	0.90	1.04	0.94	1.02
48961	IL10RB	IL-10R beta	interleukin 10 receptor, beta	1.24	1.03	1.64	1.49	1.34	1.27
48597	IL10RB	IL-10R beta	interleukin 10 receptor, beta	1.10	1.00	1.46	1.35	1.22	1.08
48640	IL11RA	IL-11R alpha	interleukin 11 receptor, alpha	1.10	1.00	1.75	1.56	0.99	1.00
50013	IL13RA1	IL-13Ralpha′	interleukin 13 receptor, alpha 1	1.70	1.65	0.92	1.02	1.10	1.06
48581	IL13RA1	IL-13Ralpha′	interleukin 13 receptor, alpha 1	1.64	1.47	0.89	1.06	1.02	1.00
46970	IL1B	IL-1, beta	interleukin 1, beta	0.05	17.39	2.02	1.64	1.10	1.08
47656	IL1B	IL-1, beta	interleukin 1, beta	0.06	3.25	2.05	1.71	1.10	1.04
48637	IL1R1	IL-1RI	interleukin 1 receptor, type I	1.82	1.62	0.75	1.21	0.90	1.00
48324	IL3RA	IL-3R alpha	interleukin 3 receptor, alpha (low affinity)	1.81	1.53	2.70	2.37	2.32	1.79
47925	IL4R	IL-4R alpha	interleukin 4 receptor	1.82	1.20	1.67	1.32	1.57	1.39
49666	IL4R	IL-4R alpha	interleukin 4 receptor	1.50	1.28	1.65	1.55	1.58	1.22
49135	IL6	interleukin-6,	interleukin 6 (interferon, beta 2)	0.48	1.98	0.96	1.00	0.93	1.00
		IFNbeta2
49264	IL6	interleukin-6,	interleukin 6 (interferon, beta 2)	0.53	1.60	0.92	1.00	0.95	1.00
		IFNbeta2
49289	IL6R	IL-6R	interleukin 6 receptor	1.78	1.66	2.11	1.82	1.71	1.52
46865	IL6R	IL-6R	interleukin 6 receptor	1.76	1.63	2.00	1.67	1.73	1.48
46856	IL8	interleukin-8	interleukin 8	0.06	15.64	0.98	1.00	0.92	1.00
50455	IMPDH1		IMP (inosine monophosphate) dehydrogenase 1	1.53	1.39	1.11	1.00	0.99	1.00
49873	INSIG1		insulin induced gene 1	0.59	1.46	1.57	1.53	0.87	1.06
49763	IQGAP2	IQGAP2	IQ motif containing GTPase activating protein 2	2.00	1.67	0.48	2.03	1.01	1.00
49796	IQGAP2	IQGAP2	IQ motif containing GTPase activating protein 2	2.21	2.06	0.44	1.39	1.09	1.00
48086	IQGAP2	IQGAP2	IQ motif containing GTPase activating protein 2	1.76	1.65	1.05	1.00	1.13	1.00
48014	IRAK1	IRAK1	interleukin-1 receptor-associated kinase 1	1.57	1.43	1.55	1.50	1.20	1.10
47186	IRAK2	IRAK-2	interleukin-1 receptor-associated kinase 2	0.54	1.53	1.36	1.05	1.03	1.00
49054	ITGA2	integrin, alpha 2,	integrin, alpha 2 (CD49B, alpha 2 subunit of	0.70	1.37	1.80	1.43	1.00	1.00
		CD49B, VLA-2	VLA-2 receptor)
46686	ITGAV	integrin alpha V,	integrin, alpha V (vitronectin receptor, alpha	0.66	1.37	1.15	1.06	0.96	1.00
		CD51	polypeptide, antigen CD51)
48127	ITGB4		integrin, beta 4	2.81	1.60	0.85	1.04	0.91	1.00
46910	ITPKC		inositol 1,4,5-trisphosphate 3-kinase C	1.64	1.33	1.41	1.18	1.12	1.03
49518	ITPR1		inositol 1,4,5-triphosphate receptor, type 1	0.61	1.32	0.85	1.00	1.05	1.00
46820	JAK1	Jak1	Janus kinase 1 (a protein tyrosine kinase)	1.29	1.21	1.46	1.38	1.03	1.00
49322	JUNB	JunB	jun B proto-oncogene	0.62	1.17	0.45	1.87	0.65	1.45
49319	JUNB	JunB	jun B proto-oncogene	0.55	1.56	0.57	1.56	0.77	1.19
50528	KAI1	CD82	kangai 1 (suppression of tumorigenicity 6,	1.52	1.23	1.59	1.42	1.44	1.15
			prostate; CD82 antigen (R2 leukocyte antigen,
			antigen detected by monoclonal and antibody
			IA4))
50495	KAI1	CD82	kangai 1 (suppression of tumorigenicity 6,	1.44	1.17	1.68	1.44	1.33	1.00
			prostate; CD82 antigen (R2 leukocyte antigen,
			antigen detected by monoclonal and antibody
			IA4))
48978	KBRAS1	KBRAS1	I-kappa-B-interacting Ras-like protein 1	0.59	1.44	0.93	1.00	1.02	1.00
49805	KBRAS2	KBRAS2	I-kappa-B-interacting Ras-like protein 2	1.46	1.28	1.74	1.46	1.41	1.25
49109	KBRAS2	KBRAS2	I-kappa-B-interacting Ras-like protein 2	1.43	1.06	1.78	1.46	1.40	1.21
49235	KCNK1		potassium channel, subfamily K, member 1	0.61	1.51	0.97	1.00	0.97	1.00
			(TWIK-1)
49239	KCNMA1		potassium large conductance calcium-	1.07	1.00	1.53	1.39	1.13	1.00
			activated channel, subfamily M, alpha member 1
47770	KIAA0062		KIAA0062 protein	2.97	2.84	1.06	1.00	0.99	1.00
48663	KIAA0089		KIAA0089 protein	1.64	1.52	1.14	1.12	1.01	1.00
50636	KIAA0101		KIAA0101 gene product	0.89	1.00	0.34	2.41	0.94	1.00
48103	KIAA0205		KIAA0205 gene product	0.71	1.34	0.85	1.15	1.03	1.00
48081	KIAA0220		KIAA0220 protein	1.59	1.38	1.47	1.31	1.54	1.50
48918	KIAA0514		KIAA0514 gene product	1.41	1.35	1.07	1.02	1.07	1.00
50582	KIAA0534		KIAA0534 protein	1.73	1.45	1.03	1.00	0.89	1.00
50283	KIAA1223		KIAA1223 protein	0.60	1.54	0.96	1.00	0.94	1.00
50568	KIF23		kinesin-like 5 (mitotic kinesin-like protein 1)	1.02	1.00	0.51	1.82	0.94	1.00
48479	KIF3C		kinesin family member 3C	0.57	1.37	0.96	1.00	1.02	1.00
48162	KIFC1		kinesin-like 2	1.07	1.00	0.37	2.25	1.03	1.00
48990	KRAS2	K-Ras	v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene	1.48	1.39	0.84	1.11	1.01	1.00
			homolog
48856	KRT2A		keratin 2A (epidermal ichthyosis bullosa of	2.49	1.71	0.81	1.06	0.86	1.00
			Siemens)
46833	KSR	KSR1	kinase suppressor of ras	2.00	1.36	0.90	1.02	1.34	1.00
48225	KSR	KSR1	kinase suppressor of ras	1.67	1.31	0.97	1.00	1.05	1.00
48621	LAMB1	LAMB1	laminin, beta 1	1.81	1.56	0.83	1.12	0.99	1.00
50042	LAMB3	LAMB3	laminin, beta 3 (nicein (125 kD), kalinin	0.30	2.95	0.94	1.00	0.85	1.04
			(140 kD), BM600 (125 kD))
48692	LAMC1	LAMC1	laminin, gamma 1 (formerly LAMB2)	0.84	1.05	0.55	1.76	1.09	1.00
50393	LAMC2	LAMC2	laminin, gamma 2 (nicein (100 kD), kalinin	0.31	2.63	1.65	1.48	0.99	1.00
			(105 kD), BM600 (100 kD), Herlitz junctional
			epidermolysis bullosa))
50037	LAMC2	LAMC2	laminin, gamma 2 (nicein (100 kD), kalinin	0.19	4.28	1.75	1.46	1.05	1.00
			(105 kD), BM600 (100 kD), Herlitz junctional
			epidermolysis bullosa))
49966	LBP	LPS binding	lipopolysaccharide binding protein	1.87	1.66	0.78	1.24	0.91	1.05
		protein
49837	LBP	LPS binding	lipopolysaccharide binding protein	1.99	1.69	0.80	1.19	0.99	1.00
		protein
46939	LDHA		lactate dehydrogenase A	1.55	1.48	0.91	1.06	1.01	1.00
49683	LEPR	leptin R	leptin receptor	1.92	1.67	1.89	1.54	1.75	1.72
49163	LGALS3		lectin, galactoside-binding, soluble, 3 (galectin	1.05	1.00	1.37	1.32	1.09	1.04
			3)
47482	LGALS4		lectin, galactoside-binding, soluble, 4 (galectin	1.25	1.03	1.58	1.35	1.05	1.00
			4)
47191	LIFR	LIFR	leukemia inhibitory factor receptor	1.51	1.24	1.54	1.41	1.05	1.00
50025	LIFR	LIFR	leukemia inhibitory factor receptor	1.55	1.32	1.41	1.22	0.97	1.00
47114	LPP		LIM domain containing preferred translocation	1.61	1.39	1.02	1.00	0.97	1.00
			partner in lipoma
48105	LTBP1		latent transforming growth factor beta binding	1.63	1.56	0.86	1.09	0.99	1.00
			protein 1
47533	LTBP4	LTBP4	latent transforming growth factor beta binding	0.68	1.34	1.36	1.04	0.82	1.11
			protein 4
46676	LYN	Lyn	v-yes-1 Yamaguchi sarcoma viral related	0.65	1.37	0.96	1.00	0.94	1.00
			oncogene homolog
49376	MAC30		hypothetical protein	1.00	1.00	0.64	1.49	1.07	1.00
47029	MAD	MAD	MAX dimerization protein	0.65	1.40	1.57	1.51	0.87	1.09
47158	MAD	MAD	MAX dimerization protein	0.61	1.36	1.58	1.52	0.90	1.00
46776	MAD2L1		MAD2 mitotic arrest deficient-like 1 (yeast)	0.98	1.00	0.43	2.18	1.07	1.00
46705	MAOA		monoamine oxidase A	2.63	1.77	1.01	1.00	0.84	1.00
48150	MAP1B		microtubule-associated protein 1B	0.68	1.29	1.89	1.73	1.17	1.00
48278	MAP2K3	MKK3	mitogen-activated protein kinase kinase 3	0.51	1.83	0.98	1.00	0.83	1.10
48028	MAP2K3	MKK3	mitogen-activated protein kinase kinase 3	0.63	1.51	1.07	1.00	0.89	1.07
47299	MAP3K10	MLK2	mitogen-activated protein kinase kinase kinase	1.46	1.00	1.77	1.60	1.19	1.05
			10
47561	MAP3K11	MLK3	mitogen-activated protein kinase kinase kinase	0.58	1.46	0.65	1.47	0.74	1.12
			11
47218	MAP3K7IP1	TAB1	transforming growth factor beta-activated	2.04	1.61	1.93	1.50	1.88	1.70
			kinase-binding protein 1
47001	MAP3K7IP1	TAB1	transforming growth factor beta-activated	1.80	1.50	2.05	1.65	1.53	1.06
			kinase-binding protein 1
47969	MAP3K8	c-cot	mitogen-activated protein kinase kinase kinase 8	0.25	2.86	0.85	1.14	0.86	1.00
48424	MAP4K4	GCK-like, HPK,	mitogen-activated protein kinase kinase kinase	0.57	1.48	1.49	1.45	1.05	1.02
		HGK, NIK	kinase 4
46601	MAPK14	p38, alpha	mitogen-activated protein kinase 14	1.48	1.39	1.27	1.00	1.04	1.00
48410	MAPK6	MAPK6	mitogen-activated protein kinase 6	0.52	1.86	1.07	1.00	1.01	1.00
48377	MAPK6	MAPK6	mitogen-activated protein kinase 6	0.52	1.82	0.98	1.00	0.99	1.00
46998	MAPK6	MAPK6	mitogen-activated protein kinase 6	0.55	1.71	0.96	1.00	1.07	1.00
46965	MAPK6	MAPK6	mitogen-activated protein kinase 6	0.56	1.69	1.00	1.00	1.03	1.00
47188	MAPK8	JNK1	mitogen-activated protein kinase 8	0.69	1.36	0.99	1.00	1.04	1.00
49304	MAPK8IP3	MAPK8IP3	mitogen-activated protein kinase 8 interacting	1.06	1.00	1.47	1.31	0.94	1.00
			protein 3
48760	MAPK8IP3	MAPK8IP3	mitogen-activated protein kinase 8 interacting	1.05	1.00	1.57	1.31	0.85	1.00
			protein 3
48108	MAT2A		methionine adenosyltransferase II, alpha	1.50	1.35	0.93	1.00	0.93	1.00
49511	MATN2		matrilin 2	1.11	1.02	0.73	1.33	1.06	1.00
50566	MCC		mutated in colorectal cancers	1.64	1.06	1.80	1.43	1.26	1.00
47123	MCM2		MCM2 minichromosome maintenance deficient	0.80	1.09	0.52	1.66	0.84	1.14
			2, mitotin (S. cerevisiae)
48470	MCM5		MCM5 minichromosome maintenance deficient	0.79	1.10	0.43	1.99	0.93	1.00
			5, cell division cycle 46 (S. cerevisiae)
48593	MEF2D	MEF2D	MADS box transcription enhancer factor 2,	0.72	1.35	0.90	1.06	0.93	1.00
			polypeptide D (myocyte enhancer factor 2D)
46692	MID1		midline 1 (Opitz/BBB syndrome)	0.86	1.10	0.62	1.35	0.96	1.00
46610	MIG-6	MIG-6	Gene 33/Mig-6	2.34	2.24	0.88	1.02	1.04	1.01
48286	MIG-6	MIG-6	Gene 33/Mig-6	2.26	1.85	0.87	1.00	1.08	1.00
47385	MLAT4		hypothetical protein FLJ10718	2.24	2.08	0.78	1.14	1.12	1.03
48966	MMP10	MMP10	matrix metalloproteinase 10 (stromelysin 2)	1.00	1.00	2.33	1.94	0.84	1.00
48003	MMP19	MMP19	matrix metalloproteinase 19	1.61	1.31	2.17	2.04	1.40	1.33
48933	MMP2	MMP2, gelatinase A	matrix metalloproteinase 2 (gelatinase A, 72 kD	0.64	1.35	0.98	1.00	0.85	1.04
			gelatinase, 72 kD type IV collagenase)
48334	MMP7	MMP7	matrix metalloproteinase 7 (matrilysin, uterine)	0.32	2.44	0.55	1.55	1.07	1.00
49124	MMP7	MMP7	matrix metalloproteinase 7 (matrilysin, uterine)	0.43	2.23	0.66	1.39	1.04	1.00
49115	MMPL1	MMPL1	matrix metalloproteinase-like 1	2.08	1.12	2.17	1.90	1.69	1.49
50034	MMPL1	MMPL1	matrix metalloproteinase-like 1	2.49	1.81	2.46	2.22	1.30	1.00
48342	MMPL1	MMPL1	matrix metalloproteinase-like 1	1.00	1.00	2.07	1.54	1.34	1.00
49259	MOX2	MOX2	antigen identified by monoclonal antibody MRC	1.75	1.59	0.87	1.02	0.98	1.00
			OX-2
47501	MOX2	MOX2	antigen identified by monoclonal antibody MRC	1.70	1.54	0.92	1.00	0.96	1.00
			OX-2
50770	MPHOSPH1		M-phase phosphoprotein 1	1.03	1.00	0.59	1.37	0.97	1.00
48187	MRPL27		mitochondrial ribosomal protein L27	1.08	1.00	0.66	1.40	1.01	1.00
49860	MSX1		msh homeo box homolog 1 (Drosophila)	0.54	1.63	0.96	1.00	0.85	1.09
47106	MT1L		metallothionein 1L	6.96	5.74	1.29	1.08	0.89	1.06
46766	MT3		metallothionein 3 (growth inhibitory factor	2.31	2.21	1.22	1.15	0.89	1.00
			(neurotrophic))
50240	MTIF2		mitochondrial translational initiation factor 2	1.52	1.43	0.96	1.00	0.93	1.04
48399	MUC1	mucin1	mucin 1, transmembrane	2.06	1.62	0.93	1.00	0.84	1.00
48735	MUC13	mucin13	mucin 13, epithelial transmembrane	0.49	1.50	0.66	1.29	0.83	1.03
50390	MUC13	mucin13	mucin 13, epithelial transmembrane	0.47	1.41	0.76	1.13	0.97	1.00
47267	MXD4	MAD4	Mad4 homolog	1.15	1.00	1.52	1.36	0.77	1.00
47640	NaGLT1		KIAA1919 protein	1.72	1.24	1.76	1.49	1.33	1.27
47562	NaGLT1		KIAA1919 protein	1.71	1.34	1.27	1.15	1.18	1.09
48487	NDN		necdin homolog (mouse)	1.66	1.26	1.70	1.57	1.31	1.18
46799	NFE2L1	NFE2L1	nuclear factor (erythroid-derived 2)-like 1	0.69	1.34	1.13	1.00	0.97	1.00
47173	NFKB1	NFkappaB, p105	nuclear factor of kappa light polypeptide gene	0.39	2.20	0.84	1.06	0.89	1.10
			enhancer in B-cells 1 (p105)
47877	NFKB1	NFkappaB, p105	nuclear factor of kappa light polypeptide gene	0.40	2.13	0.95	1.00	0.89	1.04
			enhancer in B-cells 1 (p105)
49690	NID	NID	nidogen (enactin)	0.72	1.00	0.68	1.34	0.87	1.03
48967	NID2	NID2	nidogen 2	0.93	1.00	1.85	1.72	1.05	1.00
50131	NID2	NID2	nidogen 2	1.43	1.21	1.64	1.36	1.03	1.00
49014	NINJ1		ninjurin 1	0.53	1.78	1.02	1.00	0.93	1.04
48029	NOL3	NOL3	nucleolar protein 3 (apoptosis repressor with	1.79	1.62	1.01	1.00	0.84	1.03
			CARD domain)
49158	NOS1		nitric oxide synthase 1 (neuronal)	1.46	1.28	1.79	1.30	1.48	1.17
48941	NR4A1	NAK1	nuclear receptor subfamily 4, group A, member 1	0.34	2.72	0.54	1.61	0.87	1.09
49383	NR4A1	NAK1	nuclear receptor subfamily 4, group A, member 1	0.54	1.55	0.88	1.01	0.96	1.00
47712	NR4A2	TINUR	nuclear receptor subfamily 4, group A, member 2	0.29	1.66	0.89	1.00	0.85	1.12
47679	NR4A2	TINUR	nuclear receptor subfamily 4, group A, member 2	0.33	1.48	0.93	1.02	0.88	1.02
48227	NRG1	neuregulin1, neu	neuregulin 1	0.25	3.29	0.81	1.17	0.99	1.00
		diff. Factor,
		heregulin
48468	NRG1	neuregulin1, neu	neuregulin 1	0.40	2.31	1.03	1.00	1.01	1.00
		diff. Factor,
		heregulin
47416	NTS		neurotensin	1.05	1.00	0.64	1.41	1.04	1.00
47183	OSMR	oncostatin M R	oncostatin M receptor	0.55	1.80	1.07	1.03	0.99	1.00
49778	OSMR	oncostatin M R	oncostatin M receptor	0.59	1.60	1.11	1.00	0.93	1.00
49585	OSRF		osmosis responsive factor	0.55	1.43	0.92	1.00	1.02	1.00
47860	P2RXL1	P2RXL1	purinergic receptor P2X-like 1, orphan receptor	1.59	1.40	0.89	1.00	0.97	1.00
48193	P2RY1	P2RY1	purinergic receptor P2Y, G-protein coupled, 1	0.62	1.49	0.89	1.04	1.14	1.00
47358	P2RY2	P2RY2	purinergic receptor P2Y, G-protein coupled, 2	0.84	1.02	2.23	1.87	1.13	1.00
47902	P2RY2	P2RY2	purinergic receptor P2Y, G-protein coupled, 2	1.00	1.00	2.06	1.54	0.90	1.00
48707	P4HA1	P4HA1, prolyl-4-	procollagen-proline, 2-oxoglutarate 4-	0.52	1.58	0.88	1.00	0.89	1.06
		hydroxylase	dioxygenase (proline 4-hydroxylase), alpha
		alpha1	polypeptide I
47935	P4HA1	P4HA1, prolyl-4-	procollagen-proline, 2-oxoglutarate 4-	0.54	1.72	1.03	1.00	0.96	1.00
		hydroxylase	dioxygenase (proline 4-hydroxylase), alpha
		alpha1	polypeptide I
49905	PAX3		paired box gene 3 (Waardenburg syndrome 1)	0.49	1.58	1.11	1.03	0.96	1.00
49707	PCNA		proliferating cell nuclear antigen	0.79	1.13	0.41	1.60	1.08	1.00
49705	PCYT2		phosphate cytidylyltransferase 2, ethanolamine	1.66	1.42	1.39	1.24	1.00	1.00
49933	PDE3A		phosphodiesterase 3A, cGMP-inhibited	0.76	1.00	0.65	1.42	1.05	1.00
48556	PDE4B	phosphodiesterase	phosphodiesterase 4B, cAMP-specific	0.38	2.21	1.35	1.20	1.22	1.13
		4B	(phosphodiesterase E4 dunce homolog,
			Drosophila)
48427	PDE4B	phosphodiesterase	phosphodiesterase 4B, cAMP-specific	0.40	2.15	1.41	1.27	1.13	1.00
		4B	(phosphodiesterase E4 dunce homolog,
			Drosophila)
48370	PDGFA	PDGF, alpha	platelet-derived growth factor alpha	0.82	1.03	1.89	1.63	1.17	1.00
			polypeptide
50639	PDIR		for protein disulfide isomerase-related	1.62	1.39	1.20	1.08	1.04	1.00
49965	PF4	platelet factor 4	platelet factor 4	0.66	1.39	0.95	1.00	1.04	1.00
47639	PGAM1		phosphoglycerate mutase 1 (brain)	1.60	1.42	0.87	1.08	1.13	1.00
46890	PHKA1		phosphorylase kinase, alpha 1 (muscle)	1.59	1.39	1.01	1.00	0.96	1.02
47597	PHKG2		phosphorylase kinase, gamma 2 (testis)	1.53	1.49	1.01	1.00	0.97	1.00
49854	PI3	PI3	protease inhibitor 3, skin-derived (SKALP)	0.34	2.41	1.23	1.12	1.06	1.00
47320	PI3	PI3	protease inhibitor 3, skin-derived (SKALP)	0.33	2.69	1.15	1.06	1.13	1.00
47151	PIK3C3	PI3K class 3	phosphoinositide-3-kinase, class 3	0.64	1.32	1.12	1.00	1.09	1.02
46818	PIM2	Pim-2	pim-2 oncogene	0.56	1.65	1.12	1.00	0.73	1.11
48195	PLA2G1B	phospholipase A2	phospholipase A2, group IB (pancreas)	1.74	1.41	1.67	1.58	1.76	1.46
47118	PLA2G4A	phospholipase A2	phospholipase A2, group IVA (cytosolic,	0.49	1.90	0.76	1.27	0.97	1.00
			calcium-dependent)
48023	PLAB	PLAB	prostate differentiation factor	0.08	9.91	0.72	1.18	0.75	1.17
50434	PLAB	PLAB	prostate differentiation factor	0.08	11.20	0.75	1.13	0.72	1.13
47541	PLAT	plasminogen	plasminogen activator, tissue	1.00	1.00	1.41	1.30	1.18	1.00
		activator
47537	PLAU	urokinase-type	plasminogen activator, urokinase	0.41	2.23	0.98	1.00	1.14	1.05
		plasminogen
		activator
49424	PLAU	urokinase-type	plasminogen activator, urokinase	0.42	2.26	0.78	1.02	1.08	1.00
		plasminogen
		activator
48138	PLAUR		plasminogen activator, urokinase receptor	0.28	3.27	1.04	1.00	0.94	1.00
49106	PLOD	PLOD	procollagen-lysine, 2-oxoglutarate 5-	0.83	1.00	0.70	1.37	0.93	1.00
			dioxygenase (lysine hydroxylase, Ehlers-
			Danlos syndrome type VI)
49073	PLOD	PLOD	procollagen-lysine, 2-oxoglutarate 5-	0.87	1.03	0.72	1.35	0.95	1.00
			dioxygenase (lysine hydroxylase, Ehlers-
			Danlos syndrome type VI)
50313	PLOD2	PLOD2	procollagen-lysine, 2-oxoglutarate 5-	0.39	2.39	1.09	1.00	0.89	1.05
			dioxygenase (lysine hydroxylase) 2
49325	PLOD2	PLOD2	procollagen-lysine, 2-oxoglutarate 5-	0.33	2.87	1.15	1.00	0.97	1.00
			dioxygenase (lysine hydroxylase) 2
47776	POLA		polymerase (DNA directed), alpha	0.87	1.04	0.57	1.63	0.92	1.00
46908	POLR2J		polymerase (RNA) II (DNA directed)	0.56	1.45	1.12	1.08	1.00	1.00
			polypeptide J (13.3 kD)
49950	PPAP2B		phosphatidic acid phosphalase type 2B	0.63	1.48	1.03	1.00	0.88	1.06
47328	PPFIBP1	PPFIBP1	PTPRF interacting protein, binding protein 1	0.50	1.82	1.23	1.10	1.07	1.00
			(liprin beta 1)
49413	PPID	cyclophilin D	peptidylprolyl isomerase D (cyclophilin D)	1.46	1.33	1.81	1.56	1.65	1.42
49103	PPID	cyclophilin D	peptidylprolyl isomerase D (cyclophilin D)	1.66	1.27	1.98	1.74	1.59	1.41
48616	PPIH	cyclophilin H	peptidyl prolyl isomerase H (cyclophilin H)	1.18	1.14	0.65	1.39	1.03	1.00
48726	PPP2R2B	PP2 regulatory	protein phosphatase 2 (formerly 2A), regulatory	1.45	1.12	1.74	1.56	1.53	1.18
		subunit B beta	subunit B (PR 52), beta isoform
46994	PPP2R2B	PP2 regulatory	protein phosphatase 2 (formerly 2A), regulatory	1.34	1.00	1.80	1.66	1.39	1.00
		subunit B beta	subunit B (PR 52), beta isoform
46961	PPP2R2B	PP2 regulatory	protein phosphatase 2 (formerly 2A), regulatory	1.55	1.00	1.73	1.64	1.15	1.00
		subunit B beta	subunit B (PR 52), beta isoform
47779	PRDM2		PR domain containing 2, with ZNF domain	1.30	1.09	1.47	1.42	1.00	1.00
48231	PRKACG	PKA, catalytic	protein kinase, cAMP-dependent, catalytic,	0.64	1.46	0.73	1.27	0.92	1.00
		subunit gamma	gamma
46973	PRKAR1B	PKA, regulatory	protein kinase, cAMP-dependent, regulatory,	1.66	1.36	1.82	1.52	1.39	1.06
		subunit, type I beta	type I, beta
47006	PRKAR1B	PKA, regulatory	protein kinase, cAMP-dependent, regulatory,	1.52	1.46	1.79	1.42	1.32	1.00
		subunit, type I beta	type I, beta
49738	PRKCA	PKC alpha	protein kinase C, alpha	1.19	1.02	1.76	1.43	1.38	1.26
46934	PRKCD	PKC, delta	protein kinase C, delta	1.91	1.35	0.98	1.00	0.88	1.09
47528	PRKCN	PKC, nu	protein kinase C, nu	0.68	1.45	1.14	1.08	1.01	1.00
47176	PTGES	PTGES	prostaglandin E synthase	0.61	1.55	1.07	1.00	1.22	1.10
46632	PTGES	PTGES	prostaglandin E synthase	0.63	1.43	1.00	1.00	1.17	1.08
47499	PTGS2	PTGS2, COX2	prostaglandin-endoperoxide synthase 2	0.05	18.58	0.99	1.00	0.88	1.00
			(prostaglandin G/H synthase and
			cyclooxygenase)
50665	PTGS2	PTGS2, COX2	prostaglandin-endoperoxide synthase 2	0.06	17.96	0.96	1.00	0.87	1.00
			(prostaglandin G/H synthase and
			cyclooxygenase)
49036	PTK2B	PYK2	protein tyrosine kinase 2 beta	1.51	1.22	1.68	1.30	1.38	1.34
48938	PTPN18	PTPN18	protein tyrosine phosphatase, non-receptor	1.36	1.05	1.58	1.46	1.13	1.04
			type 18 (brain-derived)
50093	PTPRA	PTP alpha	protein tyrosine phosphatase, receptor type, A	1.39	1.31	1.38	1.32	1.14	1.00
49841	PTPRCAP	CD45-assoc	protein tyrosine phosphatase, receptor type, C-	1.33	1.31	0.77	1.25	1.04	1.00
		protein	associated protein
47548	PTPRK	PTPRK	protein tyrosine phosphatase, receptor type, K	0.65	1.37	1.21	1.11	1.11	1.02
48687	PTPRM	PTPRM	protein tyrosine phosphatase, receptor type, M	1.34	1.31	1.05	1.01	0.98	1.00
47293	PTPRN	PTPRN	protein tyrosine phosphatase, receptor type, N	0.96	1.00	1.66	1.33	1.08	1.00
48886	PYGM		phosphorylase, glycogen; muscle (McArdle	2.89	2.69	1.16	1.03	1.03	1.00
			syndrome, glycogen storage disease type V)
47653	RAB10	RAB10	RAB10, member RAS oncogene family	0.72	1.32	0.77	1.09	0.96	1.00
47686	RAB10	RAB10	RAB10, member RAS oncogene family	0.70	1.33	0.77	1.07	0.92	1.00
47883	RAB4A	RAB4	RAB4, member RAS oncogene family	1.44	1.38	0.95	1.00	0.96	1.00
46924	RAB9A	RAB9	RAB9, member RAS oncogene family	0.47	2.04	1.00	1.00	0.98	1.00
47002	RAC1	Rac-1	ras-related C3 botulinum toxin substrate 1 (rho	0.59	1.60	0.93	1.05	0.98	1.00
			family, small GTP binding protein Rac1)
46969	RAC1	Rac-1	ras-related C3 botulinum toxin substrate 1 (rho	0.60	1.54	0.92	1.04	1.01	1.00
			family, small GTP binding protein Rac1)
47319	RAC1	Rac-1	ras-related C3 botulinum toxin substrate 1 (rho	0.68	1.38	0.93	1.03	1.05	1.00
			family, small GTP binding protein Rac1)
48123	RAD1		RAD1 homolog (S. pombe)	0.80	1.08	0.72	1.33	1.04	1.00
49876	RAD54L		RAD54-like (S. cerevisiae)	1.09	1.00	0.46	1.75	0.82	1.02
48732	RALA	RALA	v-ral simian leukemia viral oncogene homolog	0.57	1.48	1.03	1.00	0.90	1.00
			A (ras related)
48716	RALA	RALA	v-ral simian leukemia viral oncogene homolog	0.63	1.37	1.00	1.00	0.93	1.00
			A (ras related)
47446	RANBP1		RAN binding protein 1	1.19	1.08	0.66	1.38	1.06	1.00
49610	RANBP2L1		hypothetical protein DKFZp434P144	0.94	1.00	1.51	1.35	1.01	1.00
48542	RAP1GA1		RAP1, GTPase activating protein 1	0.62	1.31	0.63	1.24	0.83	1.00
47707	RASA2	RasGAP	RAS p21 protein activator 2	0.84	1.00	1.41	1.30	1.05	1.00
47672	RELA	p65, NFKB3	v-rel reticuloendotheliosis viral oncogene	0.51	1.76	0.99	1.00	0.78	1.19
			homolog A, nuclear factor of kappa light
			polypeptide gene enhancer in B-cells 3, p65
			(avian)
47652	RELA	p65, NFKB3	v-rel reticuloendotheliosis viral oncogene	0.53	1.60	0.97	1.00	0.80	1.01
			homolog A, nuclear factor of kappa light
			polypeptide gene enhancer in B-cells 3, p65
			(avian)
49120	RELB	l-rel	v-rel reticuloendotheliosis viral oncogene	0.44	1.93	0.81	1.06	0.89	1.00
			homolog B, nuclear factor of kappa light
			polypeptide gene enhancer in B-cells 3 (avian)
46658	RELB	l-rel	v-rel reticuloendotheliosis viral oncogene	0.65	1.39	0.79	1.02	0.91	1.00
			homolog B, nuclear factor of kappa light
			polypeptide gene enhancer in B-cells 3 (avian)
49087	RELB	l-rel	v-rel reticuloendotheliosis viral oncogene	0.43	2.02	0.85	1.00	0.88	1.00
			homolog B, nuclear factor of kappa light
			polypeptide gene enhancer in B-cells 3 (avian)
49786	RGS16	Rgs-16	regulator of G-protein signalling 16	0.47	1.65	0.89	1.01	0.96	1.00
48392	RIPK1	RIPK, RIP	receptor (TNFRSF)-interacting serine-	1.52	1.00	1.85	1.77	1.31	1.16
			threonine kinase 1
46985	RIPK2	RIP2, RICK	receptor-interacting serine-threonine kinase 2	1.79	1.66	2.12	1.67	1.91	1.77
47933	RIPK2	RIP2, RICK	receptor-interacting serine-threonine kinase 2	0.26	3.32	1.35	1.28	0.96	1.00
47774	RPA2		replication protein A2 (32 kD)	1.06	1.00	0.64	1.40	1.11	1.00
49236	RPA3		replication protein A3 (14 kD)	0.99	1.00	0.69	1.33	0.98	1.00
48930	RPS6KA1	RSK1	ribosomal protein S6 kinase, 90 kD, polypeptide 1	0.80	1.20	0.46	1.89	1.05	1.00
48594	RPS6KA2	RPS6KA2	ribosomal protein S6 kinase, 90 kD, polypeptide 2	0.91	1.00	1.67	1.53	1.28	1.00
48050	RPS6KA2	RPS6KA2	ribosomal protein S6 kinase, 90 kD, polypeptide 2	0.99	1.00	1.52	1.32	0.94	1.00
48268	RPS6KA3	RPS6KA3	ribosomal protein S6 kinase, 90 kD, polypeptide 3	0.46	1.76	0.88	1.09	0.94	1.00
48244	RPS6KA5	RPS6KA5	ribosomal protein S6 kinase, 90 kD, polypeptide 5	0.82	1.11	0.62	1.38	0.91	1.01
50683	S100A7	S100A7	S100 calcium binding protein A7 (psoriasin 1)	0.93	1.00	0.54	1.62	0.80	1.14
46891	SAA1		serum amyloid A1	15.15	14.26	1.08	1.00	0.96	1.00
49076	SARM	KIAA0524	sterile alpha and HEAT/Armadillo motif protein,	1.03	1.00	1.61	1.41	0.97	1.01
			ortholog of Drosophila
50441	SAT		spermidine/spermine N1-acetyltransferase	0.64	1.52	1.01	1.00	0.93	1.00
49507	SCNN1A		sodium channel, nonvoltage-gated 1 alpha	2.38	1.46	1.02	1.00	0.96	1.00
48646	SDCBP		syndecan binding protein (syntenin)	0.57	1.73	1.06	1.00	0.91	1.00
48329	SDHA		succinate dehydrogenase complex, subunit A,	1.34	1.00	1.84	1.64	1.31	1.15
			flavoprotein (Fp)
50708	SELE	E-selectin	selectin E (endothelial adhesion molecule 1)	0.59	1.48	1.11	1.00	0.76	1.00
47522	SERPINA1	S, C protease	serine (or cysteine) proteinase inhibitor, clade	2.10	1.92	0.89	1.06	0.90	1.06
		inhibitor	A (alpha-1 antiproteinase, antitrypsin), member 1
48378	SERPINA1	S, C protease	serine (or cysteine) proteinase inhibitor, clade	3.72	2.80	0.87	1.05	0.91	1.00
		inhibitor	A (alpha-1 antiproteinase, antitrypsin), member 1
46950	SERPINA3		serine (or cysteine) proteinase inhibitor, clade	8.82	8.09	1.52	1.34	1.05	1.03
			A (alpha-1 antiproteinase, antitrypsin), member 3
49498	SERPINA3		serine (or cysteine) proteinase inhibitor, clade	8.93	8.67	1.43	1.34	1.07	1.00
			A (alpha-1 antiproteinase, antitrypsin), member 3
47166	SERPINA6		serine (or cysteine) proteinase inhibitor, clade	1.44	1.24	1.72	1.39	1.19	1.10
			A (alpha-1 antiproteinase, antitrypsin), member 6
47037	SERPINA6		serine (or cysteine) proteinase inhibitor, clade	1.58	1.07	1.71	1.45	1.20	1.06
			A (alpha-1 antiproteinase, antitrypsin), member 6
47332	SERPINB3		serine (or cysteine) proteinase inhibitor, clade	0.40	2.32	1.38	1.24	1.04	1.00
			B (ovalbumin), member 3
47876	SERPINB3		serine (or cysteine) proteinase inhibitor, clade	0.34	2.48	1.35	1.21	0.99	1.00
			B (ovalbumin), member 3
48205	SERPINB8		serine (or cysteine) proteinase inhibitor, clade	0.36	2.62	1.27	1.18	1.11	1.03
			B (ovalbumin), member 8
49963	SERPINB8		serine (or cysteine) proteinase inhibitor, clade	0.38	2.40	1.24	1.17	1.00	1.00
			B (ovalbumin), member 8
49991	SERPINE1		serine (or cysteine) proteinase inhibitor, clade	2.87	2.69	1.95	1.83	0.90	1.01
			E (nexin, plasminogen activator inhibitor type
			1), member 1
48269	SERPINE1		serine (or cysteine) proteinase inhibitor, clade	2.94	2.89	1.93	1.83	0.94	1.00
			E (nexin, plasminogen activator inhibitor type
			1), member 1
48281	SERPINE2		serine (or cysteine) proteinase inhibitor, clade	0.23	3.77	1.21	1.18	0.96	1.00
			E (nexin, plasminogen activator inhibitor type
			1), member 2
48367	SERPINE2		serine (or cysteine) proteinase inhibitor, clade	0.27	3.45	1.29	1.14	0.93	1.00
			E (nexin, plasminogen activator inhibitor type
			1), member 2
48400	SERPINE2		serine (or cysteine) proteinase inhibitor, clade	0.27	3.15	1.24	1.13	0.95	1.00
			E (nexin, plasminogen activator inhibitor type
			1), member 2
46787	SERPINI1		serine (or cysteine) proteinase inhibitor, clade I	0.57	1.50	0.64	1.21	1.10	1.00
			(neuroserpin), member 1
47139	SERPINI1		serine (or cysteine) proteinase inhibitor, clade I	0.59	1.57	0.83	1.00	1.20	1.00
			(neuroserpin), member 1
48739	SES2		sestrin 2	0.63	1.44	1.70	1.48	1.10	1.00
49686	SHC1	SHC, Shc1	SHC (Src homology 2 domain containing)	1.90	1.77	0.98	1.00	0.94	1.04
			transforming protein 1
47644	SHC1	SHC, Shc1	SHC (Src homology 2 domain containing)	1.92	1.45	0.99	1.00	0.98	1.00
			transforming protein 1
48155	SHMT1		serine hydroxymethyltransferase 1 (soluble)	1.26	1.06	0.63	1.35	0.91	1.00
47381	ShrmL		Shroom-related protein	1.87	1.69	0.80	1.06	0.98	1.00
47270	SLC16A4		solute carrier family 16 (monocarboxylic acid	0.68	1.35	1.20	1.05	0.88	1.06
			transporters), member 4
47211	SLC26A2	SLC26A2	solute carrier family 26 (sulfate transporter),	5.38	5.16	1.00	1.00	1.00	1.00
			member 2
50646	SLC26A4		solute carrier family 26, member 4	1.00	1.00	1.98	1.70	1.00	1.00
48402	SLC29A1	ENT1	solute carrier family 29 (nucleoside	1.09	1.00	0.58	1.67	1.03	1.00
			transporters), member 1
48369	SLC29A1	ENT1	solute carrier family 29 (nucleoside	1.20	1.10	0.59	1.43	1.10	1.00
			transporters), member 1
47310	SLC29A1	ENT1	solute carrier family 29 (nucleoside	1.18	1.05	0.62	1.31	0.99	1.00
			transporters), member 1
47300	SLPI	SLPI	secretory leukocyte protease inhibitor	2.05	1.91	1.03	1.00	1.03	1.00
			(antileukoproteinase)
46678	SLPI	SLPI	secretory leukocyte protease inhibitor	2.09	1.74	1.06	1.00	1.08	1.00
			(antileukoproteinase)
47838	SMARCD2		SWI/SNF related, matrix associated, actin	1.48	1.32	0.87	1.01	0.94	1.00
			dependent regulator of chromatin, subfamily d,
			member 2
48182	SNAPC1		small nuclear RNA activating complex,	0.62	1.37	0.77	1.19	0.99	1.00
			polypeptide 1, 43 kD
47418	SNK		serum-inducible kinase	0.36	2.54	1.03	1.00	0.97	1.00
48462	SPRR2C		small proline-rich protein 2C	0.75	1.04	0.37	1.94	0.96	1.00
49446	SRC	Src	v-src sarcoma (Schmidt-Ruppin A-2) viral	0.45	1.92	0.89	1.09	1.09	1.02
			oncogene homolog (avian)
49990	SRC	Src	v-src sarcoma (Schmidt-Ruppin A-2) viral	0.45	2.02	0.93	1.00	1.05	1.02
			oncogene homolog (avian)
50450	STAT1	STAT1	signal transducer and activator of transcription	1.44	1.33	0.86	1.02	0.81	1.14
			1, 91 kD
49746	STAT1	STAT1	signal transducer and activator of transcription	1.61	1.47	0.77	1.08	0.88	1.05
			1, 91 kD
47569	STAT3	STAT3	signal transducer and activator of transcription	1.88	1.68	1.71	1.45	1.42	1.34
			3 (acute-phase response factor)
47193	STAT3	STAT3	signal transducer and activator of transcription	1.83	1.67	1.73	1.55	1.47	1.18
			3 (acute-phase response factor)
46796	STC1		stanniocalcin 1	0.08	11.73	1.49	1.31	1.07	1.02
47313	STK10	STK10	serine/threonine kinase 10	0.74	1.20	1.46	1.33	0.93	1.00
46922	STK10	STK10	serine/threonine kinase 10	0.70	1.29	1.45	1.33	0.99	1.00
48142	STOM		erythrocyte membrane protein band 7.2	3.10	2.63	1.38	1.34	1.29	1.20
			(stomatin)
48769	SUV39H1		suppressor of variegation 3-9 homolog 1	1.05	1.00	0.52	1.69	0.99	1.00
			(Drosophila)
48505	T		T, brachyury homolog (mouse)	0.52	1.82	1.03	1.00	1.18	1.00
47227	TANK	I-TRAF, TANK	TRAF family member-associated NFKB	0.67	1.41	1.04	1.00	0.92	1.00
			activator
49372	TAP1		transporter 1, ATP-binding cassette, sub-family	1.64	1.47	1.08	1.00	1.03	1.00
			B (MDR/TAP)
46613	TCF12	TCF12	transcription factor 12 (HTF4, helix-loop-helix	0.67	1.39	1.13	1.03	0.93	1.03
			transcription factors 4)
48636	TCF8	TCF8	transcription factor 8 (represses interleukin 2	1.39	1.36	0.85	1.07	0.99	1.00
			expression)
48603	TEAD4	TEAD4	TEA domain family member 4	1.49	1.16	1.82	1.56	1.78	1.48
46991	TFPI2	TFPI2	tissue factor pathway inhibitor 2	0.36	2.53	1.28	1.12	0.99	1.00
47583	TGFB2	TGF, beta2	transforming growth factor, beta 2	0.64	1.35	0.96	1.00	0.87	1.00
48907	TGFB3	TGF, beta3	transforming growth factor, beta 3	0.68	1.35	0.80	1.17	0.98	1.00
47865	TGFB3	TGF, beta3	transforming growth factor, beta 3	0.61	1.35	0.87	1.00	0.91	1.00
50579	TGIF		TGFB-induced factor (TALE family homeobox)	0.53	1.75	0.81	1.13	0.94	1.00
47593	THBD		thrombomodulin	4.04	3.85	0.97	1.00	0.94	1.00
47987	THBS1	THBS1	thrombospondin 1	4.89	3.80	0.88	1.00	1.05	1.00
48358	THY1	Thy 1	Thy-1 cell surface antigen	0.68	1.35	0.64	1.25	0.85	1.00
46859	TIEG	TGF beta-	TGFB inducible early growth response	0.66	1.34	0.98	1.00	1.11	1.05
		inducible early
		growth response
48356	TIEG	TGF beta-	TGFB inducible early growth response	0.67	1.30	1.05	1.00	1.10	1.02
		inducible early
		growth response
49785	TIMP2	TIMP2	tissue inhibitor of metalloproteinase 2	0.70	1.32	1.08	1.00	0.86	1.05
47778	TMEPAI		transmembrane, prostate androgen induced	0.41	2.04	1.28	1.08	0.86	1.00
			RNA
47918	TNFAIP1	TNFAIP1	tumor necrosis factor, alpha-induced protein 1	0.67	1.36	0.95	1.00	0.96	1.00
			(endothelial)
47993	TNFAIP2	TNFAIP2	tumor necrosis factor, alpha-induced protein 2	0.53	1.73	1.14	1.05	1.10	1.05
47642	TNFAIP3	A20, TNFAIP2, Zn	tumor necrosis factor, alpha-induced protein 3	0.67	1.36	1.38	1.24	0.99	1.00
		finger
47155	TNFAIP6	TNFAIP6	tumor necrosis factor, alpha-induced protein 6	0.42	1.86	1.44	1.35	0.95	1.00
46803	TNFAIP6	TNFAIP6	tumor necrosis factor, alpha-induced protein 6	0.32	2.56	1.45	1.24	0.94	1.00
49272	TNFRSF10B	DR5	tumor necrosis factor receptor superfamily,	0.47	1.93	1.12	1.06	1.02	1.00
			member 10b
49143	TNFRSF10B	DR5	tumor necrosis factor receptor superfamily,	0.46	1.97	1.12	1.04	1.05	1.00
			member 10b
50365	TNFRSF1A	TNFR1	tumor necrosis factor receptor superfamily,	1.09	1.01	0.65	1.41	0.91	1.04
			member 1A
50458	TNFRSF21	DR6	tumor necrosis factor receptor superfamily,	0.50	1.67	0.74	1.25	0.98	1.00
			member 21
47684	TNFRSF21	DR6	tumor necrosis factor receptor superfamily,	0.41	2.18	0.68	1.21	0.88	1.00
			member 21
47651	TNFRSF21	DR6	tumor necrosis factor receptor superfamily,	0.36	2.37	0.72	1.15	0.93	1.00
			member 21
50379	TNFRSF6	FAS	tumor necrosis factor receptor superfamily,	1.65	1.20	1.69	1.66	1.27	1.10
			member 6
49330	TNFRSF7	CD27	tumor necrosis factor receptor superfamily,	1.65	1.43	2.09	1.79	1.82	1.64
			member 7
48395	TNFRSF7	CD27	tumor necrosis factor receptor superfamily,	1.62	1.31	1.90	1.58	1.71	1.21
			member 7
48560	TNFRSF8	CD30	tumor necrosis factor receptor superfamily,	1.36	1.13	1.52	1.32	0.97	1.00
			member 8
48198	TNNC1		troponin C, slow	0.73	1.31	1.11	1.03	0.96	1.00
49877	TOB1		transducer of ERBB2, 1	0.64	1.37	0.98	1.00	0.89	1.00
46901	TP53I3		quinone oxidoreductase homolog	1.68	1.59	0.99	1.00	1.01	1.00
48288	TRAF5	TRAF5	TNF receptor-associated factor 5	1.61	1.21	1.83	1.71	1.60	1.33
48078	TRIP	TRIP	TRAF interacting protein	0.90	1.00	0.56	1.58	1.01	1.00
49901	TROAP		trophinin associated protein (tastin)	1.01	1.00	0.50	1.79	0.94	1.01
49767	TTRAP	AD022	TRAF and TNF receptor-associated protein	0.38	2.34	1.25	1.13	0.91	1.00
50738	TTRAP	AD022	TRAF and TNF receptor-associated protein	0.37	2.56	1.18	1.13	0.92	1.00
49800	TTRAP	AD022	TRAF and TNF receptor-associated protein	0.38	2.45	1.20	1.06	0.89	1.00
47470	TXNIP	VDUP1	thioredoxin interacting protein	2.40	1.63	1.25	1.23	1.44	1.00
50575	UBD		diubiquitin	0.56	1.42	0.87	1.00	1.00	1.00
48761	UBE2C		ubiquitin-conjugating enzyme E2C	1.84	1.70	0.70	1.27	0.93	1.00
49989	VTN	vitronectin	vitronectin (serum spreading factor,	0.90	1.00	0.67	1.32	0.93	1.00
			somatomedin B, complement S-protein)
49710	WSX1		class I cytokine receptor	1.35	1.23	1.64	1.53	1.20	1.07
46572	XRCC2		X-ray repair complementing defective repair in	1.31	1.12	1.50	1.36	1.26	1.08
			Chinese hamster cells 2
47836	ZNF140		zinc finger protein 140 (clone pHZ-39)	1.61	1.38	1.03	1.00	1.00	1.00
47758	ZNF184		zinc finger protein 184 (Kruppel-like)	0.50	1.75	1.07	1.00	1.04	1.00
48151	ZWINT		ZW10 interactor	0.96	1.00	0.51	1.78	1.05	1.00
IL1 + Macrolide Effects
Genes differentially expressed (≧1.3-fold) in A549 cells in response to at least one macrolide, in presence of IL-1β
Genes in bold have min fold change ≧1.3
				+IL1b +/−	+IL1b +/−		+IL1b +/− FMA,				+IL1b +/− Josa,
				Clari,	Clari,	+IL1b +/−	min	+IL1b +/− Roxi,	+IL1b +/− Roxi,	+IL1b +/− Josa,	min
				wtd	min	FMA,	fold	wtd	min	wtd	fold
SpotID	GeneSymbol	GeneName	GeneAssignment	means	fold change	wtd means	change	means	fold change	means	change
46987				1.97	1.76	1.66	1.58	2.37	2.10	1.95	1.72
48260				1.42	1.11	1.77	1.50	2.36	1.39	1.82	1.58
47048				1.45	1.01	1.62	1.43	1.39	1.17	1.71	1.54
49343				1.78	1.53	1.72	1.42	2.00	1.64	1.79	1.53
48626				1.62	1.26	1.71	1.53	1.92	1.78	1.74	1.46
49908				1.04	1.00	2.41	1.47	0.78	1.00	2.39	1.43
47003				1.70	1.32	1.84	1.60	2.02	1.56	1.67	1.43
49817				1.61	1.44	1.76	1.36	2.10	1.72	1.55	1.40
47206				1.79	1.37	1.61	1.48	1.94	1.63	1.63	1.33
50375		LBC, lymphoid blast	lymphoid blast crisis	1.41	1.25	1.35	1.21	1.38	1.15	1.50	1.33
		crisis oncogene	oncogene
47624				1.82	1.59	1.51	1.21	1.66	1.33	1.50	1.29
46609				1.68	1.40	1.64	1.38	1.87	1.56	1.47	1.27
50456				1.56	1.39	1.63	1.40	1.72	1.42	1.44	1.26
46594				1.47	1.25	1.58	1.16	1.97	1.71	1.60	1.26
49612				1.40	1.00	1.51	1.31	1.81	1.43	1.42	1.16
50468				1.46	1.32	1.39	1.00	1.64	1.23	1.44	1.15
50624				1.29	1.00	2.09	1.72	0.65	1.00	1.88	1.03
47315				1.43	1.07	1.52	1.17	1.69	1.45	1.25	1.00
46580				1.05	1.00	1.24	1.00	1.50	1.38	1.68	1.00
48036				1.32	1.06	1.70	1.53	1.46	1.22	1.19	1.00
48580				1.41	1.05	1.68	1.41	1.42	1.14	1.22	1.00
49378				1.00	1.00	1.92	1.55	1.00	1.00	1.00	1.00
47263	ACVR2		activin A receptor, type II	1.28	1.04	1.50	1.32	1.37	1.10	1.26	1.00
47535	ARHGDIA	ARHGDIA	Rho GDP dissociation	0.91	1.00	0.81	1.00	0.82	1.15	0.75	1.30
			inhibitor (GDI) alpha
48287	ARHGEF15	ARHGEF15	Rho guanine nucleotide	1.71	1.39	1.49	1.30	1.85	1.31	1.77	1.58
			exchange factor (GEF) 15
48322	ARHGEF16	ARHGEF16	Rho guanine exchange	1.73	1.28	1.25	1.10	1.82	1.51	1.49	1.34
			factor (GEF) 16
46593	ARHGEF16	ARHGEF16	Rho guanine exchange	1.42	1.05	1.24	1.00	1.98	1.72	1.43	1.07
			factor (GEF) 16
48516	ARL6IP		ADP-ribosylation factor-like	0.88	1.00	0.77	1.00	0.87	1.00	0.58	1.51
			6 interacting protein
46817	ATF3	ATF3	activating transcription	0.94	1.00	1.39	1.17	1.31	1.15	1.67	1.31
			factor 3
47568	ATF7	ATF7	activating transcription	1.73	1.48	1.66	1.51	2.26	1.80	1.64	1.43
			factor 7
47691	BATF	B-ATF	basic leucine zipper	1.22	1.00	1.54	1.44	1.68	1.27	0.85	1.12
			transcription factor, ATF-
			like
48679	BCL3	Bcl3	B-cell CLL/lymphoma 3	1.29	1.20	1.41	1.32	1.61	1.36	1.49	1.20
50489	BPAG1	BPAG1	bullous pemphigoid	1.11	1.00	1.18	1.00	1.19	1.13	1.75	1.41
			antigen 1 (230/240 kD)
46854	BTN3A2	BTN3A2	butyrophilin, subfamily 3,	1.74	1.56	1.67	1.41	2.17	1.81	1.86	1.71
			member A2
50721	CASP4	CASP4	caspase 4, apoptosis-	1.27	1.00	1.29	1.18	1.19	1.10	1.50	1.44
			related cysteine protease
47007	CASP4	CASP4	caspase 4, apoptosis-	1.34	1.14	1.25	1.15	1.15	1.00	1.52	1.37
			related cysteine protease
49807	CASP4	CASP4	caspase 4, apoptosis-	1.34	1.22	1.28	1.07	1.24	1.15	1.40	1.31
			related cysteine protease
50372	CASP6	caspase-6	caspase 6, apoptosis-	1.73	1.58	1.64	1.42	1.71	1.23	1.52	1.42
			related cysteine protease
49806	CCNA2	cyclin A2	cyclin A2	0.62	1.13	0.67	1.37	0.62	1.23	0.50	1.69
49773	CCNA2	cyclin A2	cyclin A2	0.65	1.00	0.74	1.13	0.65	1.29	0.50	1.65
49118	CCNA2	cyclin A2	cyclin A2	0.65	1.14	0.65	1.35	0.62	1.26	0.58	1.35
49085	CCNA2	cyclin A2	cyclin A2	0.65	1.03	0.76	1.08	0.66	1.24	0.55	1.34
48015	CCND3	Cyclin D3	cyclin D3	0.74	1.23	0.79	1.07	0.74	1.04	0.65	1.44
47025	CCR7	CCR7	chemokine (C—C motif)	0.90	1.00	1.84	1.11	1.72	1.33	1.41	1.00
			receptor 7
48042	CD4	CD4	CD4 antigen (p55)	1.49	1.31	1.30	1.00	1.49	1.00	1.23	1.00
50229	CDC2		cell division cycle 2, G1 to	0.70	1.05	0.79	1.03	0.74	1.24	0.56	1.50
			S and G2 to M
46603	CDC42BPB	CDC42BPB	CDC42 binding protein	1.20	1.00	1.37	1.00	1.49	1.35	1.41	1.19
			kinase beta (DMPK-like)
48631	CDKN1A	Waf1, Cip1	cyclin-dependent kinase	1.55	1.44	1.15	1.08	1.32	1.19	1.22	1.09
			inhibitor 1A (p21, Cip1)
49105	CDKN3	cyclin dependent	cyclin-dependent kinase	0.76	1.14	0.86	1.00	0.82	1.09	0.66	1.35
		kinase inhibitor 3	inhibitor 3 (CDK2-
			associated dual specificity
			phosphatase)
46849	CEBPD	CEBP delta	CCAAT/enhancer binding	0.76	1.30	0.78	1.10	0.68	1.32	0.72	1.32
			protein (C/EBP), delta
47891	CEBPD	CEBP delta	CCAAT/enhancer binding	0.77	1.23	0.69	1.37	0.68	1.36	0.74	1.13
			protein (C/EBP), delta
48313	CENPA		centromere protein A	0.78	1.02	0.74	1.14	0.79	1.23	0.47	1.63
			(17 kD)
50644	CEP2		centrosomal protein 2	1.58	1.26	1.56	1.41	1.49	1.19	1.35	1.12
49645	CX3CL1	fractalkine	small inducible cytokine	1.13	1.00	1.35	1.31	1.07	1.00	1.50	1.35
			subfamily D (Cys-X3-Cys),
			member 1 (fractalkine,
			neurotactin)
49492	CX3CL1	fractalkine	small inducible cytokine	1.09	1.00	1.45	1.36	0.97	1.00	1.15	1.00
			subfamily D (Cys-X3-Cys),
			member 1 (fractalkine,
			neurotactin)
49433	DDIT3	CHOP	DNA-damage-inducible	1.82	1.43	1.31	1.16	1.56	1.33	1.52	1.40
			transcript 3
50132	DDIT3	CHOP	DNA-damage-inducible	1.70	1.43	1.24	1.10	1.53	1.35	1.53	1.35
			transcript 3
48736	DUSP5	DUSP5	dual specificity	1.66	1.33	1.57	1.41	1.62	1.28	1.87	1.46
			phosphatase 5
49777	DUSP6	DUSP6	dual specificity	1.46	1.39	1.11	1.04	1.29	1.00	1.42	1.20
			phosphatase 6
49810	DUSP6	DUSP6	dual specificity	1.46	1.39	1.12	1.04	1.32	1.20	1.34	1.17
			phosphatase 6
48032	ECT2	ECT2	epithelial cell transforming	0.62	1.33	0.64	1.17	0.71	1.04	0.64	1.37
			sequence 2 oncogene
50140	ECT2	ECT2	epithelial cell transforming	0.90	1.00	0.72	1.04	0.70	1.33	0.63	1.36
			sequence 2 oncogene
46821	ELA2	elastase-2	elastase 2, neutrophil	1.25	1.20	1.29	1.22	1.44	1.13	1.69	1.51
46599	ERBB3	ErbB3	v-erb-b2 erythroblastic	1.77	1.27	1.79	1.66	1.37	1.17	1.85	1.54
			leukemia viral oncogene
			homolog 3 (avian)
47730	ERBB3	ErbB3	v-erb-b2 erythroblastic	1.55	1.13	1.42	1.04	1.63	1.15	1.45	1.32
			leukemia viral oncogene
			homolog 3 (avian)
49230	ESDN		endothelial and smooth	0.67	1.34	0.69	1.18	0.74	1.14	0.67	1.30
			muscle cell-derived
			neuropilin-like protein
48998	FADS1		fatty acid desaturase 1	1.80	1.66	0.97	1.01	1.59	1.45	0.96	1.01
50717	FCER1G	FCER1G	Fc fragment of IgE, high	1.00	1.00	1.36	1.30	0.90	1.00	0.96	1.00
			affinity I, receptor for;
			gamma polypeptide
49529	FGA		fibrinogen, A alpha	0.74	1.00	0.84	1.04	0.75	1.16	0.66	1.37
			polypeptide
48520	FISH		KIAA0418 gene product	1.27	1.11	1.30	1.00	1.35	1.23	1.43	1.31
49892	FLJ21918		hypothetical protein	1.00	1.00	2.04	1.52	1.00	1.00	1.00	1.00
			FLJ21918
48623	FOP	FOP	FGFR1 oncogene partner	1.01	1.00	0.74	1.17	0.88	1.00	0.64	1.34
50681	FOXM1	FOXM1	forkhead box M1	0.75	1.07	0.88	1.11	0.80	1.18	0.62	1.39
48219	FOXM1	FOXM1	forkhead box M1	0.68	1.28	0.86	1.14	0.78	1.15	0.65	1.35
47923	FRAP1	FRAP1, MTOR	FK506 binding protein 12-	1.18	1.00	1.59	1.47	1.67	1.46	1.72	1.40
			rapamycin associated
			protein 1
46725	FRZB		frizzled-related protein	0.37	1.00	3.36	1.75	0.86	1.00	1.75	1.00
50318	FTL		ferritin, light polypeptide	0.73	1.30	0.79	1.00	1.26	1.05	0.88	1.00
49675	GAB2	GAB2	GRB2-associated binding	2.02	1.72	1.91	1.73	1.70	1.18	1.75	1.45
			protein 2
48185	GAGED2		G antigen, family D, 2	1.20	1.12	1.15	1.04	1.18	1.13	1.42	1.32
47716	GATA3	GATA-3	GATA binding protein 3	0.38	1.64	1.14	1.00	1.37	1.19	1.14	1.00
46660	GFR	KIAA0277	guanine nucleotide	1.00	1.00	2.37	1.39	1.00	1.00	1.01	1.00
			exchange factor for Rap1;
			M-Ras-regulated GEF
50653	GM2A		GM2 ganglioside activator	1.46	1.34	1.32	1.05	1.39	1.12	1.28	1.07
			protein
46936	GRB10	GRB10	growth factor receptor-	1.38	1.31	1.11	1.00	1.40	1.19	1.28	1.21
			bound protein 10
50018	GRB2	Grb2	growth factor receptor-	1.53	1.33	1.30	1.01	1.52	1.35	1.33	1.06
			bound protein 2
48110	GREB1		KIAA0575 gene product	1.60	1.00	1.59	1.47	1.65	1.00	1.70	1.56
46778	HMGB2		high-mobility group	0.89	1.05	0.93	1.01	0.86	1.11	0.68	1.34
			(nonhistone chromosomal)
			protein 2
49992	HSPG2	heparin sulfate	heparan sulfate	0.64	1.34	0.65	1.41	0.69	1.32	0.71	1.15
		proteoglycan-2	proteoglycan 2 (perlecan)
49804	ICAM1	ICAM1	intercellular adhesion	1.32	1.22	1.10	1.00	1.29	1.23	1.44	1.33
			molecule 1 (CD54), human
			rhinovirus receptor
50084	IDI1		isopentenyl-diphosphate	1.85	1.77	0.95	1.00	1.39	1.35	0.92	1.07
			delta isomerase
48961	IL10RB	IL-10R beta	interleukin 10 receptor,	1.64	1.34	1.37	1.00	1.43	1.24	1.29	1.23
			beta
47509	IL13RA2	IL-13R alpha2	interleukin 13 receptor,	0.95	1.00	1.00	1.00	1.60	1.32	1.39	1.00
			alpha 2
47656	IL1B	IL-1, beta	interleukin 1, beta	1.39	1.29	1.27	1.09	1.42	1.36	2.04	1.86
46970	IL1B	IL-1, beta	interleukin 1, beta	1.42	1.13	1.27	1.11	1.46	1.41	1.84	1.53
48324	IL3RA	IL-3R alpha	interleukin 3 receptor,	1.26	1.00	1.56	1.32	1.58	1.02	2.03	1.32
			alpha (low affinity)
49666	IL4R	IL-4R alpha	interleukin 4 receptor	1.37	1.07	1.67	1.49	1.91	1.54	1.86	1.66
47925	IL4R	IL-4R alpha	interleukin 4 receptor	1.38	1.07	1.51	1.06	1.93	1.32	1.71	1.31
46865	IL6R	IL-6R	interleukin 6 receptor	1.78	1.36	1.79	1.51	2.39	2.27	1.77	1.56
49289	IL6R	IL-6R	interleukin 6 receptor	1.75	1.41	1.89	1.61	2.10	1.78	1.71	1.52
49873	INSIG1		insulin induced gene 1	2.18	1.80	0.90	1.07	1.42	1.28	1.06	1.00
47186	IRAK2	IRAK-2	interleukin-1 receptor-	1.11	1.00	1.11	1.00	1.50	1.30	1.26	1.06
			associated kinase 2
49335	IRF7	IRF-7A	interferon regulatory factor 7	1.17	1.04	1.52	1.47	1.55	1.23	1.28	1.00
50580	ISG15	ISG15, IFN stimulated	interferon-stimulated	1.72	1.47	1.73	1.40	1.75	1.24	1.59	1.46
		protein	protein, 15 kDa
46820	JAK1	Jak1	Janus kinase 1 (a protein	1.30	1.08	1.45	1.20	1.46	1.37	1.07	1.00
			tyrosine kinase)
49322	JUNB	JunB	jun B proto-oncogene	0.78	1.15	0.68	1.15	0.71	1.03	0.61	1.37
49319	JUNB	JunB	jun B proto-oncogene	0.86	1.06	0.67	1.42	0.76	1.06	0.70	1.26
50528	KAI1	CD82	kangai 1 (suppression of	1.46	1.27	1.44	1.00	1.58	1.33	1.32	1.00
			tumorigenicity 6, prostate;
			CD82 antigen.(R2
			leukocyte antigen, antigen
			detected by monoclonal
			and antibody IA4))
49805	KBRAS2	KBRAS2	I-kappa-B-interacting Ras-	1.66	1.53	1.27	1.06	1.52	1.14	1.28	1.08
			like protein 2
49109	KBRAS2	KBRAS2	I-kappa-B-interacting Ras-	1.68	1.56	1.36	1.19	1.73	1.31	1.31	1.00
			like protein 2
48081	KIAA0220		KIAA0220 protein	1.60	1.51	1.41	1.28	1.85	1.64	1.59	1.34
47562	KIAA1919		KIAA1919 protein	1.51	1.31	1.09	1.00	1.34	1.22	1.22	1.05
49362	KRT7		keratin 7	0.73	1.00	0.82	1.11	0.58	1.54	1.15	1.00
50037	LAMC2	LAMC2	laminin, gamma 2 (nicein	1.43	1.38	1.18	1.14	1.41	1.18	1.37	1.19
			(100 kD), kalinin (105 kD),
			BM600 (100 kD), Herlitz
			junctional epidermolysis
			bullosa))
49683	LEPR	leptin R	leptin receptor	1.89	1.55	1.75	1.55	2.42	2.08	1.79	1.69
49560	LST1		lymphocyte antigen 117	0.76	1.00	1.56	1.32	1.18	1.00	2.28	1.43
47356	LTB4R2		seven transmembrane	1.13	1.00	1.46	1.31	1.52	1.00	1.25	1.00
			receptor BLTR2;
			leukotriene B4 receptor
			BLT2
47533	LTBP4	LTBP4	latent transforming growth	0.70	1.13	0.90	1.00	0.89	1.00	0.65	1.38
			factor beta binding protein 4
47218	MAP3K7IP1	TAB1	transforming growth factor	1.72	1.46	1.63	1.45	2.13	1.77	1.76	1.41
			beta-activated kinase-
			binding protein 1
47001	MAP3K7IP1	TAB1	transforming growth factor	1.42	1.13	1.70	1.41	2.07	1.54	1.43	1.00
			beta-activated kinase-
			binding protein 1
47491	MATN3	MATN3	matrilin 3	1.29	1.05	1.20	1.11	1.46	1.40	1.28	1.12
50566	MCC		mutated in colorectal	1.31	1.16	1.51	1.00	1.78	1.42	1.34	1.00
			cancers
48966	MMP10	MMP10	matrix metalloproteinase	1.36	1.17	0.81	1.04	1.89	1.70	1.21	1.06
			10 (stromelysin 2)
50034	MMPL1	MMPL1	matrix metalloproteinase-	2.13	1.46	2.21	1.42	2.63	2.12	1.15	1.00
			like 1
49115	MMPL1	MMPL1	matrix metalloproteinase-	1.68	1.09	1.60	1.00	2.45	1.70	1.47	1.00
			like 1
48342	MMPL1	MMPL1	matrix metalloproteinase-	2.04	1.36	1.26	1.00	0.89	1.00	1.34	1.00
			like 1
47628	NF1	NF1	neurofibromin 1	1.28	1.05	1.33	1.17	1.33	1.24	1.51	1.42
			(neurofibromatosis, von
			Recklinghausen disease,
			Watson disease)
47584	NFAT5	NFAT 5	nuclear factor of activated	1.28	1.19	1.28	1.19	1.39	1.33	1.34	1.17
			T-cells 5, tonicity-
			responsive
50004	NGFR	NGFR, TNFRSF16	nerve growth factor	0.70	1.00	1.73	1.47	0.80	1.00	1.16	1.00
			receptor (TNFR
			superfamily, member 16)
49460	NGFR	NGFR, TNFRSF16	nerve growth factor	0.81	1.00	1.55	1.35	0.73	1.00	1.15	1.00
			receptor (TNFR
			superfamily, member 16)
49158	NOS1		nitric oxide synthase 1	1.72	1.42	1.42	1.08	1.80	1.43	1.25	1.00
			(neuronal)
47902	P2RY2	P2RY2	purinergic receptor P2Y,	1.66	1.45	1.00	1.00	1.36	1.24	1.22	1.11
			G-protein coupled, 2
49071	PARG1	PARG1	PTPL1-associated	0.73	1.33	0.82	1.00	0.81	1.00	0.92	1.00
			RhoGAP 1
48427	PDE4B	phosphodiesterase	phosphodiesterase 4B,	1.44	1.23	1.28	1.19	1.44	1.39	1.48	1.22
		4B	cAMP-specific
			(phosphodiesterase E4
			dunce homolog,
			Drosophila)
48556	PDE4B	phosphodiesterase	phosphodiesterase 4B,	1.46	1.27	1.18	1.09	1.44	1.41	1.50	1.21
		4B	cAMP-specific
			(phosphodiesterase E4
			dunce homolog,
			Drosophila)
47320	PI3	PI3	protease inhibitor 3, skin-	1.19	1.00	1.29	1.21	1.24	1.11	1.68	1.42
			derived (SKALP)
49398	PIGR		polymeric immunoglobulin	1.45	1.16	1.60	1.47	1.53	1.26	1.47	1.11
			receptor
48547	PLA2G1B	phospholipase A2	phospholipase A2, group	1.74	1.62	1.52	1.19	1.41	1.00	2.12	1.77
			IB (pancreas)
48195	PLA2G1B	phospholipase A2	phospholipase A2, group	1.48	1.13	1.79	1.55	2.06	1.82	1.74	1.50
			IB (pancreas)
50434	PLAB	PLAB	prostate differentiation	0.93	1.00	0.64	1.33	0.84	1.02	0.91	1.00
			factor
47390	PLCD1	phopholipase C, delta 1	phospholipase C, delta 1	0.82	1.00	1.27	1.00	1.11	1.00	1.95	1.61
47419	PLS3		plastin 3 (T isoform)	0.82	1.11	0.73	1.31	0.80	1.13	0.81	1.21
48206	POU2F1		POU domain, class 2,	1.29	1.00	1.46	1.27	1.33	1.21	1.75	1.53
			transcription factor 1
49103	PPID	cyclophilin D	peptidylprolyl isomerase D	1.72	1.52	1.47	1.32	1.72	1.37	1.60	1.39
			(cyclophilin D)
49413	PPID	cyclophilin D	peptidylprolyl isomerase D	1.67	1.42	1.69	1.54	1.65	1.37	1.47	1.30
			(cyclophilin D)
46961	PPP2R2B	PP2 regulatory	protein phosphatase 2	1.25	1.04	1.33	1.16	1.77	1.64	2.09	1.62
		subunit B beta	(formerly 2A), regulatory
			subunit B (PR 52), beta
			isoform
48726	PPP2R2B	PP2 regulatory	protein phosphatase 2	1.49	1.17	1.44	1.05	1.73	1.53	1.57	1.31
		subunit B beta	(formerly 2A), regulatory
			subunit B (PR 52), beta
			isoform
46994	PPP2R2B	PP2 regulatory	protein phosphatase 2	1.39	1.00	1.53	1.24	1.86	1.71	1.74	1.11
		subunit B beta	(formerly 2A), regulatory
			subunit B (PR 52), beta
			isoform
46973	PRKAR1B	PKA, regulatory	protein kinase, cAMP-	1.55	1.23	1.56	1.40	1.73	1.16	1.39	1.01
		subunit, type I beta	dependent, regulatory,
			type I, beta
47190	PRKCE	PKC epsilon	protein kinase C, epsilon	0.91	1.00	1.30	1.11	1.15	1.00	1.86	1.44
46646	PRKCE	PKC epsilon	protein kinase C, epsilon	0.73	1.00	2.01	1.40	0.98	1.00	1.60	1.03
49036	PTK2B	PYK2	protein tyrosine kinase 2	1.34	1.24	1.39	1.04	1.55	1.31	1.25	1.16
			beta
47589	PTOV1		prostate tumor over	0.84	1.14	0.73	1.32	0.83	1.00	0.75	1.25
			expressed gene 1
47698	PTPRJ	PTPRJ	protein tyrosine	1.38	1.12	1.17	1.11	1.38	1.31	1.22	1.00
			phosphatase, receptor
			type, J
48234	PTPRZ1	PTP zeta	protein tyrosine	1.00	1.00	1.00	1.00	1.77	1.48	1.00	1.00
			phosphatase, receptor-
			type, Z polypeptide 1
48359	RIPK1	RIPK, RIP	receptor (TNFRSF)-	1.61	1.50	1.27	1.00	1.34	1.00	1.11	1.00
			interacting serine-threonine
			kinase 1
48392	RIPK1	RIPK, RIP	receptor (TNFRSF)-	1.62	1.38	1.08	1.00	1.35	1.00	1.17	1.00
			interacting serine-threonine
			kinase 1
46985	RIPK2	RIP2, RICK	receptor-interacting serine-	1.83	1.41	1.70	1.43	2.23	1.85	1.87	1.59
			threonine kinase 2
48500	RPL13A		ribosomal protein L13a	1.65	1.43	1.37	1.25	1.23	1.06	1.46	1.40
50428	RPLP0		ribosomal protein, large,	0.73	1.31	0.84	1.00	0.77	1.00	1.31	1.00
			P0
48594	RPS6KA2	RPS6KA2	ribosomal protein S6	1.29	1.23	1.08	1.00	1.26	1.03	1.70	1.53
			kinase, 90 kD, polypeptide 2
48050	RPS6KA2	RPS6KA2	ribosomal protein S6	1.12	1.00	1.43	1.12	1.06	1.00	1.53	1.42
			kinase, 90 kD, polypeptide 2
46950	SERPINA3		serine (or cysteine)	1.39	1.34	1.06	1.00	1.41	1.28	1.09	1.00
			proteinase inhibitor, clade
			A (alpha-1 antiproteinase,
			antitrypsin), member 3
47166	SERPINA6		serine (or cysteine)	1.33	1.04	1.48	1.36	1.66	1.05	1.38	1.00
			proteinase inhibitor, clade
			A (alpha-1 antiproteinase,
			antitrypsin), member 6
47332	SERPINB3		serine (or cysteine)	1.39	1.24	1.22	1.06	1.33	1.25	1.43	1.40
			proteinase inhibitor, clade
			B (ovalbumin), member 3
47193	STAT3	STAT3	signal transducer and	1.62	1.47	1.47	1.32	1.64	1.25	1.47	1.08
			activator of transcription 3
			(acute-phase response
			factor)
47569	STAT3	STAT3	signal transducer and	1.42	1.05	1.34	1.19	2.00	1.69	1.34	1.00
			activator of transcription 3
			(acute-phase response
			factor)
46796	STC1		stanniocalcin 1	1.41	1.34	1.05	1.00	1.47	1.34	1.64	1.51
48603	TEAD4	TEAD4	TEA domain family	1.67	1.35	1.65	1.38	2.19	1.72	1.52	1.42
			member 4
47987	THBS1	THBS1	thrombospondin 1	0.66	1.17	0.87	1.00	0.68	1.32	0.61	1.26
47444	TKT		transketolase (Wernicke-	0.83	1.16	0.76	1.16	0.82	1.00	0.70	1.38
			Korsakoff syndrome)
48239	TLN1	TLN1	talin 1	1.53	1.20	1.41	1.34	1.57	1.51	1.25	1.00
47155	TNFAIP6	TNFAIP6	tumor necrosis factor,	1.27	1.18	1.08	1.02	1.23	1.17	1.39	1.36
			alpha-induced protein 6
50379	TNFRSF6	FAS	tumor necrosis factor	1.40	1.08	1.41	1.04	1.57	1.38	1.22	1.13
			receptor superfamily,
			member 6
47697	TNFRSF6B	DcR3	tumor necrosis factor	1.44	1.14	1.24	1.11	1.84	1.52	1.31	1.06
			receptor superfamily,
			member 6b, decoy
50491	TNFRSF6B	DcR3	tumor necrosis factor	1.36	1.00	1.56	1.36	1.60	1.17	1.29	1.04
			receptor superfamily,
			member 6b, decoy
49330	TNFRSF7	CD27	tumor necrosis factor	1.76	1.53	1.73	1.51	1.90	1.44	1.66	1.48
			receptor superfamily,
			member 7
48395	TNFRSF7	CD27	tumor necrosis factor	1.53	1.30	1.50	1.09	1.76	1.55	1.39	1.03
			receptor superfamily,
			member 7
48288	TRAF5	TRAF5	TNF receptor-associated	1.42	1.16	1.60	1.34	1.96	1.40	1.67	1.46
			factor 5
49901	TROAP		trophinin associated	0.84	1.03	0.90	1.01	0.93	1.01	0.65	1.39
			protein (tastin)
48485	UCP1		uncoupling protein 1	1.00	1.00	1.59	1.15	1.70	1.32	1.03	1.00
			(mitochondrial, proton
			carrier)
49899	WWOX		WW domain containing	0.76	1.00	1.62	1.51	1.07	1.00	0.95	1.00
			oxidoreductase

APPENDIX D
Effect of FADS1 inhibitor +/− macrolides
Genes in bold have min fold change ≧1.3
					+/−FADS1,	+FADS1 +/− Clari,	+FADS1 +/− Clari,	+FADS1 +/− Roxi,	+FADS1 +/− Roxi,
				+/−FADS1,	min fold	wtd	min	wtd	min
SpotID	GeneSymbol	GeneName	GeneAssignment	wtd means	change	means	fold change	means	fold change
47003				1.43	1.29	0.70	1.27	0.66	1.49
46594				1.40	1.24	0.66	1.31	0.68	1.41
49817				1.44	1.37	0.67	1.24	0.68	1.41
49343				1.35	1.29	0.69	1.23	0.70	1.40
48626				1.48	1.31	0.69	1.28	0.69	1.40
46609				1.39	1.27	0.65	1.38	0.68	1.38
47315				1.18	1.00	0.68	1.23	0.68	1.35
46987				1.50	1.13	0.65	1.39	0.62	1.35
50468				1.33	1.22	0.68	1.30	0.71	1.34
47624				1.41	1.39	0.71	1.29	0.72	1.29
49720				1.00	1.00	1.31	1.30	1.32	1.23
49612				1.42	1.32	0.75	1.12	0.75	1.20
47206				1.41	1.10	0.67	1.39	0.67	1.13
48260				1.56	1.48	0.66	1.37	0.75	1.05
47794				1.83	1.36	0.80	1.07	0.87	1.00
47744				1.70	1.41	0.75	1.00	0.79	1.00
48039				1.79	1.31	0.81	1.00	0.91	1.00
49952	AADAC		arylacetamide deacetylase (esterase)	1.30	1.10	0.75	1.24	0.66	1.48
47192	ARHGAP1	ARHGAP1	Rho GTPase activating protein 1	1.19	1.15	0.76	1.16	0.75	1.30
48322	ARHGEF16	ARHGEF16	Rho guanine exchange factor (GEF) 16	1.50	1.20	0.56	1.40	0.70	1.12
47568	ATF7	ATF7	activating transcription factor 7	1.38	1.11	0.70	1.32	0.67	1.33
46854	BTN3A2	BTN3A2	butyrophilin, subfamily 3, member A2	1.46	1.08	0.65	1.39	0.67	1.22
47471	C21orf18		chromosome 21 open reading frame 18	1.61	1.31	0.85	1.00	0.84	1.03
47927	CD14	CD14	CD14 antigen	1.48	1.31	0.60	1.16	0.73	1.00
47301	COL11A2	COL11A2	collagen, type XI, alpha 2	1.68	1.34	0.64	1.00	0.71	1.00
50168	COL4A5	COL4A5	collagen, type IV, alpha 5 (Alport syndrome)	0.94	1.00	0.89	1.02	0.71	1.38
48721	DAF	CD55	decay accelerating factor for complement (CD55,	0.99	1.00	1.41	1.30	1.39	1.32
			Cromer blood group system)
50745	DNAJB1	DNAJB1	DnaJ (Hsp40) homolog, subfmaily B, member 1	0.72	1.32	1.19	1.08	1.13	1.05
48998	FADS1		fatty acid desaturase 1	1.01	1.00	1.46	1.02	1.48	1.38
50580	G1P2	ISG15, IFN	interferon-stimulated protein, 15 kDa	1.43	1.34	0.69	1.25	0.72	1.35
		stimulated
		protein
49675	GAB2	GAB2	GRB2-associated binding protein 2	1.19	1.17	0.84	1.09	0.63	1.37
46611	GRB14	GRB14	growth factor receptor-bound protein 14	0.97	1.00	0.80	1.15	0.69	1.35
48110	GREB1		KIAA0575 gene product	1.20	1.03	0.66	1.31	0.72	1.27
49185	GUCA2B		guanylate cyclase activator 2B (uroguanylin)	2.02	1.38	1.00	1.00	1.30	1.13
49652	HSPA8	HSPA8	heat shock 70 kD protein 8	0.91	1.07	1.20	1.05	1.56	1.42
49448	HSPG2	heparin sulfate	heparan sulfate proteoglycan 2 (perlecan)	0.99	1.00	0.70	1.32	0.76	1.05
		proteoglycan-2
50084	IDI1		isopentenyl-diphosphate delta isomerase	0.92	1.05	1.46	1.03	1.47	1.38
47656	IL1B	IL-1, beta	interleukin 1, beta	0.91	1.00	1.20	1.11	1.38	1.32
46865	IL6R	IL-6R	interleukin 6 receptor	1.42	1.33	0.66	1.22	0.73	1.29
49873	INSIG1		insulin induced gene 1	0.97	1.00	1.37	1.00	1.93	1.50
47212	ITGB5	integrin beta 5	integrin, beta 5	0.90	1.00	1.09	1.00	1.59	1.41
49167	KDELR3		KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum	1.58	1.21	1.44	1.33	1.37	1.28
			protein retention receptor 3
49362	KRT7		keratin 7	0.52	1.67	0.94	1.00	0.91	1.00
49683	LEPR	leptin R	leptin receptor	1.46	1.15	0.69	1.06	0.70	1.34
47001	MAP3K7IP1	TAB1	transforming growth factor beta-activated kinase-	148	1.00	0.69	1.29	0.70	1.37
			binding protein 1
47218	MAP3K7IP1	TAB1	transforming growth factor beta-activated kinase-	1.45	1.34	0.68	1.20	0.67	1.34
			binding protein 1
48951	MAPK7	ERK5	mitogen-activated protein kinase 7	1.33	1.31	0.86	1.04	0.80	1.22
48760	MAPK8IP3	MAPK8IP3	mitogen-activated protein kinase 8 interacting	1.42	1.17	0.63	1.32	0.63	1.19
			protein 3
50566	MCC		mutated in colorectal cancers	1.43	1.34	0.68	1.22	0.75	1.21
49115	MMPL1	MMPL1	matrix metalloproteinase-like 1	1.58	1.38	0.60	1.14	0.61	1.07
50004	NGFR	NGFR,	nerve growth factor receptor (TNFR superfamily,	1.71	1.38	0.89	1.00	0.95	1.00
		TNFRSF16	member 16)
47416	NTS		neurotensin	0.68	1.40	1.08	1.00	0.90	1.08
47902	P2RY2	P2RY2	purinergic receptor P2Y, G-protein coupled, 2	1.00	1.00	1.74	1.41	1.23	1.02
49854	PI3	PI3	protease inhibitor 3, skin-derived (SKALP)	1.01	1.00	1.50	1.43	1.34	1.10
49398	PIGR		polymeric immunoglobulin receptor	1.29	1.18	0.71	1.20	0.71	1.32
47971	PLA2G4A	phospholipase	phospholipase A2, group IVA (cytosolic, calcium-	1.88	1.42	0.60	1.00	0.76	1.00
		A2	dependent)
49103	PPID	cyclophilin D	peptidylprolyl isomerase D (cyclophilin D)	1.37	1.25	0.72	1.27	0.73	1.33
49413	PPID	cyclophilin D	peptidylprolyl isomerase D (cyclophilin D)	1.48	1.29	0.71	1.27	0.73	1.32
46994	PPP2R2B	PP2 regulatory	protein phosphatase 2 (formerly 2A), regulatory	1.20	1.00	0.56	1.47	0.61	1.37
		subunit B beta	subunit B (PR 52), beta isoform
46961	PPP2R2B	PP2 regulatory	protein phosphatase 2 (formerly 2A), regulatory	1.18	1.00	0.63	1.33	0.64	1.28
		subunit B beta	subunit B (PR 52), beta isoform
48726	PPP2R2B	PP2 regulatory	protein phosphatase 2 (formerly 2A), regulatory	1.31	1.00	0.60	1.45	0.65	1.16
		subunit B beta	subunit B (PR 52), beta isoform
46973	PRKAR1B	PKA, regulatory	protein kinase, cAMP-dependent, regulatory, type I,	1.19	1.07	0.67	1.32	0.70	1.40
		subunit, type I	beta
		beta
47006	PRKAR1B	PKA, regulatory	protein kinase, cAMP-dependent, regulatory, type I,	1.39	1.20	0.65	1.32	0.71	1.38
		subunit, type I	beta
		beta
47109	PRKG2		protein kinase, cGMP-dependent, type II	1.78	1.36	1.07	1.00	0.88	1.00
47176	PTGES	PTGES	prostaglandin E synthase	0.88	1.01	1.16	1.00	1.43	1.36
46985	RIPK2	RIP2, RICK	receptor-interacting serine-threonine kinase 2	1.57	1.36	0.66	1.39	0.65	1.32
48500	RPL13A		ribosomal protein L13a	1.13	1.00	0.80	1.11	0.74	1.31
47876	SERPINB3		serine (or cysteine) proteinase inhibitor, clade B	1.05	1.00	1.56	1.44	1.53	1.31
			(ovalbumin), member 3
47332	SERPINB3		serine (or cysteine) proteinase inhibitor, clade B	0.93	1.00	1.43	1.28	1.50	1.31
			(ovalbumin), member 3
48711	SPP1	SPP1	secreted phosphoprotein 1 (osteopontin, bone	0.99	1.00	1.34	1.27	1.42	1.35
			sialoprotein I, early T-lymphocyte activation 1)
47193	STAT3	STAT3	signal transducer and activator of transcription 3	1.21	1.06	0.68	1.33	0.70	1.32
			(acute-phase response factor)
47569	STAT3	STAT3	signal transducer and activator of transcription 3	1.40	1.15	0.71	1.31	0.70	1.26
			(acute-phase response factor
46622	TCF7	TCF7	transcription factor 7 (T-cell specific, HMG-box)	1.16	1.02	0.72	1.14	0.70	1.30
48603	TEAD4	TEAD4	TEA domain family member 4	1.42	1.28	0.66	1.33	0.65	1.31
48577	THBS3	THBS3	thrombospondin 3	1.48	1.31	0.75	1.00	0.79	1.00
49330	TNFRSF7	CD27	tumor necrosis factor receptor superfamily, member 7	1.43	1.38	0.69	1.28	0.71	1.35
48395	TNFRSF7	CD27	tumor necrosis factor receptor superfamily, member 7	1.30	1.19	0.71	1.27	0.71	1.31
49609	TNFSF5	CD40L	tumor necrosis factor (ligand) superfamily, member	1.64	1.31	1.01	1.00	0.83	1.00
			5 (hyper-IgM syndrome)
48198	TNNC1		troponin C, slow	1.66	1.38	1.00	1.00	1.02	1.00
48275	TRAF2	TRAF2	TNF receptor-associated factor 2	0.98	1.00	0.65	1.30	0.76	1.00
48288	TRAF5	TRAF5	TNF receptor-associated factor 5	1.34	1.26	0.64	1.37	0.70	1.20

APPENDIX E
Genes statistically predictive of Clari response
Genes differentially expressed in response to Clari but not the inactive macrolides MAA or Josa
SpotID	GeneSymbol	GeneName	GeneAssignment	p value	mean group 1	mean group 2	N of expts	comparison
47705	MAD4	MAD4	Mad4 homolog	4.38E−09	0.97	1.42	58	MAA and Josa vs. Clari
49922	DHCR24		24-dehydrocholesterol reductase	1.46E−08	1.00	1.27	58	MAA and Josa vs. Clari
48470	MCM5		MCM5 minichromosome maintenance deficient 5, cell	8.57E−08	0.97	0.68	58	MAA and Josa vs. Clari
			division cycle 46 (S. cerevisiae)
49688	GSK3B	GSK3B	glycogen synthase kinase 3 beta	1.11E−07	1.05	1.26	58	MAA and Josa vs. Clari
50550	PTPRT	PTPRT	protein tyrosine phosphatase, receptor type, T	1.24E−07	0.92	1.08	57	MAA and Josa vs. Clari
48998	FADS1		fatty acid desaturase 1	1.32E−07	1.02	1.44	58	MAA and Josa vs. Clari
50639	PDIR		for protein disulfide isomeras-related	1.36E−07	0.91	1.10	57	MAA and Josa vs. Clari
49715	HNRPD		heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding	1.70E−07	0.99	0.88	58	MAA and Josa vs. Clari
			protein 1, 37 kD)
48333	DNMT1		DNA (cytosine-5-)-methyltransferase 1	1.76E−07	0.97	0.79	57	MAA and Josa vs. Clari
50654	COPB2		coatomer protein complex, subunit beta 2 (beta prime)	3.59E−07	0.99	1.12	58	MAA and Josa vs. Clari
49183	SRRM1		serine/arginine repetitive matrix 1	4.23E−07	0.96	0.81	58	MAA and Josa vs. Clari
49380	SLC35A2		solute carrier family 35 (UDP-galactose transporter), member 2	4.59E−07	0.99	1.11	58	MAA and Josa vs. Clari
47755	KIAA1922		KIAA1922 protein	4.76E−07	1.14	0.79	46	MAA and Josa vs. Clari
50412	AGPAT1		1-acylglycerol-3-phosphate O-acyltransferase 1	5.85E−07	0.99	1.12	58	MAA and Josa vs. Clari
			(lysophosphatidic acid acyltransferase, alpha)
48713	MKNK2	MNK2	G protein-coupled receptor kinase 7	1.11E−06	0.96	1.22	58	MAA and Josa vs. Clari
48451	M6PR		mannose-6-phosphate receptor (cation dependent)	1.40E−06	0.97	1.12	58	MAA and Josa vs. Clari
48530	APLP2		amyloid beta (A4) precursor-like protein 2	1.52E−06	0.95	1.15	58	MAA and Josa vs. Clari
50302	CDR2		cerebellar degeneration-related protein (62 kD)	1.55E−06	0.89	1.08	56	MAA and Josa vs. Clari
49347	HNRPA3		heterogeneous nuclear ribonucleoprotein A3	1.58E−06	1.01	0.71	55	MAA and Josa vs. Clari
49360	TEB4		similar to S. cerevisiae SSM4	1.91E−06	1.10	0.88	58	MAA and Josa vs. Clari
48644	KIAA0323		KIAA0323 protein	1.91E−06	1.01	1.14	58	MAA and Josa vs. Clari
50084	IDI1		isopentenyl-diphosphate delta isomerase	1.91E−06	0.90	1.32	58	MAA and Josa vs. Clari
50332	DAD1		defender against cell death 1	1.91E−06	1.02	1.20	58	MAA and Josa vs. Clari
50405	CHERP		calcium homeostasis endoplasmic reticulum protein	2.07E−06	1.00	0.87	58	MAA and Josa vs. Clari
49650	MAP3K10	MLK2	mitogen-activated protein kinase kinase kinase 10	2.23E−06	0.93	1.16	58	MAA and Josa vs. Clari
49735	GSK3B	GSK3B	glycogen synthase kinase 3 beta	2.23E−06	1.02	1.13	58	MAA and Josa vs. Clari
47446	RANBP1		RAN binding protein 1	2.60E−06	1.04	0.83	58	MAA and Josa vs. Clari
49705	PCYT2		phosphate cytidylyltransferase 2, ethanolamine	2.60E−06	0.92	1.24	58	MAA and Josa vs. Clari
47251	HKE4		HLA class II region expressed gene KE4	2.67E−06	0.94	1.13	57	MAA and Josa vs. Clari
49737	CHAF1B		chromatin assembly factor 1, subunit B (p60)	3.02E−06	0.99	0.84	55	MAA and Josa vs. Clari
47661	HSPA9B	HSPA9B	heat shock 70 kD protein 9B (mortalin-2)	3.03E−06	1.10	0.90	58	MAA and Josa vs. Clari
48328	FN1	FN1	fibronectin 1	3.53E−06	1.00	0.53	58	MAA and Josa vs. Clari
47947	SF3B3		splicing factor 3b, subunit 3, 130 kD	3.53E−06	1.10	0.93	58	MAA and Josa vs. Clari
49032	GSK3B	GSK3B	glycogen synthase kinase 3 beta	3.80E−06	1.06	1.23	58	MAA and Josa vs. Clari
48508	USP24		ubiquitin specific protease 24	4.10E−06	1.03	0.87	58	MAA and Josa vs. Clari
47249	AKR1A1		aldo-keto reductase family 1, member A1 (aldehyde	4.42E−06	0.93	1.08	58	MAA and Josa vs. Clari
			reductase)
48807	UNG		uracil-DNA glycosylase	4.42E−06	1.03	0.91	58	MAA and Josa vs. Clari
47123	MCM2		MCM2 minichromosome maintenance deficient 2, mitotin	4.47E−06	0.97	0.78	54	MAA and Josa vs. Clari
			(S. cerevisiae)
50337	FGFR2	FGF receptor 2	fibroblast growth factor receptor 2 (bacteria-expressed	5.39E−06	0.93	1.08	53	MAA and Josa vs. Clari
			kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1,
			Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome)
50307	MAX	MAX	MAX protein	5.94E−06	0.96	1.10	58	MAA and Josa vs. Clari
48971	P4HA2	P4HA2	procollagen-proline, 2-oxoglutarate 4-dioxygenase	6.24E−06	1.07	1.48	57	MAA and Josa vs. Clari
			(proline 4-hydroxylase), alpha polypeptide II
50319	BMP6	BMP6	bone morphogenetic protein 6	7.08E−06	0.98	1.15	56	MAA and Josa vs. Clari
47926	CCNE2	cyclin E2	cyclin E2	8.27E−06	0.98	0.73	45	MAA and Josa vs. Clari
47987	THBS1	THBS1	thrombospondin 1	8.43E−06	1.02	0.60	48	MAA and Josa vs. Clari
50659	MAX	MAX	MAX protein	8.57E−06	0.95	1.10	58	MAA and Josa vs. Clari
49169	RRS1		homolog of yeast ribosome biogenesis regulatory protein	9.04E−06	1.09	0.88	54	MAA and Josa vs. Clari
			RRS1
47212	ITGB5	integrin beta 5	integrin, beta 5	9.08E−06	0.94	1.12	57	MAA and Josa vs. Clari
46991	TFPI2	TFPI2	tissue factor pathway inhibitor 2	9.19E−06	1.00	0.57	56	MAA and Josa vs. Clari
47949	BCKDK		branched chain alpha-ketoacid dehydrogenase kinase	9.21E−06	1.07	0.94	58	MAA and Josa vs. Clari
47131	KIAA0251		KIAA0251 protein	9.78E−06	0.92	1.07	57	MAA and Josa vs. Clari
47950	DNASE1L1		deoxyribonuclease I-like 1	9.90E−06	0.96	1.06	58	MAA and Josa vs. Clari
47939	INPP5E		KIAA0123 protein	9.90E−06	0.99	0.89	58	MAA and Josa vs. Clari
50294	TM7SF2		transmembrane 7 superfamily member 2	1.09E−05	1.01	1.29	54	MAA and Josa vs. Clari
49144	PIK3R3	PI3K regulatory	phosphoinositide-3-kinase, regulatory subunit,	1.14E−05	1.01	1.15	58	MAA and Josa vs. Clari
		subunit, p55	polypeptide 3 (p55, gamma)
49989	VTN	vitronectin	vitronectin (serum spreading factor, somatomedin B,	1.17E−05	1.19	0.90	45	MAA and Josa vs. Clari
			complement S-protein)
49511	MATN2		matrilin 2	1.19E−05	0.93	1.17	55	MAA and Josa vs. Clari
47935	P4HA1	P4HA1, prolyl-4-	procollagen-proline, 2-oxoglutarate 4-dioxygenase	1.21E−05	0.95	1.27	56	MAA and Josa vs. Clari
		hydroxylase alpha1	(proline 4-hydroxylase), alpha polypeptide I
47951	COX15		COX15 homolog, cytochrome c oxidase assembly protein	1.23E−05	1.05	0.94	58	MAA and Josa vs. Clari
			(yeast)
48149	SFRS7		splicing factor, arginine/serine-rich 7 (35 kD)	1.30E−05	0.98	0.85	56	MAA and Josa vs. Clari
49006	PRSS25		protease, serine, 25	1.32E−05	1.02	1.17	58	MAA and Josa vs. Clari
48693	HSPBP1	HSPBP1	hsp70-interacting protein	1.32E−05	1.04	0.87	58	MAA and Josa vs. Clari
46579	SERPING1		serine (or cysteine) proteinase inhibitor, clade G (C1	1.41E−05	1.03	0.86	56	MAA and Josa vs. Clari
			inhibitor), member 1, (angioedema, hereditary)
48348	FN1	FN1	fibronectin 1	1.42E−05	1.00	0.53	58	MAA and Josa vs. Clari
49163	LGALS3		lectin, galactoside-binding, soluble, 3 (galectin 3)	1.52E−05	1.06	1.23	58	MAA and Josa vs. Clari
47622	TRAP1	TRAP1, hsp90 related	heat shock protein 75	1.52E−05	1.09	0.89	58	MAA and Josa vs. Clari
49172	YAF2		YY1 associated factor 2	1.60E−05	1.01	0.90	45	MAA and Josa vs. Clari
47811	ENTPD6		ectonucleoside triphosphate diphosphohydrolase 6	1.63E−05	0.93	1.11	58	MAA and Josa vs. Clari
			(putative function)
48725	IKKE	IKK-related K epsilon,	IKK-related kinase epsilon; inducible IkappaB kinase	1.63E−05	0.84	0.97	58	MAA and Josa vs. Clari
		IKK-I
50738	AD022	AD022	TRAF and TNF receptor-associated protein	1.63E−05	0.94	1.14	56	MAA and Josa vs. Clari
47754	NBS1		Nijmegen breakage syndrome 1 (nibrin)	1.71E−05	1.18	0.89	57	MAA and Josa vs. Clari
50099	CNOT3	CCR4-NOT	CCR4-NOT transcription complex, subunit 3	1.75E−05	0.95	0.84	58	MAA and Josa vs. Clari
		transcription complex,
		subunit 3
46882	HEXA		hexosaminidase A (alpha polypeptide)	1.88E−05	0.97	1.14	58	MAA and Josa vs. Clari
48182	SNAPC1		small nuclear RNA activating complex, polypeptide 1,	1.89E−05	1.00	0.87	54	MAA and Josa vs. Clari
			43 kD
48804	KIAA0217		KIAA0217 protein	1.89E−05	1.01	0.85	56	MAA and Josa vs. Clari
48471	RBM3		RNA binding motif protein 3	2.16E−05	1.06	0.87	58	MAA and Josa vs. Clari
47192	ARHGAP1	ARHGAP1	Rho GTPase activating protein 1	2.16E−05	1.10	0.94	58	MAA and Josa vs. Clari
49990	SRC	Src	v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene	2.28E−05	0.99	1.17	57	MAA and Josa vs. Clari
			homolog (avian)
48397	HIF1A	HIF-1 alpha	hypoxia-inducible factor 1, alpha subunit (basic helix-loop-	2.31E−05	1.09	0.89	58	MAA and Josa vs. Clari
			helix transcription factor)
47694	HSPA9B	HSPA9B	heat shock 70 kD protein 9B (mortalin-2)	2.31E−05	1.09	0.90	58	MAA and Josa vs. Clari
47406	MTHFD1		methylenetetrahydrofolate dehydrogenase (NADP+	2.31E−05	1.12	0.93	58	MAA and Josa vs. Clari
			dependent), methenyltetrahydrofolate cyclohydrolase,
			formyltetrahydrofolate synthetase
49364	ABCE1		ATP-binding cassette, sub-family E (OABP), member 1	2.31E−05	1.06	0.92	58	MAA and Josa vs. Clari
49608	POU4F1		POU domain, class 4, transcription factor 1	2.31E−05	0.97	1.05	58	MAA and Josa vs. Clari
48707	P4HA1	P4HA1, prolyl-4-	procollagen-proline, 2-oxoglutarate 4-dioxygenase	2.48E−05	0.97	1.25	58	MAA and Josa vs. Clari
		hydroxylase alpha1	(proline 4-hydroxylase), alpha polypeptide I
46896	CDIPT		CDP-diacylglycerol--inositol 3-phosphatidyltransferase	2.66E−05	0.91	1.04	58	MAA and Josa vs. Clari
			(phosphatidylinositol synthase)
49787	CYC1	cytochrome c-1	cytochrome c-1	2.66E−05	1.09	0.90	58	MAA and Josa vs. Clari
50224	HK2		hexokinase 2	2.85E−05	0.95	1.14	58	MAA and Josa vs. Clari
49649	FGF2	FGF-2	fibroblast growth factor 2 (basic)	2.94E−05	1.12	0.76	44	MAA and Josa vs. Clari
47535	ARHGDIA	ARHGDIA	Rho GDP dissociation inhibitor (GDI) alpha	3.05E−05	1.08	0.91	58	MAA and Josa vs. Clari
46825	MKNK2	MNK2	G protein-coupled receptor kinase 7	3.05E−05	0.94	1.15	58	MAA and Josa vs. Clari
49028	BNIP3L	BNIP3L	BCL2/adenovirus E1B 19 kD interacting protein 3-like	3.05E−05	1.03	1.25	58	MAA and Josa vs. Clari
47352	ADAM11	ADAM11	a disintegrin and metalloproteinase domain 11	3.14E−05	0.93	1.18	32	MAA and Josa vs. Clari
48006	BCL2L2	BCL2L2	BCL2-like 2	3.26E−05	0.86	1.02	58	MAA and Josa vs. Clari
49177	NEDD8		neural precursor cell expressed, developmentally down-	3.26E−05	0.97	1.06	58	MAA and Josa vs. Clari
			regulated 8
48192	OPA1		optic atrophy 1 (autosomal dominant)	3.26E−05	1.02	0.90	58	MAA and Josa vs. Clari
48396	CNOT2	CCR4-NOT	CCR4-NOT transcription complex, subunit 2	3.26E−05	1.04	0.91	58	MAA and Josa vs. Clari
		transcription complex,
		subunit 2
50464	MMP15	MMP15	matrix metalloproteinase 15 (membrane-inserted)	3.46E−05	0.87	1.10	55	MAA and Josa vs. Clari
48456	DDC		dopa decarboxylase (aromatic L-amino acid	3.46E−05	1.12	0.94	48	MAA and Josa vs. Clari
			decarboxylase)
49013	BBC3		Bcl-2 binding component 3	3.49E−05	0.93	1.07	58	MAA and Josa vs. Clari
49481	LOC55871		COBW-like protein	3.49E−05	0.90	1.05	58	MAA and Josa vs. Clari
49512	GC20		translation factor sui1 homolog	3.49E−05	1.01	1.16	58	MAA and Josa vs. Clari
47995	PTGER1	PTGER1	prostaglandin E receptor 1 (subtype EP1), 42 kD	3.54E−05	1.00	0.73	43	MAA and Josa vs. Clari
48160	ZAP3		ZAP3 protein	3.57E−05	1.08	0.92	53	MAA and Josa vs. Clari
49618	CLN2		ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-	3.74E−05	1.03	1.15	58	MAA and Josa vs. Clari
			Bielschowsky disease)
49698	CAT		catalase	3.74E−05	0.92	1.08	58	MAA and Josa vs. Clari
50532	PRKCBP1	PRKCBP1	protein kinase C binding protein 1	3.74E−05	1.07	0.94	58	MAA and Josa vs. Clari
47776	POLA		polymerase (DNA directed), alpha	3.79E−05	1.02	0.86	49	MAA and Josa vs. Clari
50349	LOC51295	ECSIT	ECSIT	3.92E−05	1.01	0.78	56	MAA and Josa vs. Clari
49155	ARTS-1		type 1 tumor necrosis factor receptor shedding	3.97E−05	1.11	0.81	49	MAA and Josa vs. Clari
			aminopeptidase regulator
46979	HSPBP1	HSPBP1	hsp70-interacting protein	4.00E−05	1.02	0.87	58	MAA and Josa vs. Clari
47793	BET3		similar to yeast BET3 (S. cerevisiae)	4.00E−05	0.95	1.08	58	MAA and Josa vs. Clari
47937	CTSB		cathepsin B	4.57E−05	0.98	1.15	58	MAA and Josa vs. Clari
49142	PPIB	cyclophilin B	Peptidylprolyl isomerase B (cyclophilin B)	4.57E−05	1.03	1.18	58	MAA and Josa vs. Clari
50284	UQCR		ubiquinol-cytochrome c reductase (6.4 kD) subunit	4.57E−05	0.83	1.00	58	MAA and Josa vs. Clari
48521	ARAF1		v-raf murine sarcoma 3611 viral oncogene homolog 1	4.57E−05	1.12	0.95	58	MAA and Josa vs. Clari
49391	PPP3CB	calcineurin A beta	protein phosphatase 3 (formerly 2B), catalytic subunit,	4.57E−05	1.02	0.92	58	MAA and Josa vs. Clari
			beta isoform (calcineurin A beta)
50342	IKKE	IKK-related K epsilon,	IKK-related kinase epsilon; inducible IkappaB kinase	4.61E−05	0.94	1.11	56	MAA and Josa vs. Clari
		IKK-I
49514	UBC		ubiquitin C	4.89E−05	0.97	1.11	58	MAA and Josa vs. Clari
50643	PROS1		protein S (alpha)	5.20E−05	0.93	1.11	56	MAA and Josa vs. Clari
50591				5.23E−05	1.01	1.17	58	MAA and Josa vs. Clari
50216				5.40E−05	0.95	1.05	57	MAA and Josa vs. Clari
48411	MGEA5	MGEA5	meningioma expressed antigen 5 (hyaluronidase)	5.78E−05	0.97	1.19	57	MAA and Josa vs. Clari
48914	TUBB		tubulin, beta polypeptide	5.97E−05	0.96	0.83	58	MAA and Josa vs. Clari
48705	SIGIRR	SIGIRR	single Ig IL-1R-related molecule	5.99E−05	0.97	1.12	56	MAA and Josa vs. Clari
48643	DIP2		KIAA0184 protein	6.38E−05	1.00	0.87	58	MAA and Josa vs. Clari
50135	RRBP1	RRBP1	ribosome binding protein 1 homolog 180 kD (dog)	6.38E−05	0.95	1.11	58	MAA and Josa vs. Clari
47111	GOLGB1		golgi autoantigen, golgin subfamily b, macrogolgin (with	6.42E−05	1.01	1.17	56	MAA and Josa vs. Clari
			transmembrane signal), 1
47034	C2orf3	GCF, TCF-9	chromosome 2 open reading frame 3	7.26E−05	1.01	0.87	50	MAA and Josa vs. Clari
49815	CDKN2C	p18	cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)	7.27E−05	1.06	0.90	58	MAA and Josa vs. Clari
50067	MBTPS1		membrane-bound transcription factor protease, site 1	7.27E−05	0.95	1.07	58	MAA and Josa vs. Clari
49197	FUCA1		fucosidase, alpha-L-1, tissue	7.27E−05	0.98	1.13	58	MAA and Josa vs. Clari
49882	LAMP2		lysosomal-associated membrane protein 2	7.76E−05	0.99	1.17	58	MAA and Josa vs. Clari
49314	PPIB	cyclophilin B	peptidylprolyl isomerase B (cyclophilin B)	7.76E−05	1.04	1.18	58	MAA and Josa vs. Clari
49435	TRRAP	TRRAP	transformation/transcription domain-associated protein	7.76E−05	1.07	0.89	58	MAA and Josa vs. Clari
49446	SRC	Src	v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene	8.28E−05	1.00	1.17	58	MAA and Josa vs. Clari
			homolog (avian)
47056	NFRKB		nuclear factor related to kappa B binding protein	8.28E−05	0.96	0.82	58	MAA and Josa vs. Clari
48646	SDCBP		syndecan binding protein (syntenin)	8.84E−05	0.97	1.11	58	MAA and Josa vs. Clari
49233	APOE		apolipoprotein E	9.43E−05	0.96	1.03	58	MAA and Josa vs. Clari
49374				9.43E−05	0.97	1.04	58	MAA and Josa vs. Clari
47524	PTK2B	PYK2	protein tyrosine kinase 2 beta	1.01E−04	1.34	1.08	58	MAA and Josa vs. Clari
48921	ITGAE	CD103	integrin, alpha E (antigen CD103, human mucosal	1.06E−04	0.85	0.99	57	MAA and Josa vs. Clari
			lymphocyte antigen 1; alpha polypeptide)
49490	VTN	vitronectin	vitronectin (serum spreading factor, somatomedin B,	1.08E−04	1.12	0.91	44	MAA and Josa vs. Clari
			complement S-protein)
49761	BCL2L2	BCL2L2	BCL2-like 2	1.13E−04	0.85	1.01	57	MAA and Josa vs. Clari
48672	CHK		choline kinase	1.14E−04	0.87	1.01	58	MAA and Josa vs. Clari
50399	DGCR6L		DiGeorge syndrome critical region gene 6 like	1.15E−04	1.02	1.17	54	MAA and Josa vs. Clari
48121	SCN1B		sodium channel, voltage-gated, type I, beta polypeptide	1.20E−04	0.90	1.07	54	MAA and Josa vs. Clari
50513	ARHC	RhoC	ras homolog gene family, member C	1.22E−04	0.91	1.02	58	MAA and Josa vs. Clari
49744	USF2	USF2	upstream transcription factor 2, c-fos interacting	1.22E−04	0.93	1.07	58	MAA and Josa vs. Clari
49930	KIAA0169		KIAA0169 protein	1.22E−04	1.03	0.95	58	MAA and Josa vs. Clari
48301	GCN5L1		GCN5 general control of amino-acid synthesis 5-like 1	1.30E−04	0.93	1.02	58	MAA and Josa vs. Clari
			(yeast)
49967	CCNE2	cyclin E2	cyclin E2	1.31E−04	1.02	0.82	50	MAA and Josa vs. Clari
49981	BMP6	BMP6	bone morphogenetic protein 6	1.32E−04	0.94	1.10	53	MAA and Josa vs. Clari
48500	RPL13A		ribosomal protein L13a	1.38E−04	1.05	0.90	58	MAA and Josa vs. Clari
47911	YWHAE	14-3-3 epsilon	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase	1.38E−04	1.04	0.95	58	MAA and Josa vs. Clari
			activation protein, epsilon polypeptide
50736	PRKDC	PRKDC	protein kinase, DNA-activated, catalytic polypeptide	1.38E−04	1.07	0.90	58	MAA and Josa vs. Clari
50085				1.47E−04	1.18	1.00	58	MAA and Josa vs. Clari
46679	KIAA1172		pre-mRNA splicing SR protein rA4	1.48E−04	1.04	0.91	56	MAA and Josa vs. Clari
46843	ARHGDIA	ARHGDIA	Rho GDP dissociation inhibitor (GDI) alpha	1.57E−04	1.08	0.91	58	MAA and Josa vs. Clari
47898	ERF	ERF	Ets2 repressor factor	1.57E−04	1.14	1.01	58	MAA and Josa vs. Clari
49915	ATP2B4		ATPase, Ca++ transporting, plasma membrane 4	1.57E−04	1.23	1.03	58	MAA and Josa vs. Clari
49352	NCBP2		nuclear cap binding protein subunit 2, 20 kD	1.66E−04	0.94	1.03	57	MAA and Josa vs. Clari
48280	ARHC	RhoC	ras homolog gene family, member C	1.67E−04	0.90	1.01	58	MAA and Josa vs. Clari
48235	DAXX	Daxx	death-associated protein 6	1.67E−04	1.02	0.93	58	MAA and Josa vs. Clari
49373	EIF3S9		eukaryotic translation initiation factor 3, subunit 9 (eta,	1.67E−04	1.06	0.94	58	MAA and Josa vs. Clari
			116 kD)
49318	YWHAH	14-3-3 eta	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase	1.78E−04	1.08	0.95	58	MAA and Josa vs. Clari
			activation protein, eta polypeptide
50222	FLJ13868		hypothetical protein FLJ13868	1.78E−04	0.93	1.06	58	MAA and Josa vs. Clari
49524	AP1G2		adaptor-related protein complex 1, gamma 2 subunit	1.78E−04	0.74	0.97	58	MAA and Josa vs. Clari
47802	GOT1		glutamic-oxaloacetic transaminase 1, soluble (aspartate	1.89E−04	1.02	0.93	55	MAA and Josa vs. Clari
			aminotransferase 1)
48000	CTSH		cathepsin H	1.89E−04	0.93	1.22	58	MAA and Josa vs. Clari
48233	MAPK12	ERK6/SAPK3, p38,	mitogen-activated protein kinase 12	1.89E−04	0.88	1.05	58	MAA and Josa vs. Clari
		gamma
50079	SCOP		SCN Circadian Oscillatory Protein (SCOP)	1.89E−04	0.97	1.05	58	MAA and Josa vs. Clari
49781	P4HB	P4HB	procollagen-proline, 2-oxoglutarate 4-dioxygenase	1.89E−04	0.98	1.10	58	MAA and Josa vs. Clari
			(proline 4-hydroxylase), beta polypeptide (protein disulfide
			isomerase; thyroid hormone binding protein p55)
49757	DDOST		dolichyl-diphosphooligosaccharide-protein	1.89E−04	0.96	1.08	58	MAA and Josa vs. Clari
			glycosyltransferase
46935	METAP2		methionyl aminopeptidase 2	2.01E−04	1.05	0.88	58	MAA and Josa vs. Clari
47439	DCTN1		dynactin 1 (p150, glued homolog, Drosophila)	2.01E−04	1.04	0.93	58	MAA and Josa vs. Clari
47418	SNK		serum-inducible kinase	2.02E−04	1.03	0.77	56	MAA and Josa vs. Clari
48415	SERPINB1		serine (or cysteine) proteinase inhibitor, clade B	2.04E−04	1.02	1.32	38	MAA and Josa vs. Clari
			(ovalbumin), member 1
48214	BAT8		HLA-B associated transcript 8	2.14E−04	1.02	1.11	58	MAA and Josa vs. Clari
49747	RPLP0		ribosomal protein, large, P0	2.14E−04	0.91	1.09	58	MAA and Josa vs. Clari
49047	GLUD1		glutamate dehydrogenase 1	2.14E−04	1.05	0.95	58	MAA and Josa vs. Clari
49794	BCL2L2	BCL2L2	BCL2-like 2	2.15E−04	0.86	1.01	57	MAA and Josa vs. Clari
50474	CEBPA	C/EBP alpha	CCAAT/enhancer binding protein (C/EBP), alpha	2.15E−04	0.97	1.29	57	MAA and Josa vs. Clari
49767	AD022	AD022	TRAF and TNF receptor-associated protein	2.15E−04	0.96	1.12	57	MAA and Josa vs. Clari
50386	TFAM	TFAM	transcription factor A, mitochondrial	2.17E−04	1.05	0.91	53	MAA and Josa vs. Clari
50689	GNB5	G protein, beta 5	guanine nucleotide binding protein (G protein), beta 5	2.21E−04	1.00	1.19	46	MAA and Josa vs. Clari
50103	IRF5	IRF5	interferon regulatory factor 5	2.27E−04	0.87	1.01	58	MAA and Josa vs. Clari
49007	TM9SF2		transmembrane 9 superfamily member 2	2.27E−04	1.08	1.20	58	MAA and Josa vs. Clari
49546	GNPI		glucosamine-6-phosphate isomerase	2.27E−04	1.05	1.16	58	MAA and Josa vs. Clari
46838	PRKAR1A	PKA, regulatory	protein kinase, cAMP-dependent, regulatory, type I, alpha	2.27E−04	1.04	0.92	58	MAA and Josa vs. Clari
		subunit, type I alpha	(tissue specific extinguisher 1)
49820	CYC1	cytochrome c-1	cytochrome c-1	2.27E−04	1.05	0.90	58	MAA and Josa vs. Clari
47850	PRLR	prolactin R	prolactin receptor	2.29E−04	1.09	0.99	55	MAA and Josa vs. Clari
50452	SIGIRR	SIGIRR	single Ig IL-1R-related molecule	2.31E−04	0.96	1.10	55	MAA and Josa vs. Clari
48266	GRB2	Grb2	growth factor receptor-bound protein 2	2.42E−04	0.93	1.06	58	MAA and Josa vs. Clari
46586	C12orf8		chromosome 12 open reading frame 8	2.42E−04	0.98	1.22	58	MAA and Josa vs. Clari
47354	ERF	ERF	Ets2 repressor factor	2.42E−04	1.15	1.00	58	MAA and Josa vs. Clari
50049	GNB2L1		guanine nucleotide binding protein (G protein), beta	2.42E−04	1.32	1.10	58	MAA and Josa vs. Clari
			polypeptide 2-like 1
48363	CNOT2	CCR4-NOT	CCR4-NOT transcription complex, subunit 2	2.44E−04	1.03	0.92	57	MAA and Josa vs. Clari
		transcription complex,
		subunit 2
50011	NFYC	NFYC	nuclear transcription factor Y, gamma	2.49E−04	1.10	0.95	56	MAA and Josa vs. Clari
48365	MAPK9	JNK2	mitogen-activated protein kinase 9	2.73E−04	1.04	0.92	58	MAA and Josa vs. Clari
49117	SERPINB1		serine (or cysteine) proteinase inhibitor, clade B	2.73E−04	1.01	0.84	58	MAA and Josa vs. Clari
			(ovalbumin), member 1
49580	PSMC4		proteasome (prosome, macropain) 26S subunit, ATPase, 4	2.73E−04	1.12	0.99	58	MAA and Josa vs. Clari
46948	MAP2K1IP1	MP1	mitogen-activated protein kinase kinase 1 interacting	2.79E−04	0.92	1.05	56	MAA and Josa vs. Clari
			protein 1
50755	MMP2	MMP2, gelatinase A	matrix metalloproteinase 2 (gelatinase A, 72 kD	2.79E−04	1.02	1.14	56	MAA and Josa vs. Clari
			gelatinase, 72 kD type IV collagenase)
47241	NUBP1		nucleotide binding protein 1 (MinD homolog, E. coli)	2.79E−04	1.04	0.93	55	MAA and Josa vs. Clari
47592	SART1		squamous cell carcinoma antigen recognised by T cells	2.90E−04	1.01	0.89	58	MAA and Josa vs. Clari
47522	SERPINA1	S, C protease inhibitor	serine (or cysteine) proteinase inhibitor, clade A (alpha-1	2.94E−04	1.04	0.94	57	MAA and Josa vs. Clari
			antiproteinase, antitrypsin), member 1
50784	AKR7A2		aldo-ket reductase family 7, member A2 (aflatoxin	3.01E−04	0.95	1.03	55	MAA and Jose vs. Clari
			aldehyde reductase)
49992	HSPG2	heparin sulfate	heparan sulfate proteoglycan 2 (perlecan)	3.04E−04	0.97	0.82	46	MAA and Josa vs. Clari
		proteoglycan-2
47960	SLC7A5		solute carrier family 7 (cationic amino acid transporter, y+	3.08E−04	1.21	1.03	58	MAA and Jose vs. Clari
			system member 5
50050	NDUFA2		NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,	3.08E−04	0.90	1.03	58	MAA and Josa vs. Clari
			2 (8 kD, B8)
49577	LOC54543		6.2 kd protein	3.08E−04	0.88	1.05	58	MAA and Jose vs. Clari
49510				3.08E−04	1.00	1.28	58	MAA and Josa vs. Clari
48468	NRG1	neuregulin1, neu diff.	neuregulin 1	3.23E−04	1.00	0.76	57	MAA and Josa vs. Clari
		Factor, heregulin
48398	MAPK9	JNK2	mitogen-activated protein kinase 9	3.27E−04	1.02	0.92	58	MAA and Josa vs. Clari
49602	RAB3GAP		RAB3 GTPase-ACTIVATING PROTEIN	3.27E−04	1.09	0.99	58	MAA and Josa vs. Clari
46927	ACY1		aminoacylase 1	3.27E−04	0.79	1.05	58	MAA and Josa vs. Clari
49241	MCP		membrane cofactor protein (CD46, trophoblast-	3.47E−04	0.87	1.00	58	MAA and Josa vs. Clari
			lymphocyte cross-reactive antigen)
48990	KRAS2	K-Ras	v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog	3.52E−04	1.03	0.90	53	MAA and Josa vs. Clari
48464	FXYD3		FXYD domain-containing ion transport regulator 3	3.53E−04	1.14	0.97	57	MAA and Josa vs. Clari
50029	ROCK2	ROCK2	Rho-associated, coiled-coil containing protein kinase 2	3.53E−04	1.07	0.95	57	MAA and Josa vs. Clari
49800	AD022	AD022	TRAF and TNF receptor-associated protein	3.53E−04	0.97	1.12	57	MAA and Josa vs. Clari
48918	KIAA0514		KIAA0514 gene product	3.59E−04	0.99	1.11	56	MAA and Josa vs. Clari
47973	USF2	USF2	upstream transcription factor 2, c-fos interacting	3.64E−04	0.96	1.08	56	MAA and Josa vs. Clari
49657	CFL1	CFL1	cofilin 1 (non-muscle)	3.68E−04	1.16	0.96	58	MAA and Josa vs. Clari
50022	HIF1A	HIF-1 alpha	hypoxia-inducible factor 1, alpha subunit (basic helix-loop-	3.68E−04	1.07	0.91	58	MAA and Josa vs. Clari
			helix transcription factor)
48498	DIRC2		hypothetical protein FLJ14784	3.84E−04	0.99	1.13	54	MAA and Josa vs. Clari
48104	KIAA0546		KIAA0546 protein	3.91E−04	0.99	1.10	58	MAA and Josa vs. Clari
46851	RRBP1	RRBP1	ribosome binding protein 1 homolog 180 kD (dog)	3.91E−04	0.97	1.09	58	MAA and Josa vs. Clari
50347	TRAP1	TRAP1, hsp90 related	heat shock protein 75	3.91E−04	1.06	0.87	58	MAA and Josa vs. Clari
47712	NR4A2	TINUR	nuclear receptor subfamily 4, group A, member 2	4.01E−04	0.96	1.24	49	MAA and Josa vs. Clari
48486				4.06E−04	1.21	0.94	30	MAA and Josa vs. Clari
48217	SF3A3	spliceosomal protein	splicing factor 3a, subunit 3, 60 kD	4.14E−04	1.05	0.96	58	MAA and Josa vs. Clari
		SAP 61
46648	ARHGAP1	ARHGAP1	Rho GTPase activating protein 1	4.14E−04	1.07	0.95	58	MAA and Josa vs. Clari
49397	FY	duffy antigen	Duffy blood group	4.14E−04	1.14	1.03	58	MAA and Josa vs. Clari
48479	KIF3C		kinesin family member 3C	4.18E−04	1.06	1.23	52	MAA and Josa vs. Clari
47417	COG2		low density lipoprotein receptor defect C complementing	4.24E−04	1.09	0.95	50	MAA and Josa vs. Clari
47609	CYFIP2		cytoplasmic FMRP interacting protein 2	4.24E−04	1.06	0.95	57	MAA and Josa vs. Clari
46988	EREG	epiregulin	epiregulin	4.29E−04	1.11	0.80	39	MAA and Josa vs. Clari
48137	FRDA		Friedreich ataxia	4.33E−04	1.03	0.88	56	MAA and Josa vs. Clari
50601	SRP19		signal recognition particle 19 kD	4.33E−04	0.95	1.08	56	MAA and Josa vs. Clari
47504	MSH3		mutS homolog 3 (E. coli)	4.35E−04	1.09	0.98	43	MAA and Josa vs. Clari
48406	CKLF1	chemokine-like factor 3	chemokine-like factor 1	4.39E−04	0.91	1.10	58	MAA and Josa vs. Clari
49873	INSIG1		insulin induced gene 1	4.39E−04	0.93	1.44	58	MAA and Josa vs. Clari
49525	PIGQ		phosphatidylinositol glycan, class Q	4.39E−04	0.90	1.05	58	MAA and Josa vs. Clari
47181	RAB2	RAB2	RAB2, member RAS oncogene family	4.66E−04	1.01	1.09	58	MAA and Josa vs. Clari
49785	TIMP2	TIMP2	tissue inhibitor of metalloproteinase 2	4.94E−04	1.07	1.35	58	MAA and Josa vs. Clari
50632	PTPRJ	PTPRJ	protein tyrosine phosphatase, receptor type, J	4.94E−04	1.12	1.30	58	MAA and Josa vs. Clari
49134	SYK	Syk	spleen tyrosine kinase	5.00E−04	0.98	1.31	16	MAA and Josa vs. Clari
50590	CKS2		CDC28 protein kinase 2	5.03E−04	0.74	0.90	55	MAA and Josa vs. Clari
48640	IL11RA	IL-11R alpha	interleukin 11 receptor, alpha	5.04E−04	0.79	0.99	49	MAA and Josa vs. Clari
47324	TCF7L2	TCF7L2	transcription factor 7-like 2 (T-cell specific, HMG-box)	5.04E−04	1.06	0.89	49	MAA and Josa vs. Clari
48360	CASP3	caspase-3	caspase 3, apoptosis-related cysteine protease	5.08E−04	0.88	1.02	57	MAA and Josa vs. Clari
47679	NR4A2	TINUR	nuclear receptor subfamily 4, group A, member 2	5.11E−04	0.95	1.20	49	MAA and Josa vs. Clari
49654	PRKCD	PKC, delta	protein kinase C, delta	5.24E−04	0.95	1.04	58	MAA and Josa vs. Clari
49818	TIMP2	TIMP2	tissue inhibitor of metalloproteinase 2	5.24E−04	1.07	1.35	58	MAA and Josa vs. Clari
48822	UGDH		UDP-glucose dehydrogenase	5.24E−04	0.94	0.84	58	MAA and Josa vs. Clari
48004	CUTL1	CUTL1	cut-like 1, CCAAT displacement protein (Drosophila)	5.27E−04	1.22	1.00	53	MAA and Josa vs. Clari
50119	TOLLIP	Tollip	Toll-interacting protein	5.55E−04	1.07	1.19	58	MAA and Josa vs. Clari
47027	TNFRSF5	CD40	tumor necrosis factor receptor superfamily, member 5	5.55E−04	0.94	1.06	58	MAA and Josa vs. Clari
48329	SDHA		succinate dehydrogenase complex, subunit A,	5.55E−04	1.03	0.90	58	MAA and Josa vs. Clari
			flavoprotein (Fp)
50351	CFL1	CFL1	cofilin 1 (non-muscle)	5.55E−04	1.16	0.97	58	MAA and Josa vs. Clari
48126	RY1		putative nucleic acid binding protein RY-1	5.70E−04	1.01	0.85	53	MAA and Josa vs. Clari
49394	CDC25A		cell division cycle 25A	5.84E−04	1.03	0.86	53	MAA and Josa vs. Clari
48620	XBP1	XBP-1	X-box binding protein 1	5.88E−04	0.98	1.10	58	MAA and Josa vs. Clari
47436	LSM1		Lsm1 protein	5.88E−04	0.87	1.01	58	MAA and Josa vs. Clari
48952	ELK1	Elk-1	ELK1, member of ETS oncogene family	5.88E−04	0.98	1.06	58	MAA and Josa vs. Clari
49434	CKLF1	chemokine-like factor 3	chemokine-like factor 1	5.88E−04	0.90	1.10	58	MAA and Josa vs. Clari
49045	TUFM		Tu translation elongation factor, mitochondrial	5.88E−04	1.02	0.91	58	MAA and Josa vs. Clari
50365	TNFRSF1A	TNFR1	tumor necrosis factor receptor superfamily, member 1A	6.07E−04	0.95	1.07	57	MAA and Josa vs. Clari
49196				6.12E−04	0.99	1.18	54	MAA and Josa vs. Clari
49933	PDE3A		phosphodiesterase 3A, cGMP-inhibited	6.15E−04	1.10	0.89	42	MAA and Josa vs. Clari
47988	RPN2		ribophorin II	6.22E−04	0.93	1.03	58	MAA and Josa vs. Clari
48303	RUVBL1		RuvB-like 1 (E. coli)	6.22E−04	1.06	0.97	58	MAA and Josa vs. Clari
50576	GGCX		gamma-glutamyl Carboxylase	6.43E−04	0.85	1.00	57	MAA and Josa vs. Clari
47569	STAT3	STAT3	signal transducer and activator of transcription 3 (acute-	6.59E−04	1.04	0.91	58	MAA and Josa vs. Clari
			phase response factor)
47156	TNFRSF5	CD40	tumor necrosis factor receptor superfamily, member 5	6.64E−04	0.93	1.06	57	MAA and Josa vs. Clari
47916	CCL2	MCP1	small inducible cytokine A2 (monocyte chemotactic	6.75E−04	1.15	0.63	31	MAA and Josa vs. Clari
			protein 1)
47292	APOC1		apolipoprotein C-I	6.82E−04	0.98	1.11	57	MAA and Josa vs. Clari
49947	RFC1		replication factor C (activator 1) 1 (145 kD)	6.95E−04	1.05	0.91	54	MAA and Josa vs. Clari
47415	CETN2		centrin, EF-hand protein, 2	6.98E−04	1.06	1.19	58	MAA and Josa vs. Clari
48891	STK39		serine threonine kinase 39 (STE20/SPS1 homolog, yeast)	7.05E−04	1.02	0.91	50	MAA and Josa vs. Clari
50430	PPM1A		protein phosphatase 1A (formerly 2C), magnesium-	7.23E−04	0.98	1.06	57	MAA and Josa vs. Clari
			dependent, alpha isoform
48085	DC2		DC2 protein	7.38E−04	0.99	1.08	58	MAA and Josa vs. Clari
49638	AKT3	AKT3, PKB	v-akt murine thymoma viral oncogene homolog 3 (protein	7.38E−04	0.99	1.16	58	MAA and Josa vs. Clari
			kinase B, gamma)
48926	UBE2B		ubiguitin-conjugating enzyme E2B (RAD6 homolog)	7.38E−04	0.96	1.07	58	MAA and Josa vs. Clari
49551	MGC19606		similar to HYPOTHETICAL 34.0 KDA PROTEIN ZK795.3	7.38E−04	1.03	0.93	58	MAA and Josa vs. Clari
			IN CHROMOSOME IV
47349	HSGT1		suppressor of S. cerevisiae gcr2	7.57E−04	1.07	0.94	56	MAA and Josa vs. Clari
46650	P2RY6	P2RY6	pyrimidinergic receptor P2Y, G-protein coupled, 6	7.67E−04	0.95	1.14	57	MAA and Josa vs. Clari
49229	ZXDA		zinc finger, X-linked, duplicated A	7.81E−04	1.01	1.15	58	MAA and Josa vs. Clari
48502	CLIC4		chloride intracellular channel 4	7.88E−04	1.17	1.02	49	MAA and Josa vs. Clari
50764	KIAA0212		KIAA0212 gene product	7.96E−04	0.99	1.13	56	MAA and Josa vs. Clari
46938	ROCK2	ROCK2	Rho-associated, coiled-coil containing protein kinase 2	8.27E−04	1.06	0.92	58	MAA and Josa vs. Clari
49893	CHD4		chromodomain helicase DNA binding protein 4	8.27E−04	1.02	0.93	58	MAA and Josa vs. Clari
48841	TAF6		TAF6 RNA polymerase II, TATA box binding protein	8.27E−04	1.06	0.95	58	MAA and Josa vs. Clari
			(TBP)-associated factor, 80 kD
49550	SETDB1		SET domain, bifurcated 1	8.27E−04	1.01	0.95	58	MAA and Josa vs. Clari
50267	IL10RB	IL-10R beta	interleukin 10 receptor, beta	8.27E−04	0.98	1.09	58	MAA and Josa vs. Clari
50517	ARHGAP4	ARHGAP4	Rho GTPase activating protein 4	8.58E−04	0.86	1.10	49	MAA and Josa vs. Clari
49728	GALK2		galactokinase 2	8.74E−04	0.95	1.05	58	MAA and Josa vs. Clari
46834	PAK4	Pak4	p21(CDKN1A)-activated kinase 4	8.97E−04	1.04	0.89	56	MAA and Josa vs. Clari
48717	PPP3CB	calcineurin A beta	protein phosphatase 3 (formerly 2B), catalytic subunit,	9.07E−04	1.09	0.95	44	MAA and Josa vs. Clari
			beta isoform calcineurin A beta)
49448	HSPG2	heparin sulfate	heparan sulfate proteoglycan 2 (perlecan)	9.21E−04	0.97	0.83	47	MAA and Josa vs. Clari
		proteoglycan-2
47658	SERPINH2		serine (or cysteine) proteinase inhibitor, clade H (heat	9.25E−04	1.03	0.95	58	MAA and Josa vs. Clari
			shock protein 47), member 2
47627	HARS		histidyl-tRNA synthetase	9.25E−04	1.04	0.97	58	MAA and Josa vs. Clari
50205	KIAA0007		KIAA0007 protein	9.25E−04	0.98	0.89	58	MAA and Josa vs. Clari
50407	SORT1		sortilin 1	9.25E−04	0.93	1.04	58	MAA and Josa vs. Clari
49710	WSX1		class I cytokine receptor	9.25E−04	0.94	1.06	58	MAA and Josa vs. Clari
47761				9.51E−04	1.14	1.02	56	MAA and Josa vs. Clari
48557	NFE2L1	NFE2L1	nuclear factor (erythroid-derived 2)-like 1	9.65E−04	0.97	1.07	57	MAA and Josa vs. Clari
50424	HTGN29		HTGN29 protein	9.65E−04	0.92	1.02	57	MAA and Josa vs. Clari
49420	TIMP2	TIMP2	tissue inhibitor of metalloproteinase 2	9.77E−04	1.09	1.40	58	MAA and Josa vs. Clari
49869	ARG2		arginase, type II	9.78E−04	1.09	0.93	52	MAA and Josa vs. Clari
Genes statistically predictive of Clari and Roxi response
Genes differentially expressed in response to Clari and Roxi but not the inactive macrolides MAA or Josa
SpotID	GeneSymbol	GeneAssignment	p value	mean group 1	mean group 2	# expts	ClusterRString1
50639	PDIR	for protein disulfide isomerase-related	3.22E−09	0.91	1.13	71	MAA and Josa vs. Clari, Roxi
50654	COPB2	coatomer protein complex, subunit beta 2 (beta	3.57E−09	0.99	1.15	72	MAA and Josa vs. Clari, Roxi
		prime)
49380	SLC35A2	solute carrier family 35 (UDP-galactose	9.46E−09	0.99	1.12	72	MAA and Josa vs. Clari, Roxi
		transporter), member 2
47705	MAD4	Mad4 homolog	3.41E−08	0.97	1.29	72	MAA and Josa vs. Clari, Roxi
50302	CDR2	cerebellar degeneration-related protein (62 kD)	4.43E−08	0.89	1.10	70	MAA and Josa vs. Clari, Roxi
47249	AKR1A1	aldo-keto reductase family 1, member A1	1.33E−07	0.93	1.09	72	MAA and Josa vs. Clari, Roxi
		(aldehyde reductase)
47131	KIAA0251	KIAA0251 protein	1.95E−07	0.92	1.10	71	MAA and Josa vs. Clari, Roxi
50332	DAD1	defender against cell death 1	2.06E−07	1.02	1.21	72	MAA and Josa vs. Clari, Roxi
50084	IDI1	isopentenyl-diphosphate delta isomerase	2.20E−07	0.90	1.24	72	MAA and Josa vs. Clari, Roxi
48470	MCM5	MCM5 minichromosome maintenance deficient 5,	2.34E−07	0.97	0.73	72	MAA and Josa vs. Clari, Roxi
		cell division cycle 46 (S. cerevisiae)
47251	HKE4	HLA class II region expressed gene KE4	2.69E−07	0.94	1.15	71	MAA and Josa vs. Clari, Roxi
47755	KIAA1922	KIAA1922 protein	3.71E−07	1.14	0.84	56	MAA and Josa vs. Clari, Roxi
49922	DHCR24	24-dehydrocholesterol reductase	4.07E−07	1.00	1.21	72	MAA and Josa vs. Clari, Roxi
49705	PCYT2	phosphate cytidylyltransferase 2, ethanolamine	5.19E−07	0.92	1.19	72	MAA and Josa vs. Clari, Roxi
50307	MAX	MAX protein	5.86E−07	0.96	1.10	72	MAA and Josa vs. Clari, Roxi
49512	GC20	translation factor sui1 homolog	6.61E−07	1.01	1.18	72	MAA and Josa vs. Clari, Roxi
49735	GSK3B	glycogen synthase kinase 3 beta	7.91E−07	1.02	1.12	72	MAA and Josa vs. Clari, Roxi
47926	CCNE2	cyclin E2	1.32E−06	0.98	0.74	56	MAA and Josa vs. Clari, Roxi
50659	MAX	MAX protein	1.80E−06	0.95	1.09	72	MAA and Josa vs. Clari, Roxi
47212	ITGB5	integrin, beta 5	2.57E−06	0.94	1.13	71	MAA and Josa vs. Clari, Roxi
48998	FADS1	fatty acid desaturase 1	2.84E−06	1.02	1.35	72	MAA and Josa vs. Clari, Roxi
50337	FGFR2	fibroblast growth factor receptor 2 (bacteria-	3.75E−06	0.93	1.07	66	MAA and Josa vs. Clari, Roxi
		expressed kinase, keratinocyte growth factor
		receptor, craniofacial dysostosis 1, Crouzon
		syndrome, Pfeiffer syndrome, Jackson-Weiss
		syndrome)
50135	RRBP1	ribosome binding protein 1 homolog 180 kD (dog)	4.46E−06	0.95	1.11	72	MAA and Josa vs. Clari, Roxi
50412	AGPAT1	1-acylglycerol-3-phosphate O-acyltransferase 1	4.72E−06	0.99	1.10	72	MAA and Josa vs. Clari, Roxi
		(lysophosphatidic acid acyltransferase, alpha)
47949	BCKDK	branched chain alpha-ketoacid dehydrogenase	5.88E−06	1.07	0.95	72	MAA and Josa vs. Clari, Roxi
		kinase
48971	P4HA2	procollagen-proline, 2-oxoglutarate 4-dioxygenase	6.08E−06	1.07	1.41	71	MAA and Josa vs. Clari, Roxi
		(proline 4-hydroxylase), alpha polypeptide II
50550	PTPRT	protein tyrosine phosphatase, receptor type, T	6.81E−06	0.92	1.05	71	MAA and Josa vs. Clari, Roxi
47123	MCM2	MCM2 minichromosome maintenance deficient 2,	6.92E−06	0.97	0.81	68	MAA and Josa vs. Clari, Roxi
		mitotin (S. cerevisiae)
48397	HIF1A	hypoxia-inducible factor 1, alpha subunit (basic	9.10E−06	1.09	0.92	72	MAA and Josa vs. Clari, Roxi
		helix-loop-helix transcription factor)
48807	UNG	uracil-DNA glycosylase	9.61E−06	1.03	0.92	72	MAA and Josa vs. Clari, Roxi
49163	LGALS3	lectin, galactoside-binding, soluble, 3 (galectin 3)	9.61E−06	1.06	1.21	72	MAA and Josa vs. Clari, Roxi
49144	PIK3R3	phosphoinositide-3-kinase, regulatory subunit,	1.07E−05	1.01	1.13	72	MAA and Josa vs. Clari, Roxi
		polypeptide 3 (p55, gamma)
47951	COX15	COX15 homolog, cytochrome c oxidase assembly	1.07E−05	1.05	0.95	72	MAA and Josa vs. Clari, Roxi
		protein (yeast)
47181	RAB2	RAB2, member RAS oncogene family	1.32E−05	1.01	1.12	72	MAA and Josa vs. Clari, Roxi
48328	FN1	fibronectin 1	1.32E−05	1.00	0.62	72	MAA and Josa vs. Clari, Roxi
49347	HNRPA3	heterogeneous nuclear ribonucleoprotein A3	1.48E−05	1.01	0.78	69	MAA and Josa vs. Clari, Roxi
48508	USP24	ubiquitin specific protease 24	1.55E−05	1.03	0.90	72	MAA and Josa vs. Clari, Roxi
49688	GSK3B	glycogen synthase kinase 3 beta	1.64E−05	1.05	1.20	72	MAA and Josa vs. Clari, Roxi
49757	DDOST	dolichyl-diphosphooligosaccharide-protein	1.72E−05	0.96	1.08	72	MAA and Josa vs. Clari, Roxi
		glycosyltransferase
48713	MKNK2	G protein-coupled receptor kinase 7	1.72E−05	0.96	1.17	72	MAA and Josa vs. Clari, Roxi
49177	NEDD8	neural precursor cell expressed, developmentally	2.24E−05	0.97	1.06	72	MAA and Josa vs. Clari, Roxi
		down-regulated 8
49989	VTN	vitronectin (serum spreading factor, somatomedin	2.71E−05	1.19	0.94	57	MAA and Josa vs. Clari, Roxi
		B, complement S-protein)
46851	RRBP1	ribosome binding protein 1 homolog 180 kD (dog)	2.75E−05	0.97	1.09	72	MAA and Josa vs. Clari, Roxi
49511	MATN2	matrilin 2	3.04E−05	0.93	1.11	69	MAA and Josa vs. Clari, Roxi
49715	HNRPD	heterogeneous nuclear ribonucleoprotein D (AU-	3.05E−05	0.99	0.91	72	MAA and Josa vs. Clari, Roxi
		rich element RNA binding protein 1, 37 kD)
48451	M6PR	mannose-6-phosphate receptor (cation	3.21E−05	0.97	1.08	72	MAA and Josa vs. Clari, Roxi
		dependent)
46882	HEXA	hexosaminidase A (alpha polypeptide)	3.37E−05	0.97	1.11	72	MAA and Josa vs. Clari, Roxi
48348	FN1	fibronectin 1	3.55E−05	1.00	0.62	72	MAA and Josa vs. Clari, Roxi
50222	FLJ13868	hypothetical protein FLJ13868	3.55E−05	0.93	1.07	72	MAA and Josa vs. Clari, Roxi
48644	KIAA0323	KIAA0323 protein	3.55E−05	1.01	1.11	72	MAA and Josa vs. Clari, Roxi
49873	INSIG1	insulin induced gene 1	3.55E−05	0.93	1.37	72	MAA and Josa vs. Clari, Roxi
49967	CCNE2	cyclin E2	3.71E−05	1.02	0.81	58	MAA and Josa vs. Clari, Roxi
47947	SF3B3	splicing factor 3b, subunit 3, 130 kD	3.73E−05	1.10	0.96	72	MAA and Josa vs. Clari, Roxi
46991	TFPI2	tissue factor pathway inhibitor 2	4.51E−05	1.00	0.66	68	MAA and Josa vs. Clari, Roxi
48952	ELK1	ELK1, member of ETS oncogene family	5.04E−05	0.98	1.07	72	MAA and Josa vs. Clari, Roxi
49047	GLUD1	glutamate dehydrogenase 1	5.85E−05	1.05	0.95	72	MAA and Josa vs. Clari, Roxi
49352	NCBP2	nuclear cap binding protein subunit 2, 20 kD	6.38E−05	0.94	1.02	71	MAA and Josa vs. Clari, Roxi
50405	CHERP	calcium homeostasis endoplasmic reticulum	6.46E−05	1.00	0.90	72	MAA and Josa vs. Clari, Roxi
		protein
47661	HSPA9B	heat shock 70 kD protein 9B (mortalin-2)	6.46E−05	1.10	0.95	72	MAA and Josa vs. Clari, Roxi
49761	BCL2L2	BCL2-like 2	6.71E−05	0.85	0.99	71	MAA and Josa vs. Clari, Roxi
49649	FGF2	fibroblast growth factor 2 (basic)	7.04E−05	1.12	0.81	51	MAA and Josa vs. Clari, Roxi
47406	MTHFD1	methylenetetrahydrofolate dehydrogenase	7.12E−05	1.12	0.95	72	MAA and Josa vs. Clari, Roxi
		(NADP+ dependent), methenyltetrahydrofolate
		cyclohydrolase, formyltetrahydrofolate synthetase
47192	ARHGAP1	Rho GTPase activating protein 1	7.12E−05	1.10	0.96	72	MAA and Josa vs. Clari, Roxi
50284	UQCR	ubiquinol-cytochrome c reductase (6.4 kD) subunit	7.85E−05	0.83	0.98	72	MAA and Josa vs. Clari, Roxi
49650	MAP3K10	mitogen-activated protein kinase kinase kinase 10	7.85E−05	0.93	1.10	72	MAA and Josa vs. Clari, Roxi
47535	ARHGDIA	Rho GDP dissociation inhibitor (GDI) alpha	7.85E−05	1.08	0.93	72	MAA and Josa vs. Clari, Roxi
50224	HK2	hexokinase 2	8.24E−05	0.95	1.11	72	MAA and Josa vs. Clari, Roxi
48333	DNMT1	DNA (cytosine-5-)-methyltransferase 1	8.61E−05	0.97	0.84	71	MAA and Josa vs. Clari, Roxi
48643	DIP2	KIAA0184 protein	9.08E−05	1.00	0.89	72	MAA and Josa vs. Clari, Roxi
50103	IRF5	interferon regulatory factors	9.08E−05	0.87	0.99	72	MAA and Josa vs. Clari, Roxi
48006	BCL2L2	BCL2-like 2	9.52E−05	0.86	0.99	72	MAA and Josa vs. Clari, Roxi
49990	SRC	v-src sarcoma (Schmidt-Ruppin A-2) viral	9.98E−05	0.99	1.13	70	MAA and Josa vs. Clari, Roxi
		oncogene homolog (avian)
47939	INPP5E	KIAA0123 protein	9.99E−05	0.99	0.91	72	MAA and Josa vs. Clari, Roxi
48192	OPA1	optic atrophy 1 (autosomal dominant)	9.99E−05	1.02	0.92	72	MAA and Josa vs. Clari, Roxi
49481	LOC55871	COBW-like protein	9.99E−05	0.90	1.01	72	MAA and Josa vs. Clari, Roxi
49608	POU4F1	POU domain, class 4, transcription factor 1	9.99E−05	0.97	1.04	72	MAA and Josa vs. Clari, Roxi
49142	PPIB	peptidylprolyl isomerase B (cyclophilin B)	9.99E−05	1.03	1.16	72	MAA and Josa vs. Clari, Roxi
49032	GSK3B	glycogen synthase kinase 3 beta	1.05E−04	1.06	1.18	72	MAA and Josa vs. Clari, Roxi
48502	CLIC4	chloride intracellular channel 4	1.08E−04	1.17	1.00	59	MAA and Josa vs. Clari, Roxi
50228	MVD	mevalonate (diphospho) decarboxylase	1.10E−04	0.92	1.17	72	MAA and Josa vs. Clari, Roxi
50319	BMP6	bone morphogenetic protein 6	1.10E−04	0.98	1.11	70	MAA and Josa vs. Clari, Roxi
50216			1.10E−04	0.95	1.04	71	MAA and Josa vs. Clari, Roxi
48672	CHK	choline kinase	1.15E−04	0.87	1.00	72	MAA and Josa vs. Clari, Roxi
49183	SRRM1	serine/arginine repetitive matrix 1	1.15E−04	0.96	0.85	72	MAA and Josa vs. Clari, Roxi
47793	BET3	similar to yeast BET3 (S. cerevisiae)	1.21E−04	0.95	1.06	72	MAA and Josa vs. Clari, Roxi
47995	PTGER1	prostaglandin E receptor 1 (subtype EP1), 42 kD	1.27E−04	1.00	0.77	53	MAA and Josa vs. Clari, Roxi
49172	YAF2	YY1 associated factor 2	1.28E−04	1.01	0.92	55	MAA and Josa vs. Clari, Roxi
47111	GOLGB1	golgi autoantigen, golgin subfamily b, macrogolgin	1.28E−04	1.01	1.14	70	MAA and Josa vs. Clari, Roxi
		(with transmembrane signal), 1
49013	BBC3	Bcl-2 binding component 3	1.33E−04	0.93	1.04	72	MAA and Josa vs. Clari, Roxi
46579	SERPING1	serine (or cysteine) proteinase inhibitor, clade G	1.33E−04	1.03	0.88	69	MAA and Josa vs. Clari, Roxi
		(C1 inhibitor), member 1, (angioedema, hereditary)
49794	BCL2L2	BCL2-like 2	1.34E−04	0.86	1.00	71	MAA and Josa vs. Clari, Roxi
50464	MMP15	matrix metalloproteinase 15 (membrane-inserted)	1.35E−04	0.87	1.04	69	MAA and Josa vs. Clari, Roxi
49781	P4HB	procollagen-proline, 2-oxoglutarate 4-dioxygenase	1.39E−04	0.98	1.10	72	MAA and Josa vs. Clari, Roxi
		(proline 4-hydroxylase), beta polypeptide (protein
		disulfide isomerase; thyroid hormone binding
		protein p55)
50099	CNOT3	CCR4-NOT transcription complex, subunit 3	1.39E−04	0.95	0.86	72	MAA and Josa vs. Clari, Roxi
49360	TEB4	similar to S. cerevisiae SSM4	1.46E−04	1.10	0.94	72	MAA and Josa vs. Clari, Roxi
48725	IKKE	IKK-related kinase epsilon; inducible IkappaB	1.46E−04	0.84	0.94	72	MAA and Josa vs. Clari, Roxi
		kinase
49514	UBC	ubiquitin C	1.53E−04	0.97	1.09	72	MAA and Josa vs. Clari, Roxi
48530	APLP2	amyloid beta (A4) precursor-like protein 2	1.53E−04	0.95	1.10	72	MAA and Josa vs. Clari, Roxi
50421	GOCAP1	golgi phosphoprotein 1	1.55E−04	1.01	1.10	71	MAA and Josa vs. Clari, Roxi
50022	HIF1A	hypoxia-inducible factor 1, alpha subunit (basic	1.60E−04	1.07	0.93	72	MAA and Josa vs. Clari, Roxi
		helix-loop-helix transcription factor)
47987	THBS1	thrombospondin 1	1.72E−04	1.02	0.71	60	MAA and Josa vs. Clari, Roxi
46679	KIAA1172	pre-mRNA splicing SR protein rA4	1.73E−04	1.04	0.92	70	MAA and Josa vs. Clari, Roxi
49446	SRC	v-src sarcoma (Schmidt-Ruppin A-2) viral	1.74E−04	1.00	1.14	71	MAA and Josa vs. Clari, Roxi
		oncogene homolog (avian)
49006	PRSS25	protease, serine, 25	1.76E−04	1.02	1.14	72	MAA and Josa vs. Clari, Roxi
48707	P4HA1	procollagen-proline, 2-oxoglutarate 4-dioxygenase	1.76E−04	0.97	1.18	72	MAA and Josa vs. Clari, Roxi
		(proline 4-hydroxylase), alpha polypeptide I
48620	XBP1	X-box binding protein 1	1.84E−04	0.98	1.10	72	MAA and Josa vs. Clari, Roxi
48921	ITGAE	integrin, alpha E (antigen CD103, human mucosal	1.87E−04	0.85	0.97	71	MAA and Josa vs. Clari, Roxi
		lymphocyte antigen 1; alpha polypeptide)
47776	POLA	polymerase (DNA directed), alpha	1.88E−04	1.02	0.89	59	MAA and Josa vs. Clari, Roxi
48456	DDC	dopa decarboxylase (aromatic L-amino acid	1.91E−04	1.12	0.97	59	MAA and Josa vs. Clari, Roxi
		decarboxylase)
47846	SSI-1	JAK binding protein	1.99E−04	1.03	0.93	69	MAA and Josa vs. Clari, Roxi
49314	PPIB	peptidylprolyl isomerase B (cyclophilin B)	2.12E−04	1.04	1.16	72	MAA and Josa vs. Clari, Roxi
47935	P4HA1	procollagen-proline, 2-oxoglutarate 4-dioxygenase	2.30E−04	0.95	1.18	70	MAA and Josa vs. Clari, Roxi
		(proline 4-hydroxylase), alpha polypeptide I
50736	PRKDC	protein kinase, DNA-activated, catalytic	2.32E−04	1.07	0.92	72	MAA and Josa vs. Clari, Roxi
		polypeptide
47811	ENTPD6	ectonucleoside triphosphate diphosphohydrolase 6	2.32E−04	0.93	1.06	72	MAA and Josa vs. Clari, Roxi
		(putative function
47622	TRAP1	heat shock protein 75	2.43E−04	1.09	0.94	72	MAA and Josa vs. Clari, Roxi
48486			2.45E−04	1.21	0.94	34	MAA and Josa vs. Clari, Roxi
50738	AD022	TRAF and TNF receptor-associated protein	2.53E−04	0.94	1.10	70	MAA and Josa vs. Clari, Roxi
46825	MKNK2	G protein-coupled receptor kinase 7	2.54E−04	0.94	1.12	72	MAA and Josa vs. Clari, Roxi
49169	RRS1	homolog of yeast ribosome biogenesis regulatory	2.55E−04	1.09	0.93	68	MAA and Josa vs. Clari, Roxi
		protein RRS1
50590	CKS2	CDC28 protein kinase 2	2.59E−04	0.74	0.89	69	MAA and Josa vs. Clari, Roxi
50050	NDUFA2	NADH dehydrogenase (ubiquinone) 1 alpha	2.66E−04	0.90	1.02	72	MAA and Josa vs. Clari, Roxi
		subcomplex, 2 (8 kD, B8)
50342	IKKE	IKK-related kinase epsilon; inducible IkappaB	2.79E−04	0.94	1.08	70	MAA and Josa vs. Clari, Roxi
		kinase
47522	SERPINA1	serine (or cysteine) proteinase inhibitor, clade A	2.85E−04	1.04	0.95	71	MAA and Josa vs. Clari, Roxi
		(alpha-1 antiproteinase, antitrypsin), member 1
50645	BET1	BET1 homolog (S. cerevisiae)	2.92E−04	0.84	1.01	70	MAA and Josa vs. Clari, Roxi
48717	PPP3CB	protein phosphatase 3 (formerly 2B), catalytic	2.99E−04	1.09	0.95	52	MAA and Josa vs. Clari, Roxi
		subunit, beta isoform (calcineurin A beta)
47950	DNASE1L1	deoxyribonuclease I-like 1	3.04E−04	0.96	1.03	72	MAA and Josa vs. Clari, Roxi
48557	NFE2L1	nuclear factor (erythroid-derived 2)-like 1	3.13E−04	0.97	1.06	71	MAA and Josa vs. Clari, Roxi
48026	SRF	serum response factor (c-fos serum response	3.18E−04	0.94	1.03	72	MAA and Josa vs. Clari, Roxi
		element-binding transcription factor)
49374			3.18E−04	0.97	1.03	72	MAA and Josa vs. Clari, Roxi
49007	TM9SF2	transmembrane 9 superfamily member 2	3.18E−04	1.08	1.18	72	MAA and Josa vs. Clari, Roxi
49737	CHAF1B	chromatin assembly factor 1, subunit B (p60)	3.23E−04	0.99	0.88	66	MAA and Josa vs. Clari, Roxi
46935	METAP2	methionyl aminopeptidase 2	3.33E−04	1.05	0.89	72	MAA and Josa vs. Clari, Roxi
46843	ARHGDIA	Rho GDP dissociation inhibitor (GDI) alpha	3.33E−04	1.08	0.93	72	MAA and Josa vs. Clari, Roxi
48804	KIAA0217	KIAA0217 protein	3.37E−04	1.01	0.88	70	MAA and Josa vs. Clari, Roxi
47439	DCTN1	dynactin 1 (p150, glued homolog, Drosophila)	3.48E−04	1.04	0.95	72	MAA and Josa vs. Clari, Roxi
47418	SNK	serum-inducible kinase	3.53E−04	1.03	0.82	70	MAA and Josa vs. Clari, Roxi
48137	FRDA	Friedreich ataxia	3.53E−04	1.03	0.90	70	MAA and Josa vs. Clari, Roxi
48693	HSPBP1	hsp70-interacting protein	3.64E−04	1.04	0.91	72	MAA and Josa vs. Clari, Roxi
49155	ARTS-1	type 1 tumor necrosis factor receptor shedding	3.65E−04	1.11	0.86	61	MAA and Josa vs. Clari, Roxi
		aminopeptidase regulator
49490	VTN	vitronectin (serum spreading factor, somatomedin	3.76E−04	1.12	0.94	54	MAA and Josa vs. Clari, Roxi
		B, complement S-protein)
46896	CDIPT	CDP-diacylglycerol--inositol 3-	3.80E−04	0.91	1.01	72	MAA and Josa vs. Clari, Roxi
		phosphatidyltransferase (phosphatidylinositol
		synthase)
48301	GCN5L1	GCN5 general control of amino-acid synthesis 5-	3.80E−04	0.93	1.01	72	MAA and Josa vs. Clari, Roxi
		like 1 (yeast)
49577	LOC54543	6.2 kd protein	3.80E−04	0.88	1.02	72	MAA and Josa vs. Clari, Roxi
50267	IL10RB	interleukin 10 receptor, beta	3.80E−04	0.98	1.08	72	MAA and Josa vs. Clari, Roxi
48233	MAPK12	mitogen-activated protein kinase 12	3.97E−04	0.88	1.03	72	MAA and Josa vs. Clari, Roxi
50584	BN51T	BN51 (BHK21) temperature sensitivity	3.97E−04	0.97	1.07	72	MAA and Josa vs. Clari, Roxi
		complementing
47241	NUBP1	nucleotide binding protein 1 (MinD homolog, E. coli)	4.11E−04	1.04	0.95	69	MAA and Josa vs. Clari, Roxi
47366	P4HB	procollagen-proline, 2-oxoglutarate 4-dioxygenase	4.15E−04	1.05	1.18	72	MAA and Josa vs. Clari, Roxi
		(proline 4-hydroxylase), beta polypeptide (protein
		disulfide isomerase; thyroid hormone binding
		protein p55)
48160	ZAP3	ZAP3 protein	4.27E−04	1.08	0.95	66	MAA and Josa vs. Clari, Roxi
48415	SERPINB1	serine (or cysteine) proteinase inhibitor, clade B	4.45E−04	1.02	1.28	45	MAA and Josa vs. Clari, Roxi
		(ovalbumin), member 1
48521	ARAF1	v-raf murine sarcoma 3611 viral oncogene	4.53E−04	1.12	0.98	72	MAA and Josa vs. Clari, Roxi
		homolog 1
49233	APOE	apolipoprotein E	4.53E−04	0.96	1.01	72	MAA and Josa vs. Clari, Roxi
50591			4.53E−04	1.01	1.13	72	MAA and Josa vs. Clari, Roxi
49435	TRRAP	transformation/transcription domain-associated	4.74E−04	1.07	0.92	72	MAA and Josa vs. Clari, Roxi
		protein
47504	MSH3	mutS homolog 3 (E. coli)	4.91E−04	1.09	0.99	54	MAA and Josa vs. Clari, Roxi
48500	RPL13A	ribosomal protein L13a	4.95E−04	1.05	0.92	72	MAA and Josa vs. Clari, Roxi
48266	GRB2	growth factor receptor-bound protein 2	4.95E−04	0.93	1.04	72	MAA and Josa vs. Clari, Roxi
49767	AD022	TRAF and TNF receptor-associated protein	5.14E−04	0.96	1.10	71	MAA and Josa vs. Clari, Roxi
49524	AP1G2	adaptor-related protein complex 1, gamma 2	5.17E−04	0.74	0.92	72	MAA and Josa vs. Clari, Roxi
		subunit
47432	GCS1	glucosidase I	5.17E−04	0.90	1.02	72	MAA and Josa vs. Clari, Roxi
49915	ATP2B4	ATPase, Ca++ transporting, plasma membrane 4	5.17E−04	1.23	1.06	72	MAA and Josa vs. Clari, Roxi
47314	EPOR	erythropoietin receptor	5.19E−04	0.99	1.14	58	MAA and Josa vs. Clari, Roxi
46633	FLJ20699	hypothetical protein FLJ20699	5.23E−04	1.00	0.81	39	MAA and Josa vs. Clari, Roxi
49679	SERPINF1	serine (or cysteine) proteinase inhibitor, clade F	5.24E−04	0.98	1.09	65	MAA and Josa vs. Clari, Roxi
		(alpha-2 antiplasmin, pigment epithelium derived
		factor), member 1
49117	SERPINB1	serine (or cysteine) proteinase inhibitor, clade B	5.39E−04	1.01	0.88	72	MAA and Josa vs. Clari, Roxi
		(ovalbumin), member 1
46988	EREG	epiregulin	5.40E−04	1.11	0.85	48	MAA and Josa vs. Clari, Roxi
49673	BTN3A2	butyrophilin, subfamily 3, member A2	5.60E−04	0.92	1.11	59	MAA and Josa vs. Clari, Roxi
47034	C2orf3	chromosome 2 open reading frame 3	5.69E−04	1.01	0.90	63	MAA and Josa vs. Clari, Roxi
48149	SFRS7	splicing factor, arginine/serine-rich 7 (35 kD)	5.70E−04	0.98	0.88	69	MAA and Josa vs. Clari, Roxi
47850	PRLR	prolactin receptor	5.74E−04	1.09	0.99	66	MAA and Josa vs. Clari, Roxi
47679	NR4A2	nuclear receptor subfamily 4, group A, member 2	5.80E−04	0.95	1.14	63	MAA and Josa vs. Clari, Roxi
47415	CETN2	centrin, EF-hand protein, 2	5.88E−04	1.06	1.18	72	MAA and Josa vs. Clari, Roxi
48747	MAFB	v-maf musculoaponeurotic fibrosarcoma oncogene	5.88E−04	1.14	0.93	25	MAA and Josa vs. Clari, Roxi
		homolog B (avian)
49028	BNIP3L	BCL2/adenovirus E1B 19 kD interacting protein 3-	6.14E−04	1.03	1.20	72	MAA and Josa vs. Clari, Roxi
		like
50349	LOC51295	ECSIT	6.25E−04	1.01	0.84	69	MAA and Josa vs. Clari, Roxi
47802	GOT1	glutamic-oxaloacetic transaminase 1, soluble	6.40E−04	1.02	0.94	69	MAA and Josa vs. Clari, Roxi
		(aspartate aminotransferase 1)
50513	ARHC	ras homolog gene family, member C	6.68E−04	0.91	1.00	72	MAA and Josa vs. Clari, Roxi
50079	SCOP	SCN Circadian Oscillatory Protein (SCOP)	6.68E−04	0.97	1.04	72	MAA and Josa vs. Clari, Roxi
50511	MGP	matrix Gla protein	6.85E−04	0.83	0.98	33	MAA and Josa vs. Clari, Roxi
48646	SDCBP	syndecan binding protein (syntenin)	6.97E−04	0.97	1.08	72	MAA and Josa vs. Clari, Roxi
49272	TNFRSF10B	tumor necrosis factor receptor superfamily,	6.97E−04	0.97	1.08	72	MAA and Josa vs. Clari, Roxi
		member 10b
49800	AD022	TRAF and TNF receptor-associated protein	7.00E−04	0.97	1.09	71	MAA and Josa vs. Clari, Roxi
48411	MGEA5	meningioma expressed antigen 5 (hyaluronidase)	7.00E−04	0.97	1.13	71	MAA and Josa vs. Clari, Roxi
50601	SRP19	signal recognition particle 19 kD	7.01E−04	0.95	1.06	70	MAA and Josa vs. Clari, Roxi
48004	CUTL1	cut-like 1, CCAAT displacement protein	7.07E−04	1.22	1.02	67	MAA and Josa vs. Clari, Roxi
		(Drosophila)
49318	YWHAH	tyrosine 3-monooxygenase/tryptophan 5-	7.28E−04	1.08	0.97	72	MAA and Josa vs. Clari, Roxi
		monooxygenase activation protein, eta polypeptide
48461	BARD1	BRCA1 associated RING domain 1	7.50E−04	0.98	0.86	51	MAA and Josa vs. Clari, Roxi
49618	CLN2	ceroid-lipofuscinosis, neuronal 2, late infantile	7.59E−04	1.03	1.12	72	MAA and Josa vs. Clari, Roxi
		(Jansky-Bielschowsky disease)
48345	CCT3	chaperonin containing TCP1, subunit 3 (gamma)	7.92E−04	0.97	1.03	72	MAA and Josa vs. Clari, Roxi
48365	MAPK9	mitogen-activated protein kinase 9	7.92E−04	1.04	0.94	72	MAA and Josa vs. Clari, Roxi
49606	CSTF3	cleavage stimulation factor, 3′ pre-RNA, subunit 3,	7.97E−04	0.98	1.07	71	MAA and Josa vs. Clari, Roxi
		77 kD
48654	FECH	ferrochelatase (protoporphyria)	8.26E−04	1.05	0.98	72	MAA and Josa vs. Clari, Roxi
47754	NBS1	Nijmegen breakage syndrome 1 (nibrin)	8.37E−04	1.18	0.97	71	MAA and Josa vs. Clari, Roxi
47446	RANBP1	RAN binding protein 1	8.61E−04	1.04	0.89	72	MAA and Josa vs. Clari, Roxi
47694	HSPA9B	heat shock 70 kD protein 9B (mortalin-2)	8.61E−04	1.09	0.95	72	MAA and Josa vs. Clari, Roxi
46648	ARHGAP1	Rho GTPase activating protein 1	8.61E−04	1.07	0.96	72	MAA and Josa vs. Clari, Roxi
49787	CYC1	cytochrome c-1	8.97E−04	1.09	0.94	72	MAA and Josa vs. Clari, Roxi
47988	RPN2	ribophorin II	8.97E−04	0.93	1.02	72	MAA and Josa vs. Clari, Roxi
46923	PACE	paired basic amino acid cleaving enzyme (furin,	8.97E−04	1.00	1.09	72	MAA and Josa vs. Clari, Roxi
		membrane associated receptor protein)
49947	RFC1	replication factor C (activator 1) 1 (145 kD)	9.29E−04	1.05	0.93	66	MAA and Josa vs. Clari, Roxi
48732	RALA	v-ral simian leukemia viral oncogene homolog A	9.36E−04	0.98	1.06	72	MAA and Josa vs. Clari, Roxi
		(ras related)
47973	USF2	upstream transcription factor 2, c-fos interacting	9.46E−04	0.96	1.05	70	MAA and Josa vs. Clari, Roxi
47352	ADAM11	a disintegrin and metalloproteinase domain 11	9.48E−04	0.93	1.10	45	MAA and Josa vs. Clari, Roxi
50351	CFL1	cofilin 1 (non-muscle)	9.75E−04	1.16	1.00	72	MAA and Josa vs. Clari, Roxi

APPENDIX F
Group of genes that affect inflammation in the lung*
				+/−Clari,	+LPS +/− Clari,
				wtd	wtd
SpotID	GeneSymbol	GeneName	GeneAssignment	means	means
47876	SERPINB3		serine (or cysteine) proteinase inhibitor, clade B	1.58	1.63
			(ovalbumin), member 3
30419	MMP12	MMP12	matrix metalloproteinase 12 (macrophage elastase)	1.00	0.47
48003	MMP19	MMP19	matrix metalloproteinase 19	0.69	0.60
48980	MMP9	MMP9, gelatinase B	matrix metalloproteinase 9 (gelatinase B, 92 kD	0.84	0.89
			gelatinase, 92 kD type IV collagenase)
9206	CTSC		cathepsin C	0.90	0.82
10515	CTSK		cathepsin K (pycnodysostosis)	0.82	0.62
11956	CXCL10	IP-10	small inducible cytokine subfamily B (Cys-X-Cys),	1.13	0.69
			member 10
11819	CXCL11	I-TAG	small inducible cytokine subfamily B (Cys-X-Cys),	0.96	0.78
			member 11
48570	CXCL9	monokine induced by	monokine induced by gamma interferon	1.09	0.47
		gamma interferon
28201	CCL18	DC-CK1	small inducible cytokine subfamily A (Cys—Cys),	0.89	0.68
			member 18, pulmonary and activation-regulated
*From Appendix C. For those having a plurality of SPOTIDs, a representative ID is shown.

Claims

1. A method of screening test macrolides to identify potential anti-inflammatory agents, comprising: 1) contacting a first biological sample with a test macrolide; and 2) detecting, as an alteration, a first level of expression or activity of a target molecule involved in inflammation in the first biological sample relative to a second level of expression or activity of the target molecule involved in inflammation in a second biological sample that has not been contacted with the test macrolide.

2. The method of claim 1, wherein a test macrolide that alters the first level of alteration of expression or activity of the target molecule involved in inflammation relative to the second level of alteration of expression or activity of the target molecule involved in inflammation identifies the test macrolide as a potential anti-inflammatory agent.

3. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the level of de novo arachidonic acid biosynthesis.

4. The method of claim 3, wherein a macrolide compound that increases or decreases the level of de novo arachidonic acid biosynthesis is selected.

5. The method of claim 4, wherein the level of de novo arachidonic acid biosynthesis is detected by measuring incorporation of labeled arachidonic acid into phospholipids.

6. The method of claim 4, wherein the level of de novo arachidonic acid biosynthesis is detected by measuring incorporation of label into an intermediate in an arachidonic acid biosynthesis pathway.

7. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the level of extracellular matrix decomposition.

8. The method of claim 7, wherein a macrolide compound that decreases the level of extracellular matrix decomposition is selected.

9. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the leucocyte infiltration number.

10. The method of claim 9, wherein a macrolide compound that decreases the leucocyte infiltration number is selected.

11. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the level of expression of a gene involved in arachidonic acid biosynthesis or activation.

12. The method of claim 11, wherein a macrolide compound that increases or decreases the level of expression of said gene is selected.

13. The method of claim 11, wherein said gene is at least one type selected from the group consisting of A5 fatty acid desaturase (FADS1), A6 fatty acid desaturase (FADS2), fatty acid elongase, arachidonyl CoA synthetase, cyclooxygenase 2, prostaglandin E receptor EP4, cytosolic phospholipase A2, fatty acid desaturase, prostaglandin E synthase, prostaglandin E receptor EP1, prostaglandin 12 receptor, and secretory phospholipase A2 receptor 1.

14. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the level of expression of a gene involved in extracellular matrix decomposition.

15. The method of claim 14, wherein a macrolide compound that increases the level of expression of said gene is selected.

16. The method of claim 15, wherein said gene is at least one type selected from the group consisting of serine proteinase inhibitor, clade B (ovalbumin), and member 3 (SERPINB3).

17. The method of claim 14, wherein a macrolide compound that decreases the level of expression of said gene is selected.

18. The method of claim 17, wherein said gene is at least one type selected from the group consisting of matrix metalloproteinase 12 (MMP12), matrix metalloproteinase 19 (MMP19), matrix metalloproteinase 9 (MMP9), cathepsin C, and cathepsin K.

19. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the level of expression of a gene involved in leucocyte infiltration.

20. The method of claim 19, wherein a macrolide compound that decreases the level of expression of said gene is selected.

21. The method of claim 19, wherein said gene is at least one type selected from the group consisting of small inducible cytokine subfamily A (Cys-Cys) member 18 (CCL18), small inducible cytokine subfamily B (Cys-X-Cys) member 10 (CXCL10), small inducible cytokine subfamily B (Cys-X-Cys) member 11 (CXCL11), and small inducible cytokine subfamily B (Cys-X-Cys) member 9 (CXCL9).

22. The method of claim 19, wherein expression of the gene is determined by detecting mRNA, protein or protein synthesis.

23. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the activity of an enzyme involved in arachidonic acid biosynthesis.

24. The method of claim 23, wherein a macrolide compound that increases or decreases the activity of said enzyme is selected.

25. The method of claim 24, wherein said enzyme is at least one type selected from the group consisting of A5 fatty acid desaturase (FADS1), A6 fatty acid desaturase (FADS2), fatty acid elongase, and arachidonyl CoA synthetase.

26. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the activity of an enzyme involved in extracellular matrix decomposition.

27. The method of claim 26, wherein a macrolide compound that increases the activity of said enzyme is selected.

28. The method of claim 27, wherein said enzyme is at least one type selected from the group consisting of serine proteinase inhibitor, clade B (ovalbumin), and member 3 (SERPINB3).

29. The method of claim 26, wherein a macrolide compound that decreases the activity of said enzyme is selected.

30. The method of claim 29, wherein said enzyme is at least one type selected from the group consisting of matrix metalloproteinase 12 (MMP12), matrix metalloproteinase 19 (MMP19), matrix metalloproteinase 9 (MMP9), cathepsin C, and cathepsin K.

31. The method of claim 1, wherein the alteration of the target molecule in said 2) is an alteration in the activity of a chemokine involved in leucocyte infiltration.

32. The method of claim 31, wherein a macrolide compound that decreases the activity of said chemokine is selected.

33. The method of claim 32, wherein said chemokine is at least one type selected from the group consisting of small inducible cytokine subfamily A (Cys-Cys) member 18 (CCL18), small inducible cytokine subfamily B (Cys-X-Cys) member 10 (CXCL10), small inducible cytokine subfamily B (Cys-X-Cys) member 11 (CXCL11), and small inducible cytokine subfamily B (Cys-X-Cys) member 9 (CXCL9).

34. The method of claim 1, wherein the biological sample comprises cells.

35. The method of claim 1, wherein the biological sample comprises a cellular extract.

36. The method of claim 1, wherein said contacting in said 1) is carried out in vitro.

37. The method of claim 1, wherein said contacting in said 1) is carried out in vivo.

38. The method of claim 1, wherein said contacting in said 1) is carried out in a cell culture.

39. The method of claim 38, wherein the cell culture comprises an epithelial cell line.

40. The method of claim 38, wherein the epithelial cell line is a macrophage cell line.

41. The method of claim 39, wherein the epithelial cell line is A549.

42. The method of claim 40, wherein the epithelial cell line is THP-1.

43. The method of claim 1, wherein said anti-inflammatory action is an action against inflammation in the lung.

44. The method of claim 43, wherein said inflammation in the lung is pulmonary emphysema, bronchitis, pulmonary fibrosis, acute lung injury, viral pneumonia, bacterial pneumonia, or acute respiratory disease syndrome (ARDS).

45. The method of any one of claims 14, wherein expression of the gene is determined by detecting mRNA, protein or protein synthesis.

46. The method of any one of claims 11, wherein expression of the gene is determined by detecting mRNA, protein or protein synthesis.